MAIN HEADLINE
PROGRAM 69TH
BOOK ANNUAL MEETING
DECEMBER 4 - 8, 2015
PENNSYLVANIA
CONVENTION CENTER
PHILADELPHIA, PA
AMERICAN EPILEPSY SOCIETY 69TH ANNUAL MEETING
1
DECEMBER 4 - 8, 2015 www.AESnet.org
UCB welcomes
you to AES
Visit us at booth 601 for exciting
information on VIMPAT® for your patients.
VIMPAT® is a registered trademark under license from Harris FRC Corporation.
©2015, UCB, Inc., Smyrna, GA 30080.
All rights reserved. USP-VI0915-0213
®
BANZEL OFFERS
2 FORMULA
AT
TIONS
FOR ADMINISTRAT
TION
00 mg
00 mg
• Ta
ablets: 200 mg and
d 400 mg
• Oral suspension: 40
0 mg/mL
LEARN MORE ABOUT BANZEL A
AT
T BOOTH 501
For more information,
o
please visit www.BANZEL.com/hcp
©2015 Eisai Inc. All rights reserved. BANZ-US0080 Sept
Distributed and marketed by Eisai Inc., Woodcliff Lak
Takingg the oral medicatioon experience to
Aw
whole new
w dimension
n
®
Intro
oduccing
g ZipDose
p
Te
echnolog
gy, the
he first and only
y drug-formulation
g
ulation p
platform to utilize three-dimensional
ree-dimensional
echnology allows product disinte
egration in seconds when taken
n with a sip of
printing (3DP). ZipDose® Te
liquid, a wide range of taste-maskin
ng capabilities, and high dose
se loading (up to 1,000 mg of
o drug).1
slowly dissolve, bu
ut it went poof
and was kind off fu
fun actuallyy..
–Intternist
“
hat is great technology
echnology..
I am veery imp
pressed.
Foor people with dr
dryy mouth
and swalloowing
disorders thiss is great.
“
“
–Innternist
“
“
t’s like magic…I eexxpected it to
What’s your
o take?
“
Exp
p erience ZipDose
p
e® Te
echnology
gy
for yourself at Bo
ooth #107
Learn more about ZiipDose® TTeechnology at Aprecia.c
A
om/AES
om/AE
S
R erence: 1. Data on file. Aprecia Pharmaceuticals
Ref
harmaceuticals Company.
© 2015 Aprecia
a Pharmaceuticals Company. All rights reser ved. PP-MA-ZD-US-0014 September 2015
LEARN WHAT MAY
BE HIDING INSIDE
SEIZURE CLUSTERS
RECOGNIZE THE PATTERNS, UNDERSTAND THE
RISKS, AND LEARN ABOUT THE NEUROSCIENCE
OF SEIZURE CLUSTERS AT
BOOTH #543
ACORDA THERAPEUTICS® and the stylized ACORDA THERAPEUTICS® logo are registered trademarks of Acorda Therapeutics, Inc.
© 2015 Acorda Therapeutics, Inc. All rights reserved. US2815
Arcc Esseentiaa E33
TTM
Your complete Brain
ain Heal
ealth Monitor for
or LTM and ICU
CU
You Track your patients’
Vitaal signs, but
b whatt aabout
their brain hea
heal
allth?
th?
Thhhe E3 is powerful.
ew
ectrode
ttings
a ooptions
Vissit us at
at booth
bootth 513
.COM
t g nerator
(800) 245-3001
3001 - info@cadwell.com
ARN MORE
VISIT BOOTH #711 TO LEARN
HELPING REAL LENNOX-GA
ASTA
AUT SYNDRO
OME
(LGS) PA
PA
AT
TIENTS FIGHT THEIR SEIZURES
ONFI® (clobazam)
azam) is indicated for the adjunctive
nctive treatment of seizures
associated
ciated with LGS in patients 2 years
ears of age or older.
ONFI is contraindicated in patients
O
nts with a history
o hypersensitivity to the drug orr its ingredients.
of
Addie,
age 17
Bobby,
age 47
Julian,
age 6
Ad
dam,
ag
ge 15
Important
Imp
portant Safety Information
• ON
NFI is contraindicated in patients with a history of hypersensitivity
to the drug or its ingredients. Hypersensitivity
itivity reactions have
inccluded serious dermatological reaction
ns.
• ON
NFI causes somnolence and sedation. In clinical trials,
so
omnolence or sedation was reported at all efffective doses
an
nd was dose-related. In general, somno
olence and sedation
be
egin within the first month of treatmentt and may diminish with
co
ontinued treatment. Prescribers should monitor patients for
so
omnolence and sedation, particularly with concomitant use
of other central nervous system (CNS) de
epressants. Prescribers
should caution patients against engaging
g in hazardous activities
tha
at require mental alertness, such as operating dangerous
ma
achinery or motor vehicles, until the effect
f
of ONFI is known.
• ON
NFI has a CNS depressant efffect. Patie
ents should be cautioned
ag
gainst the simultaneous use with other C
CNS depressant drugs or
alccohol, and cautioned that the effects of other CNS depressant
drugs or alcohol may be potentiated.
• Ass with all antiepileptic drugs (AEDs), ON
NFI should be gradually
witthdrawn to minimize the risk of precipitating seizures, seizure
exxacerbation, or status epilepticus. Withd
drawal symptoms have
be
een reported following abrupt discontin
nuation of ONFI; the risk
of withdrawal symptoms is greater with h
higher doses.
• Se
erious dermatological reactions, including Stevens-Johnson
syndrome (SJS) and toxic epidermal necrrolysis (TEN), have been
rep
ported with ONFI in both children and
d adults during the
post-marketing period. ONFI should be discontinued
scontinued at the first sign
of rash, unless the rash is clearly not drug
g-related.
©20155 Lundbeck. All rights reserved.
ONFI is a registered trademark of Lundbeck CLB-B-00224
• Patients
ts with a history of substance abuse should
ould be under careful
surveillance
ance when receiving ONFI or other psychotr
ychotropic agents
because
se of the predisposition of such patients
ts to habituation and
dependence.
dence. In clinical trials, cases of dependency
dency were reported
following
ng abrupt discontinuation of ONFI. The
e risk of dependence
increasses with increasing dose and duration of treatment.
• AEDs, including ONFI, increase the risk of suicidal
uicidal thoughts or
behavior
or in patients. Patients, their caregivers,
s, and families should
be infor
ormed of the risk and advised to monitor
tor and report any
emerge
ence or worsening of depression, suicidal
cidal thoughts or
behavior
or, or any unusual changes in mood or behavior,
behavior, or thoughts
of self-har
harm. If these symptoms occur,, consider whether it may be
related
d to the AED or illness, because epilepsy
sy itself can increase
these risks.
• Based on animal data,
data ONFI may cause fetal harm and should only
be used
d during pregnancy or while nursing if the potential benefit
justifiess the potential risk.
• The mo
ost commonly observed adverse reactions
ctions reported in
an LGS
S randomized, double-blind, placebo-contr
controlled, parallel
group clinical
c
trial of patients who received clobazam
obazam as adjunctive
therapy (≥10% in any treatment group and at least 5% greater than
placebo,
o, respectively) were somnolence or sedation
dation (32% vs. 15%),
somnolence
ence (25% vs. 12%), pyre
pyrexia (17% vs. 3%),
), lethargy (15% vs. 5%),
aggre
ession
sion (14% vs. 5%), drooling (14% vs. 3%),
irritability
ity (11% vs. 5%), ataxia (10% vs. 3%),
and constipation
nstipation (10% vs. 0%).
Please see
ee Brief Summary of Prescribing
Information
tion on the following pages. For full
Pre
escribing
ng Information, Medication Guide,
and Instrructions for Use go to ONFI.com
for more information.
Ready to Fight
ONFI® (clobazam) tablets, for oral use,
ONFI® (clobazam) oral suspension,
Brief Summary of Prescribing Information
(See package insert for full Prescribing Information or visit www.ONFI.com)
Rx Only
INDICATIONS AND USAGE – ONFI® (clobazam) is indicated for the
adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
(LGS) in patients 2 years of age or older.
CONTRAINDICATIONS – ONFI is contraindicated in patients with a history
of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions
have included serious dermatological reactions.
WARNINGS AND PRECAUTIONS – Somnolence or Sedation: ONFI causes
somnolence and sedation. In clinical trials, somnolence or sedation
was reported at all effective doses and was dose-related. In general,
somnolence and sedation begin within the first month of treatment and may
diminish with continued treatment. Prescribers should monitor patients
for somnolence and sedation, particularly with concomitant use of other
central nervous system depressants. Prescribers should caution patients
against engaging in hazardous activities requiring mental alertness, such as
operating dangerous machinery or motor vehicles, until the effect of ONFI
is known. Potentiation of Sedation from Concomitant Use with Central
Nervous System Depressants: Since ONFI has a central nervous system
(CNS) depressant effect, patients or their caregivers should be cautioned
against simultaneous use with other CNS depressant drugs or alcohol, and
cautioned that the effects of other CNS depressant drugs or alcohol may be
potentiated. Withdrawal Symptoms: Abrupt discontinuation of ONFI should
be avoided. ONFI should be tapered by decreasing the dose every week by
5-10 mg/day until discontinuation [see Dosage and Administration]. As with
all antiepileptic drugs, ONFI should be withdrawn gradually to minimize the
risk of precipitating seizures, seizure exacerbation, or status epilepticus.
Withdrawal symptoms have been reported following abrupt discontinuance
of benzodiazepines. The more severe withdrawal symptoms have usually
been limited to patients who received excessive doses over an extended
period of time, followed by an abrupt discontinuation. Generally milder
withdrawal symptoms have been reported following abrupt discontinuance
of benzodiazepines taken continuously at therapeutic doses for several
months. Serious Dermatological Reactions: Serious skin reactions,
including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN), have been reported with ONFI in both children and adults during
the post-marketing period. Patients should be closely monitored for signs
or symptoms of SJS/TEN, especially during the first 8 weeks of treatment
initiation or when re-introducing therapy. ONFI should be discontinued at
the first sign of rash, unless the rash is clearly not drug-related. If signs or
symptoms suggest SJS/TEN, use of this drug should not be resumed and
alternative therapy should be considered [see Contraindications]. Physical
and Psychological Dependence: Patients with a history of substance
abuse should be under careful surveillance when receiving ONFI or other
psychotropic agents because of the predisposition of such patients to
habituation and dependence [see Drug Abuse and Dependence]. Suicidal
Behavior and Ideation: Antiepileptic drugs (AEDs), including ONFI, increase
the risk of suicidal thoughts or behavior in patients taking these drugs for
any indication. Patients treated with any AED for any indication should be
monitored for the emergence or worsening of depression, suicidal thoughts
or behavior, and/or any unusual changes in mood or behavior. The increased
risk of suicidal thoughts or behavior with AEDs was observed as early as one
week after starting drug treatment with AEDs and persisted for the duration
of treatment assessed. Because most trials included in the analysis did not
extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond
24 weeks could not be assessed. The risk of suicidal thoughts or behavior
was generally consistent among drugs in the data analyzed. The finding of
increased risk with AEDs of varying mechanisms of action and across a
range of indications suggests that the risk applies to all AEDs used for any
indication. The relative risk for suicidal thoughts or behavior was higher
in clinical trials for epilepsy than in clinical trials for psychiatric or other
conditions, but the absolute risk differences were similar for the epilepsy
and psychiatric indications. Anyone considering prescribing ONFI or any
other AED must balance the risk of suicidal thoughts or behavior with the
risk of untreated illness. Should suicidal thoughts and behavior emerge
during treatment, the prescriber needs to consider whether the emergence
of these symptoms in any given patient may be related to the illness being
treated. Patients, their caregivers, and families should be informed that
AEDs increase the risk of suicidal thoughts and behavior and should be
advised of the need to be alert for the emergence or worsening of the signs
and symptoms of depression, any unusual changes in mood or behavior, or
the emergence of suicidal thoughts, behavior, or thoughts about self-harm.
Behaviors of concern should be reported immediately to healthcare
providers. [Please see Warnings and Precautions in the full Prescribing
Information for complete details.]
ADVERSE REACTIONS – Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical trials of a
drug cannot be directly compared to rates in the clinical trials of another drug
and may not reflect the rates observed in practice. During its development
for the adjunctive treatment of seizures associated with LGS, ONFI was
administered to 333 healthy volunteers and 300 patients with a current
or prior diagnosis of LGS, including 197 patients treated for 12 months
or more. The conditions and duration of exposure varied greatly and
included single- and multiple-dose clinical pharmacology studies in healthy
volunteers and two double-blind studies in patients with LGS (Study 1 and 2)
[see Clinical Studies]. Only Study 1 included a placebo group, allowing
comparison of adverse reaction rates on ONFI at several doses to
placebo. Adverse Reactions Leading to Discontinuation in an LGS Placebo
Controlled Clinical Trial (Study 1): The adverse reactions associated with
ONFI treatment discontinuation in ≥1% of patients in decreasing order of
frequency included lethargy, somnolence, ataxia, aggression, fatigue, and
insomnia. Most Common Adverse Reactions in an LGS Placebo Controlled
Clinical Trial (Study 1): Table 3 in the full Prescribing Information lists the
adverse reactions that occurred in ≥5% of ONFI treated patients (at any
dose), and at a rate greater than placebo treated patients, in the randomized,
double-blind, placebo-controlled, parallel group clinical study of adjunctive
AED therapy for 15 weeks (Study 1).
Table 3. Adverse Reactions Reported for ≥ 5% of Patients and More
Frequently than Placebo in Any Treatment Group
ONFI Dose Level
Placebo Lowa Mediumb Highc All ONFI
N=59 N=58
N=62
N=59 N=179
%
%
%
%
%
Gastrointestinal Disorders
Vomiting
5
9
5
7
7
Constipation
0
2
2
10
5
Dysphagia
0
0
0
5
2
General Disorders and Administration Site Conditions
Pyrexia
3
17
10
12
13
Irritability
5
3
11
5
7
Fatigue
2
5
5
3
5
Infections and Infestations
Upper respiratory
10
10
13
14
12
tract infection
Pneumonia
2
3
3
7
4
Urinary tract infection
0
2
5
5
4
Bronchitis
0
2
0
5
2
Metabolism and Nutrition Disorders
Decreased appetite
3
3
0
7
3
Increased appetite
0
2
3
5
3
Nervous System Disorders
Somnolence or Sedation
15
17
27
32
26
Somnolence
12
16
24
25
22
Sedation
3
2
3
9
5
Lethargy
5
10
5
15
10
Drooling
3
0
13
14
9
Ataxia
3
3
2
10
5
Psychomotor hyperactivity
3
3
3
5
4
Dysarthria
0
2
2
5
3
Psychiatric Disorders
Aggression
5
3
8
14
8
Insomnia
2
2
5
7
5
Respiratory Disorders
Cough
0
3
5
7
5
a
Maximum daily dose of 5 mg for ≤30 kg body weight; 10 mg for >30 kg
body weight
b
Maximum daily dose of 10 mg for ≤30 kg body weight; 20 mg for >30 kg
body weight
c
Maximum daily dose of 20 mg for ≤30 kg body weight; 40 mg for >30 kg
body weight
Post Marketing Experience: These reactions are reported voluntarily from
a population of uncertain size; therefore, it is not possible to estimate their
frequency or establish a causal relationship to drug exposure. Adverse
reactions are categorized by system organ class. Blood Disorders:
Anemia, eosinophilia, leukopenia, thrombocytopenia; Eye Disorders:
Diplopia, vision blurred; Gastrointestinal Disorders: Abdominal distention;
General Disorders and Administration Site Conditions: Hypothermia;
Investigations: Hepatic enzyme increased; Musculoskeletal: Muscle
spasms; Psychiatric Disorders: Agitation, anxiety, apathy, confusional state,
depression, delirium, delusion, hallucination; Renal and Urinary Disorders:
Urinary retention; Respiratory Disorders: Aspiration, respiratory depression;
MAIN HEADLINE
Skin and Subcutaneous Tissue Disorders: Rash, urticaria, angioedema, and
facial and lip edema.
DRUG INTERACTIONS – Effect of ONFI on Other Drugs: ONFI is a weak
CYP3A4 inducer. As some hormonal contraceptives are metabolized by
CYP3A4, their effectiveness may be diminished when given with ONFI.
Additional non-hormonal forms of contraception are recommended when
using ONFI [see Clinical Pharmacology, Patient Counseling Information].
ONFI inhibits CYP2D6. Dose adjustment of drugs metabolized by CYP2D6
may be necessary [see Clinical Pharmacology]. Effect of Other Drugs on
ONFI: Strong and moderate inhibitors of CYP2C19 may result in increased
exposure to N-desmethylclobazam, the active metabolite of clobazam. This
may increase the risk of dose-related adverse reactions. Dosage adjustment
of ONFI may be necessary when co-administered with strong CYP2C19
inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19
inhibitors (e.g., omeprazole) [see Clinical Pharmacology]. CNS Depressants
and Alcohol: Concomitant use of ONFI with other CNS depressants may
increase the risk of sedation and somnolence [see Warnings and Precautions].
USE IN SPECIFIC POPULATIONS – Pregnancy: Pregnancy Category C. Risk
Summary: There are no adequate and well-controlled studies in pregnant
women. In animal studies, administration of clobazam during pregnancy
resulted in developmental toxicity, including increased incidences of fetal
malformations, at plasma exposures for clobazam and its major active
metabolite, N-desmethylclobazam, below those expected at therapeutic
doses in patients. ONFI should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. Available human
data on the risk of teratogenicity associated with benzodiazepines are
inconclusive. There is insufficient evidence in humans to assess the effect
of benzodiazepine exposure during pregnancy on neurodevelopment.
Administration of benzodiazepines immediately prior to or during childbirth
can result in a syndrome of hypothermia, hypotonia, respiratory depression,
and difficulty feeding. In addition, infants born to mothers who have
taken benzodiazepines during the later stages of pregnancy can develop
dependence, and subsequently withdrawal, during the postnatal period. Data
for other benzodiazepines suggest the possibility of adverse developmental
effects (including long-term effects on neurobehavioral and immunological
function) in animals following prenatal exposure to benzodiazepines at
clinically relevant doses. Data: Animal - In a study in which clobazam
(150, 450, or 750 mg/kg/day) was orally administered to pregnant rats
throughout the period of organogenesis, embryofetal mortality and
incidences of fetal skeletal variations were increased at all doses. The low
effect dose for embryofetal developmental toxicity in rats (150 mg/kg/day)
was associated with plasma exposures (AUC) for clobazam and its major
active metabolite, N-desmethylclobazam, lower than those in humans
at the maximum recommended human dose (MRHD) of 40 mg/day. Oral
administration of clobazam (10, 30, or 75 mg/kg/day) to pregnant rabbits
throughout the period of organogenesis resulted in decreased fetal body
weights, and increased incidences of fetal malformations (visceral and
skeletal) at the mid and high doses, and an increase in embryofetal mortality
at the high dose. Incidences of fetal variations were increased at all doses.
The highest dose tested was associated with maternal toxicity (ataxia and
decreased activity). The low effect dose for embryofetal developmental
toxicity in rabbits (10 mg/kg/day) was associated with plasma exposures
for clobazam and N-desmethylclobazam lower than those in humans at
the MRHD. Oral administration of clobazam (50, 350, or 750 mg/kg/day)
to rats throughout pregnancy and lactation resulted in increased embryofetal
mortality at the high dose, decreased pup survival at the mid and high doses,
and alterations in offspring behavior (locomotor activity) at all doses. The
low effect dose for adverse effects on pre- and postnatal development in
rats (50 mg/kg/day) was associated with plasma exposures for clobazam
and N-desmethylclobazam lower than those in humans at the MRHD.
Pregnancy Registry: To provide information regarding the effects of
in utero exposure to ONFI, physicians are advised to recommend that
pregnant patients taking ONFI enroll in the North American Antiepileptic Drug
(NAAED) Pregnancy Registry. This can be done by calling the toll free number
1-888-233-2334, and must be done by patients themselves or their
caregiver. Information on the registry can also be found at the website
http://www.aedpregnancyregistry.org/. Nursing Mothers: ONFI is excreted
in human milk. Because of the potential for serious adverse reactions in
nursing infants from ONFI, a decision should be made whether to discontinue
nursing or to discontinue the drug, taking into account the importance of the
drug to the mother. Pediatric Use: Safety and effectiveness in patients less
than 2 years of age have not been established. In a study in which clobazam
(4, 36, or 120 mg/kg/day) was orally administered to rats during the juvenile
period of development (postnatal days 14 to 48), adverse effects on growth
(decreased bone density and bone length) and behavior (altered motor
activity and auditory startle response; learning deficit) were observed at the
high dose. The effect on bone density, but not on behavior, was reversible
when drug was discontinued. The no-effect level for juvenile toxicity
(36 mg/kg/day) was associated with plasma exposures (AUC) to clobazam and
its major active metabolite, N-desmethylclobazam, less than those expected at
therapeutic doses in pediatric patients. Geriatric Use: Clinical studies of ONFI
did not include sufficient numbers of subjects aged 65 and over to determine
whether they respond differently from younger subjects. However, elderly
subjects appear to eliminate clobazam more slowly than younger subjects
based on population pharmacokinetic analysis. For these reasons, the initial
dose in elderly patients should be 5 mg/day. Patients should be titrated
initially according to weight to 10-20 mg/day. Patients may be titrated further
to a maximum daily dose of 20 or 40 mg depending on weight, if tolerated
[see Dosage and Administration, Clinical Pharmacology]. CYP2C19
Poor Metabolizers: Concentrations of clobazam’s active metabolite,
N-desmethylclobazam, are higher in CYP2C19 poor metabolizers
than in extensive metabolizers. For this reason, the initial dose in
patients known to be CYP2C19 poor metabolizers should be 5 mg/day.
Dose titration should proceed slowly according to weight to 10-20 mg/day,
and may be titrated further depending on weight to a maximum
daily dose of 20 or 40 mg on day 21 based upon clinical response
[see Dosage and Administration, Clinical Pharmacology].
Renal Impairment: The pharmacokinetics of ONFI were evaluated in patients
with mild and moderate renal impairment. There were no significant differences
in systemic exposure (AUC and Cmax) between patients with mild or moderate
renal impairment and healthy subjects. No dose adjustment is required for
patients with mild and moderate renal impairment. There is essentially no
experience with ONFI in patients with severe renal impairment or ESRD.
It is not known if clobazam or its active metabolite, N-desmethylclobazam, is
dialyzable [see Dosage and Administration, Clinical Pharmacology]. Hepatic
Impairment: ONFI is hepatically metabolized; however, there are limited data
to characterize the effect of hepatic impairment on the pharmacokinetics
of ONFI. For this reason, the initial dose in patients with mild to moderate
hepatic impairment (Child-Pugh score 5-9) should be 5 mg/day. These
patients should be titrated according to weight to 10-20 mg/day, and may be
titrated further depending on weight to a maximum daily dose of 20 or 40 mg
on day 21 based upon clinical response. There is inadequate information
about metabolism of ONFI in patients with severe hepatic impairment.
Therefore no dosing recommendation in those patients can be given
[see Dosage and Administration, Clinical Pharmacology].
DRUG ABUSE AND DEPENDENCE – Controlled Substance: ONFI contains
clobazam which is a Schedule IV controlled substance. Abuse: ONFI
can be abused in a similar manner as other benzodiazepines, such as
diazepam. The pharmacological profile of ONFI is similar to that of other
benzodiazepines listed in Schedule IV of the Controlled Substance Act,
particularly in its potentiation of GABAergic transmission through its action
on GABAA receptors, which leads to sedation and somnolence. The World
Health Organization epidemiology database contains reports of drug abuse,
misuse, and overdoses associated with clobazam. Dependence: In clinical
trials, cases of dependency were reported following abrupt discontinuation
of ONFI. The risk of dependence is present even with use of ONFI at the
recommended dose range over periods of only a few weeks. The risk of
dependence increases with increasing dose and duration of treatment.
The risk of dependence is increased in patients with a history of alcohol or
drug abuse. Withdrawal: Abrupt discontinuation of ONFI causes withdrawal
symptoms. As with other benzodiazepines, ONFI should be withdrawn
gradually [see Dosage and Administration, Warnings and Precautions].
In ONFI clinical pharmacology trials in healthy volunteers, the most common
withdrawal symptoms after abrupt discontinuation were headache, tremor,
insomnia, anxiety, irritability, drug withdrawal syndrome, palpitations,
and diarrhea [see Warnings and Precautions]. Other withdrawal reactions
to clobazam reported in the literature include restlessness, panic attacks,
profuse sweating, difficulty in concentrating, nausea and dry retching,
weight loss, blurred vision, photophobia, and muscle pain and stiffness.
In general, benzodiazepine withdrawal may cause seizures, psychosis, and
hallucinations [see Warnings and Precautions].
OVERDOSAGE – Signs and Symptoms of Overdosage: Overdose and
intoxication with benzodiazepines, including ONFI, may lead to CNS
depression, associated with drowsiness, confusion and lethargy, possibly
progressing to ataxia, respiratory depression, hypotension, and, rarely,
coma or death. The risk of a fatal outcome is increased in cases of combined
poisoning with other CNS depressants, including alcohol. Management of
Overdosage: The management of ONFI overdose may include gastric lavage
and/or administration of activated charcoal, intravenous fluid replenishment,
early control of airway and general supportive measures, in addition to
monitoring level of consciousness and vital signs. Hypotension can be treated by
replenishment with plasma substitutes and, if necessary, with sympathomimetic
agents. The efficacy of supplementary administration of physostigmine
(a cholinergic agent) or of flumazenil (a benzodiazepine antagonist) in ONFI
overdose has not been assessed. The administration of flumazenil in cases of
benzodiazepine overdose can lead to withdrawal and adverse reactions. Its use
in patients with epilepsy is typically not recommended.
Lundbeck
Deerfield, IL 60015, U.S.A.
ONFI is a registered trademark of Lundbeck
December 2014
CLB-L-00009
TABLE OF CONTENTS
Meeting
Information
Friday
December 4
Saturday
December 5
Sunday
December 6
Monday
December 7
Tuesday
December 8
Welcome Letters ..........................................................................................................................................12
Schedule-at-a-Glance ..................................................................................................................................14
Special Interest Group Schedules ..............................................................................................................17
Poster Schedules ..........................................................................................................................................18
Poster Walking Tours....................................................................................................................................18
Scientific Exhibits and Additional Schedules ............................................................................................19
AES at the Annual Meeting ..........................................................................................................................21
AES Special Recognition ..............................................................................................................................25
Award Recipients ..........................................................................................................................................28
AES Strategic Plan ........................................................................................................................................31
Educational Sessions ..................................................................................................................................32
Exhibitors and Exhibit Hall ..........................................................................................................................90
Abstract Author Index ................................................................................................................................103
Supporter Recognition ..............................................................................................................................119
General Information ..................................................................................................................................132
Area Map and Hotels..................................................................................................................................136
Convention Center and Hotel Floor Plans ..............................................................................................137
Epilepsy Specialist Symposium ..................................................................................................................32
29th Annual Advances in the Management of Epilepsy and the Epilepsy Clinic ................................32
Annual Fundamentals of Epilepsy Symposium........................................................................................33
Special Interest Group Meetings ..........................................................................................................34, 35
Spanish Symposium ....................................................................................................................................34
13th Judith Hoyer Lecture ..........................................................................................................................35
Basic Science Skills Workshop ....................................................................................................................36
Special Interest Group Meetings ................................................................................................................37
Presidential Symposium ..............................................................................................................................38
Epilepsy Therapy Symposium ....................................................................................................................39
Investigators’ Workshops ............................................................................................................................40
Translational Research Symposium ..........................................................................................................40
Professionals in Epilepsy Care Symposium ..............................................................................................41
Poster Session 1 ............................................................................................................................................42
ASET LTM Course ........................................................................................................................................53
Investigators’ Workshops ............................................................................................................................53
Investigators' Workshops Poster Sessions ..............................................................................................54
Annual Course ..............................................................................................................................................55
Special Interest Group Meetings ................................................................................................................57
Social Networking Groups ..........................................................................................................................57
Poster Session 2 ............................................................................................................................................58
Special Interest Group Meetings ..........................................................................................................69, 70
Merritt-Putnam Symposium........................................................................................................................70
Lennox and Lombroso Lecture ..................................................................................................................71
Investigators’ Workshops ............................................................................................................................71
FDA Town Hall Update..................................................................................................................................72
Pediatric Epilepsy Highlights Session ........................................................................................................72
Platform Sessions ........................................................................................................................................73
Pediatric State of the Art Symposium........................................................................................................73
Poster Session 3 ............................................................................................................................................75
Special Interest Group Meetings ................................................................................................................85
Hot Topics Symposium ................................................................................................................................86
Scientific Symposium ..................................................................................................................................86
Skills Workshops ..........................................................................................................................................87
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
11
DECEMBER 4 - 8, 2015 www.AeSnet.org
WELCOME TO PHILADELPHIA
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
12
DECEMBER 4 - 8, 2015 www.AeSnet.org
WELCOME LETTER
On behalf of the AES Board of Directors, the Annual
Meeting program committees and the AES staff, it is
my great pleasure to welcome you to Philadelphia
and the 69th AES Annual Meeting!
The AES meeting is an exciting experience for
previous and first-time attendees alike — there is
truly something for everyone regardless of your
professional background or scientific interest. For
many of us, it is also a yearly homecoming, where
we reconnect with our friends, colleagues and
mentors in the epilepsy family. Core to what makes
the AES Annual Meeting so special are the people
and the science.
The people — the distinguished epilepsy professionals attending from more than
65 countries — represent epilepsy’s brightest minds. At this meeting, you’ll find
colleagues from across the care continuum and research spectrum. This
gathering of experts provides an unmatched opportunity for a creative exchange
of ideas that I am confident will be both professionally fruitful and personally
enriching.
For younger professionals considering or entering epilepsy — welcome to the
family. We hope that you will take advantage of the forums, investigators’
workshops, mentoring opportunities and the poster walking tours as some of the
many ways to engage, network and share your ideas with other members of the
field. AES is especially proud to expand our AES Epilepsy Fellows Program to
support 100 clinical and research trainees in epilepsy, including 15 Ph.D. postdocs engaged in epilepsy research.
One of AES’s biggest achievements this year was our reorganization and the move
of the headquarters to Chicago, and this brings a number of new faces to AES. I
encourage all of you to stop by the AES booth and attend the business meeting to
welcome our talented new AES staff members.
The science — the AES Annual Meeting is the place to discover the best science,
newest treatments and most advanced technology solutions. Our meeting
showcases the clinical, basic and translational research that are all essential to
attaining our vision to eradicate epilepsy and its consequences. The scientific
material was carefully selected by the AES Annual Meeting and Scientific Program
Committees from more than 1,500 abstracts covering a wide cross-section of
topics to appeal to any research interest.
I encourage you to download the AES Meeting App where you can access meeting
information, network with fellow attendees, organize your schedule and dig
deeper into the program. See page 16 for information on downloading the App.
I extend a personal invitation to you to join me at this year’s Presidential
Symposium: Getting to Cure – The Challenging Road to Disease Modification and
Prevention for Epilepsy taking place at 8:30 a.m. on Saturday, December 5. It is
exciting to be talking about a cure but getting there will only be possible if we
continue the collaborative spirit that makes our epilepsy community so special.
2015 AeS BOARD OF DIReCTORS
PRESIDENT
Amy Brooks-Kayal, M.D.
FIRST VICE PRESIDENT
Michael D. Privitera, M.D.
SECOND VICE PRESIDENT
Eli M. Mizrahi, M.D.
TREASURER
William D. Gaillard, M.D.
PRESIDENT EmERITUS
Elson L. So, M.D.
BOARD mEmBERS
Gregory K. Bergey, M.D.
Bruce E. Hermann, Ph.D.
Robert Edward Hogan, M.D.
Jack M. Parent, M.D.
Shlomo Shinnar, M.D., Ph.D.
Karen S. Wilcox, Ph.D.
EX-OFFICIO
Eileen M. Murray, MM, CAE
Executive Director
Elinor Ben-Menachem, M.D., Ph.D.
Council on Education
Barbara Dworetzky, M.D.
Council on Clinical Activities
Jaideep Kapur, M.D., Ph.D.
Development Council
Manisha N. Patel, Ph.D.
Research and Training Council
Joseph I. Sirven, M.D.
Communications Council
Carl E. Stafstrom, M.D., Ph.D.
Epilepsy Currents
Sheryl Haut, M.D.
North American Commission / ILAE
Once again welcome and have a great meeting!
Amy Brooks-Kayal, M.D.
President, American Epilepsy Society
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
13
DECEMBER 4 - 8, 2015 www.AeSnet.org
SCHEDULE-AT-A-GLANCE
ThuRSDAy, DeCeMBeR 3
Registration
5:00 p.m. - 7:00 p.m.
7:00 a.m. - 5:00 p.m.
8:30 a.m. - 11:30 a.m.
9:00 a.m. - 3:15 p.m.
12:30 p.m. - 3:00 p.m.
Convention Center - The Bridge, Level 200
FRIDAy, DeCeMBeR 4
Registration
1:30 p.m. - 3:00 p.m.
Convention Center - The Bridge, 200 Level
Epilepsy Specialist Symposium:
Malformations of Cortical Development
and Epilepsy
3:00 p.m. - 3:30 p.m.
3:30 p.m. - 6:00 p.m.
Convention Center - Grand Ballroom A/B
29th Annual Advances in the
management of Epilepsy and the
Epilepsy Clinic
4:00 p.m. - 5:30 p.m.
Marriott - Grand Ballroom, Salon D, Level 5
5:30 p.m. - 6:15 p.m.
Annual Fundamentals of Epilepsy
Symposium: Video-EEG Monitoring
Convention Center - Grand Ballroom A/B
1:00 p.m. - 3:00 p.m.
Fellowship Program Directors
meeting
1:30 p.m. - 3:00 p.m.
Professional Development in AES:
A Program for Junior Members and
Those in Transition
6:00 p.m. - 7:30 p.m.
6:00 p.m. - 7:30 p.m.
Convention Center - Room 204 C
Special Interest Group meetings
See Page 34
Beverage Break
Convention Center - Grand Ballroom A/B Foyer
Spanish Symposium: Frontal Lobe
Epilepsy
Convention Center - Room 204 A/B
13th Judith Hoyer Lecture in Epilepsy
Convention Center - Grand Ballroom A/B
Symposia Break
Convention Center - 12th Street Concourse,
100 Level
Special Interest Group meetings
See Page 35
Basic Science Skills Workshop
Convention Center - Room 202 B
Convention Center - Room 107
6:30 a.m. - 5:00 p.m.
6:30 a.m. - 7:15 a.m.
7:00 a.m. - 8:30 a.m.
8:30 a.m. - 11:45 a.m.
Registration
SATuRDAy, DeCeMBeR 5
Continental Breakfast
Convention Center - 12th Street Concourse,
100 Level
Special Interest Group meetings
See Page 37
Presidential Symposium: Getting to
Cure – The Challenging Road to Disease
Modification and Prevention for Epilepsy
Convention Center - Grand Ballroom A/B
Noon - 6:00 p.m.
Poster Session 1
Noon - 6:00 p.m.
Exhibit Hall: Grand Opening
Noon - 1:00 p.m.
Exhibit Hall: Lunch
2:15 p.m. - 5:00 p.m.
2:30 p.m. - 4:00 p.m.
Convention Center - The Bridge, 200 Level
Convention Center - Exhibit Hall A, 200 Level
Convention Center - Exhibit Hall A, 200 Level
Convention Center - Grand Ballroom A/B
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Investigators’ Workshop #2: Energy
Metabolism and Dynamic Brain States
4:30 p.m. - 5:15 p.m.
Symposia Break
5:30 p.m. - 7:30 p.m.
Translational Research Symposium:
Rigor in Translational Research – Issues,
Experience and Solutions
7:00 p.m. - 10:00 p.m.
Epilepsy Therapy Symposium: What
You Need to Know to Get Your Patient
into the 65% Group!
14
Convention Center - Room 103 A
2:30 p.m. - 4:00 p.m.
5:30 p.m. - 8:00 p.m.
Convention Center - Exhibit Hall A, 200 Level
Investigators’ Workshop #1: Genetics,
Biology and Treatment of the Early Life
Epilepsies
Convention Center - Room 105
Convention Center - Exhibit Hall A, 200 Level
Convention Center - Room 204
Professionals in Epilepsy Care
Symposium: Interprofessional Models
and Collaborative Care
Convention Center - Grand Ballroom A/B
Fourth Annual Wine Tasting and
mixed Company Concert
Philadelphia Center for Architecture
DECEMBER 4 - 8, 2015 www.AeSnet.org
SCHEDULE-AT-A-GLANCE
SunDAy, DeCeMBeR 6
7:00 a.m. - 5:00 p.m.
Registration
8:00 a.m. - 9:00 a.m.
Continental Breakfast Poster Area
8:00 a.m. - 4:00 p.m.
Poster Session 2
8:00 a.m. - 5:00 p.m.
Scientific Exhibits
Convention Center - Exhibit Hall A, 200 Level
10:00 a.m. - 10:30 a.m.
Convention Center - Exhibit Hall A, 200 Level
10:00 a.m. - 4:00 p.m.
ASET LTm Course: Setting Up for
Success in Long Term Monitoring
8:45 a.m. - 4:45 p.m.
Investigators’ Workshops
IW Posters & Boxed Lunch
7:00 a.m. - 5:00 p.m.
7:00 a.m. - 8:30 a.m.
8:00 a.m. - 9:00 a.m.
8:00 a.m. - 2:00 p.m.
8:00 a.m. - 5:00 p.m.
8:45 a.m. - Noon
9:00 a.m. - 10:30 a.m.
10:00 a.m. - 10:30 a.m.
10:00 a.m. - 2:00 p.m.
Noon - 1:00 p.m.
7:00 a.m. - 12:30 p.m.
6:30 a.m. - 7:15 a.m.
7:00 a.m. - 8:30 a.m.
8:45 a.m. - 10:45 a.m.
Noon - 1:00 p.m.
See Page 19
8:30 a.m. - 5:00 p.m.
8:45 a.m. - 5:15 p.m.
10:00 a.m. - 10:30 a.m.
Convention Center - The Bridge, 200 Level
Marriott - Grand Ballroom, Salon A, Level 5
See Page 54
Convention Center - Grand Ballroom A/B
Registration
Special Interest Group meetings
See Page 69
Continental Breakfast Poster Area
Convention Center - Exhibit Hall A, 200 Level
Poster Session 3
Convention Center - Exhibit Hall A, 200 Level
Scientific Exhibits
See Page 19
merritt-Putnam Symposium:
Networks In Epilepsy
3:00 p.m. - 5:00 p.m.
FDA Town Hall Update: Generic
Antiepileptic Drug Bioequivalence in
Epilepsy Patients – From Anecdotes to
Evidence
Convention Center - Exhibit Hall A, 200 Level
5:30 p.m. - 8:00 p.m.
Registration
TueSDAy, DeCeMBeR 8
8:45 a.m. - 10:45 a.m.
Continental Breakfast
11:00 a.m. - 12:30 p.m.
Convention Center - 12th Street Concourse,
100 Level
Special Interest Group meetings
12:30 p.m. - 12:45 p.m.
See Page 85
Hot Topics Symposium: Epilepsy
Updates
12:45 p.m. - 2:15 p.m.
Convention Center - Room 201
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
15
Marriott - Room 302 / 303, Level Three
Investigators’ Workshop Immune and
non-cannonical effects of inflamation in
seizure disorders
4:30 p.m. - 5:30 p.m.
Convention Center - The Bridge, 200 Level
See Page 57
Social Networking Groups
3:00 p.m. - 4:30 p.m.
Exhibit Hall
Exhibit Hall - Lunch
Convention Center - Exhibit Hall A, 200 Level
Lennox and Lombroso Lecture:
Epilepsy and Autism: Bad Luck or Bad
Connectivity?
3:00 p.m. - 5:15 p.m.
Convention Center - Exhibit Hall A, 200 Level
Exhibit Hall - Lunch
Convention Center - Exhibit Hall A, 200 Level
2:15 p.m. - 3:00 p.m.
See Page 70
Convention Center - Exhibit Hall A, 200 Level
Convention Center - Exhibit Hall A, 200 Level
Special Interest Group meetings
3:00 p.m. - 5:15 p.m.
Beverage Break
Convention Center - Exhibit Hall A, 200 Level
Exhibit Hall
6:00 p.m. - 7:30 p.m.
Convention Center - Grand Ballroom A/B
Special Interest Group meetings
Beverage Break
Beverage Break
MOnDAy, DeCeMBeR 7
Convention Center - The Bridge, 200 Level
Convention Center - Grand Ballroom A/B Foyer
3:00 p.m. - 4:00 p.m.
8:00 p.m. - 10:00 p.m.
Annual Course: Epilepsy and the Media
Beverage Break
Convention Center - Grand Ballroom A/B
Convention Center - Room 105
Convention Center - Room 204
Pediatric Epilepsy Highlights Session
Convention Center - Room 103
Platform Sessions: Three Concurrent
Sessions
See Page 74
Symposia Break
Convention Center - Grand Ballroom A/B Foyer
Pediatric State of the Art Symposium:
Death in Children with Epilepsy –
A Different Tragedy Than in Adults
Convention Center - Grand Ballroom A/B
Scientific Symposium: Personalized
Medicine in Epilepsy: A Brave New World
Convention Center - Room 204
Skills Workshops Session One:
Six Concurrent Sessions
See Page 87
Skills Workshops Lunch
Convention Center - 12th Street Concourse,
100 Level
Skills Workshops Session Two:
Six Concurrent Sessions
See Page 87
DECEMBER 4 - 8, 2015 www.AeSnet.org
The Latest
Get the most up-to-date
annual meeting
information.
Find speakers, sessions
and abstracts with
a quick search.
Network with colleagues,
share photos and
rate programs.
The Greatest
Create your personal agenda
by bookmarking sessions.
Access meeting abstracts,
handouts and the virtual
tote bag.
Locate meeting rooms,
exhibitors and event
locations easily.
Download the AES Annual Meeting App
ddut.ch/aes
ddut.ch/aes-web
App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.
SPECIAL INTEREST GROUP SCHEDULES
FRIDAy, DeCeMBeR 4
1:30 p.m. - 3:00 p.m.
SIG: Basic mechanisms and
Neuroscience
1:30 p.m. - 3:00 p.m.
SIG: Neuroendocrinology
1:30 p.m. - 3:00 p.m.
SIG: Neuropsychology
1:30 p.m. - 3:00 p.m.
SIG: SUDEP
6:00 p.m. - 7:30 p.m.
SIG: Children’s Hour
6:00 p.m. - 7:30 p.m.
SIG: Frontal Lobe Epiliepsy
7:00 a.m. - 8:30 a.m.
7:00 a.m. - 8:30 a.m.
7:00 a.m. - 8:30 a.m.
6:00 p.m. - 7:30 p.m.
Convention Center - Room 103 A
SIG: magnetoencephalography
(mEG)/magnetic Source Imaging
(mSI)
Convention Center - Room 103 B/C
Convention Center - Room 104 A
6:00 p.m. - 7:30 p.m.
SIG: Neuropharmacology
Convention Center - Room 105
6:00 p.m. - 7:30 p.m.
SIG: Tuberous Sclerosis
Convention Center - Room 108
6:00 p.m. - 7:30 p.m.
SIG: Tumor Induced Epilepsy
Convention Center - Room 108
Convention Center - Room 105
Convention Center - Room 107
Convention Center - Room 104 A
Convention Center - Room 103 A
SATuRDAy, DeCeMBeR 5
SIG: Cognitive and Behavioral
Interventions for Epilepsy
7:00 a.m. - 8:30 a.m.
Convention Center - Room 107
7:00 a.m. - 8:30 a.m.
SIG: EEG
Convention Center - Room 105
SIG: Nursing
7:00 a.m. - 8:30 a.m.
Convention Center - Room 104 A
SunDAy, DeCeMBeR 6
SIG: Private Practice Epilepsy
Convention Center - Room 103 A
SIG: Sleep and Epilepsy
Convention Center - Room 104 B
SIG: Temporal Lobe Club
Convention Center - Room 103 B/C
6:00 p.m. - 7:30 p.m.
SIG: Dietary Therapies for Epilepsy
6:00 p.m. - 7:30 p.m.
SIG: Neuroimaging
6:00 p.m. - 7:30 p.m.
SIG: Global Pregnancy Registry
Outcomes
6:00 p.m. - 7:30 p.m.
SIG: Psychogenic Nonepileptic
Seizures (PNES)
6:00 p.m. - 7:30 p.m.
SIG: Hot Topics – Where Are We
Going?
Convention Center - Room 103 A
Convention Center - Room 105
Convention Center - Room 103 B/C
Convention Center - Room 107
Convention Center - Room 108
MOnDAy, DeCeMBeR 7
7:00 a.m. - 8:30 a.m.
SIG: Critical Care Epilepsy
7:00 a.m. - 8:30 a.m.
SIG: Global Health
9:00 a.m. - 10:30 a.m.
SIG: Epidemiology
7:00 a.m. - 8:30 a.m.
SIG: Junior Investigator Workshop:
mentorship
9:00 a.m. - 10:30 a.m.
SIG: Epilepsy and Aging
9:00 a.m. - 10:30 a.m.
SIG: Genetics
9:00 a.m. - 10:30 a.m.
SIG: NINDS and Non-Profit Research
Resources
7:00 a.m. - 8:30 a.m.
7:00 a.m. - 8:30 a.m.
7:00 a.m. - 8:30 a.m.
7:00 a.m. - 8:30 a.m.
7:00 a.m. - 8:30 a.m.
7:00 a.m. - 8:30 a.m.
Convention Center - Room 105
Convention Center - Room 104 B
Convention Center - Room 104 A
SIG: Pediatric Case Discussions
Convention Center - Room 103
SIG: Psychosocial Comorbidities
Convention Center - Room 108 A
SIG: Ictal Semiology
TueSDAy, DeCeMBeR 8
7:00 a.m. - 8:30 a.m.
Convention Center - Room 108
SIG: Neonatal Seizures
7:00 a.m. - 8:30 a.m.
SIG: Neurostimulation and
Neuroengineering
7:00 a.m. - 8:30 a.m.
Convention Center - Room 103 A
Convention Center - Room 105
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
17
SIG: Surgery
Convention Center - Room 107
Convention Center - Room 108 A
Convention Center - Room 105
Convention Center - Room 107
Convention Center - Room 104 A
SIG: Post-traumatic Epilepsy
Convention Center - Room 103 C
SIG: Practice management
Convention Center - Room 104 A
SIG: Quality, Value and Safety
Convention Center - Room 104 B
DECEMBER 4 - 8, 2015 www.AeSnet.org
POSTER SCHEDULES
For complete Abstract Author Index, see pages 103 - 118.
POSTeR SeSSIOn 1
POSTeR SeSSIOn 3
Saturday, December 5
Monday, December 7
Noon – 6:00 p.m. – Convention Center, Hall A, 200 Level
See pages 42-52
Authors Present: Noon – 2:00 p.m.
Poster Walking Tours: 12:15 p.m. – 1:45 p.m.
Professionals in Epilepsy Care ..................................1.001 – 1.016
Neurophysiology ..........................................................1.017 – 1.073
Clinical Epilepsy ............................................................1.074 – 1.137
Neuroimaging ................................................................1.138 – 1.174
Comorbidity (Somatic and Psychiatric) ..................1.175 – 1.181
Antiepileptic Drugs ......................................................1.182 – 1.240
Non-AED/Non-Surgical Treatments ........................1.241 – 1.251
Surgery ............................................................................1.252 – 1.278
Behavior / Neuropsychology / Language ..............1.279 – 1.300
Genetics ..........................................................................1.301 – 1.320
Health Services ..............................................................1.321 – 1.342
Neuropathology of Epilepsy ......................................1.343 – 1.352
Practice Resources ......................................................1.353 – 1.359
Epidemiology..................................................................1.360 – 1.370
Public Health ..................................................................1.371 – 1.377
History of Epilepsy ........................................................1.378 – 1.379
Case Studies ..................................................................1.380 – 1.394
8:00 a.m. – 2:00 p.m. – Convention Center, Hall A, 200 Level
See pages 75-84
Authors Present: Noon – 2:00 p.m.
Poster Walking Tours: 12:15 p.m. – 1:45 p.m.
Translational Research ................................................3.001 – 3.109
Neurophysiology ..........................................................3.110 – 3.150
Clinical Epilepsy ............................................................3.151 – 3.203
Neuroimaging ................................................................3.204 – 3.231
Comorbidity (Somatic and Psychiatric) ..................3.232 – 3.244
Antiepileptic Drugs ......................................................3.245 – 3.275
Non-AED/Non-Surgical Treatments ........................3.276 – 3.282
Surgery ............................................................................3.283 – 3.309
Behavior / Neuropsychology / Language ..............3.310 – 3.331
Genetics ..........................................................................3.332 – 3.347
Health Services ..............................................................3.348 – 3.356
Neuropathology of Epilepsy ......................................3.357 – 3.364
Epidemiology..................................................................3.365 – 3.375
Public Health ..................................................................3.376 – 3.381
Case Studies ..................................................................3.382 – 3.395
POSTeR SeSSIOn 2
POSTeR WAlkIng TOuRS
Sunday, December 6
Beginning at 12:15pm on Saturday, Sunday and
monday
8:00 a.m. – 4:00 p.m. – Convention Center, Hall A, 200 Level
See pages 58-68
Authors Present: Noon – 2:00 p.m.
Poster Walking Tours: 12:15 p.m. – 1:45 p.m.
Translational Research ................................................2.001 – 2.100
Neurophysiology ..........................................................2.101 – 2.128
Clinical Epilepsy ............................................................2.129 – 2.197
Neuroimaging ................................................................2.198 – 2.222
Comorbidity (Somatic and Psychiatric) ..................2.223 – 2.237
Antiepileptic Drugs ......................................................2.238 – 2.288
Non-AED/Non-Surgical Treatments ........................2.289 – 2.296
Surgery ............................................................................2.297 – 2.323
Behavior / Neuropsychology / Language ..............2.324 – 2.346
Genetics ..........................................................................2.347 – 2.363
Neuropathology of Epilepsy......................................................2.364
Practice Resources ......................................................2.365 – 2.370
Epidemiology ....................................................2.371 – 2.381, 2.396
Case Studies ..................................................................2.382 – 2.395
Convention Center – Exhibit Hall A, 200 Level
Join AES leaders and visit interesting, compelling or novel
posters and discuss different perspectives on the data
presented.
Gather at the information table near the front of the
Poster Hall. A schedule of topics and tour leaders will be
available.
Poster Session 1: Saturday, December 5
Tour Leaders: Steve Roper, M.D., Andres Kanner, M.D.,
Jean Gotman, Ph.D., Joseph Sirven, M.D. and Tallie Z.
Baram, M.D., Ph.D.
Poster Session 2: Sunday, December 6
Tour Leaders: Jackie French, M.D., Ilo Leppik, M.D., David
Prince, M.D., Bruce Hermann, Ph.D and Andrew Cole,
M.D.
Poster Session 3: monday, December 7
Sunday, December 6
Tour Leaders: Anne Anderson, M.D., Greg Bergey, M.D.,
Dennis Spencer, M.D., Kimford Meador, M.D. and Eric
Kossoff, M.D.
Please note: Poster tour leaders are subject to change
Investigators’ Workshop lunch Poster Session noon – 1:30 p.m.
Convention Center, 12th Street Concourse,
Room 104, 100 Level (see page 54)
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
18
DECEMBER 4 - 8, 2015 www.AeSnet.org
SCIENTIFIC EXHIBITS AND ADDITIONAL SCHEDULES
exhibit hall
Scientific exhibits
Scientific exhibits will be on display at this year’s Annual
Meeting and will be located in Rooms 201 (A, B, and C) and
202 (A and B) on the 200 Level of the Pennsylvania
Convention Center. These exhibits will provide meeting
attendees an opportunity to update themselves on the latest
research. Authors will be present throughout the exhibit.
Saturday, December 5
Noon – 6:00 p.m.
Sunday, December 6
10:00 a.m. – 4:00 p.m.
monday, December 7
10:00 a.m. – 2:00 p.m.
SunDAy, DeCeMBeR 6 | 8:00 a.m. - 11:00 a.m.
Cyber Café
Lundbeck
Research Updates on Clobazam and Vigabatrin: Maintaining
Lundbeck's Partnership in Epilepsy
Convention Center - Room 201 B
Open during Exhibit Hall hours
The Cyber Café will be available during Exhibit Hall hours at
the Convention Center providing email access, Internet access
and a printer. You will also be able to complete the course
evaluations and obtain your CME certificate online. For your
convenience, complimentary Wi-Fi will be available in the
concourses and public areas of the Convention Center.
Sunovion Pharmaceuticals Inc.
Aptiom® (eslicarbazepine acetate) Scientific Exhibit
Convention Center - Room 201 A
UCB, Inc.
Continuing UCB’s Long-Term Commitment to Epilepsy
Management
Convention Center - Room 201 C
Meals and Breaks
During Exhibit Hall hours
SunDAy, DeCeMBeR 6 | 2:00 p.m. - 5:00 p.m.
Saturday, December 5
Lunch: Noon - 1:00 p.m.
Beverage Break: 3:00 p.m. - 3:30 p.m.
Symposia Break: 4:30 p.m. - 5:15 p.m.
marinus Pharmaceuticals, Inc.
Ganaxolone: A Novel Therapeutic for the Treatment of Epilepsy
Convention Center - Room 201 A
medtronic
Medtronic DBS and Visualase Laser Ablation: Research and
Technology Update
Convention Center - Room 201 B
Sunday, December 6
Beverage Break: 10:00 a.m. - 10:30 a.m.
Lunch: Noon - 1:00 p.m. Exhibit Hall
Beverage Break: 3:00 p.m. - 4:00 p.m.
Eisai Inc.
Research Updates for Perampanel
Convention Center - Room 201 C
monday, December 7
Beverage Break: 10:00 a.m. - 10:30 a.m.
Lunch: Noon - 1:00 p.m.
SunDAy, DeCeMBeR 6 | 8:00 a.m. - 5:00 p.m.
EQUIGEN
Equivalence Among Generic Antiepileptic Drugs (EQUIGEN and
BEEP): Research Funded by FDA, AES, and Epilepsy Foundation
Convention Center - Room 202 B
MOnDAy, DeCeMBeR 7 | 8:00 a.m. - 11:00 a.m.
Upsher-Smith Laboratories, Inc.
Pipeline Update: Enhancing Proven Therapies Through Novel
Formulation and Delivery
Convention Center - Room 201 B
Zogenix, Inc.
History of the Use of Low-dose Fenfluramine in Pediatric
Epilepsy: An Intriguing Past, Present, and Future
Convention Center - Room 202 A
MOnDAy, DeCeMBeR 7 | 8:00 a.m. - 5:00 p.m.
EQUIGEN
Equivalence Among Generic Antiepileptic Drugs (EQUIGEN and
BEEP): Research Funded by FDA, AES, and Epilepsy Foundation
Convention Center - Room 202 B
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
19
DECEMBER 4 - 8, 2015 www.AeSnet.org
Show You Care
Twice
Give the Community of Caring Pin to someone
special — a colleague, collaborator, mentor or friend.
The second benefit: all proceeds support research and
education through the AES New Initiatives Fund.
Community of Caring Pins are available for
purchase at the AeS Booth #317.
Enter to win giftcards, electronics and more with
PASSPoRT To PRIZES. Just visit select Exhibitors, get
your "passport" stamped and enter — it's that easy.
look for your PASSPORT TO PRIZeS in the
Annual Meeting Registration Bag.
EEG MACHINE BECOMES RESEARCH DOLLARS
FOR AMERICAN EPILEPSY SOCIETY
For seven years, Nihon Kohden has pioneered a unique giving program by auctioning off its EEG-1200
machine and donating 100% of the proceeds to the Lennox and Lombroso Trust for Research &
Training and the Susan S. Spencer Fund for Education and Research.
This year, Sentara Healthcare of Hampton Roads, Virginia
is the EEG-1200 Auction winner at $28,176.84.
Nihon Kohden executives will present a check to the American Epilepsy Society
on Saturday, December 5 on the floor of the Exhibit Hall.
AeS thanks nihon kohden Booth #727 for their continued support and for again
participating in the annual equipment auction.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
20
DECEMBER 4 - 8, 2015 www.AeSnet.org
AES AT THE ANNUAL MEETING
AeS Booth
Convention Center - Exhibit Hall A,
200 Level
All Annual Meeting attendees are
encouraged to visit the AES Booth #317.
Come by to:
• Get assistance with the AES Annual
Meeting App
• Show your professional connection
with the purchase of an AES necktie,
bowtie or scarf
• Recognize a colleague with a
Community of Caring Pin
for people living with epilepsy. The
process is easy: a professional
interviewer will be on hand to facilitate
the discussion.
Member stories will be shared
throughout 2016 in AES communications.
Booth #443
Open during Exhibit Hall hours.
4th Annual AeS Wine event
Saturday, December 5
7:00 p.m. - 10:00 p.m.
• Learn more about joining our dynamic
Philadelphia Center for Architecture
community 4,000 members — and
(Directly Across from Convention Center)
counting — strong
The popular AES event returns with a
• Take a breather to catch up with
twist: along with extraordinary wines
colleagues — loitering is encouraged
and culinary specialties, enjoy the
Booth #317
eclectic sounds of Mixed Company,
Open during Exhibit Hall hours.
Yale’s premier a cappella group.
American epilepsy Society
Dedicated to eradicating epilepsy
and its consequences.
The American Epilepsy Society is a
medical and scientific society
whose members are engaged in
research and clinical care for
people with epilepsy. For more
than 75 years, AES has provided a
dynamic global forum where
professionals from academia,
private practice, not-for-profit,
government and industry can
learn, share and grow.
www.AESnet.org
Executive Office
135 South LaSalle Street
Suite 2850
Chicago, IL 60603
Tel: 312-883-3800
Proceeds from the AES Wine Event
benefit AES research.
everyday excellence
in epilepsy
Convention Center - Exhibit Hall A,
200 Level
New for 2015: AES is hosting a second
booth in the Exhibit Hall dedicated to
capturing your professional experiences.
Come to Booth #443 and share your
unique story with AES — the ways, big
and small, you’re working to improve lives
General Tasting Tickets: Sample more
than 12 exceptional wines from all over
the world paired with choice cheeses
and innovative hors d'oeuvre............$175
Additional Sommelier Experience
Tickets: Add on a sommelier experience
in the special tasting room featuring rare
and exceptional wines by the glass. This
is in lieu of an auction ............................$30
Tickets are available onsite in the
registration area and at AES Booth #317.
official Annual Meeting Hashtag
#AeSmtg15
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
21
DECEMBER 4 - 8, 2015 www.AeSnet.org
Share Your Story
With Our Community
your work helps improve the lives of people with epilepsy every day. Tell your
personal story at Booth #443 — about clinical care, research, mentoring and
more — to help raise awareness in our community and beyond.
Experience matters: please share yours with AES.
BOOTh #443
Everyday Excellence in Epilepsy is an AES initiative to recognize
and relate the important work of professionals dedicated to the
prevention, treatment and cure of epilepsy.
Supported by Sunovion Pharmaceuticals Inc.
SUPPORTER RECOGNITION
69TH ANNUAL MEETING
AeS recognizes the following companies for supporting the 2015 Annual Meeting.
BeneFACTOR leVel | $500,000+
Sunovion Pharmaceuticals Inc.
leADeR leVel | $250,000 - $499,999
Eisai Inc.
Lundbeck
UCB, Inc.
PARTneR leVel | $100,000 - $249,999
Upsher-Smith Laboratories, Inc.
Supernus Pharmaceuticals, Inc.
SuPPORTeR leVel | $50,000 - $99,999
LivaNova
Cadwell Industries, Inc.
Acorda Therapeutics
GW Pharmaceuticals
Pfizer, Inc
COnTRIBuTOR leVel | $25,000 - $49,999
Nihon Kohden America, Inc.
Aprecia Pharmaceuticals Company
Compumedics
Sage Therapeutics
ADVOCATe leVel | $10,000 - $24,999
MedTech Surgical
Medtronic
Electrical Geodesics, Inc.
NeuroPace, Inc.
Lifelines Neurodiagnostics Systems, Inc.
Elekta, Inc.
Marinus Pharmaceuticals, Inc
Natus Neurology Incorporated
Rhythmlink International, LLC
Moberg ICU Solutions
Blackrock NeuroMed, LLC
PATROn leVel | $5,000 - $9,999
PMT Corporation
Medical Neurogenetics, LLC
Neuralynx, Inc.
Monteris Medical, Inc.
Nexstim, Inc.
The Jack Pribaz Foundation
Texas Children's Hospital
Transgenomic, Inc.
Mallinckrodt Pharmaceuticals, Inc.
Ad-Tech Medical Instrument Corp.
Persyst Development Corporation
Tuberous Sclerosis Alliance
Athena Diagnostics, Inc.
GeneDx
Brain Sentinel, Inc.
MoBÉ
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
23
DECEMBER 4 - 8, 2015 www.AeSnet.org
Experience AES
Join our vibrant community, 4,000 members strong
To eradicate epilepsy and its consequences — that’s the vision
of the American Epilepsy Society. AES serves as a resource for
members, as a champion of research and as a conduit for the
entire epilepsy community.
AES supports:
• Interdisciplinary exchange: through meetings,
volunteer opportunities and our online community,
AES Connect
• Clinical excellence: through educational programs
and our journal Epilepsy Currents
Find out more about AES Membership:
• Scientific excellence: through grant support,
resource creation and mentoring
AES Exhibit
Booth #317
AES Online
www.AESnet.org
• Collaboration: through organization-to-organization relationships with groups like Epilepsy
Foundation, International League Against Epilepsy,
the Epilepsy Leadership Council, NINDS and more.
During Exhibit Hall Hours
Click on Membership Tab
AES member benefits include:
• Epilepsy Currents, a commentary and literature
review journal from AES
• Epilepsia, research journal of the International
League Against Epilepsy*
• Discounts to meetings and programs, including the
Annual Meeting
• Listing in Find-A-Doctor online directory*
• AES Connect, our online, members-only community
for networking and exchange
• Research funding opportunities
• Scholarships and awards
• AES Connect email newsletter
135 South LaSalle Street, Suite 2850, Chicago, IL 60603 | P: 312.883.3800
www.AESnet.org
*Benefit of select member categories
AES SPECIAL RECOGNITION
DISTINGUISHED SERVICE
AWARD
Established in 1993, this award recognizes
outstanding service by an AES member in the
field of epilepsy (including non-educational and
non-scientific) with emphasis on exemplary
contributions to the mission of the American
Epilepsy Society and its members. A $1,000
honorarium is included with this award.
Friday, December 4, 4:00 p.m.
prior to the Judith Hoyer Lecture
Convention Center, Grand Ballroom A/B
Page B. Pennell, M.D.
Dr. Page B. Pennell is
Professor of Neurology
at Harvard Medical
School and Director of
Research for the
Division of Epilepsy at
Brigham and Women’s
Hospital, with a
secondary appointment
in the Division of
Women’s Health. She is
a clinician investigator with a focus on sexspecific research in epilepsy. Dr. Pennell’s
current research studies focus on the effects of
neurosteroids on seizure provocation,
pharmacokinetic changes of AEDs with differing
reproductive phases, and maternal and fetal
outcomes during pregnancy in women with
epilepsy. She is currently one of the multipleprincipal investigators of the “Women with
Epilepsy: Pregnancy Outcomes and Deliveries
(WEPOD)” study funded by the Epilepsy
Foundation, and the “Maternal Outcomes and
Neurodevelopmental Effects of AEDs
(MONEAD)”, study funded by NIH, NINDS and
NICHD.
Dr. Pennell’s volunteer efforts have focused on
improving the medical care of people with
epilepsy. She has served as Chair of the
Professional Advisory Board of the Epilepsy
Foundation and as Director of the Clinical
Epilepsy and the Neurologic Complications in
Pregnancy courses at the annual meeting of
the American Academy of Neurology. She
participated in the three-part AAN/AES Practice
Parameter update on management issues for
women with epilepsy.
Within AES, Dr. Pennell has served on the
Board of Directors as well as Chair of the
Council for Clinical Activities, Practice
Committee, Clinical Therapeutics Committee,
and Pregnancy Outcomes SIG. She has served
as a member of the Council on Education,
Annual Course Committee, CME Review
Committee Guidelines Task Force Research
Award Subcommittees. She has enjoyed
sharing her passion for academic epilepsy by
serving as a mentor in the AES Junior
Investigators Mentoring program, the AES
Fellows program, and the EpiPORT clinical
research training program. She is currently the
Clinical Associate Editor for Epilepsy Currents,
the official journal of AES.
EXTRAORDINARY
CONTRIBUTION AWARD
This award is one of the American Epilepsy
Society’s highest honors, presented in
recognition of exceptional service and
contributions to the field. It is usually
suggested by the Board of Directors, and is
intended to recognize extraordinary
contributions across multiple fronts, including
science, education, leadership, and advocacy.
Friday, December 4, 4:00 p.m.
prior to the Judith Hoyer Lecture
Convention Center, Grand Ballroom A/B
Story Landis, Ph.D.
Dr. Story Landis received her undergraduate degree from
Wellesley College and
her Ph.D. from Harvard University. After
postdoctoral work at
Harvard University, she
served on the faculty
of the Department of
Neurobiology there. In
1985, she joined the faculty of Case Western
Reserve University School of Medicine, where
she created the Department of Neurosciences
that, under her leadership, achieved an international reputation for excellence.
Dr. Landis joined the National Institute of
Neurological Disorders and Stroke in 1995 as
Scientific Director and worked to re-engineer
the lnstitute's intramural research program
and fostered the growth of a trans-NIH neuroscience community that led to the construction of the Porter Neuroscience Building
on the NIH campus. From 2003 to 2014, Dr.
Landis served as the Director of NINDS, overseeing an annual budget of $1.6 billion that
supported research by investigators in its intramural program and public and private institutions across the country. Together with
NIMH and NIA directors, she co-chaired the
NIH Blueprint for Neuroscience Research, a
roadmap-like effort to support trans-NIH activities in the brain sciences. In 2013 and
2014, she and Dr. Tom Insel played a key role
in launching the NIH BRAIN Initiative.
Dr. Landis currently serves on the Scientific
Advisory Boards of the Allen Institute for Brain
Science, the Vollum Institute at Oregon Health
Sciences University and the Neurological Research Institute at Baylor College of Medicine
and the Scientific Review Board of the Howard
Hughes Medical Institute.
Throughout her research career, Dr. Landis
made fundamental contributions to the understanding of how functionally appropriate
synapses form during development and the
role of neurotrophins in peripheral nervous
system. She is an elected fellow of the Institute of Medicine, the Academy of Arts and
Sciences and the American Association for
the Advancement of Science, and in 2002
was elected President of the Society for Neuroscience.
AMERICAN EPILEPSY SOCIETY 69TH ANNUAL MEETING
25
J. KIFFIN PENRY AWARD FOR
EXCELLENCE IN EPILEPSY CARE
This award, originally funded by Abbott
Laboratories, was established in 1997. The
award honors Dr. Penry’s lifelong focus on and
genuine concern for the patient with epilepsy,
by recognizing individuals whose work has had
a major impact on patient care and improved
the quality of life for persons with epilepsy as
well as recognizing excellence in the care of
persons with epilepsy. The award includes a
$3,000 honorarium.
Saturday, December 5, 2:15 p.m. prior to
Epilepsy Therapy Symposium
Convention Center, Grand Ballroom A/B
Donald L. Schomer, M.D.
Dr. Donald L. Schomer
was recruited by
Norman Geschwind and
Marc Dichter in 1980 to
establish a comprehensive epilepsy
program at Beth Israel
Deaconess Medical
Center (BIDMC) of
Harvard Medical School.
In 1982, Dr. Schomer
then recruited Patricia Shafer, RN, to join him
and establish a dedicated nursing program. In
1984 he started a fellowship program where
Steve Schachter, Jeff Buchhalter and Frank
Drislane were his first three fellows. Dr.
Schomer has now trained 46 fellows and postdoctorates, many of whom are senior clinicians
here and around the world.
Dr. Schomer, a founding member of NAEC, has
consistently managed BIDMC as a Level 4
center. He was the President of the American
Clinical Neurophysiology Society and Chair,
Board of Clinical Neurophysiology for five years.
He has been an active member of AES since
1980 and now serves as a member of the
“Oversight Committee” of the ILAE’s Diagnostic
Methods Committee. He also serves on the
Education Committee for the IFCN. He has also
served on numerous occasions as a member of
the External Committee for the Nobel Prize in
Medicine or Physiology.
Dr. Schomer is a Professor of Neurology at
Harvard and permanent member of their Subcommittee of Professors. He, along with
Fernando Lopes da Silva, are Editors of
Niedermeyer Textbook of Clinical Neurophysiology,
VIth and VIIth Eds. He also serves on numerous
Editorial Boards and is currently Associate Editor
of the Annals of Neurology, overseeing
submissions dealing with central neurophysiology
or epilepsy. He has four children; two sons are
epileptologists, one at UCONN and one at
University of Virginia. One son, a basic scientist,
runs a lab at the Koch Institute/MIT and his
daughter is in clinical trials in Neurology at Brown.
Dr. Schomer is most proud of the
accomplishments of his many fellows and his
children. Additionally, he enjoys salmon fishing in
the Alaskan wilderness and nights out with his
wife, Mary, but not in that order.
DECEMBER 4 - 8, 2015 www.AESnet.org
AES SPECIAL RECOGNITION
ReSeARCh ReCOgnITIOn AWARDS
The American Epilepsy Society Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy
research. The awards are designed to recognize professional excellence reflected in a distinguished history of research of important promise for
the improved understanding and treatment of epilepsy. The awards of $10,000 each are part of the AES grant and fellowship program.
AWARD FOR BASIC SCIenCe
AWARD FOR ClInICAl SCIenCe
Convention Center, Grand Ballroom A/B
Convention Center, Grand Ballroom A/B
monday, December 7, 8:45 a.m. prior to the
merritt-Putnam Symposium
monday, December 7, 8:45 a.m. prior to the
merritt-Putnam Symposium
kevin Staley, M.D.
Brian litt, M.D.
Dr. Kevin Staley is the Joseph P. and Rose F.
Kennedy Professor of Child Neurology and
Mental Retardation at Harvard Medical School,
and chief of the section of pediatric neurology
at Massachusetts General Hospital. Dr. Staley
trained in physics as an undergraduate at
Loyola Marymount University, and in medicine
and pediatric neurology at the University of
California, San Diego. Dr. Staley studied the
electrophysiology of epilepsy with Istvan Mody and David Prince at
Stanford. He co-chaired the inaugural Gordon Conference on
Mechanisms of Epilepsy, the 2013 NINDS Curing Epilepsy conference
and the AES Investigator Workshop and Research and Training
Committees. He currently chairs the NINDS Board of Scientific
Counselors. Dr. Staley was granted an NINDS Javits award this year.
Dr. Litt received an A.B. in Engineering and
Applied Science from Harvard University, a M.D. and neurology training at
Johns Hopkins University School of Medicine. Dr. Litt did a post-doctoral
fellowship at the Hopkins Applied Physics Laboratory and has held faculty
appointments at Johns Hopkins, Emory University and Georgia Institute
of Technology prior to coming to Penn. Dr. Litt’s research focuses on
NeuroEngineering, specifically hardware, algorithms, machine learning,
high speed computing for implantable devices. His laboratory translates
basics into new diagnostic and therapeutic technologies.
Dr. Staley and his outstanding trainees study “neuronal plumbing” —
how neurons move ions to create the differences in concentration
that drive the membrane currents underlying neurotransmitter
signaling. The lab has focused on GABA, a neurotransmitter that
sometimes excites neurons instead of inhibiting them. The conditions
under which this occurs is important for the treatment of epilepsy,
because many anticonvulsants enhance GABA signaling. The lab’s
research in this area has led to the proposed use of the diuretic
bumetanide to augment the treatment of neonatal seizures, currently
the subject of a multicenter trial (clinicaltrials.gov #NCT00830531).
Dr. Litt’s honors and awards include Dana and Klingenstein Foundation
Fellowships in Neuroscience, a Whitaker Foundation Fellowship in
Bioengineering, the American Academy of Neurology’s Dreifuss-Penry
Award for epilepsy research, the Scientific Innovations Award from the
Brain Research Foundation, and the NARSAD Distinguished Investigator
Award from the Brain and Behavior Research Foundation. He is the 2013
winner of Penn’s Luigi Mastroianni Clinical Innovator Award.
Dr. Litt serves on the editorial board of Science Translational Medicine and
is an advisor to the Obama BRAIN Initiative Panel. He holds a substantial
portfolio of patents, and has contributed to or co-founded several device
companies. His collaboration and advising relationships include
Blackfynn, Medtronic, NeuroPace, MC10, Cyberonics, IntelliMedix and
NeuroVista.
Most recently the lab has discovered the intriguing possibility that the
enormous variability in the anionic content of the brain’s extracelluar
matrix (the gelatin between cells) may actually be used to store
experiential information that is read out by anion currents flowing
through local GABA receptors. Disruption of this matrix by brain injury
may contribute to the ionic disequilibria that result in early seizures
and cytotoxic edema. These studies have been facilitated by the
optimization of a “chronic epilepsy in a dish” preparation that is also
being used to discover anticonvulsants that are uniquely active in
chronic epilepsy.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Dr. Brian Litt is Professor of Neurology,
Neurosurgery and Bioengineering at the
University of Pennsylvania. He divides his time
equally between separate tenured appointments
in the Schools of Medicine and Engineering,
directing both the Penn Epilepsy Center, and
Penn’s Center for Neuroengineering and
Therapeutics.
26
DECEMBER 4 - 8, 2015 www.AeSnet.org
AES SPECIAL RECOGNITION
lennOX AnD lOMBROSO leCTuReR
WIllIAM g. lennOX AWARD
This award, established in 1966, recognizes members of the society,
usually at a senior level, who have a record of lifetime contributions and
accomplishments related to epilepsy. The $10,000 award is funded by
the Lennox and Lombroso Trust Fund established in 1962 to advance
and disseminate knowledge concerning epilepsy in all of its aspects —
biological, clinical and social — and to promote better care and
treatment for persons with epilepsy.
monday, December 7, 2:15 p.m. - 3:00 p.m. Lennox and
Lombroso Lecture: Epilepsy and Autism — Bad Luck or
Bad Connectivity?
Convention Center, Grand Ballroom A/B
gregory l. holmes, M.D.
Dr. Gregory L. Holmes is the Chair of the
Department of Neurological Sciences at
the University of Vermont (UVM) College
of Medicine and Professor of
Neurological Sciences and Pediatrics.
Prior to his tenure at UVM, Dr. Holmes
served as Professor and Chair of the
Department of Neurology at the Geisel
School of Medicine at Dartmouth from
2002-2013 and as Professor of Neurology and Director of
Clinical Neurophysiology at Harvard Medical School from 19882002.
monday, December 7, 8:45 a.m. prior to the
merritt-Putnam Symposium
Convention Center, Grand Ballroom A/B
Christian e. elger, M.D., Ph.D., FRCP
Dr. Christian E. Elger is a Professor of
Epileptology and the Director of the Department
of Epileptology at the University of Bonn in
Germany. He received his degree in medicine
from the University of Münster and while there
obtained his education in Physiology and then
Neurology. Later, he became a Professor of
Epileptology at the University of Bonn.
Dr. Holmes received his medical degree from the University of
Virginia School of Medicine; he completed his pediatric training
at Yale University and neurology training at the University of
Virginia. He is a pediatric neurologist with both clinical and
research interests in childhood epilepsy and is widely published
as a researcher focusing on the delineation, effects and
treatment of pediatric/developmental epilepsy. He has over
380 peer-reviewed publications and hundreds of review
articles, chapters and books.
Dr. Elger was instrumental in transforming the
small Epileptology Department in Bonn into a department in which
neurologists, neuropsychologists and basic scientists could work
together in pursuit of new developments in epilepsy surgery and human
brain research. The epilepsy center has one of the most active epilepsy
surgery programs within Europe. Dr Elger is renowned for his role in
studying seizure prediction and his pioneering work within the field of
epilepsy and cognition. He was critically involved in developing
presurgical evaluation techniques which enable the prediction of
postsurgical cognitive outcome. His vision involves the use of epilepsy as
a window to human brain function and, within this context, he founded
the Center for Economics and Neuroscience in Bonn.
In addition to being active in professional society and hospital
committees, Dr. Holmes has served on the editorial boards of
10 epilepsy and neurology journals and has served on multiple
NIH study sections. He has also reviewed grants from around
the world including Canada, Israel, Australia, France, the UK and
Belgium.
He is widely published in highly-ranked journals and has over 700 peerreviewed, PubMed referenced publications and an H-factor of over 80.
He also served as Associate Editor for Brain and Epilepsy and Behavior.
Dr. Holmes is past president of the American Epilepsy Society
and has received many honors including the American Epilepsy
Society Research Award, Basic Science Award (1989); Pierre
Gloor Research Award, American Clinical Neurophysiology
Society (2001); Hoyer Lecturer, National Institutes of Health
(2009); and Sachs Lecturer, Child Neurology Society (2009).
From 2010-2012, he was a member of the National Academy of
Science sponsored Committee on the Public Health
Dimensions of the Epilepsies culminating in the book Epilepsy
Across the Spectrum. Dr. Holmes has trained more than 200
residents, graduate students and postdoctoral fellows and has
received numerous teaching awards.
Back in 1983, he was the recipient of the international Stiftung Michael
Prize for his achievements in epilepsy research. In 2005, Dr. Elger
received the Zülch Prize from the Max-Planck-Foundation in recognition
of his scientific studies in experimental epilepsy research and cognition.
Additionally, the ILAE (International League Against Epilepsy) granted him
the Ambassador of Epilepsy award. In 2010, he received the Hans-Berger
Award of the DGKN (Deutsche Gesellschaft für Klinische
Neurophysiologie und Funktionelle Bildgebung) for merit within the field
of electrophysiology in epilepsy. He was presented with The Victor and
Clara Soriano Award at the 20th World Congress of Neurology Meeting
in Marrakesh in 2011. The following year, the ILAE granted him the
European Epileptology Award.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
27
DECEMBER 4 - 8, 2015 www.AeSnet.org
AWARD RECIPIENTS
AES selects recipients for the following travel awards based on the scientific merit of submitted abstracts. Congratulations to this year’s
travel award winners.
SuZAnne AnD PeTeR BeRRy InTeRnATIOnAl TRAVel AWARDeeS
This award recognizes and honors two young investigators conducting clinical neuroscience research related to epilepsy in Asia, Africa, Oceania, the
Middle East or Latin America. Awardees receive $1,000 travel stipend along with complimentary meeting registration.
Contact Author
Abstract Title
Velmurugan Jayabal, M.B.B.S.
Pre-ictal and ictal pathological High Frequency Oscillations (HFOs) in drug
resistant focal epilepsy: Analysis of MEG recording
Vicente Camacho, M.D.
nuRSe TRAVel AWARDeeS
Working memory in TLE patients: correlation between cortical activity and
psychometric evaluations
Poster/Platform
3.221
1.056
This award recognizes and honors outstanding young investigators with nursing degrees who are conducting epilepsy research. Awardees receive a
$1,000 travel stipend.
Contact Author
Abstract Title
Sarah Doerrer, M.S., CPnP
Diet Redux: Outcomes from reattempting dietary therapy for epilepsy a second time
Rachelle Compton, Rn, MSn
The Expected Evolution of a Secondarily Generalized Tonic-Clonic Seizure
Poster/Platform
1.076
1.249
erin Fecske, MSn, Rn, CnRn, CPnP Case of Encephalocraniocutaneous lipomatosis and epileptic spasms
3.386
Megan gustafson, MSn, Rn, CPnP Extension for Community Healthcare Outcomes (ECHO) experience in a level
4 pediatric epilepsy center
eliana kovitch, MSn
Patient characteristics and utility of prolonged video-EEG monitoring in a tertiary
pediatric epilepsy monitoring unit
karen Secore, APRn, CnRn
A Randomized Trial of HOBSCOTCH: HOme Based Self-Management & Cognitive
Training CHanges Lives)
elizabeth Medaugh, CPnP
noreen Thompson, Rn, MSn
Valerie Woodard, Rn
3.380
The Impact of Implementing Epilepsy Education Tools for Nursing Staff in the Pediatric Setting
Psychogenic Non-epileptic Seizures: A Pilot Study of a Brief Educational Intervention
1.023
1.120
1.286
1.279
Comparison of Stereo-EEG and Grid-Implanted Phase II Patients' Experience
Prior to Epilepsy Surgery: the Wake Forest Experience
2.171
yOung InVeSTIgATOR AWARDeeS
This award recognizes young investigators conducting basic, translational, or clinical epilepsy research. Awardees receive a $1,200 travel stipend.
Support for this program is provided by Medtronic, Inc.
Contact Author
Marina Alvim, M.D.
Abstract Title
Comparison of surgical outcome between TLE-HS patients operated with and without
long-term video-EEG monitoring
Poster/Platform
Tufikameni Brima, Ph.D., M.Sc., B.Sc. The efficacy of the mTOR inhibitor Torin1 on spasms in the multiple-hit rat model of infantile spasms
Dario englot, M.D., Ph.D.
Suganya karunakaran, Ph.D.
Sattar khoshkhoo, B.S.
Maneesh kumar, M.D., Ph.D.
Localized interictal spikes on magnetoencephalography predicts seizure freedom in epilepsy surgery
Characterization of Epileptogenic Network Using Endogenous CCEPs
A Novel Optogenetic Mouse Model of Ictogenesis for Investigating the Role of Interneurons
in Seizure Initiation, Propagation, and Termination
2.299
3.062
1.270
3.078
3.042
Altered Metabolism in a Zebrafish Model of Dravet Syndrome
3.017
Duplication is Associated with Severe Epileptic Encephalopathy in The Presence of
Permissive Genetic Background
1.301
Jason lauer, B.S.
Long Term Outcomes after First time and Repeat Resective Surgery in Pediatric Refractory Epilepsy 2.314
Sally Mathias, M.B.B.S.
Incident Epilepsy, Irrespective of Seizure Control, Impairs Quality of Life in the Cognitively
Normal Geriatric Population
Sunita Misra, M.D., Ph.D.
Abnormal cortical network excitability in an animal model of infantile spasms
Dana Marafie, BMBCh
Mindl Messinger, Pharm.D.
lauren Monaco, B.S.
Evaluation of the Prevalence of Pharmacogenetic Polymorphisms in Pediatric Neurology
Patients with Whole Exome Sequencing
Epilepsy Quality Measurement in Resident Teaching Clinic: A Retrospective Review
and a Quality Improvement Plan
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
28
2.154
2.351
3.046
1.354
DECEMBER 4 - 8, 2015 www.AeSnet.org
AWARD RECIPIENTS
Contact Author
Abstract Title
Poster/Platform
Amy Patterson, M.D.
SmartWatch by SmartMonitor: Assessment of Seizure Detection Efficacy for Various Seizure
Types in Children, A Large Prospective Single-Center Study
Mohammad-Reza nazem-Zadeh, Ph.D. DTI Model of mTLE Laterality
Alberto Pauletti, M.D.
Rani Sarkis, M.D., M.Sc.
Meagan Siehr, B.S.
hongyu Sun, M.D., Ph.D.
Rhys Thomas, MB.Ch.B.
Jack Tung, B.S.
1.144
Anti-oxidant drugs resolve oxidative stress and preclude disulfide-HMGB1 formation
in the hippocampus after status epilepticus: implications for neuroprotection and epileptogenesis
1.355
2.014
Sleep-dependent memory consolidation in the epilepsy monitoring unit (EMU): a pilot study
2.333
Functional evidence for selective activation in a subset of developing hippocampal
neurons in early life seizures
3.008
A Critical Developmental Window for 17β-estradiol Anti-Epileptogenic Effect in a Mouse
Model of X-Linked Infantile Spasms
One in ten people with drug resistant JME have common copy number variants
3.033
1.309
Development and application of inhibitory luminopsins for the treatment of epilepsy.
3.094|A.07
gRASS yOung InVeSTIgATOR AWARDeeS
This award recognizes and honors outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy. The
Grass Foundation and AES combine resources to provide awardees with a $1,000 travel stipend and complimentary meeting registration.
Contact Author
lyndsey Anderson, Ph.D.
Abstract Title
Sodium channel inhibition with GS967 improves survival and suppresses
spontaneous seizures in Dravet syndrome mice
Poster/Platform
Alexander Ashby-lumsden, B.Sc.
Interictal and ictal ECG changes in a chronic experimental model of temporal lobe epilepsy
nicole hawkins, Ph.D.
Fine mapping of a Dravet syndrome modifier locus and candidate gene analysis by RNA-Seq
hisako Fujiwara, R.eeg/ePT, ClTM, RPSgT Language network reorganization associated with left- vs. right-predominant spikes in
Benign Epilepsy with Centrotemporal Spikes
nuri erkut kucukboyaci, M.S.
Candace Myers, Ph.D.
Imran Quraishi, M.D., Ph.D.
Tristan Shuman, Ph.D.
Post-surgical Uncinate Fasciculus Diffusivity in TLE and Its Relationship to Changes in
Executive Function after ATL
Gene discovery in epileptic encephalopathies through targeted resequencing of
candidate genes
Mechanisms of epileptic encephalopathy due to KNCT1 (Slack) mutations
In vivo interneuron circuit dysfunction in chronically epileptic mice
ADDITIOnAl AWARDS/hOnORS
3.035
3.058
2.340
1.319
1.168
1.315|C.06
3.059
3.143
JOhn (JACk) M. PellOCk AWARD In PeDIATRIC eXCellenCe
The 2015 John (Jack) Pellock Award for Pediatric Excellence recognizes and honors one outstanding young investigator conducting clinical
research in pediatrics related to epilepsy.
Contact Author
Shawn Reddy, B.S.
Abstract Title
Safety and Efficacy of Stereotactic Laser Ablation of Hypothalamic Hamartomas
ReBeCCA gOlDBeRg kAuFMAn hOnOR
Poster/Platform
2.305
The Rebecca Goldberg Kaufman Ethical Neuropsychiatry Fund works to advance a better understanding of the psychiatric aspects of epilepsy care
and treatment. The Kaufman Honor is awarded to the highest ranking abstract in the comorbidities topic category and is sessioned as Platform B.02.
The abstract honored is selected by the Scientific Program Committee from over 1,200 submitted abstracts.
Contact Author
Andres kanner, M.D.
FRITZ DReIFuSS hOnOR
Abstract Title
Psychiatric Complications of MRI-Guided Laser Ablation of Mesial Temporal
Structures for Treatment-Resistant Temporal Lobe Epilepsy
Poster/Platform
3.235|B.02
The Fritz Dreifuss Epilepsy Fund honors the leadership and passion that he brought to all aspects of his work. The Dreifuss Honor is awarded to the
highest ranking abstract in the genetics topic category and is sessioned as Platform C.02. The abstract honored is selected by the Scientific Program
Committee from over 1,200 submitted abstracts.
Contact Author
emily Robbins, M.D.
Abstract Title
Investigation of the role 82 pharmacogenes in the etiology of treatment-resistant
epilepsy in children
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
29
Poster/Platform
1.316| C.02
DECEMBER 4 - 8, 2015 www.AeSnet.org
EPILEPSY RESEARCH BENCHMARKS
nInDS Benchmarks for epilepsy Research
Beginning in 2000, and most recently in 2013, the National Institute of Neurological Disorders and Stroke (NINDS) has hosted a series of
Curing the Epilepsies conferences in partnership with epilepsy advocacy and professional organizations to assess progress in epilepsy
research and help set an agenda for future years. As an outcome, these conferences have led to the development of Benchmarks for Epilepsy
Research, which reflect shared priorities across the epilepsy community. AES supports efforts to promote research in these priority areas, and
the AES Benchmarks Stewards Committee reports on progress. The current Benchmarks are:
I. understand the causes of the epilepsies and epilepsyrelated neurologic, psychiatric, and somatic conditions
C. Develop or refine models that are aligned with etiologies and
clinical features of human epilepsies, especially treatment
resistant forms, to enable improved understanding of
ictogenesis and preclinical development to improve seizure
control with fewer side effects. Establish the sensitivity and
specificity of these models with regard to current therapies.
A. Identify new genes and pathways associated with epilepsies
and epilepsy-related conditions.
B. Identify new infectious, immune, age-related, environmental,
or other causes and risk factors associated with the epilepsies
and epilepsy-related conditions.
D. Identify, develop, and improve interventions to detect, predict,
prevent, or terminate seizures, including approaches suitable
for use in the home and other non-medical settings.
C. Determine whether factors related to age, gender,
race/ethnicity, socioeconomic status, and other features of
specific populations affect risk and mechanisms of epilepsy
and epilepsy-related conditions.
E. Identify, develop, and improve anti-seizure therapies that
target (either alone, or in combination) novel or multiple
seizure mechanisms
D. Determine whether the bi-directional relationships that exist
between the epilepsies and several co-occurring conditions
(e.g., neuropsychiatric or neurodevelopmental disorders)
result from the same underlying causal mechanisms,
interacting mechanisms, or are a consequence of the first
presenting condition
F. Develop, improve, and implement interventions for effective
self-management, including treatment adherence.
G. Develop and validate objective patient-centered outcome
metrics for clinical studies.
IV. limit or prevent adverse consequences of seizures and
their treatment across the lifespan
II. Prevent epilepsy and its progression
A. Understand epileptogenic processes involved in epilepsies
with neurodevelopmental origins, including those due to
genetic or presumed genetic causes.
A. Understand and limit adverse impacts of seizures on quality of
life, including effects on neurodevelopment, mental health,
intellectual abilities, and other neurological and nonneurological functions.
B. Understand epileptogenic processes involved in the
development of epilepsy following traumatic brain injury,
stroke, brain tumor, infections, neurodegeneration, or other
insults to the brain.
B. Understand and limit adverse impacts of anti-seizure
treatments (medical, surgical, or other interventions) on
quality of life, including effects on neurodevelopment, mental
health, intellectual abilities, and other neurological and nonneurological functions.
C. Identify biomarkers that will aid in identifying, predicting, and
monitoring epileptogenesis and disease progression, including
markers early after injury/insult that identify those people at
risk for epilepsy.
C. Understand risk factors and mechanisms involved in nonepileptic seizures (NES). Develop effective approaches for
earlier and accurate diagnosis and treatment.
D. Develop or refine models aligned with the etiologies of human
epilepsies to enable improved understanding of
epileptogenesis and rigorous preclinical therapy development
for epilepsy prevention or disease modification.
D. Identify causes, risk factors, and potential preventive strategies
for sudden unexpected death in epilepsy (SUDEP) and other
epilepsy-related mortality (for example, suicide) in people with
epilepsy.
E. Identify new targets and develop interventions to prevent or
modify epileptogenesis and the progression of epilepsy and
epilepsy-related conditions.
E. Identify the impact of pharmacological treatment of the
epilepsies on fetal and neonatal development. Develop
strategies to control seizures in pregnancy without causing
harm to either the mother or child.
III. Improve treatment options for controlling seizures and
epilepsy-related conditions without side effects
A. Understand the initiation, propagation, and termination of
seizures at the network level in different forms of epilepsy.
B. Identify biomarkers for assessing or predicting treatment
response, including markers that may identify specific
populations that are likely to have good outcomes or develop
adverse responses.
Walter koroshetz, M.D.
Director, NINDS
Raymond J. Dingledine, Ph.D.
Chair, AES Benchmarks
Stewards Committee
Emory University
Brandy Fureman, Ph.D.
Co-Chair, AES Benchmarks
Stewards Committee
NINDS
For more information about the Benchmarks and to view previous progress reports, please visit:
http://www.ninds.nih.gov/research/epilepsyweb/2014benchmarks.htm
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
30
DECEMBER 4 - 8, 2015 www.AeSnet.org
AES STRATEGIC PLAN 2015-2020
AeS VISIOn
STRATegIC gOAl #3 | BeST PRACTICeS
To eradicate epilepsy and its consequences.
AES will improve patient care through developing and
facilitating implementation of best practices.
AeS MISSIOn
To advance research and education for professionals
dedicated to the prevention, treatment and cure of epilepsy.
> STRATEGY 3A: Identify where sufficient data is lacking for
evidence-based guidelines and develop consensus
documents to fill the gaps.
AES must continue as the leader in education about epilepsy
and career development for current and next generation of
epilepsy professionals.
> STRATEGY 3C: Develop tools for performance in practice
(PIP) specifically for epileptologists.
> STRATEGY 3B: Create and disseminate tools for practice
improvement.
STRATegIC gOAl #1 | eDuCATIOn
> STRATEGY 1A: Maintain the Annual Meeting as the
premiere professional gathering on epilepsy.
STRATegIC gOAl #4 | AWAReneSS
AES will take a leadership role in improving awareness of
epilepsy and its impact among the public and health care
professionals.
> STRATEGY 1B: Create a comprehensive, accessible, up-todate repository of knowledge for the specialty.
> STRATEGY 1C: Develop digital education strategy,
leveraging content across multiple platforms.
> STRATEGY 4A: AES will facilitate development and
dissemination of a high level message communicating the
public health impact of epilepsy.
> STRATEGY 1D: Expand the scope and breadth of career
and leadership development.
STRATegIC gOAl #2 | ReSeARCh
> STRATEGY 4B: AES will take a more active role, both
collaboratively and independently, in public policy
development.
> STRATEGY 2A: Lead in developing the next generation of
basic, translational and clinical researchers.
AES will continue to improve its financial sustainability and
organizational effectiveness.
AES will be a recognized leader in setting research direction
(basic through clinical).
STRATegIC gOAl #5 | eFFeCTIVeneSS
> STRATEGY 5A: Implement and maintain optimal decision
support and technology infrastructure.
> STRATEGY 2B: Attract and support promising researchers.
> STRATEGY 2C: Partner to strategically advance research.
> STRATEGY 5B: Diversify revenue sources to support
operating needs and expand endowment.
> STRATEGY 2D: Support innovative research.
> STRATEGY 5C: Create an organizational and operational
structure that promotes efficiency and maximizes member
engagement.
To learn more, visit www.AESnet.org/about_aes
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
31
DECEMBER 4 - 8, 2015 www.AeSnet.org
FRIDAY, DECEMBER 4, 2015
Neurological Syndromes Associated with Cortical
malformations
Elliott Sherr, M.D., Ph.D.
8:30 a.m. – 11:30 a.m.
epilepsy Specialist Symposium:
Malformations of Cortical Development
and epilepsy
medical management of Syndromes Associated with
Cortical malformations
Renee A. Shellhaas, M.D., M.S.
Convention Center - Grand Ballroom A/B
OVeRVIeW
This symposium will present an update on MRI functions of
cortical development and epilepsy. The classification scheme,
imaging findings, clinical phenotypes will be presented.
Medical and surgical paradigms will be addressed. As a result
of attending this symposium, the attendee will recognize
clinical and imaging features and classify MCD patients,
ordering genetic testing, treatment and counseling.
Surgical management of Brain Developmental Anomalies
Dennis Spencer, M.D.
Case Summary and Conclusions
R. Edward Hogan, M.D.
eDuCATIOn CReDIT
3.0 CME Credits
Nurses may claim up to 3.0 contact hours for this session.
leARnIng OBJeCTIVeS
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 3.0 contact hours (0.30 CEUs).
UAN 0077-9999-15-030-L01-P. Initial Release Date: 12/4/2015
Following participation in this symposium, learners should be able to:
•
•
•
Recognize MRI and phenotype patterns of MCD,
understand the genetics of MCD, initiate genetic studies
and provide appropriate counseling
Participate in the care and counseling of patients with
MCDs
Recognize the clinical presentation of MCD and the impact
of MCD on psychological and neuropsychological function
The American Board of Psychiatry and Neurology has
reviewed the Malformations of Cortical Development and
Epilepsy Symposium and has approved this program as part
of a comprehensive program, which is mandated by the ABMS
as a necessary component of maintenance of certification.
TARgeT AuDIenCe
Basic, Intermediate and Advanced (see page 132 for details)
9:00 a.m. – 3:15 p.m.
29th Annual Advances in the Management
of epilepsy and the epilepsy Clinic
PROgRAM
Co-chairs: Ruben Kuzniecky, M.D. and R. Edward Hogan, M.D.
Separate registration required.
Introduction
Ruben Kuzniecky, M.D.
Marriott - Grand Ballroom, Salon D, Level 5
Case Presentation
R. Edward Hogan, M.D.
This intensive one-day conference is designed for those
professionals who participate in the care of persons with
epilepsy. The overall purpose is to improve services to
individuals and families affected by epilepsy. The conference is
presented by the Department of Neurology of Wake Forest
University School of Medicine, Winston-Salem, North Carolina,
through an unrestricted grant committed to the education of
Pathophysiology and Genetics of Cortical malformations
Christopher Walsh, M.D.
Neuroimaging of Cortical malformations
Ruben Kuzniecky, M.D.
AES FELLOWS PROGRAM
The AES Fellows program provides support for 85 clinical fellows and 15 postdoctoral researchers to attend the AES Annual
Meeting and learn about the latest updates in clinical and basic science epilepsy research. Fellows are selected based on
submitted applications and nominations from their fellowship directors, and they are paired with mentors during the
meeting who provide guidance regarding career planning, potential research paths, and clinical endeavors. Fellows
Program activities include dinner with the AES Board of Directors, breakfast and lunch with their mentors, and a career
pathways session in which expert panelists will share their experiences in research and clinical practice. In addition, Fellows
attend the Epilepsy Specialist Symposium, the Annual Fundamentals of Epilepsy Symposium, and the Hoyer Lecture. This
program is supported by UCB, Inc., Eisai Inc., Supernus Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc., Acorda
Therapeutics, Sunovion Pharmaceuticals Inc., Lundbeck and GW Pharmaceuticals.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
32
DECEMBER 4 - 8, 2015 www.AeSnet.org
FRIDAY, DECEMBER 4, 2015
Optimizing Use of Intracranial EEG
Jean Gotman, Ph.D.
Case Studies
Nathalie Jette, M.D.
Conclusions
Elinor Ben-Menachem, M.D., Ph.D.
health professionals, in an effort to promote the
comprehensive care of those with epilepsy and their families.
Registration for this program is done separately from the AES
Annual Meeting. Register by calling Wake Forest School of
Medicine at 800.642.0500.
Up to 5.0 AMA Category 1 CME credits will be given. Mountain
Area Health Education Center (MAHEC) is the accrediting
entity.
eDuCATIOn CReDIT
2.5 CME Credits
Nurses may claim up to 2.5 contact hours for this session.
12:30 p.m. – 3:00 p.m.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.5 contact hours (0.25 CEUs).
UAN 0077-9999-15-029-L01-P. Initial Release Date: 12/4/2015.
The American Board of Psychiatry and Neurology has
reviewed the Video-EEG Monitoring Symposium and has
approved this program as part of a comprehensive program,
which is mandated by the ABMS as a necessary component of
maintenance of certification.
Annual Fundamentals of epilepsy
Symposium: Video-eeg Monitoring
Convention Center - Grand Ballroom A/B
OVeRVIeW
This program will provide education regarding design,
implementation and use of video-EEG. It will review how to
utilize modern technology, safety protocols and nursing and
physician practice to provide optimal care for patients with
uncontrolled seizures. Effective use of video, interictal EEG,
ictal EEG and intracranial EEG will be reviewed, and
participants will learn how to integrate data obtained using
these modalities. Sample cases will be used to further
illustrate use of this method.
COMMeRCIAl SuPPORT ACknOWleDgeMenT
Supported in part by educational grants from Lundbeck and
LivaNova.
1:00 p.m. - 3:00 p.m.
Fellowship Program Directors Meeting
leARnIng OBJeCTIVeS
Convention Center - Room 204 C
Following participation in this symposium, learners should be able to:
•
•
•
•
•
Chair: David Ficker, M.D.
Design and implement installation of a video-EEG
monitoring unit, while also implementing safety measures
This second annual session is intended for current Epilepsy
Fellowship Program Directors, Clinical Neurophysiology
Program Directors and those interested in starting an ACGME
Epilepsy Fellowship. This symposium will meet ACGME
program requirement II.A.4, which advises that program
directors attend one program director meeting per year. The
objective of the symposium is to provide a forum for program
directors to address challenges encountered in running a
training program and in meeting accreditation expectations.
Recognize when to make timely referrals of uncontrolled
patients for diagnostic study
Provide better interpretation of video-EEG, providing more
accurate diagnosis of non-epileptic events. Learner will
more accurately identify surgical candidates with improved
surgical outcome
Counsel patients regarding the role of video-EEG and
explain the process
Use recognition of epileptic and non-epileptic behaviors,
improve their ability to differentiate between seizures and
psychogenic non-epileptic seizures and arrive at more
accurate diagnoses
1:30 p.m. – 3:00 p.m.
Professional Development in AeS: A Program
for Junior Members and Those in Transition
Convention Center - Room 107
TARgeT AuDIenCe
Basic and Intermediate (see page 132 for details)
AgenDA
Co-Chairs: Michael Sperling, M.D. and Elinor Ben-Menachem,
M.D., Ph.D.
Introduction
Michael Sperling, M.D.
Creating an Epilepsy monitoring Unit
Joseph Sirven, M.D.
Effective Use of Video
Nancy Foldvary-Schaefer, D.O., M.S.
Use and Interpretation of Scalp EEG
Michael Sperling, M.D.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
The American Epilepsy Society invites all interested meeting
attendees to come to a special session on volunteer and
leadership opportunities within the Society. This session will
be useful to trainees, basic scientists, clinicians and other
allied health professionals (nurses, psychologists, Pharm.D.s)
who want to know more about AES organizational structure or
who want to become more involved. The session will provide
an overview of the professional development and
volunteering opportunities within the Society, followed by
short presentations by members active in AES leadership. The
session will end with a chance to meet with AES staff and
committee leaders to learn more about available
opportunities.
33
DECEMBER 4 - 8, 2015 www.AeSnet.org
FRIDAY, DECEMBER 4, 2015
neuropsychology: Comparison of
neuropsychological Methods and Research
Programs in north America and Internationally
1:30 p.m. – 3:00 p.m.
Junior Investigators Mentoring Session
Pre-application required.
Convention Center - Room 105
Convention Center - Room 201 B
Coordinator: Gail L Risse, Ph.D.
This program for fellows, postdoctoral researchers,
instructors, and assistant professor level junior faculty will
include peer-to-peer discussion forums as well as mentoring
sessions with experienced clinical or basic science
researchers. Participants are assigned in advance to mentors
based on research interests.
Speakers: Members of the ILAE Neuropsychology
Commission
AES members who are also part of the Neuropsychology
Commission of ILAE will present an update on the work of
that commission including international clinical and research
programs involving the neuropsychology of epilepsy with the
objective of stimulating collaborative international research
projects.
1:30 p.m. – 3:00 p.m.
Special Interest group Meetings
SuDeP: Are We Ready for Trials of SuDeP
Prevention in People with epilepsy?
Basic Mechanisms and neuroscience:
Interneuron Dysfunction and epilepsy
Convention Center - Room 108
Convention Center - Room 103 A
Coordinators: Lisa Bateman, M.D., Daniel Friedman, M.D. and
Gordon Buchanan, M.D., Ph.D.
Coordinators: Katty (Jing-Qiong) Kang, M.D., Ph.D., Amy
Brewster, Ph.D. and Laura Jansen, M.D., Ph.D.
Speakers: Cynthia Harden, M.D., Tobias Loddenkemper, M.D.,
Masud Seyal, M.D., Ph.D., David Patterson, M.D. and
Dale Hesdorffer, Ph.D.
Efforts to develop AAN/AES Guidelines on SUDEP highlight our
limited understanding of clinical risk factors and potential
mechanisms of SUDEP. In this session, we will review the
guidelines with a particular focus on the evidence for
interventions to reduce SUDEP risk. We will then discuss
whether the current state of knowledge regarding the
pathophysiology and epidemiology is sufficient to design
studies of SUDEP prevention. Speakers will discuss the roles
of seizure detection devices, specific medications and public
health measures in preventing SUDEP and the barriers to
performing meaningful trials of these interventions. We will
also examine lessons learned from SIDS prevention. Finally,
we will provide a forum for the epilepsy community to discuss
these and/or other potential interventions and identify the
best strategies to test and implement them to reduce epilepsy
mortality as soon as possible.
Speakers: Katty (Jing-Qiong) Kang, M.D., Ph.D., Jay
Spampanato, Ph.D. and Eric Marsh, M.D., Ph.D.
The speakers will present evidence from animal models
supporting a role for dysfunction of inhibitory interneurons in
the pathogenesis of epilepsy. Ample time for questions and
discussion will be allotted.
neuroendocrinology: Oral Contraceptives —
AeD Interactions: Can OC Pills exacerbate
Seizures?
Convention Center - Room 104 A
Coordinators: D. Samba Reddy, Ph.D., R.Ph.
Speakers: Andrew Herzog, M.D., Ann Davis, M.D. and
D. Samba Reddy, Ph.D., R.Ph.
Contraceptive management in women with epilepsy is critical
owing to the potential maternal and fetal risks if contraception
or seizure management fails. Hormonal contraception,
including the use of oral contraceptives (OCs), is widely used
in many women with epilepsy. There is contention that the
use of OCs may increase the risk of seizures in women with
epilepsy. Although some reports suggest that OCs might
exacerbate seizures, most studies show no effect of estrogenbased contraceptives on seizure frequency. However, there
are many factors to consider in the choice of AED therapy and
hormonal contraception, since some AEDs can reduce the
efficacy of OCs owing to pharmacokinetic interactions. In this
SIG, the potential OC-AED interactions will be discussed, with
emphasis on whether the use of OC exacerbates seizures and
their neuroendocrine mechanisms.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
3:30 p.m. – 6:00 p.m.
Spanish Symposium: Frontal lobe epilepsy
Presented in Spanish
Convention Center, Room 204 A/B
34
OVeRVIeW
The symposium will provide an overview of frontal lobe
epilepsy, especially the clinical semiology of seizures and the
comorbidities associated to intractable cases, with special
reference to neuropsychological aspects which affect quality
of life including social and psychological development. It will
also provide an overview of current practices in Spanish
speaking countries to identify intractable cases and refer to
surgical management especially in the setting of limited
resources.
DECEMBER 4 - 8, 2015 www.AeSnet.org
FRIDAY, DECEMBER 4, 2015
leARnIng OBJeCTIVeS
Award Presentation: AES Service Award and AES
Extraordinary Contributions Award
Following participation in this symposium, learners should be able to:
•
•
•
•
Recognize clinical semiology and comorbidites of
intractable frontal lobe epilepsy
Evaluate patients with frontal lobe seizures utilizing ictal
video-EEG monitoring
Utilize standard protocols for presurgical planning and
surgical management
Recognize comorbidities of frontal lobe epilepsy. Learners
use standarized protocols in neurospychological
assesment and follow-up, to evaluate surgical outcomes
The 13th Judith Hoyer Lecture in Epilepsy, presented by
invited Lecturer Dr. French, is sponsored by the National
Institute of Neurological Disorders and Stroke. This series is
held in memory of Mrs. Judith Hoyer, an active member of the
Board of Directors of the Epilepsy Foundation and the late
wife of U.S. Representative Steny Hoyer (D-MD). Mrs. Hoyer
spent her life both helping families to cope with epilepsy and
promoting research into a cure and a better quality of life for
those with the disorder. The purpose of the lecture is to raise
awareness of epilepsy among researchers and the public and
provide intellectual stimulation that will encourage continuing
progress toward finding a cure for epilepsy.
TARgeT AuDIenCe
Basic and Intermediate (see page 132 for details)
Supported in part by Upsher-Smith Laboratories, Inc. and
NINDS.
PROgRAM
Co-chairs: Patricio Abad, M.D. and Mario A. Alonso-Vanegas,
M.D.
6:00 p.m. – 7:30 p.m.
Special Interest group Meetings
Introduction
Patricio Abad, M.D.
Children’s hour: FIReS (Febrile InfectionRelated epilepsy Syndrome)
Semiology of Frontal Lobe Epilepsy
Jaime Parra, M.D., Ph.D.
Convention Center - Room 108
Neuropsychological and Behavioral Problems in Frontal
Lobe Epilepsy
Andres Kanner, M.D.
Coordinators: Elaine Wirrell, M.D. and Rima Nabbout, M.D.,
Ph.D.
Surgical management of Frontal Epilepsies
Arthur Cukiert, M.D., Ph.D.
This session will address clinical presentation and DDx,
Imaging Findings and Outcomes, and Pathogenesis and
Treatment of FIRES
Speakers: Katherine Nickels, M.D., Uri Kramer, M.D. and
Catherine Chiron, M.D., Ph.D.
Presurgical Evaluation of Frontal Lobe Epilepsy
Daniel San Juan Orta, M.D.
Roundtable Discussion
Mario A. Alonso-Vanegas, M.D. and All Faculty
Frontal lobe epilepsy: Alterations of Cortical
networks in Frontal lobe epilepsy — Relation
to Seizures and Cognition
eDuCATIOn CReDIT
2.5 CME Credits
Convention Center - Room 103 A
Nurses may claim up to 2.5 contact hours for this session.
Coordinator: Andrea Bernasconi. M.D.
Speakers: Albert Aldenkamp, M.D. Ph.D., William D. Gaillard,
M.D., Paolo Federico, M.D., Ph.D., FRCPC and Matthias Koepp,
M.D. Ph.D.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.5 contact hours (0.25 CEUs).
UAN 0077-9999-15-037-L01-P. Initial Release Date: 12/4/2015.
Frontal lobe epilepsy is the second most common type of
localization-related epilepsy that undergoes surgical
treatment, and probably the most challenging in terms of
surgical management. Seizures have an impact on the cortical
organization of the frontal lobe. Speakers will discuss recent
advanced structural and functional MRI data showing seizurerelated network alterations in main functional regions,
including the motor cortex and language areas.
The American Board of Psychiatry and Neurology has
reviewed the Frontal Lobe Epilepsy Symposium and has
approved this program as part of a comprehensive program,
which is mandated by the ABMS as a necessary component of
maintenance of certification.
4:00 p.m. – 5:30 p.m.
Meg/MSI: A loud Buzz from Resting Meg —
Forget Spikes, It’s networks!
13th Judith hoyer lecture in epilepsy
Convention Center - Grand Ballroom A/B
Convention Center - Room 103 B/C
Obstacles in epilepsy Diagnosis: If you Don’t
Ask, They Won’t Tell
Coordinators: Anto Bagic, M.D., Ph.D. and Michael E. Funke,
M.D., Ph.D.
Lecturer: Jacqueline A. French, M.D.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
35
DECEMBER 4 - 8, 2015 www.AeSnet.org
FRIDAY, DECEMBER 4, 2015
Speakers: Susan Bowyer, Ph.D. and
medications including antipsychotics, antidepressants and
stimulants. Furthermore, we will also discuss seizure
provocation with the use of these medications in patients with
and without epilepsy.
1. A Personalized Brain Connectome from MRI - Leonardo
Bonilha, M.D., Ph.D. (MUSC, Charleston, SC)
2. Advanced Methods for Discerning a Loud Buzz from
Resting MEG - Susan Bowyer, Ph.D (HFHS, Detroit, MI)
Tuberous Sclerosis: Advances in neurosurgical
Approaches
3. A Spike-less MEG in Evaluating Severity of Illness and
Predicting Surgical Outcomes? - Dario J Englot, M.D., Ph.D.
(UCSF, San Francisco, CA)
Convention Center - Room 107
Coordinator: Peter Crino, M.D., Ph.D.
Although it has been increasingly accepted that very valuable
clinical information is buried in the traditionally ignored brain’s
“resting activity”, it is a relatively novel direction in clinical
research to make inferences about epileptic brains’
characteristics from “non-epileptiform MEG activity”. While
traditional “spikes or sharps” remain a holy grail of clinical
epilepsy, after oscillations “outside of Berger’s bands” have
been accepted as biomarkers of epileptic tissue, multiple
“resting” including “epileptic networks” have been inferred
recently from resting MEG without interictal epileptiform
discharges. Practically speaking, increasing evidence suggests
that an accurate localization of the epileptogenic focus may
be attainable using noninvasive spontaneous “resting-state”
activity without the need to capture interictal and/or ictal
discharges. This not only brings additional dimension to our
understanding of epilepsies, but potentially opens up new
clinical possibilities. Further meticulous research is necessary
to elucidate how inferences made from “resting state activity
without interictal epileptiform discharges” exactly relate to
those made from traditional “epileptiform abnormalities” and
even their possible role in an early diagnosis, better
localization, improved treatment and brighter prognosis of
epilepsy. The program focuses on the experts’ discussions of
the latest neurophysiologic and imaging evidence for
understanding this intriguing issue.
Speakers: Peter Crino, M.D., Ph.D., Guy McKhann, M.D. and
Howard Weiner, M.D.
Over the past decade, a number of distinct neurosurgical
approaches have been developed for epilepsy and tumor
surgery in tuberous sclerosis complex (TSC). The current TSC
SIG will focus on several phases of neurosurgical therapy in
TSC including pre-operative evaluation of TSC patients with
intractable epilepsy or subependymal giant cell astrocytoma
(SEGA), differential strategies for surgical intervention in TSC,
focal versus larger scale resection, multi-staged approaches,
disconnection surgery and device-based therapies. These
approaches will be considered in the context of the recent
availability of medical therapy with mTOR inhibitors.
Tumor-induced epilepsy: Metastatic Disease
Convention Center - Room 104 A
Coordinators: Jeffrey Politsky, M.D., FRCPC and Sandeep
Mittal, M.D.
Speakers: Sandeep Mittal, M.D., Jeffrey Politsky, M.D. and
Edward Avila, D.O.
The initial sub-topic list includes: prevalence of treatment of
seizures and status epilepticus; paraneoplastic disease;
complications of systemic treatment.
neuropharmacology: Psychoactive
Medications and Seizures — Challenges and
Pitfalls
6:00 p.m. – 7:30 p.m.
Basic Science Skills Workshop
Convention Center - Room 105
Pre-registration and tickets are required for this session. An
additional $50 registration fee applies; maximum of 30
people per session.
Coordinators: Laura Strom, M.D. and Mitra Habibi, Pharm.D.
Speakers: Mesha-Gay Brown, M.D. and Archana Shrestha
M.D.
eeg Monitoring in experimental Rodent Models
of epilepsy
This SIG focuses on individuals with a common interest in
neuropharmacology and epilepsy. Psychiatric disorders
present a significant co-morbidity associated with epilepsy,
therefore, psychoactive medications are often used in order
to optimize the medical treatment of this population. There is
potential for these medications to have an impact on seizure
threshold and concern about pharmacokinetic interactions
between antiepileptic and other psychoactive drugs. Some
psychoactive medications may also have an effect on the EEG.
This year’s session will address some of the known
electrographic changes associated with specific psychoactive
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Convention Center - Room 202 B
moderators: Atul Maheshwari, M.D. and F. Edward Dudek,
Ph.D.
This interactive workshop for basic scientists will primarily
focus on EEG monitoring, acquisition and data analysis in
mouse and rat models of epilepsy.
36
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5, 2015
7:00 a.m. – 8:30 a.m.
primary outcome measured is improvement in quality of
life including subjective memory perception. Secondary
outcomes are objective memory function, executive and
depressive symptoms as measured by validated scales.
Special Interest group Meetings
Cognitive and Behavioral Interventions for
epilepsy: Therapeutic elements of Specific
Psychobehavioral Interventions
eeg: Tools for Collaborative eeg Research
Coordinators: Lauren Frey, M.D., Rosa Michaelis, M.D., Marcio
SoteroDeMenezes, M.D., Siegward Elsas, M.D. and Steve
Schachter, M.D.
Speakers: Sándor Beniczky, M.D., Ph.D., Jonathan Halford,
M.D. and Jong Woo Lee, M.D., Ph.D.
Convention Center - Room 105
Convention Center - Room 107
Coordinators: Susan Herman, M.D. and Kitti Kaiboriboon, M.D.
Speakers: Markus Reuber, M.D., Ph.D., FRCP, Michael Privitera,
M.D. and Barbara Jobst, M.D.
Clinical research on EEG is essential to develop new EEG
techniques and to establish their utility in clinical practice.
Once these techniques are more widely used, additional
research is needed to determine optimal use, yield and costeffectiveness. Further research studies are needed to validate
higher order processing of EEG data, such as automatic spike
and seizure detection algorithms, quantitative EEG trends,
seizure prediction and source localization. Many of these
techniques compare results to “gold standard” review and
visual scoring by expert electroencephalographers. Because
large numbers of subjects and EEGs are usually required for
these studies, it is often costly to collect, score and share data.
Time and expense can be reduced by developing shared
research tools. In this session, we will discuss several large
EEG consortia projects, focusing on development of shared
research tools, such as datashare agreements, IRB
agreements, common terminology and EEG scoring criteria,
databases, and data storage and access platforms.
To follow up on recent previous SIG session topics of: (1)
hypothesized mechanisms, and (2) the scientific evaluation of
cognitive and behavioral interventions for epilepsy, this year’s
session will focus on the presentation of specific therapeutic
elements of cognitive and behavioral interventions that will
each be presented within the framework of their scientific
evaluation. Three interventions will be presented whose
delivery mode ranges from face-to-face therapy sessions, cell
phones and telephone sessions that target outcome
parameters ranging from quality of life, seizure frequency and
cognitive dysfunction:
1. Acceptance and Commitment Therapy: This intervention
approach incorporates mindfulness and behavior change
processes aimed at addressing the main problems that
patients perceive as related to their diagnosis of epilepsy.
A recent study prospectively evaluated Acceptance and
Commitment Therapy for patients with refractory epilepsy
using a patient workbook promoting the patient’s
psychological flexibility. The primary aims of this study
were to assess the effects of the intervention on measures
of health-related quality of life, social adjustment, selfesteem, depression and anxiety, as well as to evaluate the
cost-effectiveness of the therapy program. In addition, the
effects of the intervention on seizure frequency were
explored as a secondary outcome.
nursing: Research Process for nurses
Convention Center - Room 104 A
Coordinators: Tara Myers, CPNP and Wendy Miller, Ph.D., RN,
CCRN
Speakers: Wendy R. Miller, Ph.D., RN, CCRN and Tara Myers,
CPNP
In an effort to get more nurses involved in research in the
field of epilepsy, we have discussed providing education and
guidance on the research process. This session will focus
more on those nurses and nurse practitioners in clinical
practice who may have not had formal education in research
typically found in a Ph.D. program.
2. Progressive muscle Relaxation: The results of the first
large-scale randomized controlled trial of a stress
reduction intervention for epilepsy will be presented.
3. HOBSCOTCH: HOme Based Self-management and
COgnitive Training CHanges lives: This project consists of
developing and testing a home-based self-management
program, HOBSCOTCH, in the adult epilepsy population.
HOBSCOTCH is an easy to implement, cost-effective
intervention to treat memory complaints and
subsequently quality of life in epilepsy patients, while
minimizing the barriers of access to care. The program
teaches problem-solving strategies and compensatory
mechanisms to help manage cognitive dysfunction. The
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Private Practice: Private Practice epilepsy in
the Changing World of health Care
Convention Center - Room 103 A
Coordinators: Marcelo Lancman, M.D. and Pavel Klein, M.D.
Speakers: Mark Mintz, M.D., David Anschel, M.D. and Pavel
Klein, M.D.
Over the last couple of years, the consortium of private
epilepsy centers has brought together diverse private epilepsy
37
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5, 2015
8:30 a.m. – 11:45 a.m.
centers with a wide scope of different experiences in clinical,
business and research practices. This has benefited members
in the sharing of experiences and, increasingly, in forging
together common approaches to the challenges of the
specialized medical practice in the current changing health
care environment. We will discuss several topics related to
position of private practice centers in the changing health
care environment. We will address the issue of cost-based
health care delivery as a possible replacement of the current
fee for service model, ACOs and how epilepsy centers can
proactively become involved in that process. We will discuss
ways of how increasing regulation and decreasing payments
impact clinical practice, and potential ways dealing with the
regulatory burdens such as AED and procedural
preauthorization and denials. Finally, we will discuss
collaborative research opportunities both in pharmaceutical
and non-pharmaceutical epilepsy studies, with specific
examples of each, and possibilities of the SIG and the
consortium in catalyzing participation in research by practices
with research interest who are not currently involved in
research, and collaboration in research between practices
already engaged in research.
Presidential Symposium: getting to Cure —
The Challenging Road to Disease
Modification and Prevention for epilepsy
Convention Center - Grand Ballroom A/B
OVeRVIeW
Epilepsy care has focused on symptomatic treatment, that is,
control of seizures. Modification of disease progression,
underway in other clinical areas, has not been a focus of
epilepsy research until recent years. Translation from the
bench to the clinic requires collaboration among scientists,
clinical researchers and clinicians. This symposium will
address the development of clinical trials for diseasemodifying therapies including issues which can adversely
impact successful outcomes.
leARnIng OBJeCTIVeS
Following participation in this symposium, learners should be able to:
•
Sleep in epilepsy: effect of nReM/ReM
Dychotomy on Seizure Frequency
•
Convention Center - Room 104 B
Collaborate on the development of appropriate studies to
evaluate potential disease-modifying treatments
TARgeT AuDIenCe
Basic, Intermediate and Advanced (see page 132 for details)
Coordinators: Milena Pavlova, M.D. and Erik St. Louis, M.D.
Speakers: Marcus Ng, M.D. and Mark Bower, M.D.
PROgRAM
Chair: Amy Brooks-Kayal, M.D.
Seizure frequency is different in different sleep stages. The
mechanisms responsible for this difference are not fully clear,
however recent evidence suggests that the neuronal
assembly specific for each stage may be responsible. This
session will examine NREM and REM sleep separately in terms
of seizure frequency and potential basic mechanisms for this
pattern.
Introduction: Why make the Journey: The Need for DmaP
Therapies for Epilepsy
Amy Brooks-Kayal, M.D.
Picking Your Route: How Do We Identify and Validate
Targets for Disease modification?
Manisha Patel, Ph.D.
Temporal lobe Club: Why Is It So Difficult to
get Psychiatrists as Members of the epilepsy
Surgery Team and What Can We Do About It?
Beginning the Journey: The Path to Phase I
Rajesh Ranganathan, Ph.D.
Convention Center - Room 103 B/C
The Road Less Traveled: Novel Approaches to Successful
Translation of Disease-modifying Therapy
Kate Dawson, M.D.
Coordinators: Andres M. Kanner and Jerome Engel, M.D.,
Ph.D.
Detours and misdirections: Cautionary Tales of Translation
Failures
Emily Sena, Ph.D.
Speakers: John Barry, M.D. and Jay Salpekar, M.D.
Psychiatric evaluation and support are considered an
essential part of the pre- and postoperative care for patients
undergoing surgical treatment for epilepsy, yet very few
epilepsy surgery centers have a psychiatrist as an integral part
of their multidisciplinary team. This session will present the
current situation of psychiatric participation at epilepsy
surgery centers, examine the possible reasons for deficits in
support, and explore possible solutions.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Recognize role of treatments which can result in disease
modification and be aware of research into such
treatments
Getting to Cure: A Path Forward for Disease-modifying
Therapy for Epilepsy
Robert Pacifici, Ph.D.
Conclusions
Amy Brooks-Kayal, M.D.
38
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5, 2015
leARnIng OBJeCTIVeS
eDuCATIOn CReDIT
2.75 CME Credits
Following participation in this symposium, learners should be able to:
Nurse Practitioners may claim 1.5 hours of pharmacology for
this session.
•
•
Nurses may claim up to 2.75 contact hours for this session.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.75 contact hours (0.275 CEUs).
UAN 0077-9999-15-035-L01-P. Initial Release Date: 12/5/2015.
•
•
The American Board of Psychiatry and Neurology has
reviewed the Getting to Cure: The Challenging Road to
Disease Modification and Prevention for Epilepsy Symposium
and has approved this program as part of a comprehensive
program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Counsel patients and families regarding appropriate nonpharmacologic treatments
Participate in counseling patients families about the
importance of medication adherence to ensure maximum
treatment efficacy
Recognize risk factors for non-adherence to medication
recommendations and counsels patients regarding
adherence
TARgeT AuDIenCe
Basic and Intermediate (see page 132 for details)
PROgRAM:
Co-Chairs: Jerry Shih, M.D. and Cynthia Harden, M.D.
COMMeRCIAl SuPPORT ACknOWleDgeMenT
Supported in part by educational grants from Acorda
Therapeutics and Supernus Pharmaceuticals, Inc.
Introduction
Jerry Shih, M.D.
noon – 6:00 p.m.
Treatment Strategies for Newly Diagnosed Epilepsy
Emilio Perucca, M.D., Ph.D.
Poster Session 1
When is “Drug Failure” Not a Drug Failure
Patrick Kwan, M.D., Ph.D.
Convention Center - Exhibit Hall A, 200 Level
See pages 42-52
Rational Polypharmacy – What Is the Evidence?
Josiane LaJoie, M.D.
noon – 6:00 p.m. (grand Opening at noon)
exhibit hall
Update on Nonpharmacologic Treatments
Christopher Skidmore, M.D.
Convention Center - Exhibit Hall A, 200 Level
Disease modifying Therapies – Current Status
Andrew Cole, M.D.
2:15 p.m. – 5:00 p.m.
Conclusion
Cynthia Harden, M.D.
epilepsy Therapy Symposium: What you
need to know to get your Patient into the
65% group!
eDuCATIOn CReDIT
2.5 CME Credits
Convention Center - Grand Ballroom A/B
Nurses may claim up to 2.5 contact hours for this session.
Award Presentation: J. Kiffin Penry Award for Excellence in
Epilepsy Care
Nurse Practitioners may claim 2.5 hours of pharmacology for
this session.
OVeRVIeW
This symposium will guide the attendee in managing epilepsy
patients from initial diagnosis to consideration of resective
epilepsy surgery. Guidelines will be presented providing best
practice for initiating anti-seizure drug therapy. Attendees will
learn ways to recognize and manage drug "failures" that are
not due to lack of drug efficacy. Updated information on best
practices for rational polypharmacy to obtain the best patient
outcomes will be presented. Newer nonpharmacologic
treatments for patients who continue to have seizures despite
adequate trials of anti-seizure medications will also be
presented. The concept of anti-epileptic versus antiepileptogenic therapy for seizures will be discussed in a
practical, clinically-based approach.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Manage new onset epilepsy utilizing evidence based
practices
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.5 contact hours (0.25 CEUs).
UAN 0077-9999-15-031-L01-P. Initial Release Date: 12/5/2015.
The American Board of Psychiatry and Neurology has
reviewed the What You Need to Know to Get Your Patient into
the 65% Group Symposium and has approved this program
as part of a comprehensive program, which is mandated by
the ABMS as a necessary component of maintenance of
certification.
COMMeRCIAl SuPPORT ACknOWleDgeMenT
Supported in part by educational grants from Eisai Inc., UCB,
Inc., Lundbeck and Supernus Pharmaceuticals, Inc.
39
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5, 2015
leARnIng OBJeCTIVeS
2:30 p.m. – 4:00 p.m.
Investigators’ Workshops
Following participation in this symposium, learners should be able to:
•
genetics, Biology and Treatment of the early
life epilepsies
•
moderators: Ann Poduri, M.D.
•
Convention Center - Room 103 A
Speakers: Alex Paciorkowski, M.D., Ghayda Mirzaa, M.D. and
Anne Berg, Ph.D.
•
energy Metabolism and Dynamic Brain States
Describe and discuss limitations in current publications of
translational research
Critically analyze the impact of inadequate pre-clinical data
on the development of new therapeutics
Recognize the limitations of available preclinical data when
counseling patients regarding use of medications
TARgeT AuDIenCe
Intermediate and Advanced (see page 132 for details)
Convention Center - Room 105
moderator: Chris Dulla, Ph.D.
PROgRAM
Chair: Andrew Cole, M.D.
Speakers: Mark Beenhakker, Ph.D., Christophe Bernard, Ph.D.
and Susan Masino, Ph.D.
Introduction
Andrew Cole, M.D.
5:30 p.m. – 7:30 p.m.
Translational Research Symposium: Rigor in
Translational Research — Issues, experience
and Solutions
Crisis in Translation: Perspective from the NIH
Walter Koroshetz, M.D.
Rigor in Pre-Clinical Studies and Reproducibility of
Published Research Findings
Shai Silberberg Ph.D.
Convention Center - Room 204
OVeRVIeW
Clinicians are knowledgeable about interpretation of clinical
trials but have limited knowledge of pre-clinical discovery and
development of therapeutic agents and devices. This
symposium will address critical issues identified by AES and
ILAE working groups that require solutions in order to
facilitate and promote translational research in therapeutic
development for epilepsy and related co-morbidities.
Problems in reproducing pre-clinical research have increased
the risk of embarking on programs for development of new
therapies for venture and industrial sponsors. Multiple
academic studies have documented the high rate of failure to
reproduce critical preclinical studies. Criteria to increase the
rigor, and therefore the reproducibility of preclinical work have
been identified; initial efforts to implement these strategies
have identified challenges and opportunities, as well as critical
resources required to achieve the goal of increasing rigor.
Finally, effective communication of positive and negative
results, as well as reproducibility and validation studies
requires novel publication models. This symposium states the
problem, examines the components required to achieve rigor,
reviews recent experience in designing and conducting
studies designed to meet proposed criteria, and concludes
with a discussion of the effects of publication bias and a
description of a novel publication platform designed to serve
the needs of the translational research community. In addition
to addressing issues in research methodology for researchers,
the information presented at this symposium will allow
clinicians to better assess new therapeutic options.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Articulate barriers to translation in the existing system and
asses preclinical data for rigor and robustness
Practical Experience in Achieving Pre-clinical Rigor
Kevin Staley, M.D., Ph.D.
Stuck in Translation: A Crisis of Commitment?
Annamaria Vezzani, Ph.D.
Shared Data Platforms: Efficiency, Integrity, Fairness and
Utility
M. Brandon Westover, M.D., Ph.D.
Publication Bias: When Data Is AWOL
Michael Rogawski, M.D., Ph.D.
Conclusions
Andrew Cole, M.D.
CReDIT DeSIgnATIOn
2.0 CME Credits
Nurses may claim up to 2.0 contact hours for this session.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.0 contact hours (0.20 CEUs).
UAN 0077-9999-15-038-L01-P. Initial Release Date: 12/5/2015.
The American Board of Psychiatry and Neurology has
reviewed the Rigor in Translational Research -- Issues,
Experience and Solutions Symposium and has approved this
program as part of a comprehensive program, which is
mandated by the ABMS as a necessary component of
maintenance of certification.
40
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5, 2015
5:30 p.m. – 8:00 p.m.
Using medical Homes and Telehealth to Reach Pediatric
Epilepsy Patients
Rick Boyle, M.S.Ed.
Professionals in epilepsy Care Symposium:
Interprofessional Models and Collaborative
Care
Caring for Individuals with Epilepsy and Developmental
Disabilities: Collaborations with Developmental
Behavioral Pediatrics
Jane Charles, M.D.
Convention Center - Grand Ballroom A/B
OVeRVIeW
Recent research and practice recommendations include that
health professionals must work collaboratively to improve the
delivery of care and outcomes for patients and families (RWJ,
2011). Interprofessional competency domains that all health
care providers must address, including values/ethics for
interprofessional practice, roles/responsibilities,
interprofessional communication and teams and teamwork
(IPEC, 2011). The IOM Report on epilepsy includes the
recommendation to research and develop a quality
framework for epilepsy care to increase access to care, quality
of life and health outcomes (England et al., 2012). This
symposium will present recent research and practice evidence
regarding how providing interprofessional care assists health
care teams to provide comprehensive lifespan care for
persons with epilepsy and their families. Examples of existing
interprofessional models of care will be reviewed in
populations such as children, adolescents, adults and
veterans. In addition, possible interventions to accommodate
lack of resources and funding for interprofessional care
models will also be addressed.
Collaborative Care of the Epilepsy Patient in the VA
System
Karen Parko, M.D.
Conclusions
Gigi Smith, Ph.D., MSN, CPNP
Faculty Panel
All Faculty
eDuCATIOn CReDIT
2.5 CME Credits
Nurses may claim up to 2.5 contact hours for this session.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.5 contact hours (0.25 CEUs).
UAN 0077-9999-15-033-L01-P. Initial Release Date: 12/5/2015.
The American Board of Psychiatry and Neurology has
reviewed the Interprofessional Models and Collaborative Care
Symposium and has approved this program as part of a
comprehensive program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
leARnIng OBJeCTIVeS
Following participation in this symposium, learners should be able to:
•
•
•
Define interprofessional care collaboration and
competencies
COMMeRCIAl SuPPORT ACknOWleDgeMenT
Supported in part by educational grants from Eisai Inc.,
UCB, Inc., Lundbeck and Acorda Therapeutics.
Evaluate existing interprofessional models of care for
patients and families with epilepsy
Consider the development of strategies to meet specific
patient/family care needs by optimizing patient care by
using the unique and complementary abilities of all
members of the team in an epilepsy center or community
setting
7:00 p.m. – 10:00 p.m.
Fourth Annual Wine Tasting and
Mixed Company Concert
Additional fee and ticket required.
Philadelphia Center for Architecture (Directly Across from
Convention Center)
TARgeT AuDIenCe
Basic and Intermediate (see page 132 for details)
Enjoy an evening of fine wines, food pairing and camaraderie
at the Philadelphia Center for Architecture, directly across
from the Convention Center. The Event features the eclectic
sound of Yale's premier a cappella group, Mixed Company. All
proceeds benefit the basic and clinical fellowships of the
Spencer and Lennox & Lombroso Funds.
PROgRAM
Co-chairs: Gigi Smith, Ph.D., MSN, CPNP and Janelle Wagner,
Ph.D.
Introduction
Janelle Wagner, Ph.D.
Please note this event requires a separate RSVP and ticket fee.
Tickets are available onsite in the registration area.
A model of Integrated Behavioral Health
Shanna Guilfoyle, Ph.D.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
41
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
noon - 6:00 p.m.
Poster Session 1
Convention Center – Exhibit Hall A,
200 Level
PROFeSSIOnAlS In ePIlePSy CARe
nursing
1.001 The parents' experience caring for a
child with medication refractory epilepsy.| K.
Boreale
1.002 Reliability of seizure detection in the
epilepsy monitoring unit | A. Yum, R. Mani,
K. R. Kaufman, K. Sivaraaman, A.
Esfahanizadeh, S. Wong
1.003 The impact of the Epilepsy Specialist
Nurse [ESN] role in managing people with
epilepsy in the Irish healthcare setting Results from the SENsE study.| A. Higgins, J.
Varley, C. Begley, M. White, C. Doherty, C.
Normand, M. Clarke, N. Elliott
1.004 How a Nurse Coordinator Improves a
Surgery Program| J. Johnson, N. Tandon
1.005 Ictal and Postictal Clinical Assessment
by Registered Nurses in the Epilepsy
Monitoring Unit: How well do they do? What
should we do differently to improve the
clinical assessment ?| T. Aung, L. Lehnhoff,
M. Plueger
1.006 Improving the Quality of Life of
Adolescents with Epilepsy Transitioning to
Adult Care| B. Frasch
1.007 Patient Simulation in the Pediatric
Epilepsy Monitoring Unit (EMU)| A.
Abdelmoity, E. Fecske
1.008 Nurse Educational Training in an
Epilepsy Monitoring Unit in Argentina| V. L.
Muro, M. E. Marincek, M. Segalovich, G.
Decima, H. Galluzzi, C. D'Giano
Psychosocial
1.009 Screening for Suicidal Ideation and
Behavior among Youth with Epilepsy Can
Save Lives| T. Falcone, E. Pestana-Knight, D.
Hagen, D. Zemba, P. Kotagal, E. Wyllie, A.
Gupta, A. Naduvil- Valapil, L. Overman, M.
Staniskyte , J. Timmons-Mitchell
education
1.010 Using epilepsy cases to build a
simulation-based bioethics curriculum for
neurology residents| B. Tolchin, J. Willey, K.
Prager
1.011 Problems of carry over to adulthood in
children with epilepsy| H. Yamamoto
1.012 Improvements in Both Knowledge and
Competence Around the Use of New
Therapeutic Options for the Management of
Partial-Onset Seizures| T. Finnegan
1.013 Simulation in Continuing Education:
Improving Evidence-Based Decisions in
Epilepsy Management| T. Finnegan, S.
Hughes, S. Haut
1.014 Improving the Management of
Refractory Partial-Onset Seizures Through
Continuing Medical Education| T. Finnegan,
P. Chatterjee, J. Sirven
1.015 Objective Measurement of Resident
EEG Interpretation| D. Weber, D. McCarthy, J.
Pathmanathan
1.016 An automated method of EEG
teaching: the Modular Real-Time
Electroencephalogram Education Guide (MR
EEG)| J. Pathmanathan, D. McCarthy, D.
Weber
neuROPhySIOlOgy
Video eeg epilepsy Monitoring
1.017 Dilemma in the use of interictal highfrequency oscillations (HFOs) in epilepsy
surgery.| Y. Nonoda, M. Miyakoshi, A. Ojeda,
S. Makeig, C. Juhasz, E. Asano
1.018 The Clinical Value of Continuous Pulse
Oximetry For SUDEP Prevention in the EMU|
D. M. Goldenholz, W. H. Theodore, S. Inati
1.019 Ictal Characteristics Associated With
Postictal Generalized EEG Suppression
(PGES) and Postictal Immobility (PI) Following
Generalized Tonic Clonic Seizures (GTCS).
Respiratory Impairment and PI Duration Are
Associated With PGES, There Is No
Association J. Kuo, M. Seyal
1.020 Diagnostic yield of continuous video
electroencephalography for paroxysmal vital
sign changes in children| L. Dang, R.
Shellhaas
1.021 Epileptic ripples differ morphologically
from physiological ripples associated with
sleep spindles| J. C. Bruder, M.
Duempelmann, D. Lachner, M. Mader, A.
Schulze-Bonhage, J. Jacobs
1.022 Foramen Ovale Electrodes (FOEs) in
Lesional and Non-lesional Epilepsy| D. J. Lee,
E. Tecoma, L. Kansal, D. Barba, V. IraguiMadoz
1.023 Patient characteristics and utility of
prolonged video-EEG monitoring in a tertiary
pediatric epilepsy monitoring unit| E.
Kovitch, R. Luke, T. Grishaber, H. Kim
1.024 Respiratory acidosis caused by
spontaneous focal seizures in the EMU| M.
Forcadela, P. W. Carney, A. Roten, S. Mullen
ICu
1.025 Yield and Impact of Continuous EEG
Monitoring in non-ICU Hospitalized Patients|
S. Sinha, S. Billakota
1.026 EEG Parameters Related to Seizures
during Continuous EEG Monitoring in
Critically Ill Patients and Outcomes| J.
Leibner, K. Mims, A. Tumkur, S. Smart, S.
Sinha
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
42
1.027 Retrospective study of continuous EEG
patterns in 50 patients admitted to
Neurological Intensive Care Unit at University
of Maryland Medical Center| J. Pritchard, C.
Srikanth Mysore
1.028 A region of interest approach to
comparing electrocorticography and
electrocortical stimulation for clinical
language mapping| Y. Wang, M. S. Fifer, A.
Flinker, A. Korzeniewska, M. Cervenka, D.
Boatman, W. Anderson, N. Crone
1.029 Predictors of mortality in newborns
with continuous electroencephalographic
monitoring in the intensive care unit| F. R.
Coughlin, I. Sánchez Fernández, A. J.
Sansevere, J. Klehm, P. Pearl, T.
Loddenkemper
1.030 Reduction of Hospital Aquired
Pressure Ulcers (HAPU) associated with long
term monitoring of EEG in neonatal
therapeutic hypothermia| R. Patterson, W.
Morton
1.031 Patient characteristics and seizure
prevalence in children with abusive head
trauma| H. Kim, A. Oh, L. Olson, J. Chern
1.032 EEG characteristics of successful burst
suppression for status epilepticus| E.
Johnson, E. K. Ritzl
1.033 Incidence and predictors of early and
late onset seizures after subarachnoid
hemorrhage| P. Puntambekar, S. Iyengar, I.
Ugorec, J. Politsky
1.034 Periodic and Rhythmic Patterns in the
critically ill: characteristics associated with
seizures| A. Rodriguez, J. Vlachy, J. Lee, E.
Gilmore, T. Ayer, H. Arif, N. Gaspard, L. Hirsch,
S. Laroche
Other Clinical eeg
1.035 Electrographic seizures during aortic
arch reconstruction surgery using deep
hypothermic circulatory arrest.| A. M. Feyissa,
A. Pochettino, T. Bower, G. Nuttall, J.
Mandrekar, J. W. Britton
1.036 Circadian Patterns of Epileptiform
Activity from Long-term Intracranial
Recordings in Ambulatory Subjects| D.
Spencer, F. Sun, S. N. Brown, B. C. Jobst, N. B.
Fountain, V. S. Wong, E. A. Mirro, M. Quigg
1.037 Unique Characteristics of the
Photoparoxysmal Response in Patients with
Neuronal Ceroid Lipofuscinosis type 2: Can
EEG be a Biomarker?| D. V. Albert, H. Yin, E.
De Los Reyes, J. Vidaurre
1.038 The evolution of EEG findings in
children with autism spectrum disorders| D.
Thodeson, D. Sirsi, S. Golla, P. Monga, U.
Hayyat, P. Evans, S. Arnold
1.039 How To Distinguish Primary
Generalized Epilepsy Mimicking Focal
Epilepsy From Surgically Remediable Focal
Epilepsy| D. Ba-Armah, A. Ye, S. Doesburg, H.
Otsubo, O. Snead, A. Ochi
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.040 What is the impact of Periodic
Lateralized Discharges on the clinical
outcome of critically Ill Children?| S.
Jirasakuldej, A. Dallara, D. McBrian, A. Mandel,
J. Cappell, P. Pojomovsky McDonnell, C.
Akman
1.041 Preictal collapse of
excitation/inhibition balance in the seizure
onset zone in focal epilepsy| Y. Sato, S.
Doesburg, S. Wong, A. Ochi, H. Otsubo
1.042 Interrater Agreement of EEG
Interpretation in Preterm Infants| G. Chari, Z.
Ibrahim, T. McSween, A. Reznikov, J. Weedon,
S. A. Baki, R. Kim, J. Aranda, J. Cracco
1.043 Evidence for Cross-Frequency PhaseAmplitude Coupling Mediating Seizure
Generalization| T. A. Wozny, A. Alhourani, M.
J. Randazzo, E. Kondylis, W. J. Lipski, A. Bagic,
A. Antony, M. Richardson
1.044 Interrater Agreement for Spike
Detection in Routine EEG: Spike Scoring
Competition Results| A. Arain, G.
Kalamangalam, S. laRoche, L. Bonilha, M.
Basha, N. Azar, E. Kutluay, G. Martz, C.
Waters, B. Dean, J. Halford
1.045 Chronic Ambulatory Human ECoG as a
Tool to Assess Response to Antiepileptic
Medications| T. Crowder Skarpaas, S. Arcot
Desai, F. Sun, M. Morrell
1.046 Sub-acute and long-term
electrocorticographic changes after
implantation of depth and subdural
electrodes| F. Sun, S. Arcot Desai, T. Tcheng,
M. Morrell
1.047 The decrease of “Scalp” High
Frequency Oscillations along with the
improvement of epilepsy ∼A new biomarker
in epilepsy treatments∼| T. Nagasawa, H.
Terashima, M. Kubota
Meg
1.048 Comparison of bilateral iEEG and MEG
findings in patients with non-lateralizing
seizures| P. Chen, E. Castillo, J. Baumgartner,
J. Seo, M. Korostenskaja, K. Lee
1.049 Disrupted Hippocampal Functional
Organization in Mesial Temporal Lobe
Epilepsy using Magnetoencephalography| A.
Alhourani, T. A. Wozny, M. J. Randazzo, M. J.
Ward, A. Niranjan, A. Bagic, A. Ghuman, M.
Richardson
1.050 Relative Yield of MEG and EEG Spikes
in Simultaneous Recordings| J. S. Ebersole, J.
Camerone, J. Politsky
1.051 Comparison of MEG and intracranial
EEG findings in non-lesional drug-resistant
partial epilepsy.| A. Vuppala, Z. Li, C. T.
Anderson, C. Carlson, W. Mueller, M.
Raghavan
1.052 Laterality and locality diagnosis using
dynamic statistical parametric mapping
analysis of ictal magnetoencephalography|
H. Yamamoto, K. Yagyu, K. Egawa, H. Shiraisi
1.053 Detection and source localization of
fast oscillations (40-160 Hz) in
magnetoencephalography (MEG)| C. Grova,
N. von Ellenrieder, G. Pellegrino, T. Hedrich, J.
Lina, E. Kobayashi
1.064 Safety and tolerability of transcranial
magnetic stimulation for motor and language
mapping| R. Gersner, L. Oberman, H. L. Kaye,
M. J. Sanchez, N. Chiriboga, A. Boes, A.
Pascual-Leone, A. Rotenberg
1.055 Magnetoencephalographic Recordings
(MEG) in Infants using a Standard-Sized
Array: Technical Adequacy and Diagnostic
Yield| S. Shibata, J. Mosher, P. Kotagal, A.
Gupta, A. Alexopoulos, R. Burgess
1.066 A Case of Vagal Nerve Stimulator
Dysfunction after DC Cardioversion leading to
Persistent Dysphagia.| N. Dike, A. Synowiec
1.054 Combining Stereotactic EEG and MEG
to localize seizure focus in children| M.
McManis, F. Perkins, P. Ferrari, M. Lee, D. F.
Clarke
1.056 Pre-ictal and ictal pathological High
Frequency Oscillations (HFOs) in drug
resistant focal epilepsy: Analysis of MEG
recording| V. Jayabal
Brain Stimulation
1.057 Modulation of the interictal
paroxysmal activity in a focal cortical
dysplasia by the centromedian thalamic
nucleus stimulation in one patient and in a
thalamocortical network model| A. Nica, P.
Benquet, Y. Denoyer, C. Haegelen, A. J.
Biraben
1.058 Safety and functional outcomes of
brain mapping with stereo EEG| O.
Taraschenko, D. Drane, C. Epstein, J. Willie, R.
Gross, K. Gotay, J. Ehrenberg, R. Fasano
1.059 Measurement of cortical excitability in
patients with primary brain tumours by
transcranial magnetic stimulation: predicting
seizures and antiepileptic drug response| Z.
Rahman, P. Menon, C. Wong, S. KIm, N.
Geevasinga, M. Van den Bos, M. Kiernan, S.
Vucic, A. Bleasel
1.060 Long-term outcome of adults with
medically intractable frontal lobe seizures
treated with responsive neurostimulation| B.
Jobst, R. Kapur, G. L. Barkley, M. Berg, G.
Bergey, S. Cash, A. Cole, M. Duchowny, R.
Duckrow, N. Fountain, R. Gross, R. Gwinn, A.
Herekar, D. King-Stephens, I. Miller, A. Murro,
D. Nair, K. Noe, M. A. Rossi, P. Rutecki, C.
Skidmore, D. Spencer, W. Tat
1.061 Alteration of Corrected QT Interval
Associated with Generalized Tonic-Clonic
Seizures induced by Electroconvulsive
Therapy (ECT)| Y. Suzuki, M. Miyajima, K.
Ohta, N. Yoshida, M. Okumura, M. Nakamura,
T. Sasano, T. Kawara, M. Matsuura, E.
Matsushima
1.062 Risk factors for stimulation-induced
seizures with direct cortical stimulation
during brain tumor resection surgeries| A. J.
Hani, A. Husain
1.063 Motor mapping by transcranial
magnetic stimulation reveals persistent
ipsilateral corticospinal connections in the
epileptic hemisphere in patients with
intractable focal epilepsy.| H. L. Kaye, R.
Gersner, A. Rotenberg
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
43
1.065 Interim review of efficacy, safety and
tolerability of 1 Hz deep repetitive
transcranial magnetic stimulation (rTMS) for
treatment of temporal lobe epilepsy| L.
Oberman, R. Gersner, A. Zangen, A.
Rotenberg
Computational Anaysis & Modeling of
eeg
1.067 A storm of fast (40-150 Hz) oscillations
during hypsarrhythmia in West syndrome| K.
Kobayashi, T. Akiyama, M. Oka, F. Endoh, H.
Yoshinaga
1.068 Unification of Spikes, Seizures, and
Spreading Depression| S. Schiff, Y. Wei, G.
Ullah
1.069 A Unified Statistical Model for the
Electrocorticogram| G. Kalamangalam, M.
Chelaru, J. D. Slater
1.070 Dynamic Model of Articulatory Loop
System Interactions in Human Brain| A.
Korzeniewska, N. Crone, M. Nishida, G.
Toyoda, N. Ofen, E. C. Brown, E. Asano
1.071 Scalp EEG ictal gamma activity in the
centroparietal channels indicates focal
cortical onsets of epileptic spasms in West
Syndrome| H. Nariai, B. Jules, A. S.
Galanopoulou, S. Bickel, Y. Sogawa, R. Jehle, S.
Shinnar, S. Moshe
1.072 Analysis of epileptic discharge in
patients with Sturge-Weber syndrome by
using implanted subdural electrodes.| Y.
Iimura, H. Sugano, M. Nakajima, T. Higo, H.
Suzuki, H. Arai
1.073 Seizure onset zone localization from
ictal high-density EEG in five patients| W.
Staljanssens, G. Strobbe, R. Van Holen, G.
Birot, C. Michel, M. Seeck, S. Vandenberghe,
V. Serge, P. van Mierlo
ClInICAl ePIlePSy
Classification and Symdromes
1.074 Age at onset in patients with temporal
lobe epilepsy and mesial temporal sclerosis.|
A. Asadi-Pooya, M. R. Sperling
1.075 Electroclinical Spectrum of SCN1A
Mutation Positive Patients: Beyond Classic
Dravet Syndrome| I. Yoo, S. Choi, S. Kim, Y.
Lee, H. Kim, H. Hwang, J. Chae, J. Choi, T. Ko, K.
Kim, Y. Hwang, B. Lim
1.076 The Expected Evolution of a
Secondarily Generalized Tonic-Clonic
Seizure| R. Compton, V. Iragui-Madoz, E.
Tecoma
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.077 Development of a classifier to identify
patients with Lennox–Gastaut syndrome in
health insurance claims databases via the
random forest methodology| F. Vekeman, J.
Pina-Garza, W. Cheng, E. Tuttle, P. GiguereDuval, A. Oganisian, J. Damron, M. Sheng
Duh, V. Shen, J. Isojarvi, G. Montouris
1.078 Novel SCN2A mutations S988P &
c.2962 T>C are associated with frequent
neonatal seizures and severe burstsuppression EEG in a neonate.| Z. Liu, A.
Tolaymat
1.079 Headache as an aura of focal seizures;
video-EEG monitoring study| J. Jin, D. Kim, S.
Lee
Clinical Diagnosis
1.080 A case report of syncope, seizureinduced bradycardia and asystole| F. Tong
1.081 Lateralizing value of clinical semiology
of Generalized Tonic Clonic seizures in
Temporal Lobe Epilepsy patients admitted to
the EMU| A. Abubakr
1.082 A biosensor for tracking seizures:
linking a wrist accelerometer to an online
seizure database| M. Velez, R. Fisher, V.
Bartlett, S. Le
1.083 Better Chance to Detect
Extratemporal Epilepsy in dEEG than 10-20
System: Demonstration in Three VA Cases|
H. Hasegawa
1.084 Usual ictal urination without
secondary generalization may be a localizing
sign| A. J. Biraben, A. Nica, C. Ricordeau, C.
haegelen, G. Taurin
1.085 Clinical epidemiology of newly
diagnosed early life epilepsy: underlying
causes and contributions from genetics.| A.
Berg, J. Mytinger, K. G. Knupp, R. Shellhaas, T.
Loddenkemper, R. Saneto, W. D. Gaillard, J.
Sullivan, Z. Grinspan, C. Chu, C. Keator, C.
Wusthoff, J. Coryell, E. Wirrell, A. Hartman, N.
Ryan, I. Valencia, D. R. Nordli
1.086 Cerebral folate deficiency presenting
as refractory seizures and CSWS in and
adult.| U. Thome, P. Klima, A. N. Moosa, G.
Ajay, E. M. Pestana Knight
1.087 Time Interval providing Highest Yield
for Initial EEG in New Onset Seizures| P.
Sofat, B. Teeter, K. Kavak, R. Gupta, P. Li
1.088 Localization Value Of Ictal Turning
Prone Along The Horizontal Body Axis| P.
Rawal, N. Azar, P. Singh, B. Abou-Khalil, M. AlKaylani, A. Arain
1.089 Epilepsy in Qatar: Causes, treatment
and outcome| N. Haddad, G. Melikyan, H. Al
Hail, A. Al Jurdi, B. Uthman, B. Mesraoua, D.
Deleu, N. Akhtar, L. Streletz, Z. Mahfoud
1.090 Associated Viruses in Benign
Convulsions with Mild Gastroenteritis| G.
Kim, B. Eun, J. Byeon
1.091 The yield of routine metabolic
diagnostic testing in the initial evaluation of
early life epilepsies.| D. R. Nordli, R. Saneto,
A. Hartman, J. Mytinger, K. G. Knupp, S. Joshi,
W. D. Gaillard, C. Keator, J. Sullivan, Z.
Grinspan, C. Chu, C. Wusthoff, E. Wirrell, J.
Coryell, I. Valencia, T. Loddenkemper, N.
Ryan, A. Berg
1.092 Lateralized periodic discharges (LPDs)
and electrographic seizures recorded in the
critical care setting increase the risk of long
term epilepsy.| V. Punia, L. Jehi, S. Hantus
1.093 Ictal biting injuries in the epilepsy
monitoring unit: a year's experience| D.
Dufresne, K. Dubovec, N. So, P. Kotagal
1.094 Seizures and Status Epilepticus in AirMedevac Patients| K. Haas, J. Brywczynski
1.095 Structured Data Collection in Epilepsy|
J. Narayanan
1.096 Temporal-spatial quantification of
neonatal seizures| D. M. Smith, L. Dicker, J.
Davis, R. Clancy
1.097 Ipsilateral choreiform-like movements
of upper limb presenting as an ictal
manifestation of parietal lobe seizures.| S.
Naik, H. Kamal, K. Warren, A. Memon, A.
Abokhamis
1.098 Ictal asystole in Focal Epilepsy as a Risk
Factor of Sudden Unexpected Death in
Epilepsy| Y. Krutoshinskaya, E. Cruz, G.
Pushchinska
1.099 Epileptic Encephalopathy in GABATransaminase Deficiency| P. Pearl, M. Koenig,
J. Riviello, M. Christie, K. Averill, W. Chung, J.
Bain, C. Chiriboga, R. M. Hodgeman, M.
Parviz, K. M. Gibson
1.100 Case Report – Rare Complication of
Bilateral Carotid Endarterectomy : Cerebral
Hyperperfusion Syndrome| M. Kurukumbi,
A. Truong, K. Eberly
1.101 Epileptic Seizures in Focal Cortical
Dysplasia| C. Chi, H. Lee, H. Yu, C. Chen, H.
Chen, C. Lin, S. Hsu, S. Kwan, T. Wong, Y. Shih
1.102 Neuronal antibodies in late-onset
partial epilepsies – a population-based
study| F. von Podewils, J. Lange, A. Dressel, C.
Kessler, U. Runge, C. Bien
1.103 RINCH motions- localizing and
lateralizing value in a general EMU
population| N. Zaher, B. Abou-Khalil
1.104 The clinical entity of anti-GAD related
epilepsy| F. Schaper, M. Majoie, M. Vlooswijk,
S. Koudijs, J. Damoiseaux, R. Rouhl
Clinical Treatments
1.105 EMU to Knife: Analyzing the Duration
of Epilepsy Surgery Evaluation and Causes
for Delay| H. Kadiwala, R. Hays, M. Agostini,
K. Ding
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
44
1.106 The Risk Factors and Profile Review for
30-day Readmission in Seizure/Epilepsy
Patients| A. Abdulsattar, S. Choudry, K.
Moravineni, M. Xu
1.107 Can Diffusion Weighted Imaging be
used as a marker for PLEDS associated with
seizures on EEG?| J. Narayanan
1.108 A Systematic Review and Meta-analysis
of Levetiracetam in Neonatal Seizures| D. C.
McHugh, L. N. Manganas
1.109 Tailored disconnection based on
presurgical evidence in catastrophic epilepsy:
A case series of 4 infants| J. Park, J. Sweet, S.
Manjila, R. Tangen, M. Cohen, A. Shahid, I.
Tuxhorn, M. Jonathan
1.110 Initial treatment for children <3 years
with new-onset epilepsy has changed
dramatically from 1977-2015 but remains
largely empirical| R. Shellhaas, W. D. Gaillard,
T. Loddenkemper, A. Patel, J. Sullivan, C.
Keator, K. G. Knupp, C. Chu, Z. Grinspan, A.
Hartman, C. Wusthoff, J. Coryell, E. Wirrell, E.
Novotny, I. Valencia, N. Ryan, D. R. Nordli, C.
Camfield, P. Camfield, A. Berg
1.111 The Effects of Anticonvulsant Therapy
in Post-anoxic Status Epilepticus| L. Ferraro,
S. Schmitt, D. Becker, K. Davis
1.112 Ketogenic Diet Efficacy in Treating
Increased Spike and Wave Discharges in
Sleep| C. Stillman, J. Oliver, K. Chapman
1.113 Use of Lacosamide (LAC) in Acute
Repetitive Seizures (ARS) in an Infant| B. E.
Swartz, A. Monibi, T. Blazer
1.114 Should physicians restrict driving in
seizure free patients undergoing antiepileptic
drug taper?| J. Kang, M. R. Sperling
1.115 LGI-1 autoimmune synaptic
encephalitis: EEG as a biomarker?| Z.
Guduru, D. Agrawal, S. Ramanathan, K.
Malhotra, A. Synowiec
1.116 Complications and safety of vagus
nerve stimulation – 25 years experience at a
single center| D. Revesz, B. Rydenhag, E. BenMenachem
1.117 Treatment Outcome of Infantile
Spasms in Children with Down Syndrome| E.
Marandi, A. Kumar, R. Munian Govindan, A.
Kaddurah, H. Chugani
1.118 Seizure Outcome of Intravenous
Levetiracetam in Children with Acute
Repetitive or Prolonged Seizures: Can be
Predictive?| K. Kim, S. Nam, S. Lyu, Y. Kim, G.
Yeon, Y. Lee
1.119 Demographics and Clinical
Characteristics of Adult Patients Experiencing
Seizure Cluster: A Retrospective Chart
Review| B. Vazquez, M. Sidovar, E. Wu, D.
Macaulay, R. Sorg, D. Squillacote, A. Guo
1.120 The Impact of Implementing Epilepsy
Education Tools for Nursing Staff in the
Pediatric Setting| E. Medaugh, S. Adduchio,
G. Kumar
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.121 Electrographic seizure detection and
effectiveness of responsive neurostimulation
in periventricular nodular heterotopias| P.
Van Ness, S. Arcot Desai, F. Sun, R. Kapur, D.
King-Stephens, G. Bergey, C. W. Bazil, A.
Herekar, M. Morrell
1.122 Response To Second Medication Trial
For Infantile Spasms| K. G. Knupp, E. Leister,
N. Ryan, K. Nickels, J. Coryell, A. Berg, D. R.
Nordli, J. Millichap, S. Joshi, R. Shellhaas, D.
Dlugos, J. Mytinger, W. D. Gaillard, C. Keator,
T. Loddenkemper, J. Sullivan, L. Zawadzki, W.
Mitchell, G. Kumar, D. Arkilo, E. Yozaw
1.123 Continuous intravenous therapy
versus intermittent bolus therapy for
pediatric refractory status epilepticus (RSE)|
K. Chapman, H. Goodkin, R. Tasker, I.
Sanchez Fernández, A. Topjian, A. Wilfong, A.
Helseth, J. Carpenter, J. Goldstein, K. Peariso,
K. Williams, M. Wainwright, M. Jackson, M.
Mikati, N. Abend, J. N. Brenton, R. Arya, T.
Glauser, W. D. Gaillard, T. Lodde
1.124 Antiepileptic treatment before the
onset of seizures in patients with tuberous
sclerosis complex: long-term observation of
ten children.| S. Jozwiak, K. Sadowski, D.
Domanska-Pakiela, J. Borkowska, B. Lojszczyk,
D. Chmielewski, K. Kotulska
1.125 Subjective Evaluation of Cognitive
Functioning By Patients With Epilepsy And
Their Physicians: How Accurate Are They?| E.
Firouztale, E. Barnoski, B. Anand, N. Pflaster,
L. Buck
1.126 Utility of Dipolar Source Estimation
Software For Ictal Onset Localization in
Pediatric Patients Undergoing Intracranial
EEG Monitoring| F. Perkins, M. Mcmanis, M.
Lee, D. F. Clarke
1.127 Lyrica (pregabalin) - Overview and
Status of Pediatric Epilepsy Clinical Program|
V. Pitman, D. Mann, J. Liu, J. Antinew
1.128 Quality of Sleep in patients treated
with Perampanel (PER)| M. Toledo, M.
Gonzalez, A. Molins Albanell, J. Miro Llado, M.
Falip, A. Martinez, S. Fernandez, M. Quintana,
E. Santamarina, J. Salas Puig
Prognosis
1.129 Procalcitonin for prognosis in status
epilepticus: An eight-year observation| R.
Sutter, M. Valença, S. Tschudin-Sutter, S.
Rueegg, S. Marsch
1.130 Perhaps 6 is Better than 7: Rethinking
the Scoring of the SUDEP-7 Inventory| B. D.
Moseley, C. M. DeGiorgio
1.131 High Incidence of Spontaneous
Hypothermia in Patients with Super
Refractory Non-Convulsive Status
Epilepticus| V. Sabharwal, H. McGrade, I.
Iwuchukwu, R. Shumate, R. Martinez, M.
Irland, F. Khan, R. Ramsay
1.132 Seizure cessation within 48 hours of
seizure detection in the neuro-ICU is
associated with increased survival| M. E.
Fleming, C. Cheyuo, T. White, J. Rosenthal, H.
Sy, K. Perrine, D. Ledoux, G. Aygok, C. Harden
1.144 DTI Model of mTLE Laterality| M.
Nazem-Zadeh, J. Schwalb, E. Air, K. Elisevich,
G. Divine, M. Kaur, V. S. Wasade, H. BagherEbadian, F. Mahmoudi, S. Shokri, H.
Soltanian-Zadeh
1.134 Longitudinal Change of Psychosocial
Measures After Temporal Lobe Epilepsy
Surgery| J. Winslow, G. Tesar, I. Najm, L. Jehi
1.146 Do seizures age the brain?: machine
learning analysis of structural MRI| H. R.
Pardoe, J. H. Cole, T. Thesen, K. Blackmon, R.
Kuzniecky
1.133 Stimulus-Induced Rhythmic, Periodic
or Ictal Discharges (SRIPIDs): Associated
Factors and Prognostic Implications| S. A.
Braksick, D. B. Burkholder, S. Tsetsou, L.
Martineau, J. Mandrekar, A. Rossetti, M.
Savard, J. W. Britton, A. Rabinstein
1.135 Predicting mortality in epilepsy in
general practice.| K. A. Ewert, J. Engbers, T.
Sajobi, C. Josephson, N. Jette, S. Wiebe
1.136 Status Epilepticus in Intra-Cerebral
Hemorrhage Hospitalizations - Results from
the Last Decade| R. Agarwal, A. Sakhuja
1.137 Clinical characteristics and outcome of
status epilepticus in patients with and
without a prior diagnosis of epilepsy| M.
Jackson, I. Sánchez Fernández, N. Abend, R.
Arya, J. N. Brenton, J. Carpenter, K. Chapman,
W. D. Gaillard, T. Glauser, J. Goldstein, H.
Goodkin, A. Helseth, M. Mikati, K. Peariso, R.
Tasker, A. Topjian, M. Wainwright, A. Wilfong,
K. Williams, T. Lodde
neuROIMAgIng
Structural Imaging
1.138 Magnetic resonance imaging findings
in low-Apgar-score infants: Correlations with
neonatal seizures and epilepsy| T. Fukasawa,
T. Kubota, T. Negoro
1.139 Altered Cortical Thickness and Volume
in New Onset Childhood Absence Epilepsy|
E. Kim, M. Yum, H. Yoon, W. Shim, Y. Lee, M.
Kim, T. Ko
1.140 Automated MRI Volumetric Analysis of
Rasmussen's Encephalitis| Z. Wang, B.
Krishnan, N. Al-Sharif, D. Shattuck, A. Joshi, R.
Leahy, A. Alexopoulos, R. Burgess, J. Mosher,
U. Udayasankar, A. N. Moosa, S. Jones
1.141 Relation to Cortical blood flow and
electrographic activity in Childhood-onset
Seizures: Correlation Between MRI-SWI and
EEG| Y. Lee, S. Nam, J. Hwang, K. Kim, S. Lyu,
G. Yeon, Y. Kim, Y. Kim
1.142 Diffusion tensor imaging and
hippocampal volumetry in Dravet syndrome|
J. Natsume, C. Ogawa, H. Yamamoto, Y. Ito, T.
Takeuchi, S. Yokoi, Y. Sakaguchi, Y. Azuma, N.
Ishihara, H. Kidokoro, K. Miura, T. Negoro, K.
Watanabe
1.143 Decreased white matter integrity
associated with cognitive impairment in
children with early onset epilepsy| M. Yoong,
M. Hunter, J. Shetty, A. McLellan, M.
McPhillips, M. Bastin, R. Chin
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
45
1.145 Diffusion MRI of the Subcortical White
Matter in Temporal Lobe Epilepsy: Relation to
Hippocampal Volume and Cortical
Thickness| M. Liu, B. Bernhardt, S. Hong, B.
Caldairou, A. Bernasconi, N. Bernasconi
1.147 In-vivo MRI signatures of hippocampal
subfield pathology in drug-resistant epilepsy|
M. Goubran, B. Bernhardt, S. De Ribaupierre,
R. Hammond, J. G. Burneo, S. Mirsattari, D.
Steven, A. Parrent, A. Bernasconi, N.
Bernasconi, A. Khan, T. Peters
1.148 Heterogeneity of grey matter atrophy
patterns exists within frontal and temporal
lobe epilepsies.| Y. Tan, R. C. Knowlton, K.
Laxer, S. Mueller
Functional Imaging
1.149 the predictive value of FDG-PET with
3D-SSP for postsurgical outcome in patients
with temporal lobe epilepsy.| T. Higo, H.
Sugano, M. Nakajima, Y. Iimura, H. Suzuki, H.
Arai
1.150 Laterality of Functional Connectivity
Associated with Language in Children with
Left Focal Epilepsy| X. You, L. Sepeta, J.
Facella-Ervolini, W. Gaillard, M. Berl
1.151 Hippocampal Connectivity in Children
with Left Focal Epilepsy| L. Sepeta, X. You, J.
Facella-Ervolini, M. Berl, W. D. Gaillard
1.152 Functional Connectivity of the Seizure
Onset Zone in Human Focal Non-Lesional
Epilepsy| K. Karkar, A. Soomro, F. Salinas, O.
V. Lie, T. Q. Duong, C. Szabo
1.153 Altered network hubs in JME| S.
Yaakub, J. O'Muircheartaigh, C. Vollmar, G.
Barker, M. Koepp, M. P. Richardson
1.154 Temporal lobe functions in patients
with Juvenile Myoclonic Epilepsy and
unaffected siblings: neuropsychometry and
functional magnetic resonance imaging| L.
Caciagli, B. Wandschneider, C. Vollmar, M.
Centeno, P. Thompson, J. O'Muircheartaigh,
M. P. Richardson, J. Duncan, M. Koepp
1.155 Ictal PET in Status epilepticus: a
valuable presurgical tool in selected patients
with status epilepticus (SE)| Y. Chinvarun
1.156 The role of [F-18]-Fluorodeoxyglucosepositron emission tomography (FDG-PET)
scans in the evaluation of children with
schizencephaly & intractable seizures| T.
Govil Dalela, A. Kumar, P. Konka, H. Chugani
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.157 Realtime oscillation analysis for
epilepsy diagnosis and surgery and awake
craniotomy| K. Kamada, H. Ogawa, C.
Kapeller, R. Prueckl, S. Hiroshima, C. Guger
1.158 Altered functional connectivity at sites
of malformation of cortical development| C.
Beers, A. Cull, I. Gaxiola Valdez, D. J. Pittman,
P. Federico
1.159 Regional Network Properties are
Altered in Focal Epilepsy: fMRI Dynamic
Connectivity at High Temporal Resolution|
M. Pedersen, A. Omidvarnia, E. Curwood, J.
Walz, G. D. Jackson
1.160 EEG Resting-State Directed
Connectivity Alterations in Temporal Lobe
Epilepsy vs Healthy Controls| A. Coito, M.
Genetti, F. Pittau, G. Iannotti, A.
Thomschewski, Y. Höller, E. Trinka, M. Seeck,
R. Wiest, C. Michel, G. Plomp, S. Vulliemoz
1.161 Utility of Gray-matter Segmentation of
Ictal-Interictal SPECT and FDG-PET in
Medically Refractory Epilepsy| K. Elkins, L.
Olson
1.162 Prediction of postoperative language
outcome using high gamma
electrocorticography, fMRI, and TMS| A.
Babajani-Feremi, C. Holder, S. Narayana, R.
Rezaie, B. Potter, S. Fulton, A. F. Choudhri, J.
Wheless, A. C. Papanicolaou
1.163 Absence Seizure Networks – Spatial
Correspondence Between fMRI and MEG| J.
Tenney, W. Agler, L. Rozhkov, H. Fujiwara, D.
Rose, J. Vannest, J. Xiang, S. Holland, T.
Glauser
1.164 Deep Brain Stimulation of the Rodent
SNr: a Clinical Target for Neocortical
Epilepsy| N. Van Den Berge, D. Albaugh, C.
Vanhove, R. Van Holen, G. Stuber, Y. Shih
1.165 Altered functional connectivity of
stress response-related brain regions in
patients with psychogenic non-epileptic
seizures (PNES)| J. Allendorfer, R. Nenert, K.
Hernando, A. Thomas, N. Billeaud, J. DeWolfe,
I.Pati, L. Ver Hoef, J. Szaflarski
Other emerging Techniques
1.166 Advanced diffusion imaging of
periventricular nodular heterotopia in 2
drug-resistant epilepsy patients| L. Kini, C.
Coto, J. M. Stein, K. Davis
1.167 Prolonged post-ictal PO2 vascular
changes occur in human focal epilepsy – An
intracranial oxygenation and arterial spin
labeling MRI study.| I. Gaxiola Valdez, S.
Singh, S. Sandy, E. Li, P. Federico
1.168 Post-surgical Uncinate Fasciculus
Diffusivity in TLE and Its Relationship to
Changes in Executive Function after ATL| N.
Kucukboyaci, K. Leyden, D. Lee, H. Girard, O.
Puckett, E. Tecoma, V. Iragui-Madoz, C.
McDonald
1.169 Clinical relevance of EEG-MEG Fusion
Source Analysis of Inter-ictal spikes| R. A.
Chowdhury, G. Pellegrino, J. Lina, E.
Kobayashi, C. Grova
1.170 Pattern of Implantation of SEEG
Electrodes in non Lesional Frontal Lobe
Epilepsy, Radiological and Anatomical
Localization based on Talairach Atlas| S.
Alomar, S. Smithason, J. Mullin, B. Krishnan, Z.
I. Wang, J. Gonzalez-Martinez
1.171 Mapping Epileptic Networks using
Glutamate Chemical Exchange Saturation
Transfer (GluCEST): A Comparison of Lesional
and Nonlesional Refractory Temporal Lobe
Epilepsy| S. Chen, R. Nanga, S. Das, C. Coto,
P. Hadar, H. Hariharan, M. Elliott, J. Detre, R.
Reddy, K. Davis
1.172 Arterial Spin Labeling (ASL) colateralization with brain MRI in lesional
epilepsy: the role of lesion type and seizure
frequency.| K. Khusiwilai, J. Murnick, K.
Havens, W. Gaillard, T. Zelleke
1.173 Brain tissue sodium concentration in
temporal lobe epielpsy: a dual sodium
proton imaging study at 3T| J. Lin, G. Gulsen
1.174 Florbetapir PET/CT Neuroimaging to
Evaluate Brain Amyloid Deposition in Chronic
Temporal Lobe Epilepsy| B. K. Day, J.
McConathy, C. Owen, T. Benzinger, R. E.
Hogan
COMORBIDITy (SOMATIC AnD
PSyChIATRIC)
Psychiatric Conditions
1.175 Electronic medical record analysis of
emergency room visits and hospitalizations
in individuals with epilepsy and mental illness
comorbidity| M. Sajatovic, E. Welter, C.
Tatsuoka, A. T. Perzynski, D. Einstadter
1.176 Psychological Evaluation of New-Onset
Pediatric Epilepsy Patients: Relationships
between Psychiatric Symptoms, Seizure
Localization, and Seizure Severity| A.
Hughes-Scalise, J. Doss, E. Adams, C.
Opperman
1.177 Depression, Quality of life, and Anxiety
in patients admitted for diagnostic Video
EEG monitoring| E. Koontz, P. Pritchard
1.178 The utility of Prolonged Exposure
Therapy (PET) in the treatment of patients
who are dually diagnosed with PNES and
PTSD| L. Myers, U. Vaidya, M. Lizardo
1.179 Integrating psychology into outpatient
pediatric epilepsy care: psychological
comorbidities, service delivery, and
effectiveness| M. Stoeckel, C. Roberts, J.
Coryell, C. Wray, A. Frank, D. Kriz
1.180 WITHDRAWN
1.181 Assessing depressive symptoms in
youth with epilepsy: The NDDI-E-Y vs
NeuroQol in the prediction of CDI-2 scores|
T. Kellermann, J. L. Wagner, G. Smith, B.
Brooks, M. Mueller
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
46
AnTIePIlePTIC DRugS
Clinical Trials
1.182 Quality of Life Improvement among
Patients with Refractory Partial-Onset
Seizures: A Clinical Trial Analysis of Patients
who Responded to Eslicarbazepine Acetate
Monotherapy| J. Cramer, F. Velez, T. Bond, K.
Plante Anastassopoulos, X. Wang, H. Cheng,
R. Sousa, D. Blum
1.183 Relationship between Serum Sodium
Level ([Na+]) and Treatment-Emergent
Adverse Events (TEAEs) in Patients Taking
Eslicarbazepine Acetate (ESL) Monotherapy:
Pooled Analysis of Two Phase III Studies| M.
L. McNulty, M. Smith, D. G. Vossler, R.
Sachdeo, L. Strom, T. Grinnell, H. Cheng, D.
Blum
1.184 Effect of Adjunctive Perampanel in
Pediatric Subjects With Epilepsy: Preliminary
Safety and Efficacy Results From Study 232|
R. Davis, J. Ferreira, D. Kumar, H. Yang, A.
Laurenza, S. Dispoto
1.185 Efficacy of Eslicarbazepine Acetate
(ESL) as Adjunctive Treatment: Sensitivity
Analyses of the Impact of Early Termination
(ET)| H. Cheng, Y. Li, T. Grinnell, F. Rocha, P.
Soares-da-Silva, D. Blum
1.186 Incidence of Treatment Emergent
Adverse Events in Three Phase III Studies of
Adjunctive Eslicarbazepine Acetate, in
Patients Taking or Not Taking Lamotrigine at
Baseline| B. Abou-Khalil, P. Klein, A. Shah, P.
Ryvlin, L. M. Specchio, H. Gama, F. Rocha, D.
Blum, T. Grinnell, R. Claus
1.187 Pharmacokinetics of Perampanel in
Children With Epilepsy Aged 2 to <12 Years|
B. Renfroe, Y. Umetsu, M. Mintz, S. Dispoto, J.
Ferry, B. Rege, H. Yang, A. Laurenza, Z.
Hussein
1.188 Efficacy of Perampanel by Baseline
Seizure Frequency in Patients with Partial
Seizures (Phase III Double-Blind Studies)| B.
Williams, M. R. Sperling, A. Laurenza, T. Ma, H.
Yang
1.189 Suicidality Events in Patients With
Primary Generalized Tonic-Clonic Seizures
(PGTCS): A Review of Study 332| A. Ettinger,
B. Renfroe, C. Dobrinsky, H. Yang, A. Laurenza,
B. Williams, A. Patten, F. Bibbiani
1.190 Psychiatric and Behavioral Events with
Perampanel in Patients with Primary
Generalized Tonic-Clonic Seizures (PGTCS):
Study 332| C. Dobrinsky, A. Ettinger, W.
Rosenfeld, B. Williams, A. Laurenza, H. Yang,
A. Patten, F. Bibbiani
1.191 Subanalysis by Baseline Antiepileptic
Drugs (AEDs): Results From Perampanel
Study 332 in Patients With Primary
Generalized Tonic-Clonic Seizures (PGTCS)|
B. Kirmani, A. Laurenza, H. Yang, B. Williams,
A. Patten, F. Bibbiani
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.192 Review of Pregnancy Events in
Perampanel Clinical Studies| B. Vazquez, C.
Dobrinsky, H. Yang, B. Williams, D. Kumar, A.
Laurenza, C. Harden
1.193 Effect of Duration of Epilepsy on
Adjunctive Perampanel Treatment in Patients
With Drug-Resistant Partial Seizures| J.
Halford, H. Yang, B. Williams, T. Ma, A.
Laurenza
1.194 Analysis of Falls in the Phase III
Perampanel Study of Primary Generalized
Tonic-Clonic Seizures (PGTCS)| I. Leppik, B.
Williams, T. Ma, A. Patten, A. Laurenza, F.
Bibbiani
1.195 Clinical Laboratory Evaluation and
TEAEs Related to Cardiac, Hepatic and Renal
Disorders: Perampanel PGTC Phase III
Study| W. McElveen, D. Vossler, B. Williams,
A. Laurenza, A. Patten, F. Bibbiani
1.196 Long-Term Perampanel Treatment in
Patients With Drug-Resistant Partial Seizures:
≥75% Responders and Seizure-Free Status|
H. Yang, G. Krauss, B. Williams, T. Ma, A.
Laurenza
1.197 An indirect comparison of selected
adjunctive treatments for refractory partial
onset seizures: Does evidence matter?| J. D.
Slater, S. Chung, L. Huynh, M. Sheng Duh, B.
Gorin, C. McMicken, A. Ziemann, J. Isojarvi
1.198 Early experience with levetiracetam
monotherapy - Current status at an acute
care general hospital covering neurological
emergency through epilepsy treatment| T.
Yamamoto, T. Yamazoe, A. Fujimoto, K. Sato,
T. Okanishi, T. Yokota, H. Enoki
1.199 Time from First Exposure to
Discontinuation due to Adverse Events or
Lack of Efficacy in the Brivaracetam Clinical
Program| S. Elmoufti, J. Whitesides , S.
Borghs
1.200 Deconstructing Tolerance With
Clobazam: Post Hoc Analyses From an OpenLabel Extension Study| R. Sankar, B. E. Gidal,
R. Wechsler, G. Montouris, S. White, J. C.
Cloyd, G. Peng, D. M. Tworek, V. Shen, J.
Isojarvi
1.201 Comparisons of the utilization, costs,
and services by location of care for
employees whose spouses with epilepsy
have partial onset seizures and are managed
by monotherapy or adjunctive therapy| F.
Velez, R. A. Brook, D. D. Wingenbach, J. E.
Smeeding
1.202 Predictors of 50% Seizure Frequency
Reduction among Epilepsy Patients with PartialOnset Seizures: Analysis of Phase III Trials of
Adjunctive Treatment with Eslicarbazepine
Acetate| K. Plante Anastassopoulos, F. Velez, T.
Bond, R. Sousa, D. Blum
1.203 Long-term healthcare costs in the UK
associated with enzyme-inducing
antiepileptic drugs (EIAEDs) vs non-enzyme
active antiepileptic drugs (nEAAEDs)| S.
Borghs , S. Thieffry, J. Chan, P. Dedeken, L.
Byram , J. Logan, R. Storb, V. Kiri
1.204 Dose-response relationships of AEDs
in refractory epilepsy| N. Poolos,
C. Castagna, S. Williams , A. Miller, T. Story
1.205 Expanded analysis of antiepileptic
drug comparative efficacy in refractory
epilepsy| C. Castagna, S. Williams, A. Miller, T.
Story, N. Poolos
1.206 Development of Cognitive Functions in
Children with Fetal Antiepileptic Drug
Exposure: Study in Georgia| S. Kasradze
1.207 Role of Lacosamide in neuroncology|
A. Molins Albanell, M. Quintana, E.
Santamarina, J. Salas Puig, M. Toledo
1.208 Continuous Electroencephalography
In The Intensive Care Units Significantly
Impacts AED Modifications| A. M. Khawaja,
G. Wang, G. Cutter, J. Szaflarski
1.209 Population Pharmacokinetics
Associated with Adverse Effects of
Oxcarbazepine in Korean Patients with
Epilepsy| T. J. Kim, J. Byun, J. Moon, J. Sunwoo,
J. A. Lim, S. Lee, K. Jung, S. Lee, K. Chu, S. Lee
Drug Interaction
1.210 Factors Influencing Topiramate
Pharmacokinetics in Adults Patients with
Epilepsy: A Population Pharmacokinetic
Analysis| E. Bae
1.211 Model-predicted relationships
between perampanel plasma concentrations
and efficacy for partial-onset seizures (POS)
and primary generalized tonic-clonic (PGTC)
seizures| B. Gidal, R. Wechsler, G. Krauss, J.
Ferry, B. Rege, F. Bibbiani, A. Patten, B.
Williams, H. Yang, Z. Hussein
1.212 Protein Binding of Perampanel in
Human Plasma: Does Protein-Binding
Displacement Occur?| T. Ueno, B. Gidal, K.
Kikuchi, J. Ferry
1.213 Risk of pharmacokinetic interactions
between antiepilepsy and other drugs in a
United States Medicare population| R.
Faught, J. Richman, E. Funkhouser, J.
Szaflarski, T. Peace, L. Juarez, L. Piper, A.
Brown, R. Martin, M. Pisu
1.214 Pharmacokinetics of adjunctive
perampanel in patients with partial-onset
seizures or primary generalized tonic-clonic
seizures in idiopathic generalized epilepsy:
pooled data from four randomized, doubleblind Phase III studies| G. Krauss, R.
Wechsler, B. Gidal, F. Bibbiani, A. Patten, B.
Williams, H. Yang, Z. Hussein
1.215 Analysis of Cannabidiol Interactions
with Antiseizure Drugs| M. D. Smith, K. S.
Wilcox, S. White
1.216 Co-Administration of Valproic Acid and
Lamotrigine in the Treatment of Refractory
Epilepsy| M. Jiang, M. Andriola, J. Miller-Horn
1.217 Oral loading dose of lacosamide in
daily Clinical Practice| B. Pedersen
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
47
Side effects
1.218 Lamotrigine concentrations over 20
mg/L: clinical pharmacology and clinical
correlates| P. Ramey, M. Osborn, B. AbouKhalil
1.219 Evaluation of the Pharmacokinetic
Interaction of Brivaracetam on Other
Antiepileptic Drugs in Adults with PartialOnset Seizures| C. Otoul, A. Stockis
1.220 The clinical experience with
Perampanel of the Danish Epilepsy Center:
Focus on aggression as adverse effect with
emphasis on concomitant medication and on
mental retardation| S. Juhl
1.221 The patients’ perception of adverse
effects, adherence and quality of life to
antiepileptic drug treatment| M. Mevaag, O.
Henning, S. Johannessen, C. J. Landmark
1.222 Vigabitrin use does not correlate with
lower serum taurine levels in children| E. A.
Mathews, B. Porter
1.223 Psychiatric and behavioral side effects
in adolescents and children with epilepsy| B.
Chen, K. Detyniecki, H. Choi, A. D. Katz, L.
Hirsch, A. W. Legge, K. Kato, L. Tibbetts, S.
Harris, R. Wong, A. Jiang, A. Ullah, R. Ha, N.
Maloney, A. Komaragiri, A. Javed, R.
Buchsbaum, P. Farooque
1.224 Brivaracetam-Induced Elevation of
Carbamazepine-Epoxide Levels: A Safety
Analysis| B. McDonough, A. Colson, A.
Stockis, M. Johnson , J. Whitesides
Other
1.225 Treatment stability in newly diagnosed
epilepsy patients: A US database analysis| D.
Thurman, R. Faught, S. Helmers, H. Kim, T.
Durgin , L. Kalilani
1.226 Patient characteristics and treatment
patterns in newly diagnosed epilepsy
patients: a US database analysis| L. Kalilani ,
S. Helmers, R. Faught, D. Thurman, H. Kim, T.
Durgin
1.227 Population Pharmacokinetics and
Exposure-Response Modeling of
Brivaracetam in Adult Subjects Using Daily
Seizure Counts| A. Stockis, R. Schoemaker
1.228 Evaluation of serum Phenytoin levels
24 hours following a single intravenous
loading dose| O. Selioutski, L. Liu, A.
Hilmarsson, D. M. Bonno, A. Fessler, R. Gross
1.229 Staged anticonvulsant screening for
chronic epilepsy| Y. Saponjian, Y.
Berdichevsky, K. Park, W. Swiercz, K. Lu, F. E.
Dudek, K. Staley
1.230 Real-world experience with lacosamide
as early add-on treatment in focal epilepsy.|
J. Ojeda, D. Sopelana, F. Cabrera, O. Sánchez,
M. Villar, M. Domínguez, L. Galiano, J.
Almajano, A. Gago, M. de Toledo, M. Ceballos,
A. Martín-Araguz, E. Aragón, S. López
Gallardo, I. Ybot, M. Martínez
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.231 Creation and Implementation of
Antiepileptic Drug Patient Education Cards:
Establishing a Process for Consistent,
Accurate, and Concise Medication
Counseling in Pediatric Patients| T. Baierlipp,
M. Messinger, S. DiCarlo, A. Wilfong
1.243 The use of the Ketogenic Diet in
Pediatric patients with severe epileptic
disorders.| M. Salam, R. Cappa, C. R. Dike, S.
Obaid, A. Hashim
1.233 Safety and efficacy of eslicarbazepineacetate in elderly patients with focal epilepsy
in real-life practice| A. Gomez-Ibanez, V.
Villanueva, J. Serratosa, M. Garces, M. Toledo,
A. Castillo, E. Guillamon, B. Giraldez, J. SalasPuig, F. Lopez-Gonzalez, J. Flores, J. Rodriguez
Uranga, E. Lopez-Gomariz, P. Giner, N. Torres,
J. Palau, A. Molins Albanell
1.245 Blood Beta-Hydroxybutyrate Levels
Correlate with Seizure Frequency in Epileptic
Patients Treated with the Ketogenic Diet| J.
M. Rho, J. D. Smith, S. D'Alfonso, R. Singer, M.
Connolly, A. Michoulas, D. Sinasac E. Fung N.
Singh, J. Buchhalter
1.232 Anti epileptic drug prescribing in a
small Scottish City| K. White, M. McTiernan, I.
Morrison
1.234 Comparative Efficacy by Lobe of 13
Antiepileptic Drugs in almost 2000 Adults
with Focal Epilepsy| A. D. Katz, K. Detyniecki,
L. Hirsch, B. Chen, A. Ullah, A. Jiang, R. Wong,
A. Komaragiri, A. Legge, A. Javed, R.
Buchsbaum, H. Choi
1.235 The effects of antiepileptic drugs on
transporter expression in BeWo cells as a
model of the human trophoblast| M.
Rubinchik-Stern, M. Shmuel, S. Eyal
1.236 Antiepileptic Treatment Satisfaction
Among Patients with Epilepsy: Analysis of
Predictors| F. Velez, L. Lee, D. Pomerantz, M.
D. DiBonaventura
1.237 Extrapolation of a Brivaracetam
Exposure-Response Model from Adults to
Children| R. Schoemaker, A. Stockis
1.238 Effect of Body Mass Index on
Intravenous Fosphenytoin Loading Dosing:
Efficacy of Treatment, Adverse Effects and
Length of Hospital Stay| S. Clark, M. Leloux,
R. Dierkhising, S. Hocker, G. Cascino
1.239 Penetration ratio of Lacosamide
compared with classic anticonvulsants using
an in vitro model of blood-brain barrier| O.
A. Martinez, M. Pacha, L. Orellana, N. Pelisch
1.240 Lacosamide levels in adult epilepsy
patients are influenced by race| A.
Mahulikar, A. Shah, N. Seraji-Bozoergzad, M.
Basha
nOn-AeD/nOn-SuRgICAl
TReATMenTS
Pediatrics
1.241 Ketogenic Diet Initiation Calorie and
Meal Progression Protocol: Three-day versus
Two-day Initiation| J. Oliver, C. Stillman, V.
Allen, M. Stevenson, L. Pinnick, S. Criteser, S.
Brightwell, K. Chapman
1.242 The Effects of Ketogenic diet on
Growth in Pediatric Patients| C. R. Dike, M.
Salam, S. Obaid, A. Hashim
1.244 Spirituality and Patterns of
Complementary and Alternative Medicine
use in a regional Pediatric Epilepsy
Monitoring Unit| M. Thompson, M. Goyal, J.
Beattie, P. Parks
1.246 Ketogenic Diet Treatment for SuperRefractory Status Epilepticus in Pediatric
Patients| B. Appavu, L. Vanatta, J. Condie, R.
Jarrar
1.247 What are the Effects of the Ketogenic
Diet on Biomarkers of Lipid Metabolism in
Children with Epilepsy?| S. Karia, L. Dority, D.
Hanrahan, D. DellaValle
1.248 Ketogenic diet aborts super refractory
status epilepticus| Y. Liu, M. Zak, H. Lowe, J.
Kobayashi, V. Chan, E. Donner
All Ages
1.249 Diet Redux: Outcomes from
reattempting dietary therapy for epilepsy a
second time| S. C. Doerrer, S. P. Winesett, M.
C. Cervenka, Z. Turner, B. J. Henry, S.
Bessone, E. Kossoff
1.250 Two-Year Outcome of Japanese
Registry of VNS Therapy for Drug-Resistant
Epilepsy| K. Kawai, T. Tanaka, H. Baba, M.
Bunker, Y. Inoue, S. Kameyama, S. Kaneko, A.
Kato, E. Maruoka, T. Nozawa, M. Osawa, T.
Otsuki, S. Tsuji, E. Watanabe
1.251 Everolimus shows sustained efficacy
for refractory epilepsy in Tuberous Sclerosis
Complex (TSC)| D. Krueger, A. Wilfong, C.
Talley, K. Agricola, D. Franz
SuRgeRy
Adult
1.252 Functional connectivity measurements
in focal epilepsy using MEG| D. J. Englot, R. C.
Knowlton, E. F. Chang, H. E. Kirsch, S. S.
Nagarajan
1.253 Intraoperative subcortical-cortical
evoked potential for subcortical fiber
mapping| R. Enatsu, S. Ohtaki, A. Kanno, Y.
Akiyama, S. Ochi, N. Mikuni
1.254 Surgical outcome of before and after
introduction of ictal HFO analysis in adult
patients with MRI-negative neocortical
epilepsy| T. Maehara, M. Inaji, K. Hara
1.255 Unidirectional laser ablation for Mesial
Temporal Lobe Epilepsy| C. M. Pearson, P.
Camarata, K. Shah, U. Uysal, P. Landazuri
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
48
1.256 Characteristics of epilepsy with
temporal encephalocele: utility of
electrocorticography and surgical outcome|
Y. Li, F. Panov, E. F. Chang, R. C. Knowlton, S.
Cornes
1.257 The optimal surgical extents of
cavernous angioma in patients with epilepsy|
W. Hwnag, E. Joo, D. Seo, S. Hong, S. Hong
1.258 Stereo-EEG exploration in adults with
complex motor and hypermotor intractable
seizures: technical note and outcome| A. H.
Ewida, M. Anadani, A. Marashly, S. Deepak, J.
Miller, S. Pati
1.259 The utility of FDG-PET and Ictal SPECT
in patients with non-lesional focal epilepsy
undergoing stereoencephalography for
presurgical evaluation.| F. Chowdhury, A.
McEvoy, T. Wehner, A. Miserocchi, J. Duncan,
C. Scott, R. Rodionov, M. Nowell, B. Diehl
Pediatrics
1.260 Parents’ Perspective: Functional and
Behavioral Outcomes of Epilepsy Surgery in
Children with Autism| M. Kokoszka, P.
McGoldrick, M. La Vega-Talbott, H. Raynes, C.
Palmese, S. Wolf, S. Ghatan
1.261 Significance of ictal infraslow activity in
subdural/depth electroencephalography
(EEG) analysis of medically intractable
epilepsy caused by focal cortical dysplasia| P.
Laoprasert, M. Handler, B. Habtke
1.262 Antiepileptic drug reduction and
withdrawal after epilepsy surgery in children
with focal cortical dysplasia | K. Havens, C.
Oluigbo, S. Magge, T. Tsuchida, J. Schreiber, A.
Kao, T. Zelleke, J. Conry, S. Weinstein, W.
Gaillard, D. Depositario-Cabacar
1.263 Verbal memory after temporal lobe
epilepsy surgery: A decade of experience in a
pediatric hospital | L. Brenner, K. Boyer, J.
Bolton, J. Madsen, D. P. Waber, C. Vega
1.264 Vagus nerve stimulation for Pediatric
Epilepsy: Seizure outcome and prognostic
factors| R. Yu, H. Kang, H. Kim, D. Kim, J. Lee
1.265 Resection of the Insula and adjoining
epileptogenic zone: Safety and Efficacy| S.
Sen, M. Lee, D. F. Clarke
1.266 Outcome predictors after callosotomy|
D. Bezerra, J. A. Burattini, C. M. Cukiert, A.
Cukiert
1.267 Modified functional subtotal
hemishperectomy: A technical note | M.
Ranjan, L. Bello-Espinosa, W. Hader
1.268 EEG findings in patients with
hypothalamic hamartoma (HH), and utility of
EEG and PET scan in presurgical evaluation of
patients with HH, for laser ablation.| K. Mir, C.
Talley, D. Curry, A. Wilfong
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.269 Validation of MEG as a Pre-surgical
Evaluation Tool in Pediatric Patients With
Intractable Epilepsy (previously presented at
AAN 2014)| H. Barkan, J. Kestle, C. Van
Orman, M. Funke
All Ages
1.270 Localized interictal spikes on
magnetoencephalography predicts seizure
freedom in epilepsy surgery| D. J. Englot, S.
S. Nagarajan, R. C. Knowlton, H. E. Kirsch, E. F.
Chang
1.271 The significance of lateralized interictal
slow activity on MEG versus EEG in focal
epilepsy| D. J. Englot, D. D. Wang, J. D.
Rolston, D. Mizuiri, S. M. Honma, M. Mantle,
R. C. Knowlton, S. S. Nagarajan, E. F. Chang,
H. E. Kirsch
1.272 Magnetoencephalography and
dynamic changes of epileptic discharges in
epilepsy patients carrying vagus nerve
stimulation| K. Iida, K. Kagawa, M. Kartagiri,
A. Hashizume, K. Kurisu
1.273 SEEG Guided Robotic Laser Ablation in
Non-Lesional Refractory Focal Epilepsy| L.
Ross, J. Mullin, J. Gonzalez-Martinez
1.274 The treatment of foci resection and
bipolar electro-coagulation on functional
cortex in multifocal epilepsy associated with
tuberous sclerosis complex involving
eloquent cortex| F. Zhai
1.275 Epilepsy Surgery in focal epilepsy as
part of GEFS+| K. Vezyroglou, I. Scheffer, E.
Hirsch, K. Strobl, C. Barba, R. Guerrini, S.
Sisodiya, J. Cross
1.276 SEEG-guided radiofrequency
thermocoagulation in drug resistant focal
epilepsy| P. Bourdillon, J. Isnard, S. Rheims,
H. Catenoix, A. Montavont, P. Ryvlin, M.
Guénot
1.277 Usefulness of Repeat Review of the
Head MRI at Presurgical Epilepsy
Conference| D. Kenney, K. Krecke, W. Robert,
R. Watson, A. Kotsenas, E. Wirrell, K. Nickels,
L. Wong-Kisiel, E. So
1.278 Does the volume of resection matter?
Resection Volume and Seizure Recurrence
analysis in SEEG guided frontal resections.| J.
Jones, J. Mullin, S. Smithason, J. Gale, J.
Gonzalez-Martinez
BehAVIOR/neuROPSyChOlOgy/
lAnguAge
Adult
1.279 Psychogenic Non-epileptic Seizures: A
Pilot Study of a Brief Educational
Intervention| N. Thompson, J. Peltzer, L.
Connelly, W. Nowack, E. Hunter, I. Osorio
1.280 Do measures of depression help
predict epilepsy surgery outcomes?| L. Shah,
J. P. Valeriano, A. Synowiec, K. M. Kelly, J.
Wilberger, C. J. Schramke
1.281 Influence of cerebral collateral
circulation on preoperative evaluation of
speech and memory dominance estimated
by intracarotid propofol test| T. Kunieda, N.
Mikuni, R. Inano, T. Kikuchi, T. Inada, Y.
Takahashi, S. Nishida, T. Nakae, S. Shibata, Y.
Yamao, Y. Arakawa, R. Matsumoto, A. Ikeda,
R. Takahashi, S. Miyamoto
1.282 Cognitive Performance of Newly
Treated Patients with Focal Epilepsy at
Enrollment in the HEP Study| K. J. Meador, C.
Morrison, T. O'Brien, P. Penovich, D. Darby, A.
Schembri, K. McKenna, S. Cristofaro
1.283 Fatigue and sleep in Korean people
with epilepsy| O. Kwon, S. Jung, W. Nam, S.
Park
1.284 Neurocognitive Outcome Following
MRI-Guided Laser Ablation of MesioTemporal Structures| G. J. Rey, J. Jagid, M.
Lopez, M. lowe, M. Palomeque, G. Rey, R.
Ribot, E. Serrano, L. Tornes, A. Kanner
1.285 Cognitive Differences between
Psychogenic Non-Epileptic Seizure Patients
with and without Alexithymia| K. Lebeau, L.
Myers, R. Trobliger, M. Lancman, S. Iyengar,
M. Lancman, J. Jones, J. Sabri
1.286 A Randomized Trial of HOBSCOTCH:
HOme Based Self-Management & COgnitive
Training CHanges Lives| K. Secore, B. C.
Jobst, T. Caller, R. Roth
1.287 Postical Semiology in Psychogenic
Non-epileptic Seizures| S. Izadyar, R.
O'Dwyer Vourganti, V. Shah
1.288 Sleep hygiene in adults with epilepsy:
relationship to sleep disturbances and
quality of life| J. H. Baek, S. A. Lee
1.289 Predicting Language and Memory
Decline after Left Temporal Lobe Resection
in Patients with Mesial Temporal Sclerosis| L.
Ferguson, D. P. Floden, I. Najm, R. M. Busch
Pediatrics
1.290 Memory Outcome Following Temporal
Lobe Resection in Children Using Reliable
Change Indices| R. M. Busch, L. Ferguson, T.
T. Lineweaver, P. Klaas, W. Bingaman, D.
Lachhwani, J. S. Haut
1.291 Patterns of Verbal Learning and
Memory in Children with Intractable
Temporal Lobe or Frontal Lobe Epilepsy| M.
Smith, A. Fuentes
1.292 Intervention to Improve Adherence to
Antiepileptic Medication in Pediatric Epilepsy:
The Supporting Treatment Adherence
Regiment (STAR) Study| A. Modi, K. Mann, J.
Rausch, S. Guilfoyle, S. Ollier
1.293 Brief computerized screening detects
cognitive changes in children with epilepsy|
M. E. Bone, R. Triplett, P. Rubin, M. R. Asato
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
49
1.294 Measurement Equivalence of the
Quality of Life in Childhood Epilepsy
Questionnaire (QOLCE-55) Across Age and
Gender| M. Ferro, S. Goodwin, M. Sabaz, K.
Speechley
1.295 Minnesota Epilepsy Group’s
Multidisciplinary Clinic for New Onset
Pediatric Epilepsy (NOPE): Overview of NOPE
Clinic Including One-Year Follow-Up| E.
Adams, J. Doss, K. Berg, C. Opperman, F.
Ritter
1.296 Long-term Follow-up of Health-related
Quality of Life in Children with Epilepsy: Eight
Years Post-diagnosis| K. Speechley, M. Ferro,
C. Camfield, W. Huang, S. Levin, M. Smith, S.
Wiebe, G. Zou
1.297 The relationship between subjective
concerns and objective performance on
pediatric naming tasks in children with
epilepsy| K. Walsh, M. Smith, W. MacAllister,
M. J. Hamberger
1.298 Global Frontal Lobe Dysfunction in
Children with Temporal Lobe Epilepsy| T.
Oyegbile, J. W. VanMeter, B. Hermann, W.
Gaillard
1.299 Neurocognitive and Behavioral change
after surgery in Pediatric Frontal and
Temporal lobe Epilepsy| S. Eom, H. Kang, J.
Lee, H. Kim, H. Chung
1.300 Auditory and visual naming in children
with lateralized epilepsy| M. J. Hamberger, M.
Smith, W. MacAllister, A. Williams, W. T. Seidel
geneTICS
human Studies
1.301 MECP2 Duplication is Associated with
Severe Epileptic Encephalopathy in The
Presence of Permissive Genetic Background|
D. Marafie, B. Suter, V. H. Pacheco, D. Glaze, J.
Drabek, A. Goldman
1.302 De novo GRIN1 mutations cause
encephalopathy with infantile-onset epilepsy,
hyperkinetic and stereotyped movement
disorders, mimicking neurotransmitter
disease| J. Tohyama, C. Ohba, M. Shiina, K.
Haginoya, T. Lerman-Sagie, N. Okamoto, S.
Magara, Y. Kobayashi, K. Okazaki, T.
Komatsubara, L. Blumkin, D. Lev, S. Mukaida,
F. Nozaki, M. Uematsu, A. Onuma, M.
Nakashima, M. Kato, K. Ogata, H. Saitsu, N.
Matsumoto
1.303 Delineation of the EEF1A2-epileptic
encephalopathy phenotypic spectrum| K. L.
Helbig, R. Huether, E. H. Brilstra, F. E. Jansen,
L. O. Rohena, T. Feyma, C. Depienne, C. Nava,
K. Farwell, S. Tang, B. P. Koeleman, M. C. Kruer
1.304 Predicting response to AED treatment
in patients with mesial temporal lobe
epilepsy based on clinical and
pharmacogenetic information| R. Secolin, M.
S. Silva, B. S. Carvalho, E. Bilevicius, C. V.
Maurer-Morelli, F. Cendes, I. Lopes-Cendes
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.305 Somatic mutations in the MTOR gene
cause focal cortical dysplasia type IIb| H.
Saitsu, M. Nakashima, N. Takei, J. Tohyama, M.
Kato, H. Kitaura, M. Shiina, H. Shirozu, H.
Masuda, K. Watanabe, C. Ohba, Y. Tsurusaki,
N. Miyake, Y. Zheng, T. Sato, H. Takebayashi,
K. Ogata, S. Kameyama, A. Kakita, N.
Matsumoto
1.306 Gain-of-function missense mutation in
human FHF1 as a novel cause of early-onset
epileptic encephalopathy with cerebellar
atrophy| G. M. Buyse, A. Siekierska, M. Isrie,
Y. Liu, C. Scheldeman, N. Vanthillo, L. Lagae,
P. A. de Witte, H. Van Esch, M. Goldfarb
1.307 Vagal Nerve Stimulator Therapy for
Genetic Epilepsies| J. Schreiber, C. Oluigbo,
A. Kao, K. Havens, T. DeFreitas, J. Conry, W. D.
Gaillard
1.308 An international, curated KCNQ2
registry, database and website| N. Joshi, E. C.
Cooper, M. Taglialatela, S. Weckhuysen
1.309 One in ten people with drug resistant
JME have common copy number variants| R.
Thomas, G. Sills, S. Chung, S. Jose, W. O.
Pickrell, V. Bhardwa, S. Morgan, K. Hamandi,
P. Smith, T. Marson, M. Rees
1.310 Variants in PROSER1 are implicated in
Juvenile Myoclonic Epilepsy with absence| J.
Wight, M. Medina, C. Patterson, V. Nguyen, Y.
Lin, R. M. Duron-Martinez, Y. Molina, M.
Tanaka, I. E. Martínez-Juárez , A. Ochoa, A.
Jara-Prado, L. M. Guilhoto, E. Yacubian, J.
Bailey, A. Delgado-Escueta
1.311 Targeted Analysis of Whole Exome
Sequencing in Early Onset Epilepsy| M.
Demos, S. E. Buerki, I. Guella, E. Toyota, D.
Evans, M. Mckenzie, C. Boelman, L. Huh, A.
Datta, A. Michoulas, K. Selby, B. Bjornson, G.
Sinclair, G. Horvath, E. Slade, C. van
Karnebeek, P. Eydoux, S. Adam, M. Van Allen,
T. Nelson, M. Connolly, M. Farre
1.312 Benign familial neonatal seizures
exquisitely sensitive to carbamazepine| T. T.
Sands, M. Balestri, G. Bellini, M. Oldham, G.
Holmes, E. Gennaro, E. Miraglia del Giudice,
F. Vigevano, M. Taglialatela, M. Cilio
1.313 Loss of synaptic Zn2+ transporter
function increases risk of febrile seizures| M.
Hildebrand, A. Phillips, S. Mullen, P. Adlard, K.
Hardies, J. Damiano, S. Bellows, J. McMahon,,
R. Burgess, R. Hendrick, S. Weckhuysen, A.
Suls, P. de Jonghe, I. Scheffer, S. Petrou, S.
Berkovic, C. Reid
1.314 Gene mutation analysis in 253
Chinese children with unexplained epilepsy
and intellectual/developmental disabilities|
Y. Zhang, W. Kong, Y. Gao, X. Liu, K. Gao, H.
Xie, Y. Wu, Y. Zhang, J. Wang, F. Gao, X. Wu, Y.
Jiang
1.315 Gene discovery in epileptic
encephalopathies through targeted
resequencing of candidate genes| C. Myers,
J. McMahon, A. Schneider, R. S. Møller, I.
Scheffer, H. Mefford, Epi4K Consortium
1.316 Investigation of the role 82
pharmacogenes in the etiology of treatmentresistant epilepsy in children| E. Robbins, B.
Almoguera, D. Dlugos, H. Hakonarson
1.317 Mutations in HUWE1 cause intellectual
disability, speech difficulties and epileptic
encephalopathies| K. Johannesen, C. Fenger,
S. Schweiger, K. L. Helbig, R. Abrahamsen, R.
Schubert, P. Striano, P. Uldall, A. Eysturoy, L.
Larsen, K. Baranano, J. Cohen, N. Tommerup,
E. Gardella, H. Dahl, U. Zechner , G. Rubboli,
R. S. Møller
Animal Studies
1.318 The effect of T-cell intracellular
antigen-1 deletion on brain Cyclooxygenase2 expression, acute seizure generation, and
epileptogenesis.| Y. Gong, J. Hewett
1.319 Fine mapping of a Dravet syndrome
modifier locus and candidate gene analysis
by RNA-Seq| N. Hawkins, N. Zachwieja, J. A.
Kearney
1.320 A natural polymorphism in the Nterminal region of Kcnq3 encodes a
gain-of-function effect and is a candidate
modifier for Gria4 deficiency associated
seizures in mice| W. Frankel, K. Duignan, C.
Mahaffey, T. McGarr, A. Tzingounas
heAlTh SeRVICeS
Delivery of Care
1.321 A Health Economic Study of Genetic
Testing in Refractory Epilepsy Patients| J. M.
Paolicchi, D. Shiffman, C. Tong, J. J. Devlin, J.
Higgins
1.322 Fall Prevention and Bathroom Safety in
the Epilepsy Monitoring Unit| S. Spritzer, A.
Z. Crepeau, M. Hoerth, J. Gerke, J. Berry, J.
Sirven, J. Drazkowski, K. Noe
1.323 Predicting Frequent Emergency Visits The Pediatric Epilepsy Emergency Room
Score (PEER). Development and Validation
using Three Datasets| Z. Grinspan, B.
Haridas, B. Hafeez, P. Johnson, R. Kaushal, J.
S. Shapiro, L. M. Kern, A. Patel
1.324 Quality and Safety in the EMU: A
systematic review and meta-analysis| K.
Sauro, N. Wiebe, S. Macrodimitris, S. Wiebe,
N. Jette
1.325 Adherence and validity of the new
AAN's epilepsy quality measures as a
surrogate of improved seizure control| L. V.
Moura, D. Mendez, J. D. Jesus, R. Andrade, J.
Weissman, B. Vickrey, D. Hoch
1.326 Caught on Camera: A Comparison
Between Adult and Pediatric Video EEG
Studies at UK| F. Sultan, S. Kapoor
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
50
1.327 Attitudes Toward Rescue Medications
and Discussion of Seizure Emergencies
Among Physicians, Patients, and Caregivers|
J. Weisman, R. Davis, W. Mitchell, C. Szabo
1.328 Comparing Perceptions of the Impact
of Seizure Clusters Among Clinicians,
Patients, and Caregivers| J. Wheless, P.
Penovich, J. Buelow, J. Sirven
1.329 The Patient-Clinician Relationship in
Seizure Cluster Management| P. Penovich, J.
Sirven, J. Buelow, J. Wheless
1.330 Burden of Seizure Clusters on Patients
with Epilepsy and Caregivers| J. Sirven, J.
Wheless, P. Penovich, J. Buelow
Access to Care
1.331 Ketogenic Diet Leads to Decreased
Health Care Utilization| S. Whiting, E. Donner,
R. Ramachandran Nair, J. A. Grabowski, D.
Rodriguez
1.332 Barriers to seizure management in
schools: perceptions of school nurses| D.
Terry, D. Cohen, A. Patel, D. Scherzer, G.
Rebecca, J. Kline
1.333 Quality of Life and Impact on Patient
Care in a Level 4 Epilepsy Monitoring Unit| R.
C. Davis, L. Ngo, T. Fisher, H. Shin
health Care Models
1.334 Patient perceptions of healthcare value
in epilepsy management extend beyond
costs to humanistic aspects| J. Fishman, G.
Cohen, B. Leymon-Porter
1.335 Budget Impact of Perampanel for
Treating Primary Generalized Tonic Clonic
Seizures (PGTC) Patients in Addition to
Existing Partial-Onset Seizures (POS) Patients
in the US| G. Tremblay, V. Barghout, V. Patel,
Z. Wang
1.336 Assessing pediatric primary care
attitudes and readiness for epilepsy comanagement| L. Shelton, D. Ploof, R. Boyle, R.
Turchi, M. Asato
1.337 Epilepsy Care Pathway development
for primary care provider clinics| D. Anisman,
J. Neider, R. Orlandi, J. Ryan, H. Barkan
Special Populations
1.338 Life after SUDEP| R. Ramachandran
Nair, S. M. Jack
1.339 The epilepsy transition care gap in
young adults with childhood-onset epilepsy|
C. Bower Baca, B. Vickrey, R. Caplan, F. Barry,
A. Berg
1.340 School-Aged Children and Parents’
Experiences of Epilepsy and Care: A
Qualitative Study| R. E. Parry, J. Harden, M.
Pickersgill, R. Chin
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
1.341 Religiosity, spirituality and interest in
genetic counseling in multiplex epilepsy
families| S. Sorge, J. C. Phelan, D. Hesdorffer,
S. Shostak, J. Goldsmith, M. Winawer, W. K.
Chung, R. Ottman
1.342 Bridging the knowledge gap in Women
with Epilepsy of Childbearing potential:
Impact of a Multidisciplinary Counseling and
Prenatal Care Clinic| A. Shrestha, P. Wong, J.
Bainbridge
neuROPAThOlOgy OF ePIlePSy
human Studies
1.343 LGI1: Expression in Tumor Tissue and
Detection of Autoantibodies in Patients with
Glioblastoma| C. Nobile, E. Dazzo, E. Pasini,
S. Furlan, D. De Biase, R. Michelucci
1.344 International consensus classification
of hippocampal sclerosis in children:
Etiologic diversity and long-term seizure
outcome| F. Soylemezoglu, C. Gunbey, B.
Bilginer, K. Karli Oguz, N. Akalan, M. Topcu, G.
Turanli, D. Yalnizoglu
1.345 Temporal lobe epilepsy with
hippocampal sclerosis as a progressive
condition: a clinical, neurophysiological and
histopathological analysis| J. T. Corso, A. P.
Jardim, S. M. Comper, L. R. De Marchi, M. B.
Guaranha, R. Centeno, E. Yacubian
1.346 KCNQ2 encephalopathy: novel single
amino acid deletion variants strongly
suppress currents and are responsive to
SF0034| L. Li, E. C. Cooper
1.347 Pathological diagnosis of focal cortical
dysplasia in western China: an urgent gap for
filling| C. Huang, X. Chi, J. Li, D. Zhou
1.348 Defining ILAE subtypes of
hippocampal sclerosis utilising MAP2 and
ZnT3 quantitative immunohistochemistry
and correlation with pre-operative memory
deficits.| A. P. Jardim, J. Baber, J. Liu, Z.
Michalak, C. Reeves, M. Ellis, S. Sisodiya, P.
Thompson, M. Thom
1.349 Hyperphosphorylated tau burden in
chronic epilepsy follows the Braak
distribution and correlates to cognitive
decline over time: a clinico-pathology study
of post-temporal lobectomy patients| X. Tai,
M. Koepp, J. Duncan, P. Thompson, N. Fox, M.
Thom
1.350 Delineating the Pre-Botzinger nucleus
in SUDEP| S. Patodia, M. Tachrount, J. Pichat,
M. Modat, S. Ourselin, T. Yousry, S. Sisodiya,
M. Thom
1.351 Cortical dysplasia with balloon cells in
the dentate gyrus| M. Morita, F. Rogerio, M.
K. Alvim, C. Yasuda, N. Paschoal, E. Ghizoni,
H. Tedeschi, L. Queiroz, F. Cendes
1.352 Acute uncontrolled seizures with
discrete brain lesion on MR imaging may be
due to unrecognized immune mediated
inflammatory process| D. Zutshi, M. Basha,
W. Kupsky, S. Mittal, A. Shah
PRACTICe ReSOuRCeS
1.353 Modifying the Emergency Room
Evaluation of New Onset Seizures| M.
Frucht, M. Dominski, Q. Holzheimer, M. Joel,
S. Bradley, G. Kelli
1.354 Epilepsy Quality Measurement in
Resident Teaching Clinic: A Retrospective
Review and a Quality Improvement Plan| L.
Monaco, M. Jacobson, C. Gutierrez
1.355 SmartWatch by SmartMonitor:
Assessment of Seizure Detection Efficacy for
Various Seizure Types in Children, A Large
Prospective Single-Center Study| A.
Patterson, B. Mudigoudar, S. Fulton, A.
McGregor, K. Van Poppel, M. Wheless, L.
Brooks, J. Wheless
1.356 Patient and caregiver view on seizure
detection devices: a survey study| D. F. Tovar
Quiroga, P. Lupton, J. W. Britton, E. Wirrell
1.357 Epilepsy Monitoring at a District
Epilepsy Centre in Ottawa, Canada – 1 year
review.| A. Aziz, A. Doja, D. Pohl, E. Sell, S.
Whiting
1.358 Standardization of pediatric epilepsy
outcome measures and creation of
outcomes dashboards in near-time: proof of
principle| J. Buchhalter
1.359 Subway map of Epileptogeni-City| T.
Ono, K. Toda, R. Honda, N. Koide, H. Baba
ePIDeMIOlOgy
1.360 Incidence and Risk Factors for Early
Seizure in Patients with Traumatic Brain
Injury. Analysis from National Trauma Data
Bank| S. Majidi, A. I. Qureshi, M. Z. Koubeissi
1.361 Predictors of Health-Related Quality of
Life in Children with Intractable Epilepsy| E.
Widjaja, M. Ferro, K. Speechley, M. Connolly,
C. Snead, M. Smith
1.362 Predictors and rates of seizure
freedom with vagus nerve stimulation for
drug-resistant epilepsy| K. Hassnain, C.
Wright, D. J. Englot, E. F. Chang
1.363 Epilepsy, birth weight and academic
school readiness in Canadian Children: Data
from the National Longitudinal Study of
Children and Youth.| A. Prasad, B. Corbett
1.364 Risk for recurrent febrile seizures in
the FEBSTAT study| S. Shinnar, D. Hesdorffer,
S. Seinfeld, D. Lax, D. R. Nordli, J. Pellock, R.
Shinnar, M. Chen, W. Gallentine, D. Lewis, M.
Frank, S. Moshe, S. Sun, FEBSTAT Study Team
– Moved to Sunday, Poster 2.396
1.365 Psychotropic drug utilization in
children with epilepsy in 29 US states from
1999 to 2010| X. Liu, P. Carney, R. Bussing, R.
Segal, L. Cottler, A. Winterstein
1.366 Suicide among People with Epilepsy: A
Population-Based Study from 17 U.S. States,
2003-2011| N. Tian, W. Cui, M. Zack, R.
Kobau, M. Gladden, K. Fowler, D. Hesdorffer
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
51
1.367 Predicting epilepsy after pediatric
traumatic brain injury: A population based
study| A. L. Numis, H. J. Fullerton, S. Sidney, J.
Sullivan, D. Lowenstein, C. K. Fox
1.368 Seizure Frequency Distribution of
Common Epilepsy Trial Cohorts: Too Many
Have Too Few| U. Uysal, N. B. Fountain, M.
Liu, M. Quigg
1.369 Different impacts of epilepsy/seizure
diagnostic code revisions on trends of
hospitalization rates of epilepsy
subcategories and associated procedures,
U.S. Nationwide Inpatient Sample (NIS)/
Healthcare Cost and Utilization Project
(HCUP), 1993-2012| Y. Luo
1.370 History of Accidental Injuries in
Children with Epilepsy from the Seizures and
Outcomes Study| A. Bumbut, M. E. Ardini, S.
Shih, W. D. Gaillard, B. Kroner
PuBlIC heAlTh
1.371 Epilepsy and Driving Licence:
Restrictions and Medicolegal Issues| N. J.
Jovic
1.372 A life-course assessment of treatment
patterns and healthcare costs of Lennox–
Gastaut syndrome| G. Montouris, J.
Pina-Garza, F. Vekeman, W. Cheng, E. Tuttle, P.
Giguere-Duval, M. Sheng Duh, V. Shen, J.
Isojarvi
1.373 The influence of socio-economic status
on health resource utilization for pediatric
epilepsy in a universal health insurance
system| K. Puka, M. Smith, R. Moineddin, C.
Snead, E. Widjaja
1.374 Caregiver Burden: An UnderRecognized Aspect of Epilepsy Care| S.
Helmers, S. Gupta, S. Huang, A. Berk, R. L.
Knoth
1.375 The impact on emergency department
utilization and associated costs for patients
prescribed intranasal midazolam versus
rectal diazepam| S. Nunley, D. Cohen, J. Cole,
A. Patel
1.376 Development of an Epilepsy Selfmanagement Decision-Support Tool:
Spanish-MINDSET 4.1| S. Rueda, R.
Sepulveda, J. Chong, C. Begley, R. Shegog, D.
Labiner
1.377 Researching women with epilepsy: a
declining trend| V. S. Wong
hISTORy OF ePIlePSy
1.378 Electrical Stimulation Therapy in
Epilepsy: A Historical Review 1742-1946| L.
Turco, S. P. Singh
1.379 The epileptic seizure as a personal
experience of death testimonies and
metaphysics| M. Mann
DECEMBER 4 - 8, 2015 www.AeSnet.org
SATURDAY, DECEMBER 5: POSTER SESSION 1
CASe STuDIeS
1.380 Challenges in Identifying Lennox–
Gastaut Syndrome: A Case Series Illustrating
its Changing Nature| J. Pina-Garza, S. Chung,
G. Montouris, R. Radtke, T. Resnick, R.
Wechsler
1.381 A case of recurrent asystole
associated with seizures responding to
sodium channel inhibition in an infant with
novel SCN8A mutation| S. R. Tomko, S. N.
Misra, R. Coorg, A. Wilfong
1.382 Refractory epilepsy responsive to
nonspecific immunossupression:
autoimmune or autoinflammatory disease? A
case report and review of literature| C. H.
Moreira, L. O. Mendonça, V. Passarelli, C. L.
Jorge, A. Pontillo, M. T. Barros, L. M. Castro
1.383 Resolution of Postural Orthostatic
Tachycardia Syndrome (POTS) following
epilepsy surgery| G. Kaur, M. Mendoza, R.
Beach
1.384 Activation of the HMGB1/ TLR
signaling pathway in surrounding tissues of a
frontal lobe cavernous angioma that
triggered ictal asystole| M. Nakajima, H.
Sugano, Y. Iimura, T. Higo, H. Arai
1.385 Case report: Vagus nerve stimulation
and late-onset bradycardia and asystole| F.
Pascual
1.386 Delayed deterioration of EEG
background rhythm in patients treated with
therapeutic hypothermia post cardiac arrest|
T. Fantaneanu, K. Avery, M. O'Brien, B. Scirica,
G. Henderson, J. Lee
1.387 Incidence and associated features of
EEG recorded Stimulus Induced Rhythmic,
Periodic, or Ictal Discharges (SIRPIDS) in
unresponsive patients in a Neurological ICU
using a standard stimulation protocol| K.
Alsherbini, J. Plancher, D. Ficker, M. Privitera
1.388 Hypersexuality Following Right
Temporal Resection: Oh behave!| E. Garcia
1.389 Acute Intermittent Porphyria
presenting with Posterior Reversible
Encephalopathy Syndrome and Lateralized
Epileptiform Discharges on CEEG| M. Bashir,
D. Joshua, F. Bonpietro, D. C. Silveira
1.391 Clinical Spectrum Caused by ATP1A2
mutations: Two Pediatric Case Reports| C. C.
Trandafir, J. Lankford, I. Butler
1.392 ANNA-1 related epilepsy in children:
report of 2 cases| A. Fine, J. Tillema, K.
Nickels, E. Wirrell
1.393 Delayed Diagnosis of an Infrequent but
not Unusual Condition: Three Cases of
Hashimoto’s Encephalitis.| A. Swaminathan,
R. Ward-Mitchell, S. Kapoor, M. BensalemOwen
1.394 Left-Insular Damage, Cardiac Instability
and SUDEP| N. Lacuey Lecumberri, W.
Theerannaew, C. Tatsuoka, B. Zonjy, L.
Kenneth, S. Lhatoo
1.390 Encephalocele with Epilepsy: Repair,
Resection or Lobectomy| F. Bannout, T.
Losey
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
52
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015
8:00 a.m. - 8:30 a.m.
over the last year. Participants include established and junior
epilepsy investigators as well as researchers outside the
epilepsy community who have specialized expertise that may
be applied to epilepsy basic science. In addition, one of the
workshops features presentations by junior investigators in
cutting-edge areas of research.
AeS Annual Business Meeting
Marriott - Liberty Ballroom, Level Three
All AES members are encouraged to attend this yearly meeting.
The Clinical Investigators’ Workshops provide a series of
working seminars in matters of active clinical investigation and
controversy. Speakers present results from their ongoing
research and place their findings in the context of current
understanding.
8:00 a.m. - 4:00 p.m.
Poster Session 2
Convention Center - Exhibit Hall A, 200 Level
See pages 58 - 68
Most of the workshops will run as concurrent sessions on
Sunday, with two workshops on Saturday afternoon and the
final one Monday afternoon.
8:00 a.m. - 5:00 p.m.
Scientific exhibits
TARgeT AuDIenCe
Basic scientists, neurologists, neuroscientists,
pharmacologists, neuropsychologists and neurosurgeons who
are performing research in epilepsy.
Convention Center - Rooms 201 A, 201 B, 201 C and 202 B
See page 19
8:30 a.m. - 5:00 p.m.
ASeT lTM Course: Setting up For Success In
long Term Monitoring
PROgRAM
Investigators’ Workshop: Michael Wong, M.D., Ph.D.
Separate registration required.
Clinical Investigators’ Workshop: Edward J. Novotny Jr., M.D.
Marriott - Grand Ballroom, Salon A, Level 5
This one-day course is sponsored by ASET – The
Neurodiagnostic Society. This course is designed for nurses,
technologists and physicians who work in an epilepsy
monitoring program (LTM and ICU monitoring) with the goal
of building the most successful service possible. Several
essential components of epilepsy monitoring will be
discussed in depth:
• Selecting the right equipment configuration, software and
networking features
• Initiating quality improvement initiatives to ensure efficient
monitoring sessions, reduce the length of stay and
implement patient safety measures
• Preventing skin breakdown and electrode-related injuries
• Designing staffing models to address patient needs 24/7
• Managing data during and after acquisition to enable rapid
interpretation and intervention
To register for this course, please visit the ASET website. The
registration fee for this course is $125. The full course
schedule and faculty will be posted on the ASET website.
Morning Session I: 8:45 a.m. - 10:15 a.m.
1. Translational Research: Bench to Bedside means
Academics to Industry: Facilitating Translational
Partnerships
Convention Center - Room 103 A
moderator: Martha Morrell, M.D.
Speakers: John Kehne Ph.D., Gilmore O’Neill M.D. and Jeffrey
Nye M.D., Ph.D.
2. Idiopathic Childhood Epilepsy Syndromes: Can We
Consider Them Benign?
Convention Center - Room 107
moderator: Jeffrey Tenney, M.D., Ph.D.
Speakers: Jennifer Vannest, Ph.D., Tracy Glauser, M.D. and
David Loring, Ph.D.
3. Emerging Technologies for Imaging the Neural Circuits
Underlying Seizures
Convention Center - Room 105
moderators: Karen Wilcox, Ph.D. and Doug Coulter, Ph.D.
Speakers: Jin Hyung-Lee, Ph.D., Hajime Takano, Ph.D. and
Kyle Lillis, Ph.D.
8:45 a.m. to 4:45 p.m.
Morning Session II: 10:30 a.m. – noon
4. A model Approach for Developing Antiepileptogenic
Drugs: Targets, Biomarkers and Barriers in Tuberous
Sclerosis
Convention Center - Room 103 A
moderators: Mike Wong, M.D., Ph.D. and Darcy Kreuger,
M.D., Ph.D.
Speakers: Joyce Wu, M.D., Martina Bebin, M.D., M.P.A. and
Mike Wong, M.D., Ph.D.
Investigators’ Workshops
These workshops, conducted informally and designed to
encourage interaction, will address several important areas of
rapidly-emerging knowledge in clinical and basic research in
epilepsy. The workshops are intended to identify challenges in
current research, propose methods to overcome those
challenges and encourage areas for future investigation.
The Basic Science Investigator Workshops will highlight a
number of research areas that have been developing rapidly
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Supported in part by GW Pharmaceuticals.
53
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015
5. mR-Guided Stereotactic Laser Ablation of the
Hippocampus and Amygdala: Reducing Collateral
Damage
Convention Center - Room 107
moderator: John W. Miller, M.D., Ph.D.
Speakers: Daniel Drane, Ph.D., Robert Gross, M.D., Ph.D.
and John Miller, M.D., Ph.D.
3.033 A Critical Developmental Window for 17β-estradiol AntiEpileptogenic Effect in a Mouse Model of X-Linked Infantile
Spasms/M. S. Siehr
3.041 Abnormal astrocytic Ca2+ signaling in the sclerotic
hippocampus of awake mice: a two-photon imaging study using the
unilateral intracortical kainate injection model of mesial temporal
lobe epilepsy/R. Enger
3.042 A Novel Optogenetic Mouse Model of Ictogenesis for
Investigating the Role of Interneurons in Seizure Initiation,
Propagation, and Termination/Sattar Khoshkhoo
6. Role of Potassium Ions and Channels in Shaping
Seizure Dynamics
Convention Center - Room 105
moderator: Omar Ahmed, Ph.D.
Speakers: Attila Gulyas, M.D., Ph.D., Steven Schiff, M.D.,
Ph.D. and Bernardo Rudy, M.D., Ph.D.
3.043 Hippocampal CRH Neurons: Linking Stress Signaling and
Seizure Susceptibility/Andrew A. Hooper
3.046 Abnormal cortical network excitability in an animal model of
infantile spasms/Sunita N. Misra
3.049 High-throughput drug discovery using a zebrafish model for
Dravet syndrome/Matthew T. Dinday
noon – 1:30 p.m.
3.058 Interictal and ictal ECG changes in a chronic experimental
model of temporal lobe epilepsy/Alexander Ashby-Lumsden
Investigators’ Workshops Poster Session (lunch)
3.059 Mechanisms of epileptic encephalopathy due to KNCT1 (Slack)
mutations/Imran Quraishi
Convention Center - 12th Street Concourse Room 104, 100 Level
3.060 Acute kainic acid-induced status epilepticus is augmented in
mice lacking the interleukin-1beta receptor type 1/Rosa Leon
Note: Number below refers to poster assignment
3.001 Ictal activation of s. oriens interneurons precedes pyramidal
cell activity in a chronic in vitro epilepsy model/Kyle Lillis
3.061 Neonatal ischemic seizures: Age at ischemic insult differentially
modulates long-term comorbidities in a mouse model/Seok Kyu
Kang
3.002 Downregulation of Adenosine A1 Receptor & Upregulation of
Adenosine Kinase in Pediatric Cortical Dysplasia Type IIB/T. Li
3.062 The efficacy of the mTOR inhibitor Torin1 on spasms in the
multiple-hit rat model of infantile spasms/Tufikameni Brima
3.003 Diazepam effect correlates with the developmental decrease
in intracellular chloride concentration during early neocortical
development/Joseph Glykys
3.063 Understanding Network Level Effects of Calcium Channel
Electrophysiology with a Computer Model of Spike and Wave
Discharges/Andrew Knox
3.004 Testing for correlation between seizure frequency and
numbers of mossy cells, ectopic granule cells, and gabaergic
interneurons/Paul Buckmaster
3.064 Seizure phenotypes, natural progression and sleep-wake
patterns in epileptic Kcna-1 null mutant mice/Rama Maganti
3.005 The complex role of miR-124 in epileptogenesis/G. P. Brennan
3.006 Acute Formation of Aberrant Excitatory Connections onto
Pyramidal Cells Following Neocortical Injury/Feng Gu
3.065 Peroxisome proliferator-activated receptor type alpha
activation as new therapeutic approach to treat epilepsy/M.
Puligheddu
3.008 Functional evidence for selective activation in a subset of
developing hippocampal neurons in early life seizures/Hongyu Sun
3.070 Overactivation of mTOR signaling pathway in human therapyresistant temporal lobe epilepsy./L. M. Jacobs
3.066 Interictal epileptogenic network dynamics in tuberous sclerosis
complex/A. Ye
3.007 Neuronal sodium elevation and COX-2 activation in posttraumatic epileptogenesis in vitro/Trevor Balena
3.097 Evaluation of epileptiform discharges as electrographic
biomarkers for epileptogenesis/Hoameng Ung
3.011 Role of Tonic and M Currents in the Hippocampal Dentate
Gyrus in Controlling Neuronal Excitability and Seizure
Susceptibility/Chase Carver
3.140 Synaptic connectivity of transplanted MGE interneurons within
host circuits/MacKenzie Howard
3.012 A personalized, molecular diagnosis of Lafora disease patient
mutations via structural insights/Matthew Gentry
3.014 Synaptic Dysfunction of Munc18-1 in Infantile Epileptic
Encephalopathies/Jacqueline Burre
3.142 A mouse model of a human SCN8A epileptic encephalopathy
mutation exhibits increased persistent sodium current in bipolar and
pyramidal hippocampus neurons./L. F. Lopez-Santiago
3.022 Role of Kainate Receptors on Modulation of Synaptic
Transmission during in Vitro Asphyxia in the Neonatal Mouse
Hippocampus/Santina Zanelli
3.204 The Periaqueductal Gray and Other Brainstem Structures are
Critical Nuclei in Seizure-Induced Sudden Death in the DBA/1 Mouse
Model of SUDEP/Carl Faingold
3.143 In vivo interneuron circuit dysfunction in chronically epileptic
mice/T. Shuman
3.018 Pharmacological rescue of KCNQ2 channels carrying EarlyOnset Epiletic Encephalopathy mutations/M. Soldovieri
3.216 Glial waves during seizures – coupled or uncoupled with
neurovascular activity?/Hongtao Ma
3.023 A novel role for autophagy in endogenous GABA-A receptor
modulation/Armen M. Abramian
3.246 Bumetanide Suppresses Kainic Acid Induced Seizures And
Prevents Development of Pharmacoresistance/Sudhir Sivakumaran
3.024 An in vitro hippocampal slice model to probe the role of innate
inflammation in epilepsy/S. Chong
3.361 Genetic and pharmacological targeting of α2δ-1 prevents
pathological synaptogenesis and epileptogenic circuit reorganization
following neonatal cortical insult/L. Andresen
3.025 Functional Reduction in Heterotypic Inhibition of Dentate
Basket Cells in Epilepsy: Impact on Network Rhythms/A. Proddutur
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
54
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015
Afternoon Session I: 1:30 p.m. – 3:00 p.m.
7. Using Functional Connectivity to Target Stimulation
Therapy for Epilepsy and Its Comorbidities
Convention Center - Room 103 A
moderator: Bernard Chang, M.D.
Speakers: Mouhsin Shafi, M.D., Ph.D., Michael Fox, M.D.,
Ph.D. and Stephen A. VanHaerents, M.D.
8:45 a.m. – 5:15 p.m.
Annual Course: epilepsy and the Media
Convention Center, Grand Ballroom A/B
OVeRVIeW
This year’s Annual Course will focus on the complex
relationship between patients with epilepsy, their treating
neurologists and other care providers, and the media. This
topic is very timely in light of the growth and impact of the
Internet and social media. The Annual Course will delve into
detail about the way information is portrayed and
communicated about epilepsy through the media. Rather
than the usual case vignettes, vignettes will focus on the
common interactions over the course of a working day
between an epileptologist and patients, families and
caregivers focused on media-provided information. Didactic
lectures and debates will be combined with illustrative
examples, interspersed before breaks. Topics will include
seizure detection (dogs and devices), driving rules,
cannabadiols and SUDEP.
8. Targeting mitochondrial Function as an Antiseizure
Strategy
Convention Center - Room 107
moderators: Kristina Simeone, Ph.D. and Manisha Patel,
Ph.D.
Speakers: Elizabeth Jonas, M.D., Timothy Simeone, Ph.D.
and Lindsey Gano, Ph.D.
9. Hot Topics and Late-breaking Research from Young
Investigators in the Epilepsy Community
Convention Center - Room 105
moderators: Mike Wong, M.D., Ph.D. and
Viji Santhakumar, Ph.D.
Altered metabolism in a Zebrafish model of
Dravet’s Syndrome
Maneesh Kumar, M.D., Ph.D.
leARnIng OBJeCTIVeS
Following participation in this symposium, learners should be able to:
Functional Evidence for Selective Activation in a
Subset of Developing Hippocampal Neurons
in Early Life Seizures
Hongyu Sun, M.D., Ph.D.
•
Genetic and Pharmacological Targeting of α2δ-1
Prevents Pathological Synaptogenesis and
Epileptogenic Circuit Reorganization Following
Neonatal Cortical Insult
Lauren Andresen
•
Ictal Patterns of Local Field Potentials, High
Frequency Oscillaions and Unit Activity
in Human mesial Temporal Lobe Epilepsy
Shennan Aibel Weiss, M.D., Ph.D.
•
Afternoon Session II: 3:15 p.m. – 4:45 p.m.
10.Cutting Edge Technologies for multi-Scale Recording in
Epilepsy
Convention Center - Room 103 A
moderator: Brian Litt, M.D.
Speakers: Duygu Kuzum, Ph.D., Adam Cohen, Ph.D. and
Lee Bassett, Ph.D.
•
11.Spikes and Cognition: Should We Treat Spikes?
Convention Center - Room 107
moderator: Tobias Loddenkemper, M.D.
Speakers: Ivan Sanchez Fernandez, M.D., Kevin Chapman,
M.D. and Roberto Tuchman, M.D.
12.The Role of Fragile X mental Retardation Protein in
Epilepsy, Ion Channels, and Behavioral Comorbidities
Convention Center - Room 105
moderators: Joaquin Lugo, Ph.D. and Amy Brewster, Ph.D.
Speakers: Christina Gross, Ph.D., Tim Benke, M.D., Ph.D.
and Joaquin Lugo, Ph.D.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Recognize the complex relationship between physicians
and the media in regards to epilepsy and has an improved
ability to be interviewed, answer patient questions about
media reports and effectively respond to media-generated
debates about topics such as seizure detection devices,
SUDEP, driving restrictions, cannabadiols and epilepsy
stimulation techniques
Answer patient/care giver questions about media reports
related to epilepsy care including discussions of seizure
detection devices, SUDEP, driving restrictions,
cannabadiols, and epilepsy stimulation techniques
Become aware of the issues related to controlled
substances, black box warnings and teratogenicity as well
as the evidence for and against utilization of cannabadiol
for epilepsy treatment
Be aware of the impact of media reports on patient
decision-making on topics such as new detection devices,
driving and therapies. Learner utilizes resources provided
by patient advocacy support groups to assist in addressing
psychological functioning of patients
TARgeT AuDIenCe
Basic, Intermediate and Advanced (see page 132 for details)
55
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015
PROgRAM
Chair: Eric Kossoff, M.D.
2:10 p.m Lecture: Doing media Interviews: AES Policy and
Advice
William Theodore, M.D.
DIAgnOSTIC ISSueS AnD The MeDIA
8:45 a.m. Introduction: The Complex Interaction of
Patients, Physicians and the media
Eric Kossoff, M.D.
2:30 p.m Lecture: RNS, VNS, DBS, Oh my!
Christianne Heck, M.D.
2:55 p.m Debate: Laser Surgery Is the Best Option
Dan Curry, M.D. (Pro)
Kristen Riley, M.D. (Con)
8:55 a.m. “8:00 am: A Facebook Friend Request”
Akila Venkataraman, M.D.
3:25 p.m Break
9:00 a.m. Lecture: Should You Friend Your Patients?
Facebook and Social media
Adam Hartman, M.D.
3:40 p.m “9pm: A Cocktail Hour Question about
Cannabis”
Kelly Knupp, M.D.
9:25 a.m. Lecture: Epilepsy and the Internet
Patty Shafer, MN, RN
3:45 p.m Lecture: Getting Your message to the Public:
How to Navigate the World of Reporters and
Lawyers
Robert Field, J.D., Ph.D.
9:50 a.m. Debate: Dogs and Devices: Does Seizure
Detection Work?
Elizabeth Donner, M.D. (Pro)
Gregory Krauss, M.D. (Con)
4:05 p.m Lecture: Epilepsy Journals and Free Access for
Patients — A Good Idea?
Steven Schachter, M.D.
10:20 a.m. Break
10:35 a.m. “Noon: A Seizure-related Crash on the News”
Kathryn Davis, M.D.
4:25 p.m Debate: Cannabadiol — Helpful or Just Reefer
madness?
Elizabeth Thiele, M.D., Ph.D. (Pro)
Eric Marsh, M.D., Ph.D. (Con)
10:40 a.m. Flash Panel: Advocacy Groups and Their Role
with the media Epilepsy Foundation
Phil Gattone, M.Ed.
4:55 p.m Conclusions
Eric Kossoff, M.D.
CURE
Susan Axelrod
eDuCATIOn CReDIT
6.0 CME Credits
Lennox Gastaut Syndrome Foundation
Christina SanInocencio, M.S.
Nurses may claim up to 6.0 contact hours for this session.
Epilepsy Information Service
Pat Gibson, M.S.SW.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 6.0 contact hours (0.60 CEUs).
UAN 0077-9999-15-028-L01-P. Initial Release Date: 12/6/2015.
11:20 a.m. Lecture: SUDEP and media Resources
Lisa Bateman, M.D.
11:35 a.m. Lecture: Driving Accidents in the News, What Is
Our Role with the mVA?
Allan Krumholz, M.D.
The American Board of Psychiatry and Neurology has
reviewed the Annual Course: Epilepsy and the Media and has
approved this program as part of a comprehensive program,
which is mandated by the ABMS as a necessary component of
maintenance of certification.
11:50 a.m. morning Wrap-up
Eric Kossoff, M.D.
Noon-2 p.m. Lunch Break
Convention Center - Exhibit Hall A, 200 Level
COMMeRCIAl SuPPORT ACknOWleDgeMenT
Supported in part by an educational grant from GW
Pharmaceuticals.
TReATMenT InnOVATIOnS AnD The MeDIA
2:00 p.m Introduction to the Afternoon Session
Eric Kossoff, M.D.
10:00 a.m. – 4:00 p.m.
2:05 p.m “5pm: CNN Interview about Surgery
Alternatives”
Lara Jehi, M.D.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
exhibit hall
Convention Center - Exhibit Hall A, 200 Level
56
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015
hot Topics – Where Are We going?
6:00 p.m. – 7:30 p.m.
Special Interest group Meetings
Convention Center - Room 108
Coordinators: Raman Sankar, M.D., Ph.D. and Tobias
Loddenkemper, M.D.
Dietary Therapies for epilepsy: Dietary
Therapies for Status epilepticus
Speakers: Raman Sankar, M.D., Ph.D. and Tobias
Loddenkemper, M.D.
Convention Center - Room 103 A
Coordinators: Christina Bergqvist M.D. and Tim Simeone Ph.D.
Description: The future, as discernible insights from big data,
potential for gene therapy, personal tech – monitoring with
the Apple Watch, etc.
Speakers: Rima Nabbout M.D., McKenzie Cervenka M.D., and
Lindsey Gano Ph.D.
This session will cover our current knowledge of using dietary
therapies during status epilepticus. It will include a “how to”
section and discussions of the central nervous system
changes that occur during status and possible mechanisms
by which the dietary therapies may work to stop this process.
A “breaking news” section will end the session. This will consist
of six brief presentations by authors of dietary therapy-related
studies. Prior to the meeting we will request abstract
submissions for the “breaking news” section and select the
top three clinical and basic science abstracts for presentation.
This “breaking news” section will be followed by a short Q & A
session. Also prior to the meeting we will request from our
email list dietary therapy recipes that will be compiled and
shared with attendees. At the end, we will present a small
prize to the winner of the “breaking news” section and the
best recipe.
neuroimaging: Advanced network Analysis
Methods: Are They Clinically useful?
Convention Center - Room 103 B/C
Coordinator: Neda Bernasconi, M.D., Ph.D.
Speakers: Matthias Koepp M.D., Ph.D., Joseph Tracey, Ph.D.,
and Boris Bernhardt, Ph.D.
Speakers will discuss the clinical utility of novel MRI-based
network analysis methods in relation to drug-response,
cognition and surgery.
Psychogenic nonepileptic Seizures (PneS):
Presenting the Diagnosis of PneS – Do’s and
Don’ts
Convention Center - Room 107
global Pregnancy Registry Outcomes
Coordinator: Sigita Plioplys, M.D.
Convention Center - Room 105
Speakers: Barbara Dworetzky, M.D., Gaston Baslet, M.D.,
Marcus Reuber, M.D., Ph.D., FRCP, Selim Benbadis, M.D.,
Susan Koh, M.D., Julia Doss, Psy.D., Rochelle Caplan, M.D.,
Lorna Myers and Christopher Patrick Brown, M.D.
Coordinators: Esther Bui, M.D. FRCP and Elizabeth Gerard,
M.D.
Speakers: Australian Pregnancy Register – Terrence O’Brien,
M.D.; EURAP – Torbjörn Tomson, M.D., Ph.D; NEAD/
MONEAD – Kimford Meador, M.D. and Page Pennell, M.D.;
North American AED Pregnancy Registry – Lewis Holmes, M.D.
and Allen Hauser, M.D.; UK and Ireland Pregnancy Register –
John Craig, M.D.
Speakers will represent multidisciplinary teams of adult and
pediatric expert clinicians typically involved in the diagnostic
process of patients with PNES. They will discuss how to
effectively and sensitively present the PNES diagnosis to the
patients and their families using hands-on practical materials
such as video recordings of actual clinical cases, dialogs, and
team discussions.
The management of epilepsy during pregnancy is one of the
most rapidly evolving fields within neurology and one that
generates a great deal of anxiety among providers. The
international pregnancy registries have been essential to
pushing forward our understanding of how to treat and
counsel this extremely vulnerable group of patients (and their
children). The pregnancies registry SIG provides the
opportunity for AES attendees to review the constantly
evolving data being generated by these powerful registries at
one time. Attendees receive critical emerging data that may
dramatically influence their care of all women of childbearing
age with epilepsy.
8:00 p.m. – 10:00 p.m.
Social networking groups
Registration is not required.
Marriott - Room 302 / 303, Level Three
Informal gathering and networking for SIG participants. Space
is limited so participants are welcome on a first-come, firstserved basis. Roundtable topics to be covered this year will be
announced.
The 2015 SIG will involve a case-based discussion/debate
format. Speakers will debate controversial points in
management with evidence from registry data. We will also
invite audience participation.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
57
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
8:00 a.m. - 4:00 p.m.
Poster Session 2
Convention Center – Exhibit Hall A,
200 Level
TRAnSlATIOnAl ReSeARCh
Mechanisms
2.001 Depletions of NeuN labeling within the
dysgranular retrosplenial cortex after status
epilepticus in adult rats is not associated
with cell death| L. K. Friedman, J. Wongvravit,
S. Hu, A. Slomko, D. Greentree
2.013 Induction of c-Fos immunoreactivity by
vagus nerve stimulation in the rat brain| M.
Katagiri, K. Iida, K. Ishihara, K. Harada, K.
Kagawa, A. Hashizume, R. Hanaya, K. Arita, K.
Kurisu
2.014 Anti-oxidant drugs resolve oxidative
stress and preclude disulfide-HMGB1
formation in the hippocampus after status
epilepticus: implications for neuroprotection
and epileptogenesis| A. Pauletti, G. Terrone,
D. Antoine, A. Pastore, S. Balosso, E. Del
Giudice, T. Ravizza, A. Vezzani
2.002 Rewiring of the rat neocortex in acute
seizures and in chronic epilepsy| R. Serafini,
J. Loeb
2.015 Targeting mammalian target of
rapamycin down-regulates the expression of
P-glycoprotein in a pharmacoresistant
epilepsy rat model kindled by coriaria
lactone| X. Chi, C. Huang, J. Li, D. Zhou
2.004 Treatment of drug-resistant seizures
with new cation-chloride co-transporter
modulators| V. Dzhala, Y. Saponjian, K. Staley
2.017 Reduced KCC2 function increases
seizure severity| M. R. Kelley, T. Z. Deeb, N. J.
Brandon, J. Dunlop, S. Moss
2.003 Delayed Activation Of Pro-resolving
Mechanisms During Epileptogenesis In
Mice| F. Frigerio, A. Torello, K. Leclercq, C.
Vandenplas, E. van Vliet, E. Aronica, P.
Foerch, R. Kaminski, A. Vezzani
2.005 Severe cerebral edema and neuronal
loss in rat piriform cortex after
lithium/pilocarpine-induced status
epilepticus| L. Shao, C. Stafstrom
2.006 Developmental plasticity of dentate
gyrus granule cells following epileptiform
activity in vitro| K. P. Patterson, Y. Chen, Y.
Noam, G. P. Brennan, C. Ly, T. Baram
2.007 Neuroinflammation in non-Mesial
Temporal Lobe Epilepsy| L. Gershen, P.
Zanotti-Fregonara, I. Dustin, J. Hirvonen, J.
Liow, K. Jenko, S. Inati, M. Fujita, C. Morse, C.
Brouwer, J. Hong, V. Pike, S. Zoghbi, R. Innis,
W. Theodore
2.008 Mechanisms of seizures and edema
after brain injury: Photolysis of a single
neuron alters the cytoplasmic chloride in
neighboring neurons| K. Egawa, T. Balena, K.
Lillis, V. Dzhala, H. Shiraishi, K. Staley
2.009 Short-term ceftriaxone treatment after
traumatic brain injury in rats transiently
upregulates GLT-1 and mitigates long-term
loss of parvalbumin gene expression.| M.
Hameed, A. Rotenberg
2.010 O-linked N-acetylglucosamine
transferase OGT activity couples to DNA
methylation changes in the epileptic
hippocampus| R. Sanchez, R. R. Parrish, R.
Lockhart, D. Ross, K. Riley, F. Lubin
2.011 Zinc Inhibition of Anticonvulsant
Neurosteroids at Extrasynaptic GABA-A
Receptors in the Dentate Gyrus| S. Chuang,
C. Carver, D. Reddy
2.012 Homeostatic activity regulation in the
development and prevention of
posttraumatic epilepsy| X. Ping, W. Xiong, G.
Chavez, J. Gao, X. Jin
2.016 The ability of cognitive effort to
suppress epileptic after discharges is
dependent on brain state| S. F. Muldoon, J.
Costantini, R. Lesser, H. J. Lesser, W. Webber,
D. S. Bassett
2.018 The effects of a ketogenic diet in
neurons, astrocytes and microglia| D. Fleck,
M. A. Huntley
2.019 Probing Controllers of the Epileptic
Network With Virtual Cortical Resection| A.
N. Khambhati, K. Davis, B. Litt, D. S. Bassett
Models
2.020 Behavioral and neurodegeneration
patterns after inhibition of Na+/glucose
cotransporter 1 (SGLT1) in a model of
Temporal Lobe Epilepsy| I. S. Melo, Y. O.
Santos, A. Pacheco, M. A. Costa, N. T. Silva, M.
S. Araújo, R. Silva, O. W. Castro
2.021 Synaptic scaling in the hippocampus in
a mouse model of viral-induced temporal
lobe epilepsy| D. Patel, P. Bhuyan, E. Dahle,
R. S. Fujinami, H. White, M. Patel, K. S. Wilcox
2.022 Deep Hypothermia Stops Refractory
Status Epilepticus And Reduces Its
Consequences| C. Wasterlain, R. Baldwin, M.
Gezalian, J. Niquet
2.023 A CRISPR mutant zebrafish model of
STXBP1 deficiency| B. P. Grone, M. Marchese,
K. Hamling, S. Baraban
2.024 Dexmedetomidine as a treatment for
nerve agent-induced status epilepticus| H.
McCarren, S. Costinas, W. Driwech, E. Dunn,
A. Hubbard, C. Jackson, R. Krempel, E.
McFarland, C. Oppel, J. McDonough
2.025 Multi-electrode array recordings
detect enhanced synchrony and spatial
coherence of neuronal firing patterns in
zebrafish acute seizure models.| M. Meyer,
S. Dhamne, A. Poduri, A. Rotenberg
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
58
2.026 Pharmacokinetics and
Pharmacodynamics of Diazepam and
Topiramate in Dogs with and without
Naturally-occurring Epilepsy| L. Coles, D.
Crepeau, G. Worrell, I. Leppik, J. Cloyd, I. Vuu,
P. Maglalang, U. Mishra, A. Eckert, E. Patterson
2.027 Evidence of Seizures, Spreading
Depression and SUDEP in a murine model of
Post-Malarial Epilepsy| F. Bahari, P.
Ssentongo, D. G. Sim, F. Gilliam, S. Weinstein,
A. Robuccio, E. C. Price, A. Nabi, B.
Shanmugasundaram, M. W. Billard, P. J. Drew,
A. F. Read, S. Schiff, B. Gluckman
2.028 Early-life seizures alter postnatal
development of PV interneurons in the
primary auditory cortex| Y. Song, J. Lippman
Bell, H. Sun, M. Handy, A. Gruenewald, F.
Jensen
2.029 Antiepileptogenic and postictal effects
induced by transcranial focal electrical
stimulation via concentric ring electrodes in
freely moving cats| A. Valdés-Cruz, B.
Villasana-Salazar, W. Besio, V. M. MagdalenoMadrigal, D. Martínez-Vargas, S.
Almazán-Alvarado, R. Fernández-Mas
2.030 A Computational Platform for
Prototyping Intelligent Closed-Loop
Hippocampal Stimulation Control Systems|
M. J. Connolly, R. Gross, B. Mahmoudi
2.031 Effects of low-frequency stimulation of
central piriform cortex on kainate-induced
seizures in rats.| M. Skopin, A. Bayat, M.
Siddu, L. Mukharesh, M. Koubeissi
2.032 Postictal apnea is a biomarker of
sudden death in two mouse seizure models.|
Y. Kim, E. Bravo, G. Richerson
2.033 Potential confounding effects of
murine EEG electrode implantation are not
evident in surgical controls: Example in a two
hit model of temporal lobe epilepsy| I.
Balzekas, J. White, J. Hernandez, S. Koh
2.034 Restoring consciousness during and
after seizures with dual-site thalamic and
pontine neurostimulation| A. J. Kundishora,
A. Gummadavelli, C. McCafferty, C. Ma, M. Liu,
W. Biche, L. Feng, J. Gerrard, H. Blumenfeld
2.035 Toward a combined optogenetic/MEG
model of epilepsy in non-human primates|
G. Alberto, D. Klorig, I. McGowin, J. StapletonKotloski, G. Popli, C. Constantinidis, J. Daunais,
D. Godwin
2.036 Time and sleep state dependent
regulation of the cardio-respiratory effects of
seizures in mice| G. F. Buchanan, K. I.
Claycomb, M. Hajek
2.037 Expression of α4βδ GABAA receptors
at puberty reduces ictal discharge of CA1
hippocampus exposed to high K+| L. Merlin,
L. Yang, S. Smith
2.038 Sleep Regulation as Epilepsy Therapy:
A Study of the Effects of Ambient
Temperature on Mouse Sleep| A. Ajwad, F.
Yaghouby, C. Schildt, B. O'Hara, S. Sunderam
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
2.039 Rapid Development of Chronic
Neuroendocrine Dysfunction in an Animal
Model of Temporal Lobe Epilepsy| A. C.
Wulsin, J. P. Herman, S. Danzer
2.040 Behavioral depression and memory
impairment following organophosphate
diisopropyl fluorophosphate induced status
epilepticus in rats| K. Phillips, L. Deshpande,
B. Huang, R. DeLorenzo
2.041 SUDEP and Functional Remodeling of
Vagal Complex Activity in a Mouse Model of
Acquired Temporal Lobe Epilepsy| I. Derera,
B. P. Delisle, B. Smith
2.042 EEG Stage Predicts Impairment of
Spatial Memory and Learning after Kainic
Acid-Induced Experimental Status Epilepticus
in the Rat| S. T. Marsh, D. M. Treiman
2.043 Structural modeling of Nav1.1 to
improve molecular diagnostic predictions in
infantile epileptic encephalopathies| A.
Smith, G. Pinchin, T. L. Klassen
2.044 Phenobarbital delays seizures but
does not improve damage in a rat neonatal
stroke model | L. Morin, N. Dupuis, G.
Perrotte, P. Leger, C. Marlangue, S. Auvin
2.045 Selective Sensing and Modulation of
Brain Networks using High Density DBS
Electrode Arrays| B. He, A. Sohrabpour
2.046 Genetic background influences
electrophysiologic activity in the setting of
acute TBI| R. Kotloski, P. Rutecki, T. Sutula
2.047 Alpha-2A adrenergic agonist
guanfacine hydrochloride suppress acute
kindling-induced afterdischarges in a dose
dependent manner.| N. Inoue, K. Tsuchiya,
M. Inagaki, A. Ueda, S. Kogure
2.048 Effects of celastrol and edaravone in
the multiple-hit rat model of infantile
spasms| O. Shandra, Y. Wang, W. Mowrey, S.
Moshé, A. S. Galanopoulou
2.049 Effect of Levetirecetam on Functional
Recovery and Gene Expression in an
Experimental Rat model of Traumatic Brain
Injury| G. Anderson, B. E. Elmore, E. D.
Kantor, T. Bammler, F. M. Farin, J. W.
MacDonald, M. R. Hoane
2.050 WAG/Rij absence seizure rats differ
from Wistar rats in development of cortical
excitability| P. Mares, H. Kubova
2.051 Epileptogenesis in organotypic
hippocampal cultures has limited
dependence on culture medium
composition| Y. Berdichevsky, J. Liu
2.052 A mutation in SCN8A results in
arrhythmogenic events with altered
intracellular calcium handling in a mouse
model of early-infantile epileptic
encephalopathy with SUDEP.| C. R. Frasier, J.
Wagnon, Y. Bao, J. Parent, M. Meisler, L. Isom
2.053 Murine Model of Post-Malarial
Epilepsy (PoME)| P. Ssentongo, A. Robuccio,
D. G. sim, A. Geronimo, G. Thuku, J. Bacon, F.
Bahari , B. Shanmugasundaram, K. W. Short,
M. W. Billard, S. L. Weistein, E. C. Price, P. J.
Drew, J. A. Stoute, F. Gilliam, A. F. Read, B.
Gluckman, S. Schiff
2.054 Comparison of Connectivity Estimators
in Ictal and Interictal States in Intracranial
EEG in Patients with Intractable Epilepsy| A.
Lai, T. A. Wozny, A. Popescu, M. Baldwin, G.
Ghearing, J. Pan, M. Akcakaya, M. Richardson,
A. Bagic, A. Antony
2.055 Seizure protection in Shank3 knockout
mice| S. Dhamne, S. Lammers, E. Chadwick,
M. Hameed, M. Sahin, A. Rotenberg
2.056 Deregulation of β-catenin networks
leads to infantile spasms and seizures| M.
Jacob, A. Pirone, J. Alexander, L. Andresen, C.
Dulla
2.057 Development of a Modified Flurothyl
Kindling Model| M. Deodhar, S. A. Matthews,
T. Simeone
human Studies
2.058 The first epilepsy brain bank in
Canada| F. Moien-Afshari, L. HernandezRonquillo, L. Kalynchuk, C. Taghibiglou, F. S.
Cayabyab, R. Borowsky , H. Aftab, M.
Vrbancic, A. Saad, C. Robinson, M. Hiken, M.
Mickleborough, R. Huntsman, A. Wu, J. TellezZenteno
2.059 Engaging People with Epilepsy in
Collaborative, Patient-Centered Research| D.
Dieguez, D. Hesdorffer, B. Kroner, J. Buelow
2.060 Development of a Platform for Realtime EEG Analysis and Caretaker Notification
in the Neurointensive Care Unit| S.
Baldassano, B. Oommen, D. Leri, J. Echauz, P.
Kadakia Bhalla, M. Debski, C. Garzon Mrad, B.
Litt, J. Wagenaar
2.061 Ictal patterns of local field potentials,
high frequency oscillations, and unit activity
in human mesial temporal lobe epilepsy.| S.
A. Weiss, C. Alvarado-Rojas, A. Bragin, E.
Behnke, T. Fields, I. Fried, J. Engel Jr., R. Staba
2.062 Targeted transcranial electrical
stimulation protocols: spatially restricted
intracerebral effects via improved stimulation
and recording techniques| M. Voroslakos, A.
Oliva, K. Brinyiczki, T. Zombori, B. Ivanyi, G.
Buzsaki, A. Berenyi
2.063 Antiepileptic Drug Prescribing Patterns
in Women with Epilepsy during Pregnancy:
Findings from the MONEAD Study| P.
Pennell, K. Meador, R. May, J. French, E.
Gerard, L. Kalayjian, N. Velez-Ruiz, P.
Penovich, J. Cavitt, A. Pack, J. Miller, E. Moore,
D. Ippolito
2.064 A machine learning approach to
differentiate Ictal onset pattern from Ictal
spread pattern within Hippocampi| B.
Krishnan, O. Grinenko, Z. I. Wang, J.
Gonzalez-Martinez, A. Alexopoulos, I. Najm
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
59
2.065 High Frequency Activities detected
during simultaneous intracerebral EEG and
fMRI acquisition| M. Saignavongs, C. Ciumas,
J. Lachaux, M. Petton, R. Bouet, S. Boulogne,
S. Rheims, P. Ryvlin
2.066 From the Patient’s Perspective: Anxiety
and Waiting in the Epilepsy Monitoring Unit|
E. Yates, P. Ford, J. Sorrell, J. Bautista, B. Esplin,
X. F. Jimenez, B. Tilahun
2.067 Genotype-phenotype Analysis of
Epilepsy in CDKL5 Encephalopathy| S.
Demarest, M. Gibbons, M. Saenz, T. Benke
2.068 The Majority of Children with Epilepsy
Are Affected by Postictal Phenomena, Often
Preventing a Return to Normal Activities of
Childhood| S. MacEachern, N. Thornton, J.
Buchhalter
2.069 Seizure-onset mapping based on highdensity intracranial EEG time-varying
multivariate connectivity estimation:
preliminary results| O. V. Lie, P. van Mierlo
2.070 Temporal Lobe Epilepsy modifies the
gene expression of transcription factor
REST/NRSF in human hippocampus| V.
Navarrete-Modesto, I. A. Feria-Romero, S.
Orozco-Suarez, M. Alonso-Vanegas, L. Rocha
2.071 Pharmacoresistant temporal lobe
epilepsy modifies histamine turnover and H3
receptors in human hippocampus and
temporal neocortex| I. Banuelos-Cabrera, M.
Cuellar-Herrera, A. Velasco, F. Velasco
Campos, M. Alonso-Vanegas, J. AriasMontaño, L. Rocha
2.072 Insular cortex displays pain-specific
gamma-band oscillations, possibly disrupted
by insular epileptiform activity| S. Ferrao
Santos, G. Liberati, A. Klöcker, M. Safronova,
R. El Tahry, J. Ribeiro Vaz, C. Raftopoulos, A.
Mouraux
2.073 TMS does not have utility as a
predictive marker of treatment outcome in
chronic medically refractory epilepsy| A. D.
Pawley, L. Nashef, B. Ceronie, R. Elwes, M. P.
Richardson
2.074 Seizure-associated ventricular
repolarization abnormalities and instability in
children with epilepsy| A. Anderson, W. Ali, B.
Bubolz, L. Nguyen, Y. Lai
Devices, Technologies, Stem Cells
2.075 Detecting seizures using a single
surface differential recording: Towards a
minimally invasive seizure monitoring device|
D. R. Cleary, H. Zaveri, R. Duckrow, J. L.
Gerrard
2.076 Optimization of Transparent Graphene
Electrodes for Neural Sensing and
Stimulation| D. Kuzum, H. Takano, H. Juul, A.
Richardson, T. Lucas, M. Dichter, D. Coulter, B.
Litt
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
2.077 Performance of quantitative EEG
display in automated seizure identification at
a busy university hospital| K. Arora, A. M.
Khawaja, F. Qaiser, A. H. Ewida, A. Thomas, J.
DeWolfe, N. Billeaud, L. Ver Hoef, J. Szaflarski,
S. Pati
2.078 Novel Depth Electrode Placement
Planning System for Direct Cortical
Stimulation Therapy and Validation using
Subtracted Activated SPECT| L. Cendejas
Zaragoza, M. A. Rossi
2.079 Medial temporal lobe epilepsy alters
theta oscillations in animals behaving in a
spatial recognition memory task| A. Izadi, A.
Pevzner, S. Huang, A. Ekstrom, S. Cowen, K.
Shahlaie, G. Gurkoff
2.080 Subtracted Post-ictal Diffusion Tensor
Imaging as a Tool for Visualizing IctalAssociated Propagation Pathways| A. Nava
Lagunes, D. Garibay Pulido, L. Cendejas
Zaragoza, M. A. Rossi
2.081 Evidence of Epileptic Networks
Activation and Modulation by Electrical
Stimulation and Interstitial Ablation of
Epileptic nodes as defined by SEEG
recordings| J. Gonzalez-Martinez, S. Jones, J.
Bulacio, D. Nair, P. Chauvel, W. Bingaman, I.
Najm
2.082 Partial Directed Coherence in
Simultaneous Scalp and Intracranial EEG in
Patients with Intractable Epilepsy.| K. Durai,
T. A. Wozny, A. Popescu, G. Ghearing, M.
Baldwin, J. Pan, C. Plummer, M. Akcakaya, M.
Richardson, A. Bagic, A. Antony
2.083 A comparative study of Seizure
suppression by closed-loop electrical
stimulation at earlier and later stages of
seizure formation in two rat models of
epilepsy| M. T. Salam, H. Kassiri, J. Perez
Velazquez, R. Genov
2.084 Intracerebral Delivery of Carbon
Nanotubes Augments the Extent of
Activation for Direct Neurostimulation
Therapy| T. J. Harris, L. Cendejas Zaragoza,
M. A. Rossi
2.085 Twenty Four Month Long Term Patient
Follow-up from the AspireSR E-36 Trial| P.
Boon, K. van Rijckevorsel, R. El Tahry, C. Elger,
N. Mullatti, A. Schulze-Bonhage, K. Vonck, G.
Wagner, W. Van Grunderbeek, A. Jones, L. Bu,
R. McGuire
2.086 A SMART EEG headset system for a
home monitoring| M. T. Salam, M. Guirgis, M.
Dadkhah, R. Gonzalez, M. Del Campo, P.
Carlen, B. Bardakjian
2.087 Modeling SCN8A mutant epilepsy in
patient-derived cortical and peripheral
neurons| A. Tidball, L. Lopez-Santiago, X. Du,
K. Glanowska, L. L. Isom, J. Parent
neuROPhySIOlOgy
2.088 Transplanted Medial Ganglionic
Eminence-derived GABAergic progenitors
selectively wire with newborn granule cells in
the dentate gyrus of mice with pilocarpineinduced temporal lobe epilepsy| J. Gupta, J.
Radell, E. Paquette, A. Fine, S. Gonzalez, G.
Aaron, B. Luikart, J. Naegele
2.101 A "flipped" approach to
electroencephalography (EEG) education in
neurology residency| J. Moeller, P. Farooque,
G. Leydon, M. Schwartz
2.089 Magnetic resonance spectroscopy
detects regional glutamate and glutathione
imbalance in the early stages of posttraumatic epiletogenesis| R. Guerriero, M.
Hameed, N. Hodgson, B. Rowland, P. Pearl, T.
Hensch, A. Lin, A. Rotenberg
2.103 Midline spikes in children, is long-term
treatment needed?| B. Brebesh, J. P.
Appendino
Biomarkers
2.090 Automatic detection of hippocampal
paroxysmal discharges in epileptic mice| J.
Modolo, P. Houitte, F. Wendling
2.091 Translational profiling of the dentate
mature granule cells after pilocarpineinduced status epilepticus| K. Cho, S. Yun, G.
Nam, A. Eisch, J. Hsieh
2.092 Is IDH-1 status associated with seizure
activity in glial tumors?| M. Johnson, S.
Schmitt
2.093 Comparing Microarray Profiles of
Hippocampal Subregions with Amygdala
Cortical Complex Reveals Distinct Gene
Expression Following Multiple Early Life
Seizures| S. Hu, A. SLOMKO, K. Yee, J.
Mancuso, L. K. Friedman
2.094 Decreased CSF hypocretin-1 in
patients after repetitive generalised tonicclonic seizures and convulsive status
epilepticus| K. Rejdak, M. Godek, A.
Martyniuk, L. Balicka-Adamik, P. Grieb
2.095 Automatic High Frequency Oscillations
Detection in Epilepsy by a New Algorithm
Using Maximum Distributed Energy to
Calculate Baseline| G. Ren, J. Yan, Z. Yu, D.
Wang, S. Mei, X. Li, Y. Li, X. Wang, X. Yang
2.096 The role of potential biomarkers in
status epilepticus | R. Gurses, M. Atmaca, A.
Telci
2.097 Propagation of Interictal High
Frequency Oscillations in Children with
Epilepsy| C. Papadelis, E. Park, C. Doshi, T.
Nayak, J. Bolton, T. Loddenkemper, E. Grant,
P. Pearl, J. Madsen
2.098 MicroRNA Biomarkers in Blood Predict
the Development of Post-Traumatic Epilepsy
after Experimental Traumatic Brain Injury in
the Rat| D. M. Treiman, D. E. Schooley, S. T.
Marsh, L. Treiman
2.099 An Imaging Biomarker of the
Psychiatric Comorbidity of Pediatric
Epilepsy| R. Caplan, P. Siddarth, D. Tosun, J.
Levitt, S. Gurbani
2.100 Interictal relative gamma power as a
biomarker for anti-epileptic drug response in
absence epilepsy| A. Maheshwari, R. Marks,
K. Yu, J. Noebels
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
60
Other Clinical eeg
2.102 Hippocampal Spiking Influences the
Occurrence of Hippocampal Sleep Spindles|
B. Frauscher, N. Bernasconi, B. Caldairou, N.
von Ellenrieder, A. Bernasconi, J. Gotman, F.
Dubeau
2.104 Noise Reduction with Tripolar
Concentric Ring Electrode
Electroencephalography (tEEG)| K. Inoyama,
A. Aghaei-Lasboo, H. Kaur, W. Besio, R. Fisher
2.105 Diagnostic Yield of Outpatient Routine
and Extended Video-EEG in the Veteran
Population| R. Lopez-Baquero, I. Sen-Gupta,
J. W. Chen
2.106 Comparison of Routine (30-minute)
versus 2-hour Sleep EEG Recordings in the
Initial Diagnosis of Epilepsy| E. Erbayat Altay,
L. Güvelioğlu, N. Helvaci Yilmaz, B. Polat
2.107 Angelman Syndrome: review of clinical
and EEG findings| O. Muthaffar, B. Minassian
2.108 Quantification and characterization of
blue lens effect on Photoparoxysmal
Response| A. Tadevosyan, S. Rydjeski, S.
Burroughs, R. Morse, E. J. Kobylarz
2.109 Reliability of intensive care unit
electroencephalography interpretation using
smartphone videos| C. M. Cabrera Kang, S.
Laroche, A. A. Rodriguez Ruiz, R. E. Fasano, J.
Pathmanathan, L. M. Veras Rocha de Moura,
M. Westover, I. Karakis
2.110 Voltage topographic map in the
absence of epileptic spikes: a new biomarker
of epileptic activity?| F. Pittau, M. Genetti, G.
Birot, M. I. Tomescu, S. Baldini, V. Serge, C.
Michel, M. Seeck
2.111 Inverse relationship between EEG
desynchronization and interictal epileptic
activity in a depth EEG study of human sleep|
J. Gotman, N. von Ellenrieder, F. Dubeau, B.
Frauscher
Animal Studies
2.112 Computation of center of mass from
voltage and current source density of
epileptiform activity in the hippocampus| W.
Zapfe, F. Ortiz, R. Gutierrez
2.113 Dentate granule cell hyperactivation in
chronic epilepsy: network determinants of
aberrant circuit activation| C. Dengler, C. Yue,
H. Takano, D. Coulter
2.114 Abnormal firing activity in hippocampal
neurons from a mouse model of SCN8A
epileptic encephalopathy| Y. Yuan, J. Wagnon,
L. F. Lopez-Santiago, J. Parent, M. Meisler, L. L.
Isom
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
2.115 The role of Kvβ2 in modulating in vitro
seizure activity in mice treated with the
ketogenic diet.| R. Parent, R. Z. Bell, G. Fisher,
H. Burns, G. Murphy
2.116 Changes in hilar network physiology
and connectivity in a model of temporal lobe
epilepsy| T. Hedrick, N. Zachwieja, J. A.
Kearney, G. Swanson
2.117 Electrophysiological properties of agedefined dentate granule cells in a rodent
model of temporal lobe epilepsy.| A. Althaus,
S. Moore, H. Zhang, G. Murphy, J. Parent
2.118 Both Chloride Transporters and
Impermeant Intracellular Anionic Charges
Regulate Transmembrane Chloride Levels in
Hippocampal Dentate Granule Cells.| F. Hsu,
H. Takano, D. Coulter
2.119 Acute amygdala seizures suppressed
by halorhodopsin activation in vivo| J. Zhou,
D. Wang, P. Carney
2.120 Effects of a Dravet syndrome-linked
Scn1a mutation on breathing in mice| C.
Massey, Y. Wu, Y. Kim, E. Bravo, G. Richerson
Computational Analysis &
Modeling of eeg
2.121 Electrocorticographic Mapping of
Expressive Language Function Utilizing a
Passive Receptive Language Task| A. de
Pesters, A. M. Taplin, M. A. Adamo, T. M.
Lynch, A. Ritaccio, G. Schalk
2.122 Cross Frequency Coupling during
Sleep in Patients with Focal Epilepsy| M.
Amiri, B. Frauscher, J. Gotman
2.123 Relevant memory specific brain
oscillations in the inferior frontal lobe – an
intracranial EEG study| S. Gollwitzer, S.
Rampp, M. Fellner, M. Hagge, J. Lang, C.
Leupold, G. Nikkhah, G. Kreiselmeyer, K.
Kurzbuch, K. Roessler, S. Schwab, M.
Schwarz, S. Hanslmayr, H. Hamer
2.124 Electrical source analysis in epileptic
spasms suggests involvement of the
interhemispheric cortical regions| M. Quach
2.125 Control profiles of seizure networks|
Z. Nadasdy, J. Shen, D. Briggs, D. F. Clarke, R.
Buchanan, M. Lee, P. Modur
2.126 EEG Ripple Band Power, Phase
Synchronization, and Phase Clustering in
Epileptogenic Zones in 256-Channel
Interictal Scalp EEG Data| M. D. Holmes, C.
Ramon, K. Jenson
2.127 Dense Array scalp EEG in Presurgical
Epilepsy Evaluation in Children| D. Rose, H.
Fujiwara, H. Greiner, J. Tenney, K. Holland, D.
Morita, T. Arthur, R. Arya, S. Jain, F. Mangano,
P. Luu, M. Terrill, D. Tucker
2.128 Brain network dynamics of the human
articulatory loop | M. Nishida, A.
Korzeniewska, N. Crone, G. Toyoda, N. Ofen,
E. C. Brown, E. Asano
ClInICAl ePIlePSy
Classification and Syndromes
2.129 Factors contributing the focal seizure
development in the hyperglycemic patients|
M. Lee, D. Kim, K. Jo, W. Jang, K. Heo
2.130 Lateralizing and Localizing Value of
Experiential Auras| H. Kim, K. Cho, Y. Cho, K.
Heo, B. Lee
2.131 Risk factors associated with drug
resistant focal epilepsy in adults Pragma
Laboni Roy, Samantha Buckley, José F. Téllez
Zenteno, Lizbeth Hernandez Ronquillo| P. L.
Roy, J. F. Téllez Zenteno, L. Hernandez
Ronquillo, S. Buckley
2.132 The clinical phenotype of ADLTE
related to Reelin mutations| R. Michelucci, P.
Pulitano, C. Di Bonaventura, S. Binelli, C. Luisi,
E. Pasini, S. Striano, P. Striano, G. Coppola, A.
La Neve, A. Giallonardo, O. Mecarelli, E.
Serioli, E. Dazzo, C. Nobile
2.133 Lateralizing Value of Ictal Oral
Automatism Subtypes in Temporal Lobe
Epilepsy| N. J. Beimer, K. Kluin, T. Mihaylova
2.134 Characterization of Endocrine
Abnormalities in Children with Dravet
Syndrome| K. Eschbach, K. G. Knupp, S. Hsu,
V. Allen
2.135 New onset status epilepticus in
pediatric patients| S. Jafarpour, R. M.
Hodgeman, C. De Marchi Capeletto, M. T. de
Lima, K. Kapur, I. Sanchez Fernández, T.
Loddenkemper
Clinical Diagnosis
2.136 Clinical and Electrographic Features of
Neonates and Children with Congenital
Heart Disease Undergoing Continuous
Electroencephalography in the Intensive
Care Unit| A. J. Sansevere, C. Rollins, R.
Guerriero, E. Buraniqui, P. Pearl, T.
Loddenkemper
2.137 Does Age of Seizure Onset Predict the
Location on the Focal Cortical Dysplasia?| P.
Sudachan, L. Jehi, R. Burgess, N. FoldvarySchaefer, A. Naduvil Valappil, A. Gupta, P.
Kotagal, E. Wyllie, E. M. Pestana Knight
2.138 Impact of Seizure Type on Recognition
of Epilepsy| R. Hennessy, J. French, S. Haut, J.
Hixson, K. Detyniecki, HEP Investigators
2.139 Results of pre-operatory workup of
703 patients in a tertiary epilepsy center in
central Brazil: particularities of a developing
country.| F. Arruda, P. C. Ragazzo, S. E. MeloSouza, H. van der Linden Jr, A. Bastos
2.140 Characteristics and Outcomes of
Patients with Psychogenic Nonepileptic
Seizures With and Without Comorbid
Epilepsy| Y. J. Yu, S. LaPalme-Remis, S.
Mirsattari, J. G. Burneo, R. McLachlan, D.
Diosy
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
61
2.141 Novel seizure mimic: a case of REMinduced heart block and convulsive syncope|
M. Dolatshahi, M. Ng
2.142 Ictal Motor Sequences: Lateralization
and Localization values| A. Marashly, R.
Agarwal, A. H. Ewida, K. Younes, H. Luders
2.143 Clinical and electrographic features of
children undergoing continuous
electroencephalography in the intensive care
unit after cardiac arrest| A. Jayakar, A. J.
Sansevere, R. Guerriero, F. E. Dolzany
Rosales, E. Buraniqi, P. Pearl, T.
Loddenkemper
2.144 Correlation between Antiphospholipid
Antibodies and Epilepsy: A Systematic
Review| S. Brown, J. G. Burneo, C. Huang, T.
Rahman, B. Del Pozzo, E. Boyce, A. LazoLangner
2.145 Familial Frontal Lobe Epilepsy with
Focal Cortical Dysplasia| F. Dubeau, N.
Bernasconi, E. Rioux, A. Bernasconi, B.
Frauscher
2.146 Reflex Epilepsy, triggered by exiting the
shower: A case report| J. Fox, B. Appavu, R.
Little, J. Kerrigan
2.147 Semiological features in frontal lobe
epilepsy at different ages| M. Hintz, A.
Schulze-Bonhage
2.148 TOSCA – TuberOus SClerosis registry to
increase disease Awareness: Baseline data
with focus on epilepsy associated with TSC|
R. Nabbout, S. Jozwiak, G. B. d’Augères, E.
Belousova, T. Carter, R. Castellana, V. Cottin,
S. Crippa, P. de Vries, J. Ferreira, C. Fladrowski,
M. Feucht, G. Gislimberti, C. Hertzberg, A.
Jansen, Q. Jiong, J. Lawson, A. Macaya, F.
O'Callaghan, M. Benedik, V. Sander, M.
Sauter, Y. Takahashi, R. Touraine, S.
Youroukos, B. Ulker, B. Zonnenberg, J. C.
Kingswood, P. Curatolo
2.149 First Time Seizure: Is it worth admitting
them?| H. AlHashemi, R. S. Siddiqui, M. A.
Arif, R. Radhakrishnan, R. K. Siddiqui, S. Sinha,
K. Siddiqui
2.150 Focal cortical dysplasia with clinical
manifestations mimicking febrile infection
related epilepsy syndrome |H. Lee, C. Chi, H.
Yu, H. Chen, C. Lin, S.P.C. Hsu, Y. Shih
2.151 Fact or Artifact II Carol Riley REEG/EPT.
CNIM, RPSGT, RST. VA Boston Healthcare
System Fun interactive poster with 12 all new
and interesting artifacts - or is it real? This
poster presents some common and
uncommon artifacts, abnormalities and
normal var| C. L. Riley
2.152 The clinical spectrum of GABRA1
mutations| G. Rubboli, K. Johannesen, S.
Pfeffer, C. Marini, H. Hjalgrim, R. S. Møller, M.
Nikanorova, L. Larsen, H. Dahl, R. Guerrini, E.
Gardella, O. maier, E. Lohmann, D. Mei, T.
Dorn, S. biskup, H. Lerche, S. Maljevic, J.
Lemke
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
2.153 Does antibody type affect the clinical
phenotype and treatment response in
Hashimoto’s encephalopathy?| H. Skinner, K.
Ewing, S. A. Messina, J. W. Kevill, K. Lee
2.154 Incident Epilepsy, Irrespective of
Seizure Control, Impairs Quality of Life in the
Cognitively Normal Geriatric Population| S. V.
Mathias, M. Bensalem-Owen, G. Jicha
2.155 Advanced Dynamic Statistical
Parametric Mapping (AdSPM) for Focal
Cortical Dysplasia at the Bottom of Sulcus
(BOSD)| M. Nakajima, S. M. Wong, Y. Sato, E.
Widjaja, S. Baba, A. Ochi, S. Doesburg, H.
Otsubo
2.156 Causes of seizures following solid
organ transplantation in children| J.
MacLean, E. Higuchi, D. Olson
2.157 Staff Response Times in the Epilepsy
Monitoring Unit: A Study of
Diurnal/Nocturnal Variability| N. Witek, S.
Cornes, M. Hegde
2.158 Development of a discrete, wearable,
EEG device for counting seizures| M.
Lehmkuhle, M. Elwood, J. Wheeler, J. Fisher, F.
Dudek
2.159 A validated pediatric epilepsy
diagnostic tool for use in resource-limited
settings| A. A. Patel, O. Ciccone, A. Njau, S.
Shanungu, A. K. Grollnek, F. Frederick, R. M.
Hodgeman, G. Sideridis, K. Kapur, C. Harini,
E. Kija, J. Peters
2.160 Automatic Computer-controlled
Behavioral Testing to Assess Ictal and
Postictal Consciousness in Epilepsy Patients|
G. Touloumes, R. Gebre, L. Gober, W. Chen,
A. Sivaraju , E. Grover, R. Khozein, E. Morse, J.
Dente, R. Lilenbaum, H. Blumenfeld
Clinical Treatments
2.161 Parent and patient attitudes towards
use of complementary and alternative
medicine in children with epilepsy| G.
Kumar, M. Chikkannaih, A. Stolfi
2.162 Memory Improvement over 6 years by
Seizure Control in a Middle-aged Male
Diagnosed as Mild Cognitive Impairment| M.
Kinoshita, T. Murai, K. Hayashi, R. Matsumoto
2.163 Etiology and Development are Not
Significant Predictors of Treatment Response
in Infantile Spasms| J. Coryell, K. Nickels, N.
Ryan, E. Leister, A. Berg, D. R. Nordli, J.
Millichap, S. Joshi, R. Shellhaas, D. Dlugos, J. R.
Mytinger, W. Gaillard, C. Keator, T.
Loddenkemper, J. Sullivan, L. Zawadzki, W.
Mitchell, G. Kumar, D. Arkilo, E. Yozawitz, C.
Joshi
2.164 Cannabadiol in Genetic Refractive
Epilepsy in Dravet and Non-Dravet Cases| M.
Chez
2.165 A retrospective study of the overall
yield of continuous bedside EEGs ordered
for NCSE at Tampa General Hospital| J.
Gierbolini, J. Rathod, P. Sureja , C. A. Robles, S.
Maciver, S. Benbadis, A. Frontera
2.166 Psychosocial Outcomes of Vagal Nerve
Stimulation (VNS) in adults for intractable
epilepsy| V. S. Wasade, L. Schultz, K.
Mohanarangan, A. Gaddam, J. Schwalb, M.
Spanaki
2.178 Breaking the cycle: A comparison
between Intravenous immunoglobulins and
high dosage corticosteroids in the treatment
of medically refractory epilepsy in children| J.
A. Mailo, E. Spinelli, R. Tang-Wai
2.168 Association of Rescue Medication Use
with Clinical Outcomes and Healthcare
Resource Utilization in Patients with Seizure
Clusters: A Retrospective Chart Review| D.
Squillacote, B. Vazquez, D. Hesdorffer, E. Wu,
D. Macaulay, R. Sorg, M. Sidovar, A. Guo
2.180 The risk of inhospital seizures of
epilepsy patients, for admissions other than
epilepsy| O. Bican, J. Pillai
2.167 Febrile infection-related epilepsy
syndrome (FIRES); Treatment Strategies and
Long-term Outcomes| M. Kim, M. Yum, Y.
Lee, T. Ko
2.169 The Use of Adjunctive Lacosamide for
Uncontrolled Seizures| O. Erdinc, D. Ilhan
Algin, G. Akdag, G. Uzuner
2.170 Outpatient Treatment of Depression
and Anxiety Disorders in Veterans with
epilepsy. Why aren’t patients getting better?|
M. Lopez, A. Kanner
2.171 Comparison of Stereo-EEG and GridImplanted Phase II Patients' Experience Prior
to Epilepsy Surgery: the Wake Forest
Experience| V. Woodard, J. Boggs, D.
Couture, A. Laxton, G. Popli, M. Silvia, M. Sam,
H. Munger-Clary, M. Wong, C. O'Donovan
2.172 Long-term Outcome of Adults with
Medically Intractable Mesial Temporal Lobe
Seizures Treated with Responsive
Neurostimulation| P. Van Ness, E. Mizrahi, D.
King-Stephens, D. Nair, C. Bazil, R. Goodman,
B. Jobst, R. Gross, D. Shields, G. L. Barkley, V.
Salanova, G. Bergey, R. Wharen, G. Worrell, R.
Marsh, K. Noe, A. M. Murro, A. Cole, J. C.
Edwards, D. Spencer, M. Smith, E. Geller, R.
Gwinn, C. Skidmore, M. Berg, C. Heck, M.
Agostini, N. Fountain, P. Rutecki, A. Herekar,
R. Duckrow, T. Crowder Skarpaas, R. Kapur,
M. Morrell
2.173 Focal EEG abnormalities in drug
resistant juvenile myoclonic epilepsy| Y.
Kitazawa, K. Jin, K. Kato, Y. Kakisaka, M.
Fujikawa, M. Iwasaki, F. Tanaka, N. Nakasato
2.174 Large-Scale, Long Term, Observational
Study of SUDEP in Patients with Drug
Resistant Epilepsy treated with VNS Therapy|
P. Ryvlin, D. Hesdorffer, M. Sperling, E. So, O.
Devinsky, D. Freedman, M. T. Bunker, C. M.
Gordon, B. Olin
2.175 Is there an EEG marker of increased
SUDEP risk?| A. Rabiei, J. Kang, M. Nei
2.176 An Evaluation of Adherence in Patients
with both Epilepsy and Obstructive Sleep
Apnea| J. McAuley, J. Cios
2.177 The Safety and Diagnostic Yield of
Epilepsy Monitoring Unit Evaluations Using a
Pre-Admission Fast Antiepileptic Drug Taper|
A. Shah, A. Shah, D. Zutshi, M. Basha, R.
Waheed
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
62
2.179 Improvement on EEG using the
ketogenic diet in pediatric patients| P.
Trudeau, M. Koehn, D. M. Staab, T. Timmler, K.
Henry, E. Sandok
2.181 Clinical characteristics and first
treatment choice effectivity in new onset
epilepsy patients| A. Can, M. Jackson, L.
St.Louis, J. Klehm, K. Kapur, T. Loddenkemper
2.182 Efficacy and safety of levetiracetam
monotherapy on children with epilepsy| Y.
Zhang
Prognosis
2.183 Factors associated with status
epilepticus duration in children| T.
Loddenkemper, I. Sánchez Fernández, M.
Jackson, N. Abend, R. Arya, J. Brenton, J.
Carpenter, K. Chapman, W. D. Gaillard, T.
Glauser, J. Goldstein, H. Goodkin, A. Helseth,
M. Mikati, K. Peariso, A. Topjian, M.
Wainwright, A. Wilfong, K. Williams, R. Ta
2.184 Insomnia in epilepsy is prevalent and
associated with seizures, health care use, and
circadian delay| M. Quigg
2.185 The Efficacy Of Intracranial EEG
Monitoring Using Subdural Electrodes In The
Outcome Of Epilepsy Surgery| E. Al-Shehri, K.
Alqadi, Y. Al-Said, S. Baeesa
2.186 Predictors of mortality in children with
continuous electroencephalographic
monitoring in the intensive care unit| I.
Sanchez Fernández, A. Sansevere, R.
Guerriero, J. Klehm, R. Tasker, P. Pearl, T.
Loddenkemper
2.187 Assessment of Status Epilepticus in
Elderly Population: Geriatric Onset vs. nonGeriatric Onset Epilepsy| H. Rajebi, G. Fahimi,
K. Ogden, S. Izadyar, P. Kent, A. Sanders, R.
O'Dwyer
2.188 The characteristics of temporal lobe
epilepsy in children: seizure and
developmental outcome in surgical cases| R.
Honda, H. Baba, K. Toda, T. Ono, N. Koide
2.189 Reversal of Ohtahara Syndrome Due to
SCN2A Duplication with Phenobarbital| F.
Baumer, J. Peters, C. Achkar, P. Pearl
2.190 Outcomes in Super Refractory Status
Epilepticus Treated with Pharmacologic
Suppression| T. Aung, C. Schusse
2.191 Predicting Drug-Resistance in
Generalized Epilepsy in an Adult population:
a case-control study| A. R. Voll, L. Hernandez
Ronquillo, S. Buckley, J. F. Téllez Zenteno
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
Women’s Issues
2.192 Effects of Hormonal versus NonHormonal Contraception on Seizures:
Findings of the Epilepsy Birth Control
Registry| H. Mandle, K. E. Cahill, K. M. Fowler,
A. R. Davis, W. Hauser, A. Herzog
2.193 Contraceptive Counseling for Women
with Epilepsy| A. R. Espinera, I. Garic, S.
Schuele, M. Macken, E. Gerard
2.194 Differential Impact of Various
Antiepileptic Drug Categories on the Effects
of Hormonal Contraception on Seizures:
Findings of the Epilepsy Birth Control
Registry| A. Herzog, H. Mandle, K. E. Cahill, K.
M. Fowler, A. R. Davis, W. Hauser
2.195 Collaborative Epilepsy - Family
Planning Model Clinic Increases Use of
Effective Contraception| J. Kennedy, C.
Cansino, P. Parikh, J. Melo, M. Hou, M. Chen,
K. Park, E. Gerard, M. Seyal, M. Creinin
2.196 Epilepsy and Reproductive Issues in
Women of Hispanic Origin Living in United
States| O. Laban-Grant, M. Lancman, C. B. de
la Pena, M. Malik, S. S. Iyengar, E. Fertig, P.
Klein, M. Lancman
2.197 Ovulation Rates in Women with
Epilepsy Seeking Pregnancy compared to
Healthy Controls| N. Llewellyn, P. Pennell, C.
Lau, C. Harden, J. French, E. Bagliella, A. R.
Davis, S. Barnard, S. Cornely
neuROIMAgIng
Structural Imaging
2.198 Thalamic structural changes in
hippocampal sclerosis: a combined
structural and diffusion tensor MRI analysis|
J. Kim
2.199 Post-Operative Short-Term Brain
Plasticity in Children with Surgically
Refractory Epilepsy: A Preliminary
Longitudinal DTI Connectome Analysis| J.
Jeong, E. Asano, C. Juhasz, H. Chugani
2.200 Tractography of hippocampal
association fibers in patients with
hippocampal sclerosis and temporal lobe
epilepsy| T. Hammen, J. Nakagawa, M.
Reisert, H. Urbach, A. Schulze-Bonhage, K.
Egger
2.201 Volumetric Network Reorganization in
Temporal Lobe Epilepsy| V. L. Morgan, B.
Conrad, B. Abou-Khalil, B. P. Rogers
2.202 Focal Cortical Dysplasia Type-II: MRIbased Profiling and Subtype Prediction| S.
Hong, B. Bernhardt, D. Schrader, N.
Bernasconi, A. Bernasconi
2.203 Age-related atrophy of hippocampal
subfields in patients with TLE and controls:
left TLE with hippocampal sclerosis declines
faster| C. Yasuda, B. Braga, M. Morita, G. C.
Beltramini, A. Coan, F. Bergo, D. Gross, F.
Cendes
2.204 7T whole brain MRI provides increased
statistical power for morphometric analysis
of neuroanatomy| H. R. Pardoe, W. Shin, M.
Lowe, H. Hetherington, R. Kuzniecky, J. Pan
2.205 Cortical and Subcortical Structural
Abnormalities in Juvenile Myoclonic Epilepsy:
Tract-based Spatial Statistics (TBSS) and
Constrained Laplacian-based Anatomic
Segmentation with Proximity (CLASP)
Algorithm| S. Lim, S. Kim, W. Kim, J. Kim, Y.
Shon
2.206 Neuroanatomical correlates of
depression and anxiety in new onset focal
epilepsy: preliminary results from the Human
Epilepsy Project| H. R. Pardoe, A. Kanner, D.
Hesdorffer, S. Nadkarni, T. O'Brien, M.
Winawer, S. Cristofaro, K. McKenna, J. Barry,
R. Kuzniecky, J. French
Functional Imaging
2.207 Focus diagnosis for intractable
epilepsy by functional Nearinfrared
Spectroscopy (fNIRS)| K. Oguro, H. Yokota, E.
Watanabe
2.208 Identifying Microstructural Predictors
of Temporal Lobe Epilepsy through Machine
Learning of Diffusional Kurtosis Imaging.| J.
Del Gaizo, N. Mofrad, L. Bonilha
2.217 Semiology and Functional Imaging of
Hypermotor Seizures| U. Thome, K. Alqadi, R.
R. Sankaraneni, A. Alexopoulos, Z. I. Wang, G.
Wu, P. Kotagal
2.218 Cerebral blood flow interactions during
complex partial seizures in patients with
mesial temporal lobe epilepsy| Z. Zhao, C.
Wong, S. Wang, W. Liao, A. Bleasel
2.219 Effect of Epilepsy Surgery on Regional
Language Dominance| E. Emery, S. C.
Germeyan, L. Sepeta, M. Berl, E. Wiggs, W.
Gaillard, W. Theodore
2.220 A Segmentation Method to Identify
MRI and FDG-PET Negative Focal Cortical
Dysplasia| L. Olson
2.221 A Virtual Morris Water Maze; A Method
to Study Allocentric Memory in Humans| G.
P. Thomas, A. Titiz, P. Lenck-Santini, B. Jobst
2.222 Functional integrity of resting-state
networks predicts seizure outcome after
anterior temporal lobectomy| G. Doucet, X.
He, M. Sperling, A. Sharan, J. Tracy
COMORBIDITy (SOMATIC AnD
PSyChIATRIC)
Medical Conditions
2.209 Epilepsia Partialis Continua (EPC) in
Children studied with F-18Flourodeoxyglucose (FDG)-PET| P. Konka, A.
Kumar, T. Govil Dalela, V. Pilli, H. Chugani
2.223 System-based comorbidities in the
Rare Epilepsy Network (REN)| D. Hesdorffer,
E. Mayerson, B. Kroner, J. French, J. Buelow,
REN Organizations
2.211 Usefulness of double density fNIRS
(DD-fNIRS) for the diagnosis of neocortical
epilepsy focus| H. Yokota, K. Oguro, E.
Watanabe
2.225 Vagus Nerve Stimulation Reduces
Cardiac Electrical Instability Assessed by
Quantitative T-Wave Alternans Analysis in
Patients with Drug-Resistant Epilepsy
Enrolled in the Aspire SR E-36 Trial| R. L.
Verrier, B. Nearing, B. Olin, S. Schachter, P.
Boon
2.210 Localize Interictal Spikes and Seizure
Onset With Dense Array
Electroencephalography| C. Kuo, D. Tucker,
P. Luu, K. Jenson, J. Hou, J. Song, M. D. Holmes
2.212 Noninvasive Imaging of Epileptogenic
Zone from EEG/MEG by Sparse Source
Imaging| A. Sohrabpour, Y. Lu, G. Worrell, B.
He
2.213 Metabolic Correlate of the IctalInterictal Continuum: FDG-PET during
continuous EEG| A. Struck, M. B. Westover,
G. Deck, A. Cole, E. Rosenthal
2.214 Source localization of the seizure
onset zone from ictal EEG/MEG| G.
Pellegrino, T. Hedrich, R. Chowdhury , J. Lina,
F. Dubeau, J. Hall, E. Kobayashi, C. Grova
2.215 Time-dependence of graph theory
metrics in functional connectivity analysis| S.
Chiang, A. Cassese, S. J. Yeh, Z. Haneef, J.
Stern
2.216 EEG source imaging of interictal spikes
using volumetric priors for presurgical focus
localization| G. Strobbe, E. Carrette, D. Van
Roost , A. Meurs, K. Vonck, P. Boon, S.
Vandenberghe, P. van Mierlo
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
63
2.224 The STOP-BANG Questionnaire
Improves the Detection of Epilepsy Patients
at Elevated Risk for Obstructive Sleep Apnea|
A. Sharma, J. Molano, B. D. Moseley
2.226 Epilepsy and long QT syndrome type
2 – different clinical presentations of the
same channelopathy?| I. T. Dahl, P. Larsson,
K. H. Haugaa, E. Tauboll
2.227 A Pilot Study of an Education and
Exercise Program to Improve Bone Health in
Patients with Epilepsy| S. Girgis, M. L.
Wagner, D. Sukumar, S. Balachandar, R. Mani,
K. Sivaraaman
2.228 Early seizures after stroke: is there a
difference in patients with left and right
hemispheric lesions?| A. Guekht, W. Hauser,
N. Gulyaeva, I. Kaimovsky, A. Yakovlev, A.
Lebedeva, A. Shpak, E. Gusev
2.229 Sleep difficulties are frequent in Dravet
syndrome| I. Scheffer, S. H. Licheni, A.
Schneider, M. Davey, J. McMahon
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
Psychiatric Conditions
2.230 Bilateral Hippocampal Dysfunction
with Specific Frontal and Temporal
Dysfunction in Temporal Lobe Epilepsy| C.
Charyton, B. Tang, J. Moore
2.231 Mesial temporal lobe epilepsy with
psychiatric comorbidities: more than just
hippocampal neuron loss| M. Monteiro, L.
Kandratavicius, R. C. Scandiuzzi, C. G. Carlotti,
J. A. Assirati, J. E. Hallak, J. Leite
2.232 Anxiety and Attention Deficit
Hyperactivity Disorder in Children and
Adolescents with Epilepsy| M. Phelps, C.
Salorio, J. Salpekar
2.233 Higher IQ in juvenile myoclonic
epilepsy: Dodging cognitive obstacles and
“masking” impairments | M. Mendoza, S.
Moschetta, P. Rzezak, S. de Vincentiis, R.
Demarque, A. Coan, C. Guerreiro, K. Valente
2.234 Evaluation of dissociation, self-efficacy
and rates of trauma in patients with
psychogenic nonepileptic seizure (PNES)
events or epilepsy.| E. Wagner, D. Drane
2.235 Epileptic Seizures Produce a Transient
Improvement in Mood in Patients with
Epilepsy and Depression| M. Cassady, K.
Grimes, S. Yin, K. Turlington, M. Richert, M.
Kvarta, S. Thompson, J. Hopp
2.236 Altered responsiveness during
psychogenic non-epileptic seizures:
relationship to underlying psychopathology
and clinical risk factors| G. Baslet, B. Tolchin,
J. Zinser, B. Dworetzky
2.237 PHQ-9 depression inventory scores in
patients with epileptic and non-epileptic
events| J. Wang, J. Jirsch
AnTIePIlePTIC DRugS
Animal Studies
2.238 Clinical Development of an
Intravenous Formulation of Ganaxolone for
Acute Care Patients Supported by NonClinical Toxicity Studies Conducted in Rats
and Rabbits| J. Tsai, V. Lauriault, R. Avery, S.
Dalton, Z. Antonio, S. Smith, A. Patroneva
2.239 Effect of perampanel on
neuroprotection in the lithium-pilocarpine
rat model of status epilepticus| T. Wu, K. Ido,
Y. Osada, S. Kotani, T. Hanada
2.240 Anticonvulsant efficacy of SAGE-217, a
second generation neuroactive steroid, in a
mouse model of chronic medial temporal
lobe epilepsy| R. Hammond, G. Belfort, G.
Martinez, A. J. Robichaud, J. Doherty
2.241 The protective effects of lestaurtinib
(CEP-701) against long-term behavioral
deficits following early life hypoxic seizures|
J. Goenaga, B. Appavu, J. Fox, J. Oelze, R. Kuk,
D. Fox, K. Burke, J. Miguel, J. Ryan, P. Adelson,
D. M. Treiman, M. Obeid
2.242 Perampanel, a potent noncompetitive
AMPA receptor antagonist, enhances survival
in tetramethylenedisulfotetramine-induced
status epilepticus| D. Zolkowska, Boosalis, D.
A. Bruun, P. J. Lein, B. Hammock, M. Rogawski
Clinical Trials
2.243 Mortality in Phase III Studies of
Adjunctive and Monotherapy Eslicarbazepine
Acetate in Patients with Partial-Onset
Seizures| E. Trinka, A. J. Cole, E. Andermann,
H. Gama, F. Rocha, D. Blum, T. Grinnell, H.
Cheng, P. Ryvlin
2.244 Long-term exposure and safety of
lacosamide monotherapy for the treatment
of partial-onset seizures: results from a
multicenter, open-label extension trial| D.
Vossler, R. Wechsler, P. Williams, W. Byrnes, S.
Therriault
2.245 A Double-Blind, Placebo-Controlled,
Randomized Trial to Assess the Effects of
Lacosamide on Patient-Reported Sleep
Outcomes in Adults with Epilepsy| N.
Foldvary-Schaefer, S. Neme-Mercante, N.
Andrews, M. Bruton, S. Morrison, L. Wang, J.
Bena
2.246 Safety and Tolerability of
Eslicarbazepine Acetate (ESL) Monotherapy
in Patients Previously Taking Oxcarbazepine
(OXC)| R. Wechsler, I. Ali, M. Sam, D. Blum, T.
Grinnell, H. Cheng
2.247 Efficacy, Tolerability, and
Pharmacokinetics of Fosphenytoin Loading
in Patients with Subarachnoid Hemorrhage|
J. Kim, D. Kim, K. Kim
2.248 Efficacy and tolerability of
Eslicarbazepine: Post Marketing Analysis| M.
B. Tom, B. Abou-Khalil, N. Azar, K. Haas, P.
Singh, A. Arain
2.249 Change in Depressive Symptoms
among Patients with Refractory Partial-Onset
Seizures Treated with Eslicarbazepine
Acetate Monotherapy: A Pooled Analysis of
Clinical Trials| T. Bond, F. Velez, K. Plante
Anastassopoulos, X. Wang, J. Cramer, R.
Sousa, D. Blum
2.250 Efficacy and tolerability of perampanel
in patients (pts) with secondarily generalized
(SG) or primary generalized tonic-clonic
seizures (PGTC): a pooled analysis of four
randomized, Phase III studies| T. O'Brien, A.
Patten, F. Bibbiani, H. Yang, B. Williams, A.
Laurenza
2.251 Efficacy and safety of adjunctive
lacosamide for the treatment of partial-onset
seizures in Chinese and Japanese adults: a
multicenter, double-blind, randomized,
placebo-controlled study| Z. Hong, W. Liao,
H. Meng, X. Wang, W. Wang, L. Zhou, L.
Zhang, O. Togo, F. Tennigkeit, Y. Inoue
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
64
2.252 Tolerability of Adjunctive
Eslicarbazepine Acetate in Elderly Patients
with Epilepsy: an Exploratory Post-Hoc
Analysis of Three Phase III Studies| W.
Rosenfeld, P. Penovich, J. B. Rogin, F. Cendes,
M. Carreno, H. Gama, F. Rocha, D. Blum, T.
Grinnell
2.253 Efficacy of Brivaracetam Stratified
According to Pathological Substrate: Findings
from a Phase III Clinical Trial| A. Beydoun, F.
Semah, V. Villanueva, B. O'Boyle, S. Elmoufti, J.
D'Souza
2.254 Efficacy and Safety of Eslicarbazepine
Acetate (ESL) Monotherapy in Patients
Previously Taking Carbamazepine (CBZ)| L.
Pazdera, M. Sperling, J. Harvey, D. Blum, T.
Grinnell, H. Cheng
2.255 The International Collaborative Infantile
Spasms Study (ICISS): comparing hormonal
therapies (prednisolone or tetracosactide
depot) and vigabatrin versus hormonal
therapies alone in the treatment of infantile
spasms: early clinical and electro-clinical
outcomes| F. O'Callaghan, S. Edwards, E.
Hancock, A. Johnson, C. Kennedy, A. Lux, M. T.
Mackay, A. Mallick, R. Newton, M. Nolan, R. M.
Pressler, D. Rating, B. Schmitt, C. Verity, J.
Osborne
2.256 Pharmacokinetics of Midazolam Nasal
Spray (USL261) in Healthy Geriatric and NonGeriatric Adults| P. J. Van Ess , M. J. Myrvik, A.
K. Berg
2.257 Evaluation of Clobazam Conversion
Therapy Replacing Clonazepam in Patients
with Medically Refractory Epilepsy - A 12
Month Follow-up| S. Marsh, S. Chung
2.258 Eslicarbazepine acetate as add-on
treatment to antiepileptic monotherapy in
patients with partial-onset seizures who
previously did not respond to
carbamazepine: real-world evidence from the
EPOS study| R. McMurray, C. Karlsson, R.
Sousa, M. Holtkamp
2.259 Tolerability and Pharmacodynamics of
Midazolam Nasal Spray (USL261) in Healthy
Geriatric and Non-Geriatric Adults| A. K.
Berg, M. J. Myrvik, P. J. Van Ess
2.260 Additional Responder Analyses on a
Phase 2 Study of Ganaxolone in Patients with
Partial Onset Seizure Epilepsy| A. Patroneva,
E. Laska, J. Tsai
2.261 Real-world data on eslicarbazepine
acetate as add-on treatment to antiepileptic
monotherapy in elderly patients (>60 years)
with partial-onset seizures| C. Karlsson, R.
McMurray, R. Sousa, M. Holtkamp
2.262 Low-dose Fenfluramine Significantly
Reduces Seizure Frequency in Dravet
Syndrome: A Prospective Study of a New
Cohort of Belgian Patients| B. Ceulemans, A.
Schoonjans, B. Gunning, A. Gammaitoni, L.
Lagae
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
2.263 Efficacy and safety of adjunctive
perampanel (PER) in adolescents with
inadequately controlled partial-onset
seizures (POS): randomized, double-blind
and open-label extension (OLE) study| V.
Villanueva, B. Renfroe, H. Yang, B. Williams, D.
Kumar, A. Laurenza
Drug Side effects
2.264 Genetic risk factors for AED-induced
hypersensitivity reactions in Israeli
populations| S. Eyal, D. Ekstein, C. Brautbar,
S. Israel
2.265 Adverse psychological effects of
levetiracetam in adults with epilepsy in
general practice| J. Engbers, C. Josephson, M.
Lunney, M. Lowerison, S. B. Patten, N. Jette, S.
Wiebe
2.266 Cardiovascular Side Effects of Lowdose Fenfluramine Treatment in Dravet
Syndrome: A Prospective Echocardiographic
Pilot Study| A. Schoonjans, F. Marchau, L.
Lagae, B. Paelinck, B. Ceulemans
2.267 EQUIvalence among GENeric AEDs
(EQUIGEN): Single-dose study| M. Berg, M.
Privitera, F. Diaz, B. Dworetzky, E. Elder, B.
Gidal, W. Jiang, R. Krebill, N. McBee, J. Pollard,
R. Alloway, A. Paige, J. Szaflarski, P. Bolger, T.
Welty
2.268 Specific adverse effects of antiepileptic
drugs in common mono- and duotherapies|
M. Holtkamp, F. Weissinger, A. Kowski
2.269 The Impact of Lacosamide on
Cognition, Mood and Quality of Life| M.
Lancman, E. Fertig, R. Trobliger, K. Perrine, M.
Malik, L. Myers, J. Sabri
2.270 Assessing Relationships Between
Clobazam Serum Level, Daily Dose, and
Toxicity| A. W. Legge, K. Detyniecki, L. Hirsch,
R. Buchsbaum, S. Harris, K. Kato, L. Tibbetts,
B. Chen, H. Choi
2.271 The Relationship of Co-medications
and Charlson Scores in Elderly Nursing
Home Residents Receiving Antiseizure
Drugs| B. M. Kistner, S. Bathena , I. Leppik, A.
Birnbaum
Other
2.272 Outcomes Assessment in Clinical
Practice: Retrospective Record Review of
Patients Treated with Trokendi XR®
(extended-release topiramate)| W. O'Neal, E.
Hur, T. Liranso, P. Barr, D. Y. Ko
2.273 Topiramate and Zonisamide are not
effective in secondary prevention of infantile
spasms| J. Lay, R. Rajaraman, R. Sankar, S. A.
Hussain
2.274 Levetiracetam and phenobarbital
exhibit similar efficacy in the treatment of
seizures associated with neonatal hypoxic
ischemic injury| T. Zaki, A. Cho, L. M. Rao, T.
Chanlaw, M. garg, R. Sankar, S. A. Hussain
2.275 ESLI-ATLANTICO: Experience with
eslicarbazepine acetate in focal epilepsies in
Galicia, Spain.| F. L. Gonzalez, X. Rodriguez
Osorio, M. Saavedra Piñeiro, E. Corredera, E.
Rodríguez Castro, A. Fernández Lebrero, E.
Rubio-Nazábal, J. Abella Corral, A. López
Ferreiro, A. Puy Núñez, D. García Estevez, M.
Pardo
2.287 ARK™ Oxcarbazepine Metabolite Assay
for the Beckman Coulter AU480 Automated
Clinical Chemistry Analyzer| S. J. Oh, K. Pham,
M. Yim, B. Moon, J. Valdez
2.277 Lacosamide distribution between
serum and cerebrospinal fluid may be
altered in patients with brain tumors
compared to non-lesional epilepsy| S. Mittal,
S. Michelhaugh, A. Shah
nOn-AeD/nOn-SuRgICAl
TReATMenTS
2.276 Response to Vigabatrin in Different
Seizure Types in a Pediatric Population| S.
Thome-Souza, M. Jackson, J. Klehm, S.
Jafarpour, T. Loddenkemper
2.278 Use of Ketamine in the treatment of
refractory status epilepticus in adults: A
retrospective single center seven year
experience| C. Maideniuc, A. Wang, M.
Srinivas, D. Parker, A. Shah, G. Norris, M.
Basha
2.279 Plasma Exchange Decreases
Levetiracetam Levels in a Patient with
Neuromyelitis Optica and Epilepsy| O.
Danoun, D. Zutshi, M. Basha, N. SerajiBozoergzad
2.280 Lacosamide for Status Epilepticus: An
Effective and Safe Option?| H. Doshi, K.
Suchdev, D. Kandipalli, D. Parker, G. Norris, D.
Zutshi
2.281 Clinical experience with
Eslicarbazepine acetate in adults focusing on
elderly| N. Andersen Becser, M. Nielsen
Kromann
2.282 The Association Between Antiepileptic
Drug Pill Burden at Monotherapy Initiation
and Epilepsy-Related Hospital Admissions
and Emergency Department Visits in the
United States| J. S. Korsnes, F. Velez, S. D.
Candrilli
2.283 Efficacy of bedtime clonazepam as
add on therapy in children with ESES| G.
Turanli, E. Gultekin
2.284 Clinical Practice Data to Aid Narrow
Therapeutic Index Drug Classification:
Lamotrigine| J. T. Guptill, H. Wu, R.
Greenberg, M. Gostelow, D. Gonzalez, C. P.
Hornik, N. Zheng, W. Jiang, M. CohenWolkowiez, K. D. Hill
2.285 The importance of a therapeutic drug
monitoring (TDM) service for patients with
refractory epilepsy based on the patients’
opinion| C. J. Landmark, M. A. Mevåg, H.
Oliver, M. Burns, A. Baftiu, S. Johannessen
2.288 Retrospective study about
effectiveness and tolerability of perampanel
in drug resistant myoclonic epilepsies| F. J.
Gil, J. Aparicio, M. Falip Centellas, J. López
González, I. García Morales, P. Serrano, R.
Toledano Delgado, A. Gil-Nagel, A. Molins
Albanell, M. Carreno
Pediatrics
2.289 Ketone Production and Seizure Control
with the Medium Chain Triglyceride and
Classic Ketogenic Diets| H. Lowe, S. Aimola, Y.
Liu, M. Zak, V. Chan, J. Kobayashi, E. Donner
2.290 Risk Factors for Acidosis During
Ketogenic Diet Initiation| M. Zaiderman, S.
Vogel, B. Cines, A. Kao
2.291 Challenges in Setting up an Integrative
Epilepsy Clinic for Patients with Non-epileptic
Seizures| A. Koehler, E. Dill, G. Wilkening, S.
Brown, P. Levisohn
2.292 Efficacy of ketogenic diet in resistant
myoclono-astatic epilepsy: a french
multicentric retrospective study| A. de Saint
Martin, E. Stenger, M. Schaeffer, C. Cances, J.
Motte, S. Auvin, D. Ville, H. Maurey, R.
Nabbout
2.293 Short-term Efficacy of Low Glycemic
Index Diet in Intractable Pediatric Epilepsy.|
S. Kim, M. Cho, J. BAEK, J. Lee, H. Chung, H.
Kim
2.294 Prevalence of acidosis in patients on a
ketogenic diet, and assessing the need for
supplementations to treat it| A. Abdelmoity,
S. Abdelmoity, A. Hall, K. Pawar, T. Myers, L.
Thompson
2.295 The efficacy of different
benzodiazepine treatments in combination
with a ketogenic diet| A. Abdelmoity, S.
Abdelmoity
2.296 Long-term efficacy and tolerability of
add-on cannabidiol for drug-resistant
pediatric epilepsies| M. Oldham, J. Sullivan, N.
Singhal, N. Tilton, M. Cilio
2.286 Effectiveness of Once Daily Dosing of
High Dose ACTH for Infantile Spasms| R. M.
Hodgeman, A. Paris, C. Marti, A. Can, T.
Loddenkemper, A. Bergin, A. Poduri, N.
Lamb, S. Jafarpour, C. Harini
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
65
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
SuRgeRy
Adult
2.297 Stimulation and Response Analysis for
Identification of Seizure Onset Zones| T.
Davis, P. House
2.298 “I love my brain”: Decision Making
among Patients with Refractory Focal
Epilepsy, weighing disease severity against
risks and benefits of surgery.| H. Peters, S.
Dewar
2.299 Comparison of surgical outcome
between TLE-HS patients operated with and
without long-term video-EEG monitoring| M.
K. Alvim, M. Morita, C. L. Yasuda, H. Tedeschi,
E. Ghizoni, F. Cendes
2.300 Comprehensive evaluation of the role
of non-seizure outcome measures on postepilepsy-surgery quality of life – a
prospective study| G. Shukla, A. Mohammed,
N. Singh, P. Agarwal, V. Goyal, A. Srivastava,
M. Behari
2.301 A prospective, randomized, double
blinded, clinical trial to examine the safety
and efficacy of deep brain stimulation of the
ATN for the treatment of focal, refractory
epilepsy in adult patients.| H. Herrman, A.
Egge, E. Heminghyt, K. Osnes, E. Dietrichs, E.
Taubøll
2.302 Identification of themes relevant to
patients’ evaluation of their satisfaction with
epilepsy surgery through focus group
discussions| M. Lunney, K. Sauro, M. J.
Atkinson, C. Josephson, F. Girgis, S. Singh, S.
B. Patten, N. Jette, T. Sajobi, W. Hader, S.
Wiebe
2.303 3D printing for intracranial EEG
electrodes localization: individualized surgical
planning for resective epilepsy surgery| M.
Xu, K. Urbain, S. Xu
2.304 Cortical evoked potentials after pairedpulse stimulation: evaluation of cortical
excitability in epilepsy patients| T. Sato, M.
Iwasaki, K. Jin, N. Nakasato, T. Tominaga
Pediatrics
2.305 Safety and Efficacy of Stereotactic
Laser Ablation of Hypothalamic
Hamartomas| S. Reddy, D. Elledge, C. Talley,
A. Ho, D. Curry, A. Wilfong
2.306 Number of anti-epileptic drugs tried at
time of surgical evaluation in pediatric
epilepsy patients| J. Bolton, A. Rotenberg
2.307 Seizure outcome after pediatric
epilepsy surgery using intraoperative MRI
(iMRI)| N. Warsi, C. Saint-Martin, J. L. Montes,
J. Atkinson, J. Farmer, R. W. Dudley
2.308 Evaluation of the Natural History of
Epilepsy Associated with Low Grade
Gangliogliomas and Dysembryoplastic
Neuroepithelial Tumors in Children| A. M.
Faramand, J. Cross, M. Tisdall
2.309 Epilepsy surgery for epileptic
encephalopathy in infancy| A. Takahashi, T.
Otsuki, N. Ikegaya, T. Kaido, Y. Kaneko, E.
Nakagawa, K. Sugai, M. Sasaki
2.310 Clinical characteristics and outcomes
in pediatric patients undergoing repeat
epilepsy surgery| A. Jayakar, J. Bolton
2.311 Resective surgery for focal cortical
dysplasia in children: a comparative analysis
of the utility of intraoperative magnetic
resonance imaging (iMRI)| C. Oluigbo, M.
Sacino, T. DeFreitas, S. Magge, J. Myseros, C.
Ho, R. Keating, W. Gaillard
2.312 Can neuropsychological examination
define the margin of resective surgery in
children with intractable epilepsy?| S. Baba,
E. Kerr, V. Vakorin, O. Muthaffar, A. Ochi, C.
Go, J. Drake, J. Rutka, E. Donner, C. Snead, H.
Otsubo
2.313 Utility of electrocorticography in
resection of deep focal cortical dysplasia in
children | D. Depositario-Cabacar, K. Havens,
C. Oluigbo, S. Magge, G. Vezina, W. Gaillard
2.314 Long Term Outcomes after First time
and Repeat Resective Surgery in Pediatric
Refractory Epilepsy| J. R. Lauer, H. Kim, C.
Rozzelle, J. Blount, P. Kankirawatana
All Ages
2.315 WITHDRAWN
2.316 Opportunities and Pitfalls with MRI
Guided Laser Ablation in Medically
Refractory Focal Epilepsy| D. Eliashiv, S.
Dewar, N. Salamon
2.317 Factors Influencing Delay in Epilepsy
Surgery. A retrospective data review for
Western New York| G. Ahmad, N. Chaudhry,
B. Mahmood, A. Weinstock, P. Li
2.318 The Relationship Between MRI Brain
Abnormalities Outside the Surgical Bed and
Seizure Recurrence Following Epilepsy
Surgery| M. Hegazy, C. Garcia-Gracia, W.
Bingaman, J. Gonzalez-Martinez, L. Jehi
2.319 Left Temporal Lobe Epilepsy Due to
Large Sphenoidal Encephalocele with
Surgical Outcomes| T. L. Fisher, H. Shin, H.
Albert, M. Elkay, D. Sasaki-Adams
2.320 Outcome of surgery for drug resistant
epilepsy due to autoimmune encephalitis|
M. Carreno, C. Bien, M. Sperling, A. AsadiPooya, P. Marusic, T. Wehner, J. Pimentel, J.
Rodriguez Uranga, F. Gil, J. Rumia, M. Falip
Centellas, A. Donaire Pedraza, J. Dalmau, F.
Graus
2.321 Surgery for Focal Cortical Dysplasia| B.
Malla, J. Chaturvedi, A. A, S. Sinha, A.
Mahadevan, S. Parthasarathi
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
66
2.322 The Clinical Impact of Integration of
Magnetoencephalography in the Presurgical
Workup of Nonlesional Epilepsy| I.
Mohamed, T. Tayah, A. Bouthillier, A. Berube,
P. Cossette, P. Finet, M. Robert, J. Leroux, C.
Grova, M. Lassonde, D. Nguyen
2.323 Intra-operative electrocorticography in
epilepsy surgery: indications, utility and
correlations to pre-surgical anatomo-electroclinical data, neuropathology and outcome|
G. Didato, R. Garbelli, G. Tringali, F. Deleo, C.
Bruzzo, A. Dominese, I. Pappalardo, R.
Spreafico, M. de Curtis, F. Villani
BehAVIOR/neuROPSyChOlOgy/
lAnguAge
Adult
2.324 Attentional processes in temporal lobe
epilepsy determined by hippocampal
sclerosis: The relevance of prefrontal
dorsolateral cortex and hippocampus | K.
Valente, G. Busatto, F. Duran, E. Lima, S. de
Vincentiis, P. Rzezak
2.325 Decision-making in patients with
temporal lobe epilepsy: Delay gratification
ability is not impaired in patients with
hippocampal sclerosis | P. Rzezak, E. Lima, F.
Pereira, A. Gargaro, E. Coimbra, S. Vincentiis,
T. Rodrigues Velasco, J. Leite, G. Busatto, K.
Valente
2.326 Seizure frequency and polytherapy
impact everyday memory in patients with
temporal lobe epilepsy caused by
hippocampal sclerosis | E. Lima, P. Rzezak, A.
Gargaro, E. Coimbra, S. de Vincentiis, T.
Rodrigues Velasco, J. Leite, G. Busatto, K.
Valente
2.327 Naming Assessment of Spanishspeakers with Epilepsy: Preliminary Findings|
K. Bortnik, M. J. Hamberger
2.328 Assessing naming in non-native English
speakers with epilepsy| A. L. Gooding, J. R.
Cole, M. J. Hamberger
2.329 Development of the Art Therapy
seizure assessment sculpture at the
Cleveland Clinic Epilepsy Center| S. Brown, T.
Shella
2.330 Failure to Discuss Sudden Unexpected
Death in Epilepsy(SUDEP): Omertà or
Omission?| S. Duncan, A. McLellan, C. Derry,
L. Davidson
2.331 Depression, Anxiety and Quality of Life
Improve One Year After Surgical Intervention
in an Underserved Hispanic Population with
Intractable Epilepsy| M. Armacost, N.
Jimenez, S. Shaw, D. Millett, C. Liu, J. Smith
2.332 Patients with psychogenic nonepileptic spells perform worse on six
psychometric measures when compared to
patients with epileptic seizures| J. Croom, H.
Morris, R. Fields, J. Burd, N. Patil, C. Ledo
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
2.333 Sleep-dependent memory
consolidation in the epilepsy monitoring unit
(EMU): a pilot study| R. Sarkis, J. Alam, M.
Pavlova, B. Dworetzky, P. Pennell, R. Stickgold,
E. Bubrick
2.334 The Development of a Cognitive
Intervention for Persons with Epilepsy and
Memory Impairment| A. M. Gregory, R.
Martin, J. Beattie, J. Szaflarski
2.335 Rates of Subjective Cognitive
Impairment in Adult Epilepsy Clinic Patients|
L. Gotterer, J. Bautista
Pediatrics
2.336 Parent-Child Discrepancies in QOL
and Mental Health Reporting in Epilepsy| N.
Fayed, A. M. Davis, D. L. Streiner, P. L.
Rosenbaum, C. E. Cunningham, L. Lach, M.
Boyle, G. Ronen
2.337 Quality of Life Changes and Health
Care Charges among Youth with Epilepsy| S.
Guilfoyle, J. Ryan, M. McGrady, K. Junger, J.
Peugh, K. Loiselle, A. Arnett, A. Modi
2.338 Cognitive Development in Pediatric
Epilepsy Using Graph Theory| C. GarciaRamos, J. Lin, B. Hermann
2.339 Cognitive comorbidities in rolandic
epilepsy and their relation with default-mode
connectivity| I. Ofer, J. Jacobs, N. Jaiser, B.
Akin, J. Hennig, A. Schulze-Bonhage, P. LeVan
2.340 Language network reorganization
associated with left- vs. right-predominant
spikes in Benign Epilepsy with
Centrotemporal Spikes| H. Fujiwara, T.
Maloney, J. Tenney, C. Spencer, J. Szaflarski, D.
Morita, T. Glauser, J. Vannest
2.341 Neurobehavioural impairment is
detectable in children with early-onset
epilepsy: A population-based case-control
study| M. B. Hunter, M. Yoong, K. Verity, R.
Sumpter, A. McLellan, R. Chin
2.342 New Onset Pediatric Epilepsy:
Psychological Functioning at Onset and OneYear Evaluation| J. Doss, E. Adams, A.
Hughes-Scalise, K. Berg
2.343 Neurodevelopmental outcome in
neonates with hypoxic-ischemic
encephalopathy treated with hypothermia:
two years of follow-up| M. Balestri, M. Lispi,
S. Pro, D. Longo, F. Vigevano, M. R. Cilio
2.344 Presence of seizure and lactate in
Brain Magnetic Resonance Spectroscopy
(MRS) predict poor long-term outcome in
children after cardiac transplantation| P.
Pichon, H. Barbara, S. Ashwal, K. Vidhya, K.
Freier
2.345 Developmental impairment following
complex febrile seizures: within the first year
post-onset| E. Sheppard, I. Knoth, R. Cook,
M. Lagacé, L. Carmant, J. Gravel, S. Lippé
2.346 Cognitive Functioning among Children
in the New Onset Pediatric Epilepsy (NOPE)
Clinic: Measurable Change and Increased
Risk Identified at 1-year Follow-Up| K.
Kaszynski, E. Adams, J. Doss, F. Ritter
geneTICS
human Studies
2.347 Predictive Genetic Markers for
Phenytoin-induced Severe Cutaneous
Adverse Drug Reactions in Thai Patients| K.
Yampayon, C. Sukasem, C. Limwongse, Y.
Chinvarun, P. Kijsanayotin
2.348 Whole Exome and Methylation
Profiling identifies Candidate Aberrations in
Epilepsy Surgery Patients Who Died of
SUDEP| D. Friedman, A. Faustin, K. Kannan,
S. Shroff, C. Thomas, M. Karajannis, A. Heguy,
J. Serrano, T. Wisniewski, D. Zagzag, M.
Snuderl, O. Devinsky
2.349 Genetic Testing Strategies and
Diagnostic Yield for Patients with Epilepsy
and Neurodevelopmental Disorders| D.
McKnight, M. Stosser, K. Retterer, J. Juusola, T.
Brandt, G. Richard, S. Suchy
2.350 Diagnostic yield of clinical nextgeneration Sequencing panels for Pediatric
Epilepsy| E. Sell, A. Doja, D. Pohl, S. Whiting,
S. Venkateswaran, A. Aziz, D. Dyment
2.351 Evaluation of the Prevalence of
Pharmacogenetic Polymorphisms in
Pediatric Neurology Patients with Whole
Exome Sequencing| M. Messinger, E. Alter,
M. Bernhardt, S. DiCarlo, A. Wilfong
2.352 Carbamazepine-Induced Toxic Effects
and HLA-B*1502 Prospective Screening in
Thai| N. Koomdee, T. Jantararoungtong, S.
Prommas, S. Santon, M. Chamnanphol, A.
Puangpetch, C. Sukasem
2.353 Loss of function mutations in SLC12A5
in autosomal recessive epilepsy of infancy
with migrating focal seizures.| A. McTague, T.
Stodberg, A. Ruiz, H. Hirata, J. Zhen, P. Long, I.
Farabella, E. Meyer, A. Kawahara, G. Vassallo,
S. Stivaros, M. K. Bjursell, H. Stranneheim, S.
Tigerschiöld, B. Persson, I. Bangash, K. Das,
D. Hughes, N. Lesko, J. Lundeberg, R. Scott, A.
2.354 EFHC1 Variant Reanalysis and
Classification based on NHGRI and
ACMG/ACP guidelines for assignment of
disease-causality to sequence variants| C.
Patterson, A. Delgado-Escueta, L. de Nijs, R.
M. Duron-Martinez, M. Medina, I. MartinezJuarez, A. Ochoa, A. Jara-Prado, Y. Molina, M.
Tanaka, T. Suzuki
2.355 De novo mutations in the eukaryotic
translation elongation factor, EEF1A2 cause
epileptic encephalopathy.| G. L. Carvill, J.
McMahon, A. Schneider, C. Myers, R. S.
Møller, I. Scheffer, H. Mefford
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
67
2.356 Heterozygous Variants In Intestinal Cell
Kinase Implicated in Juvenile Myoclonic
Epilepsy, Impair Mitosis, Cell Cycle Exit, and
Radial Cell Migration| J. Bailey, L. de Nijs, D.
Bai, M. Tanaka, T. Suzuki, M. Medina, J.
Serratosa, R. M. Duron-Martinez, M. E.
Alonso, C. Patterson, J. Wight, Y. Lin, I.
Martinez-Juarez, A. Ochoa, A. Jara-Prado, L. M.
Guilhoto, E. Yacubian, Y. Inoue, S. Kaneko, S.
Hirose, M. Osawa, H. Oguni, T. Grisar, K.
Yamakawa, B. Lakaye, A. Delgado-Escueta
2.357 The role of polymorphisms of
receptors 5HTR1A in temporal lobe epilepsy
caused by hippocampal sclerosis | S. de
Vincentiis, J. Alcantara, P. Rzezak, D. Kerr, W. F.
Gattaz, H. van der Linden Jr, F. Arruda, P. C.
Ragazzo, T. Chaim, M. Serpa, F. Fernandes, R.
Moreno, G. Busatto, R. Alessi, R. Demarque,
K. Valente
2.358 Clinical predictors of a diagnostic
epilepsy gene panel result| H. Olson, L.
Smith, B. Sheidley, A. Poduri
2.359 How Frequent Is Familial Mesial
Temporal Lobe Epilepsy| P. Perucca, D. E.
Crompton, S. Bellows, A. McIntosh, M.
Newton, P. Kwan , T. O'Brien, I. Scheffer, S.
Berkovic
2.360 Delineating the GRIN1 spectrum – a
distinct genetic NMDA receptor
encephalopathy| J. Lemke, K. Geider, K. L.
Helbig, H. O. Heyne, I. Helbig, J. Michaud, B.
Laube, S. Syrbe, Consortium GRIN1 Study
Group
2.361 The phenotypic spectrum associated
with GABRB3 mutations: from febrile seizures
to severe epileptic encephalopathies| R. S.
Møller, G. Rubboli, T. V. Wuttke, M.
Nikanorova, E. H. Brilstra, U. Vaher, I.
Borggraefe, I. Talvik, T. Talvik, G. Kluger, C.
Betzler, J. Lemke, C. Myers, L. Larsen, M.
Pendziwiat, Y. Mang, K. Van Gassen, H. Dahl,
N. Tommerup, I. Helbig, H. Mefford, H.
Lerche, S. Maljevic, H. Muhle
2.362 Enlarging the spectrum of SCN8Arelated epileptic syndromes| E. Gardella, K.
M. Johannesen, G. Rubboli, J. Larsen, F.
Becker, J. Schubert, J. Lemke, G. Kluger, S.
Syrbe, B. Jepsen, P. Gellert, M. Nikanorova, H.
Hjalgrim, S. Beniczky, H. Lerche, Y. Weber, R.
S. Møller
2.363 A novel inherited SCN1A mutation
associated with GEFS+ with benign and
encephalopathic epilepsy.| L. Manganas, A.
Gauthier, C. Cardoza, R. Mattson
neuROPAThOlOgy OF ePIlePSy
2.364 Pathogenic mechanisms of recurrent
epileptogenic mutations in sodium channel
SCN8A (Nav1.6)| J. Wagnon, B. S. Barker, J. A.
Hounshell, M. Patel, M. Meisler
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUNDAY, DECEMBER 6, 2015: POSTER SESSION 2
PRACTICe ReSOuRCeS
2.365 Parent to Parent Support – Trained
Volunteers in Pediatric Epilepsy| C. Ryan, P.
Pearl
2.375 Socioeconomic Characteristics of
Patients in the Alabama Study of Cannabidiol
(CBD) Use to Treat Epilepsy| B. Hansen, M.
Szaflarski, M. Bebin, J. Szaflarski
2.385 Recurrent focal electrographic seizures
refractory to treatment in a patient with
subacute encephalopathy and seizures in
alcoholics (SESA)| R. Medel, D. C. Silveira
2.377 Polypharmacy aspects in elderly vs
younger patients with epilepsy in a
population based study| A. Baftiu, S. Feet, P.
Larsson, O. Henning, E. Sætre, S.
Johannessen, C. J. Landmark
2.387 Two Cases of Hypermotor Seizures
without Frontal lobe Involvement| S.
Thanaviratananich, A. Shahid
2.366 Applying Quality Improvement
Methodology to Improve Abortive Seizure
Medication Dosing and Prescribing| C. P.
Allen, A. Patel, D. Cohen
2.376 Significance of sleep as a risk factor for
SUDEP| A. Ali, J. Tao
2.368 A Novel Web-based Immersive Art
Therapy Studio Experience for Individuals
with Epilepsy| M. Caicedo, J. Endres, L.
Cendejas Zaragoza, M. A. Rossi
2.378 Prevalence of Epilepsy in the Veterans
Health Administration| R. Rehman, P. K.
Foxworth, A. Frontera, A. Husain, M. Lopez, D.
Riley, S. Sajan
2.367 Emergency Department Diversion for
Epilepsy Patients Using Quality Improvement
Methodology| E. G. Wood, D. Cohen, A. Patel
2.369 Optimal duration of continuous videoelectroencephalography in term infants with
hypoxic-ischemic encephalopathy and
therapeutic hypothermia.| N. Mahfooz, A.
Weinstock, D. V. Lowy, M. Noor, B. Afzal, S.
Finnegan, S. Lakshminrusimha
2.370 EEG correlates to symptoms during
combined EEG-tilt table testing| J. Neider, N.
Sanders, J. Ryan, M. Ball, H. Barkan
ePIDeMIOlOgy
2.371 Rich and poor children with epilepsy
have the same long term seizure outcome: A
population-based study| C. Camfield, P.
Camfield
2.372 Characteristics of new-onset status
epilepticus: the Korean Initiative for Status
Epilepticus Registry study| Y. Koo, J. Moon, J.
Byun, J. Sunwoo, S. Lee, K. Jung, K. Chu, S.
Lee, Y. Kim, S. Lee, K. Kim, D. Kim, H. Kim, D.
Kim, J. Kim, H. Moon
2.373 Seizures matter! A national
community-based survey of the impact of
epilepsy on persons living with epilepsy| N.
Jette, A. G. Bulloch, J. Williams, D. Lavorato, K.
Fiest, S. B. Patten
2.374 Association of disturbed sleep and the
presence of epilepsy in patients with autistic
spectrum disorder| R. Villalobos-Nieto, A. P.
Villalobos, B. Naranjo, R. Flores
2.379 Assessment of Psychogenic
Nonepileptic Seizures: Demonstrating
Psychotherapist Preference for a
Biopsychosocial Approach| X. F. Jimenez, J.
Bautista, G. Tesar
2.380 The Yale Seizure Cluster Study:
Prevalence, Treatment, and Consequences|
T. Choezom, S. Zhang, C. Ma, R. Joshi, H.
Zaveri, A. Komaragiri, B. Weiss, J. Bonito, L.
Hirsch, K. Detyniecki
2.381 Patterns of seizure clustering in
Tuberous Sclerosis Complex: results from
the SeizureTracker database| V.
Ferastraoaru, R. Moss, D. M. Goldenholz, S.
Haut
CASe STuDIeS
2.382 Progressive epilepsy with cerebral
hemiatrophy in adults: a diagnostic and
therapeutic challenge| A. Gonzalez, E.
Tauboll , L. Sveberg
2.383 Glucose transporter 1 deficiency: a
treatable protean condition that can present
with opsoclonus or mimic benign myoclonic
epilepsy of infancy (BMEI)| B. Appavu, T.
Mangum, M. Obeid
2.384 Prolonged QT in a patient with LQT2
syndrome on levetiracetam| N. Issa, W. G.
Fisher, J. Narayanan
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
68
2.386 Novel clinical features of KCNQ2
encephalopathy associated with the gain-offunction variant, R201C| S. B. Mulkey, B.
Ben-Zeev, E. C. Cooper, M. Cilio
2.388 Thermal Ablation for Intractable
Epilepsy due to Cavernous Malformation| M.
Abdennadher, J. Shen, M. Lee, D. Leake, P.
Modur
2.389 Ictal alien hand phenomena| Y.
Tadokoro, K. Kanemoto
2.390 Clobazam Successfully Terminates
Hemispheric Electrical Status Epilepticus
During Sleep (ESES) Due to Unilateral
Polymicrogyria| A. Al-Otaibi
2.391 Early Experience Of Vagus Nerve
Stimulation Therapy With The Novel Aspire SR
Device in Children| N. J. Barnes, K. Das, C.
Harrison, M. Tisdall, S. Varadkar
2.392 Seizure prediction using Online
Learning and Anomaly Detection| H. Khan, N.
Dhulekar, L. Marcuse, B. Yener
2.393 Palinacousis Palinacousis| M. Fields, L.
Marcuse, J. Yoo, S. Ghatan
2.394 Features and Outcomes of Post-Anoxic
Non-Convulsive Status Epilepticus| F. Khan,
R. Ramsay, V. Sabharwal, H. McGrade, J.
Milburn, R. Shumate, M. Irland
2.395 Broadening the phenotype of early
infantile epileptic encephalopathy caused by
STXBP1 gene mutations, a case series| S.
Carapetian, R. Ferri, J. Piantino, C. Wray
ePIDeMIOlOgy
2.396 Risk for recurrent febrile seizures in
the FEBSTAT study| S. Shinnar, D. Hesdorffer,
S. Seinfeld, D. Lax, D. R. Nordli, J. Pellock, R.
Shinnar, M. Chen, W. Gallentine, D. Lewis, M.
Frank, S. Moshe, S. Sun, FEBSTAT Study Team
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015
Pediatric epilepsy Case Discussions
7:00 a.m. – 8:30 a.m.
Special Interest group Meetings
Convention Center - Room 103
Coordinator: Elaine Wyllie, M.D.
Critical Care epilepsy: hot Topics in Critical Care
epilepsy
Speakers: Raman Sankar, M.D., Ismail Mohamed, M.D., Ajay
Gupta, M.D. and Elaine Wyllie, M.D.
Convention Center - Room 105
The faculty members will each present an eye-opening
pediatric epilepsy case from his or her personal experience
and then lead a spirited discussion with the audience. Please
join us for another round of terrific pediatric epilepsy case
discussions with peers and colleagues.
Coordinator: Howard Goodkin, M.D., Ph.D. and Cecil Hahn, M.D.
Speakers: James Riviello, Jr., M.D., and Shlomo Shinnar, M.D.,
Ph.D., Andres Rodriguez, M.D., Emily Johnson, M.D. and Joshua
Leibner, M.D.
This year's Critical Care SIG will include a data blitz of critical
care epilepsy highlights garnered from poster presentations
at the meeting followed by presentations by Dr. James Riviello
discussing the development of AES status epilepticus
guideline and Dr. Shlomo Shinnar on the recently published
definition of status epilepticus.
Psychosocial Comorbidities: Screening for
Psychosocial Comorbidities in Adults and
Children with epilepsy — Why and how to
Screen
Convention Center - Room 108 A
global health: how you Can get Involved
Coordinators: Jana Jones, Ph.D. and Gaston Baslet, M.D.
Convention Center - Room 104 B
Speakers: Miya Asato, M.D., Lorie Hamiwka, M.D., Nathalie
Jette, M.D., M.Sc., FRCPC and David Loring, Ph.D.
Coordinators: Sheryl Haut, M.D.
Psychosocial comorbidities in epilepsy are well established
and have a significant impact on quality of life and long-term
prognosis. Prompt recognition of these comorbidities is
necessary to provide comprehensive care and improve life
outcomes. In this SIG we will discuss practical measures that
clinicians in epilepsy care can utilize to identify specific
psychiatric and cognitive disorders. Examples of validated selfreport screening tools for depression in adults with epilepsy
include the NDDI-E, PHQ-9 and PHQ-2, all of which are easy to
administer in a clinical setting and will alert the clinician to
symptoms of depression. Given the high rates of mood
disorders in children with epilepsy, the feasibility, necessity
and benefits of routine screening in the clinic using tools such
as the SDQ will be reviewed. To characterize cognition,
clinicians can use screening questionnaires, rating scales, as
well as brief screening measures and computerized
measures. In children, given concerns about the
developmental impact of seizures and long-term effects on
scholastic achievement, cognitive screening can also include
brief parental surveys to supplement neuropsychological
assessment.
Speakers: David Labiner, M.D., Lionel Carmant, M.D. and Mylo
Schaaf, M.D.
Participation in epilepsy-related global health projects is
exciting, productive and important! Many people are still
unaware of the possible avenues to pursue global health. This
SIG will focus on opportunities for international
collaborations, professorships and partnerships around the
world, both in person and via telemedicine.
Junior Investigator Workshop: The Academic
Juggling Act: Balancing Research effort and
everything else
Convention Center - Room 104 A
Coordinator: Mackenzie Cervenka, M.D.
Speakers: Jackie French, M.D., Jaideep Kapur, M.D., Ph.D., Dan
Lowenstein, M.D. and William Theodore, M.D.
Establishing a successful research career requires protected
time. Whether you are a clinician scientist or a basic scientist
focused on epilepsy research, demands on your time often
include educational, administrative, and/or clinical activities
that must be balanced with your research effort. Our
interactive panel will discuss successful strategies for juggling
academic and clinical activities with the demands of being a
productive researcher.
Surgery: Battle Royale: Stereo eeg vs. Subdural
electrodes
Convention Center - Room 107
Coordinators: Saadi Ghatan, M.D. and Gerald Grant, M.D.
Panelists will be asked to describe their distribution of effort
and how it has changed over time during their careers,
strategies for negotiating to redistribute effort (how and how
often to do so) and how these decisions can affect promotion
and research productivity.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Speakers: Saadi Ghatan, M.D. and Gerald Grant M.D.
Presenters will be divided between specialists who
recommend Stereo EEG over grid and strip electrodes and
vice versa for their most difficult intracranial monitoring cases.
69
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015
8:00 a.m. – 2:00 p.m.
The Concepts of Networks
Olaf Sporns, Ph.D.
Poster Session 3
Functional Imaging, Networks and Epilepsy
Danielle Bassett, Ph.D.
Convention Center - Exhibit Hall A, 200 Level
See pages 75 - 84
Electrophysiology: Spanning Units, Local Field Potentials,
Large-Scale Networks in Epilepsy
Catherine Schevon, M.D., Ph.D.
8:00 a.m. – 5:00 p.m.
Scientific exhibits
Cells/Assemblies/Networks of Physiological Activity and
Seizures
Sydney S. Cash, M.D., Ph.D.
Convention Center - Rooms 201 B, 202 A and 202 B
See page 19
Networks in Cognition and Epilepsy Surgery
Hal Blumenfeld, M.D., Ph.D.
8:45 a.m. – noon
Merritt-Putnam Symposium: networks in
epilepsy
Conclusions
Gregory Worrell, M.D., Ph.D.
Convention Center - Grand Ballroom A/B
Award Presentation: AES Research Recognition Awards in
Basic Science and Clinical Science and William G. Lennox
Award
eDuCATIOn CReDIT
3.0 CME Credits
Nurses may claim up to 3.0 contact hours for this session.
OVeRVIeW
Network science is a multidisciplinary field based on
fundamental discoveries in mathematics and physics that has
had significant impact on a wide range of disciplines spanning
engineering, medicine, biology, social and information
technology. Advances in the science of networks have led to a
deeper understanding of the role of the cellular constituents,
assemblies and large-scale brain networks underlying normal
and pathological brain activity, and has important implications
for epileptogenesis, seizures and epilepsy. In this MerrittPutman symposium we review the science and technology
driving the rapidly evolving, interdisciplinary field of networks,
and address some of the key opportunities and challenges.
This will include discussion of the role of networks in clinical
epilepsy, including evaluation of cognition and planning
epilepsy surgery.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 3.0 contact hours (0.30 CEUs).
UAN 0077-9999-15-032-L01-P. Initial Release Date: 12/7/2015.
The American Board of Psychiatry and Neurology has
reviewed the Networks in Epilepsy Symposium and has
approved this program as part of a comprehensive program,
which is mandated by the ABMS as a necessary component of
maintenance of certification.
9:00 a.m. – 10:30 a.m.
Special Interest group Meetings
epidemiology: Patient Reported Outcomes in
epilepsy
leARnIng OBJeCTIVeS
Convention Center - Room 108 A
Following participation in this symposium, learners should be able to:
•
•
•
Recognize the role of epileptic networks and the emerging
evidence for its role in focal epilepsy using EEG or fMRI
Coordinators: Nathalie Jette, M.D., FRCPC and Christine
Bower Baca, M.D.
Counsel families regarding prognosis of epilepsy surgery
based on understanding of the role of networks
Speakers: Rosemary Kobau, M.P.H., M.A.P.P., Gabrielle Ronen,
M.D., Frank Gilliam, M.D., M.P.H. and Joyce Cramer
Participate in counseling families regarding role of
networks on memory circuits and association with network
phenomena and prognosis
Patient reported outcomes (PRO) are becoming increasingly
important in health services and clinical research including
randomized controlled trials. This special interest group will
address important PRO initiatives and data sources, examples
of epilepsy specific PROs, the application of PROs in
population based research and in clinical care and suggested
approaches to reporting and analyzing PROs.
TARgeT AuDIenCe
Intermediate and Advanced (see page 132 for details)
PROgRAM
Chair: Gregory Worrell, M.D., Ph.D.
Introduction
Gregory Worrell, M.D., Ph.D.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
70
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015
epilepsy and Aging: Clinical, Cognitive and
Basic Science Aspects of Aging and epilepsy
Speakers: NINDS and Non-profit Funding Organizations
Each group will present on specific programs they offer.
NINDS will present the Anticonvulsant Screening Program
(ASP) and several non-profit groups will offer their funding
opportunities that are of interest to investigators.
Convention Center - Room 105
Coordinators: Bruce Hermann, Ph.D.; Kimford Meador, M.D.
and Helen Scharfman, Ph.D.
Additionally, information will be shared on the Rare Epilepsy
Network — a rich registry of data waiting to be mined. An
update on the Epilepsy Research Connection — a one-stop
website for finding funds and collaborative opportunities —
also will be shared.
Speakers: Asla Pitkänen, M.D., Ph.D., D.Sc., Bernd PohlmannEden, M.D., Ph.D. and Matti Sillanpaa, M.D., Ph.D.
The Epilepsy and Aging SIG will again develop a thematic
approach to a topic of interest to neuropsychology, clinical
neurology and basic science. One theme of interest for this
year’s SIG is “Amyloid and Epilepsy”.
10:00 a.m. – 2:00 p.m.
exhibit hall
genetics: Is your Variant Pathogenic?
Convention Center - Room 107
Convention Center - Exhibit Hall A, 200 Level
Coordinators: Tara Klassen, Ph.D. and Eric Marsh, M.D., Ph.D.
2:15 p.m. – 3:00 p.m.
Speakers: Sameer Zuberi, M.D., Andreas Brunklaus, M.D. and
Ingo Helbig, M.D., Ph.D.
lennox and lombroso lecture: epilepsy and
Autism — Bad luck or Bad Connectivity?
This SIG will be a combination of presentations describing
variant pathogenicity algorithms employed in bioinformatic
analysis. The differences in variant calling for research and
gene testing for single genes, gene panels and NGS
approaches will be discussed; followed by an open forum
dialogue about the deleteriousness of individual genetic
variants. The conversation will include discussion of what
different people mean when they use the term mutation vs.
variant vs. polymorphism and what is meant when a variant is
said to be pathogenic, causative or of unknown significance.
Convention Center - Grand Ballroom A/B
Lecturer: Gregory L. Holmes, M.D.
There are multiple genetic and environmental causes for both
autistic spectrum disorder and epilepsy and both can be
conceptualized as disorders of aberrant connectivity. Evidence
is accumulating that the co-occurrence may be explained by
the same nascent insult. For example, early life seizures may
result in the altered function of neurotransmitter systems and
intrinsic neuronal properties during neurodevelopment leading
directly to disrupted cortical connectivity. The clinical expression
of this derailment can result in seizures or devastating
impairments in social communication and behavior, or both.
Investigations in animal models with both epilepsy and autisticlike behavior are shedding light into many unanswered
questions regarding this important co-occurrence.
The initial speakers will discuss the process of calling variants,
discussing methods used for assessing the potential
pathogenicity of variants, including information on the
available algorithms, databases and filtering strategies
currently in use. This will be followed by a speaker who will
provide some specific examples of gene variants in both
known and novel genes. This speaker will also talk about the
challenges associated with assigning pathogenicity and
causation, and how this differs in clinical vs research context.
Following the presentations, the SIG Chairs will lead an open
discussion with audience and panel members. The audience
will be encouraged to share variants with the group to answer
the question “Is your variant pathogenic?” If needed, Drs.
Klassen and Marsh will have a number of pre-submitted
variants, including benign, pathogenic and VUS variants for
further discussion, should time and interest permit.
3:00 p.m. – 4:30 p.m.
Investigators’ Workshop
This workshop is an AES Research Grant funded study
Convention Center - Room 105
Immune and non-cannonical effects of
Inflammation in Seizure Disorders
moderators: Viji Santhakumar, Ph.D. and Anne Anderson, M.D.
nInDS & non-Profit Foundation Research
Resources: Partnership Programs and Research
Funding Opportunities
Speakers: Lisa Boulanger, Ph.D., Amy Brewster, Ph.D. and
Sookyong Koh, M.D., Ph.D.
Convention Center - Room 104 A
Coordinators: Randall Stewart, Ph.D., Brandy Fureman, Ph.D.,
William Benzing, Ph.D., Steve Roberds, Ph.D., Ilene Miller, J.D.,
L.L.M. and Seth Wohlberg, M.B.A.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
71
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015
3:00 p.m. – 5:00 p.m.
eDuCATIOn CReDITS
2.0 CME Credits
FDA Town hall update: generic Antiepileptic
Drug Bioequivalence in epilepsy Patients:
From Anecdotes to evidence
Nurses may claim up to 2.0 contact hours for this session.
Nurse Practitioners may claim 2.0 hours of pharmacology for
this session.
Convention Center - Room 204
OVeRVIeW
Uncontrolled studies suggested lack of efficacy or increased
adverse events when people with epilepsy switched from
brand to generic AEDs. Some neurologists, patients and
patient advocacy groups questioned the FDA whether product
bioequivalence established in healthy volunteers can ensure
AED bioequivalence in people with epilepsy receiving
concomitant medications. To address the epilepsy
community’s concern, the FDA Office of Generic Drugs (OGD)
has funded a series of prospective brand-to-generic AED
switching studies in epilepsy patients starting in 2010,
including the Bioequivalence in Epilepsy Patients (BEEP) study
and Equivalence in Generic Drugs (EQUIGEN) study. The
research findings from BEEP and EQUGEN studies will be
presented. Some other factors which may affect AED clinical
outcomes, including pill appearance, patient adherence and
patient/physician perception about generic drugs, will be
discussed. FDA OGD’s continued efforts on generic AEDs
including narrow therapeutic index (NTI) drug classification
and modified release products will be updated.
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.0 contact hours (0.2 CEUs).
UAN 0077-9999-15-039-L01-P. Initial Release Date: 12/7/2015.
The American Board of Psychiatry and Neurology has
reviewed the FDA Town Hall Update: Generic Antiepileptic
Drug Bioequivalence in Epilepsy Patients: From Anecdotes to
Evidence and has approved this program as part of a
comprehensive program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
3:00 p.m. – 5:15 p.m.
Pediatric epilepsy highlights Session
Convention Center - Room 103
Award Presentation: First Annual John (Jack) M. Pellock
Award in Pediatric Excellence
This session will showcase selected scientific abstracts
focused on topics in clinical care and research in pediatric
epilepsy. Authors will present a six-minute overview of their
work. Presentations are chosen from all submitted abstracts.
Participants will be able to view posters and meet the authors
at the end of the program.
leARnIng OBJeCTIVeS
Following participation in this symposium, learners should be able to:
•
•
•
Describe results and conclusions from current single- and
multiple-dose AED bioequivalence trials in epilepsy
patients
List factors which may impact AED clinical outcomes
Delineate NTI drug classification process
2.305 Safety and Efficacy of Stereotactic Laser Ablation of
Hypothalamic Hamartomas | Shawn Reddy
1.001 The parents' experience caring for a child with medication
refractory epilepsy | Kathleen Boreale
1.009 Screening for Suicidal Ideation and Behavior among Youth with
Epilepsy Can Save lives | T. Falcone
PROgRAM
Chair: Michael Privitera, M.D.
1.085 Clinical epidemiology of newly diagnosed early life epilepsy:
underlying causes and contributions from genetics | Anne Berg
Introduction
Michael Privitera, M.D.
1.158 Altered functional connectivity at sites of malformation of
cortical development | C. Beers
1.294 Measurement Equivalence of the Quality of Life in Childhood
Epilepsy Questionnaire (QOLCE-55) Across Age and Gender | Mark
Ferro
BEEP Study Findings
Tricia Ting, M.D.
EQUIGEN Single Dose Study Update
Michael Privitera, M.D.
1.311 Targeted Analysis of Whole Exome Sequencing in Early Onset
Epilepsy | Michelle Demos
1.346 KCNQ2 encephalopathy: novel single amino acid deletion
variants strongly suppress currents and are responsive to SF0034 |
Li Li
Authorized Generics, Pill Appearance and Patient
Adherence
Joshua Gagne, Pharm.D., Sc.D.
2.074 Seizure-associated ventricular repolarization abnormalities
and instability in children with epilepsy | Yi-Chen Lai
FDA OGD Updates on Generic AEDs and NTI Designation
Wenlei Jiang, Ph.D.
2.128 Brain network dynamics of the human articulatory loop | Eishi
Asano
Panel Discussion
moderators: Michel Berg, M.D. and Xiaohui Jiang, Ph.D.
Panel members: Tricia Ting, M.D., James Polli, Ph.D., Michael
Privitera, M.D., Michel Berg, M.D., Joshua Gagne, Pharm.D.,
Sc.D., Xiaohui Jiang, Ph.D. and Wenlei Jiang, Ph.D.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
2.137 Does Age of Seizure Onset can Predict the Location on the
Focal Cortical Dysplasia? | P. Sudachan
2.202 Focal Cortical Dysplasia Type-II: MRI-based Profiling and
Subtype Prediction | S. Hong
72
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015
3:00 p.m. – 5:15 p.m.
PROgRAM
Co-Chairs: Carol Camfield, M.D. and Elizabeth Donner, M.D.
Platform Sessions: Three Concurrent
Sessions
Introduction and Case Presentations
Carol Camfield, M.D. and Elizabeth Donner, M.D.
See Page 74 for Locations
What Are the Epidemiological Facts?
Elaine Wirrell, M.D.
Attend three concurrent sessions highlighting select
scientific abstracts. Authors will present a ten minute
overview of their work followed by five minutes of questions
and answers.
Leading Theories about the Cause of SUDEP in Children
and Prevention
Tobias Loddenkemper, M.D.
5:30 p.m. – 8:00 p.m.
Why Is the Data So Different for Children Than Adults?
Peter Camfield, M.D.
Pediatric State of the Art Symposium:
Death in Children with epilepsy — A
Different Tragedy Than in Adults
What Should We Say to Parents about Death Related to
Epilepsy and When?
Jeffrey Buchhalter, M.D., Ph.D.
Convention Center - Grand Ballroom A/B
Dealing with Grief after Expected and Unexpected Death
in Children
Linda Coughlin-Brooks, RN, BSN, CT
OVeRVIeW
This symposium will present a detailed review of mortality in
children with epilepsy with emphasis on what is currently
fact. A discussion of SUDEP will outline why this catastrophe
is different in children than adults and the quality of
evidence for prevention. There will be a careful discussion
of what to tell patients and families about the risk of death
and how to assist families should their child die.
Conclusions
Elizabeth Donner, M.D.
eDuCATIOn CReDIT
2.5 CME Credits
Nurses may claim up to 2.5 contact hours for this session.
leARnIng OBJeCTIVeS
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.5 contact hours (0.25 CEUs).
UAN 0077-9999-15-034-L01-P. Initial Release Date: 12/7/2015.
Following participation in this symposium, learners should be able to:
•
•
•
•
•
Discuss the risk of death with families and children with
epilepsy
Provide critical guidance about appropriate evidencebased preventative strategies
Counsel families effectively in the event of a death
Counsel families about the low risk of death and guide
appropriate evidence-based preventative strategies
Encourage patients to be very compliant with
medication, a key way to prevent seizures and a key to
preventing sudden unexplained death in children with
epilepsy
The American Board of Psychiatry and Neurology has
reviewed the Death in Children with Epilepsy -- A Different
Tragedy Than in Adults Symposium and has approved this
program as part of a comprehensive program, which is
mandated by the ABMS as a necessary component of
maintenance of certification.
COMMeRCIAl SuPPORT ACknOWleDgeMenT
Supported in part by an educational grant from Eisai Inc.,
Lundbeck and LivaNova.
TARgeT AuDIenCe
Basic and Intermediate (see page 132 for details)
#AeSmtg15
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
73
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015
3:00 p.m. – 5:15 p.m. Platform Sessions: Three Concurrent Sessions
There will be three concurrent sessions consisting of selected key scientific abstracts. Authors will present a 10-minute overview
of their work followed by a five-minute Q & A.
A: TRAnSlATIOnAl
Convention Center, Room 107, 100 Level
B: COMORBIDITIeS
C: geneTICS
Convention Center, Room 108A, 100 Level
Convention Center, Room 108B, 100 Level
3:15 p.m.
A.01 Loss of Clock results in dysfunction of
brain circuits that underlie pediatric focal
epilepsy/J. Liu, X. Fu, P. Li, M. Tenga, J. Curiel, B.
Martin, C. Oluigbo, A. Yaun, T. Tsuchida, M. M.
Huntsman, G. Valdez, W. Gaillard
A.02 MicroRNA Biomarkers in Blood Predict
the Development of Post-Traumatic Epilepsy
after Experimental Traumatic Brain Injury in
the Rat/D. M. Treiman, D. E. Schooley, S. T.
Marsh, L. Treiman
B.01 One year follow-up of cognitive
behavioral therapy-informed psychotherapy
treatment trial for psychogenic nonepileptic
seizures/W. C. LaFrance, R. Ranieri, G. Baird, A.
Blum, G. I. Keitner
C.01 Identifying genetic variants underlying
sudden unexpected death in epilepsy
(SUDEP)/D. E. Crompton, R. Bagnall, S.
Petrovski, B. Regan, S. I. Garry, S. Berkovic, C.
Semsarian, I. Scheffer
3:30 p.m.
A.03 Modeling SCN8A mutant epilepsy in
patient-derived cortical and peripheral
neurons/A. Tidball, L. Lopez-Santiago, X. Du, K.
Glanowska, L. L. Isom, J. Parent
B.03 System-based comorbidities in the Rare
Epilepsy Network (REN)/D. Hesdorffer, E.
Mayerson, B. Kroner, J. French, J. Buelow, REN
Organizations
3:45 p.m.
A.04 Synaptic Dysfunction of Munc18-1 in
Infantile Epileptic Encephalopathies/J. Burre,
R. Wragg, J. Messinger, J. Gottshall, A. Daab, G.
Petsko, J. Dittman
B.04 Seizure-induced activation of the HPA
axis contributes to seizure susceptibility/J.
Maguire, K. O'Toole, S. Wakefield, A. Hooper
C.03 Loss of function mutations in SLC12A5 in
autosomal recessive epilepsy of infancy with
migrating focal seizures./A. McTague, T.
StÃdberg, A. Ruiz, H. Hirata, J. Zhen, P. Long, I.
Farabella, E. Meyer, A. Kawahara, G. Vassallo,
S. Stivaros, M. K. Bjursell, H. Stranneheim, S.
Tigerschiöld, B. Persson, I. Bangash, K. Das, D.
Hughes, N. Lesko, J. Lundeberg, R. Scott, A.
Poduri, I. Scheffer, H. Smith, P. Gissen, S.
Schorge, M. A. Reith, M. Topf, D. Kullmann, R. J.
Harvey, A. Wedell, M. A. Kurian
4:00 p.m.
A.05 Optimization of Transparent Graphene
Electrodes for Neural Sensing and
Stimulation/D. Kuzum, H. Takano, H. Juul, A.
Richardson, T. Lucas, M. Dichter, D. Coulter, B.
Litt
B.05 SSRI antidepressants accelerate epilepsy role for 5-HT2 receptors?/N. Jones, G. Dezsi, E.
Ozturk, D. Wong, M. Morris, M. Salzberg, T.
O'Brien
A.06 Evidence of Epileptic Networks Activation
and Modulation by Electrical Stimulation and
Interstitial Ablation of Epileptic nodes as
defined by SEEG recordings/ J. GonzalezMartinez, S. Jones, J. Bulacio, D. Nair, P.
Chauvel, W. Bingaman, I. Najm
B.06 Epilepsy and long QT syndrome type 2 –
Different clinical presentations of the same
channelopathy?/I. T. Dahl, P. Larsson, K. H.
Haugaa, E. Tauboll
A.07 Development and application of
inhibitory luminopsins for the treatment of
epilepsy/J. Tung, C. A. Gutekunst, R. Gross
B.07 Evaluation of dissociation, self-efficacy
and rates of trauma in patients with
psychogenic nonepileptic seizure (PNES)
events or epilepsy/E. Wagner, D. Drane
A.08 A mutation in SCN8A results in
arrhythmogenic events with altered
intracellular calcium handling in a mouse
model of early-infantile epileptic
encephalopathy with SUDEP/C. R. Frasier, J.
Wagnon, Y. Bao, J. Parent, M. Meisler, L. L.
Isom
B.08 Sleep difficulties are frequent in Dravet
syndrome/I. Scheffer, S. H. Licheni, A.
Schneider, M. Davey, J. McMahon
3:00 p.m.
4:15 p.m.
4:30 p.m.
4:45 p.m.
5:00 p.m.
Moderators: Robert Hunt, Ph.D. &
Bret N. Smith, Ph.D.
A.09 Reduced KCC2 function increases
seizure severity/M. R. Kelley, T. Z. Deeb, N. J.
Brandon , J. Dunlop, S. Moss
Moderators: Barbara C. Jobst, M.D. & Daniel
Friedman, M.D.
B.02 Psychiatric Complications of MRI-Guided
Laser Ablation of Mesial Temporal Structures
for Treatment-Resistant Temporal Lobe
Epilepsy/A. Kanner, J. Jagid, M. Lopez, M. Lowe,
M. Palomeque, G. J. Rey, R. Ribot, L. Tornes, E.
Serrano
Selected for the Goldberg Kauffman Honor
B.09 Epileptic Seizures Produce a Transient
Improvement in Mood in Patients with
Epilepsy and Depression/M. Cassady, K.
Grimes, S. Yin, K. Turlington, M. Richert, M.
Kvarta, S. Thompson, J. Hopp
Moderators: Heather C. Mefford, M.D., Ph.D.
& Tara L. Klassen, Ph.D.
C.02 Investigation of the role 82
pharmacogenes in the etiology of treatmentresistant epilepsy in children/E. Robbins, B.
Almoguera, D. Dlugos, H. Hakonarson
Selected for the Fritz Dreifuss Honor
C.04 Mutations of the sonic hedgehog
pathway underlie hypothalamic hamartoma
and gelastic epilepsy/M. S. Hildebrand, N. G.
Griffin, J. Damiano, E. J. Cops, R. Burgess, B.
Darbro, E. Ozturk, N. Jones, R. Leventer, J. L.
Freeman, A. S. Harvey, I. Scheffer, D. Goldstein
J. Kerrigan, S. Berkovic, E. Heinzen
C.05 Gain-of-function missense mutation in
human FHF1 as a novel cause of early-onset
epileptic encephalopathy with cerebellar
atrophy/G. M. Buyse, A. Siekierska, M. Isrie, Y.
Liu, C. Scheldeman, N. Vanthillo, L. Lagae, P. A.
de Witte, H. Van Esch, M. Goldfarb
C.06 Gene discovery in epileptic
encephalopathies through targeted
resequencing of candidate genes/C. Myers, J.
McMahon,, A. Schneider, R. S. Møller, I.
Scheffer, H. Mefford, Epi4K Consortium
C.07 KCNQ2 p.Arg198Gln, a gain-of-function
variant presenting recurrently as West
syndrome without preceding neonatal
seizures/J. Millichap, F. Miceli, B. Tran, C.
Keator, N. Joshi, M. Soldovieri, E. C. Cooper, M.
Taglialatela
C.08 The phenotypic and genetic spectrum of
DNM1 encephalopathy/I. Helbig, D. Shinde, R.
Huether, C. Lourenço, K. L. Helbig, S. von
Spiczak, M. Pendziwiat, M. Nunes, D. Sarco, R.
Kaplan, D. Dlugos, H. Kirsch, M. Cervenka, L.
Hernandez-Hernandez, B. Maher, S.
Weckhuysen, R. S. Møller, S. Pena, S. Sisodiya
C.09 Delineating the GRIN1 spectrum – a
distinct genetic NMDA receptor
encephalopathy/J. Lemke, K. Geider, K. L.
Helbig, H. O. Heyne, I. Helbig, J. Michaud, B.
Laube, S. Syrbe, Consortium GRIN1 Study
Group
The Rebecca Goldberg Kaufman Honor is awarded to the highest ranking abstract in the comorbidities topic category and is sessioned as Platform B.02. The abstract honored is selected by the
Scientific Program Committee from over 1,200 submitted abstracts.
The Fritz Dreifuss Honor is awarded to the highest ranking abstract in the genetics topic category and is sessioned as Platform C.02. The abstract honored is selected by the Scientific Program
Committee from over 1,200 submitted abstracts.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
74
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
8:00 a.m. – 2:00 p.m.
Poster Session 3
Convention Center - Exhibit Hall A,
200 Level
TRAnSlATIOnAl ReSeARCh
Mechanisms
3.001 Ictal activation of s. oriens
interneurons precedes pyramidal cell activity
in a chronic in vitro epilepsy model| K. Lillis,
K. Staley
3.002 Downregulation of Adenosine A1
Receptor & Upregulation of Adenosine
Kinase in Pediatric Cortical Dysplasia Type
IIB| T. Li
3.003 Diazepam effect correlates with the
developmental decrease in intracellular
chloride concentration during early
neocortical development| J. Glykys, K. Staley
3.004 Testing for correlation between
seizure frequency and numbers of mossy
cells, ectopic granula cells, and gabaergic
interneurons | P. Buckmaster, E. Abrams
3.005 The complex role of miR-124 in
epileptogenesis| G. P. Brennan, D. Dey, K. P.
Patterson, A. Hall, E. J. Magnetta, Y. Mei, K.
Ma, T. Baram
3.006 Acute Formation of Aberrant
Excitatory Connections onto Pyramidal Cells
Following Neocortical Injury| F. Gu, I. Parada,
D. Takahashi, D. Prince
3.007 Neuronal sodium elevation and COX-2
activation in post-traumatic epileptogenesis
in vitro| T. Balena, Y. Saponjian, K. Park, K.
Staley
3.008 Functional evidence for selective
activation in a subset of developing
hippocampal neurons in early life seizures|
H. Sun, M. Wang, M. Handy, F. Jensen
3.009 Signaling pathway perturbations in
mouse and human epilepsies| A. Carrel, M.
M. Ahmed, A. Thomas, K. J. Gardiner, A.
Brooks-Kayal
3.010 Plasma cytokines in children following
febrile status epilepticus.| W. Gallentine, S.
Shinnar, D. Hesdorffer, L. Epstein, D. R.
Nordli, D. Lewis, L. Frank, S. Seinfeld, R.
Shinnar, K. Cornett, M. Chen, S. Moshe, S.
Sun
3.011 Role of Tonic and M Currents in the
Hippocampal Dentate Gyrus in Controlling
Neuronal Excitability and Seizure
Susceptibility| C. Carver, C. Taylor, R.
Brenner, M. Shapiro, D. Reddy
3.012 A personalized, molecular diagnosis of
Lafora disease patient mutations via
structural insights| M. Gentry, M.
Raththagala, M. K. Brewer, C. Vander Kooi
3.013 Functional Evaluation of a De Novo
GRIN2A Mutation Identified in a Patient with
Severe Global Developmental Delay and
Intractable Epilepsy| W. Chen, A. Tankovic, S.
Traynelis, H. Yuan
3.014 Synaptic Dysfunction of Munc18-1 in
Infantile Epileptic Encephalopathies| J. Burre,
R. Wragg, J. Messinger, J. Gottshall, A. Daab,
G. Petsko, J. Dittman
3.015 Functional Analyses of a Human
GRIN2A Pre-M1 Mutation Associated with
Epilepsy: from Molecular Mechanism to
Rescue Pharmacology| H. Yuan, W. Chen, A.
Tankovic, G. Kosobucki, K. Odgen, E.
Aizenman, S. Traynelis
3.016 Mutation-Specific Consequences of
PI3K/AKT/MTOR Pathway Activation in Focal
Cortical Dysplasia| L. Jansen, S. A. Gunter, A.
Shashipadme, S. Geyer
3.017 Altered Metabolism in a Zebrafish
Model of Dravet Syndrome| M. Kumar, S.
Rowley, R. Fulton, M. T. Dinday, S. Baraban, M.
Patel
3.018 Pharmacological rescue of KCNQ2
channels carrying Early-Onset Epiletic
Encephalopathy mutations| M. Soldovieri, P.
Ambrosino, M. De Maria, I. Mosca, F. Miceli, P.
Striano, S. Weckhuysen, E. C. Cooper, M.
Taglialatela
3.019 Loss of Clock results in dysfunction of
brain circuits that underlie pediatric focal
epilepsy| J. Liu, X. Fu, P. Li, M. Tenga, J. Curiel,
B. Martin, C. Oluigbo, A. Yaun, T. Tsuchida, M.
M. Huntsman, G. Valdez, W. Gaillard
3.020 Epilepsy Causes Abnormal Blood Flow
Leading to Spatially Distinct Neural
Degeneration Patterns| R. Leal-Campanario,
L. Alarcon-Martinez, H. Rieiro, S. MartinezConde, S. Macknik
3.021 Music and the Brain: Synchronization
in Epilepsy| C. Charyton, J. Benson, C. Hall
3.022 Role of Kainate Receptors on
Modulation of Synaptic Transmission during
in Vitro Asphyxia in the Neonatal Mouse
Hippocampus.| S. Zanelli, D. Grosenbaugh, J.
Kapur
3.023 A novel role for autophagy in
endogenous GABA-A receptor modulation|
A. M. Abramian, J. Sorokin, C. Makinson, J.
Huguenard
Models
3.024 An in vitro hippocampal slice model to
probe the role of innate inflammation in
epilepsy| S. Chong, S. Balosso, A. Vezzani, C.
Wolff, R. Kaminski, I. Niespodziany
3.025 Functional Reduction in Heterotypic
Inhibition of Dentate Basket Cells in Epilepsy:
Impact on Network Rhythms| A. Proddutur,
J. Yu, B. Sweitek, V. Santhakumar
3.026 EFHC1/Myoclonin1 modulates the
post-translational modification of
microtubules| L. Medard, J. Godin, B.
Coumans, T. Grisar, A. Delgado-Escueta, B.
Lakaye, L. de Nijs
3.027 Computational models of Ictogenesis
in the CA3 hippocampal region| T. Jacob, W.
Swiercz, K. Staley
3.028 A model of poststroke epilepsy in the
mouse| J. Zelano
3.029 Protective effects of choline
alfoscerate on seizure-induced neuronal
injury and cognitive impairment| D. Shin, H.
Song
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
75
3.030 Minimally stressful rat head fixation to
investigate electrophysiological, behavioral
and hemodynamic correlates of absence
seizures| C. McCafferty, A. J. Kundishora, E.
Johnson, J. Sampognaro, N. Smith, Y. Si, P.
Antwi, P. Vitkovskiy, A. Morawo, H. Blumenfeld
3.031 Automated seizure detection reveals a
circadian pattern of spontaneous
electrographic seizures in the tetanus toxin
model of epilepsy in the rat| S. Arcot Desai,
N. Hasulak, M. Bosworth, A. Saghyan, C.
Wang, T. Crowder Skarpaas, M. Morrell, T.
Tcheng, J. Goodman
3.032 mTOR-associated Kv1.1 channel
dysregulation in the NS-Pten knockout
mouse model of cortical dysplasia| L.
Nguyen, A. E. Anderson
3.033 A Critical Developmental Window for
17β-estradiol Anti-Epileptogenic Effect in a
Mouse Model of X-Linked Infantile Spasms|
M. S. Siehr, R. D. Lucero, J. W. Lalonde, J.
Noebels
3.034 Assessment of the Anticonvulsant
Effects and Tolerability of GW
Pharmaceuticals’ Cannabidiol in the
Anticonvulsant Screening Program| N. Jones,
T. Hill, C. Stott, S. Wright
3.035 Sodium channel inhibition with GS967
improves survival and suppresses
spontaneous seizures in Dravet syndrome
mice| L. Anderson, J. A. Kearney, A. L. George
3.036 Chronic epilepsy causing an acquired
cardiac channelopathy with altered
expression of both T-type calcium channels
and HCN channels| K. Powell, R. Shannon, S.
Singh, T. O'Brien
3.037 Opportunities for improving animal
welfare in rodent models of epilepsy and
seizures| K. Lidster, J. Jefferys, I. Blumcke, V.
Crunelli, P. Flecknell, B. Frenguelli, W. Gray, R.
Kaminski, A. Pitkanen, I. Ragan, M. Shah, M.
Simonato, A. Trevelyan, H. Volk, M. Walker, N.
Yates, M. Prescott
3.038 Characterization of depressive-like
behaviors in the Wistar Audiogenic Rat (WAR)
strain: endophenotype model for EpilepsyDepression comorbidity.| L. D. Godoy, E. H.
Umeoka, N. Garcia-Cairasco
3.039 Exploring the Mechanism-of-action of
Fenfluramine, an Anti-Epileptic Drug in the
Treatment of Dravet Syndrome, Using an
scn1Lab Mutant Zebrafish Model| J.
Sourbron, L. Lagae, I. Smolders, P. A. de Witte
3.040 Adaptive closed-loop deep brain
stimulation using reinforcement learning in
an acute in vivo rodent seizure model| V.
Nagaraj, T. I. Netoff
3.041 Abnormal astrocytic Ca2+ signaling in
the sclerotic hippocampus of awake mice: a
two-photon imaging study using the
unilateral intracortical kainate injection
model of mesial temporal lobe epilepsy| R.
Enger, K. Heuser, C. Nome, W. Tang, V.
Jensen, P. Helm, K. Vervaeke, P. Bedner, C.
Steinhaeuser, E. Tauboll , E. A. Nagelhus
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.042 A Novel Optogenetic Mouse Model of
Ictogenesis for Investigating the Role of
Interneurons in Seizure Initiation,
Propagation, and Termination| S.
Khoshkhoo, V. Sohal
3.043 Hippocampal CRH Neurons: Linking
Stress Signaling and Seizure Susceptibility|
A. A. Hooper, J. Maguire
3.044 Febrile status epilepticus alters
hippocampal networks and spatial
cognition| J. Barry
3.045 The Development of BIS-001 for the
Treatment of Seizure-related Disorders| J.
Johnstone, S. Schachter, H. Carlson, R.
Gersner, A. Rotenberg, S. Collins
3.046 Abnormal cortical network excitability
in an animal model of infantile spasms| S. N.
Misra, J. Swann
3.047 Acute Cognitive Impact of Antiseizure
Drugs in Naïve Rodents and Corneal-Kindled
Mice| M. Barker-Haliski, F. Vanegas , M. Mau ,
T. Underwood, H. White
3.048 Fluoxetine Blocks Seizure-Induced
Respiratory Arrest by Action in the Brain| C.
Zeng, S. Peng, X. Long, C. Faingold, H. Feng
3.049 High-throughput drug discovery using
a zebrafish model for Dravet syndrome| M.
T. Dinday, S. Baraban
3.050 Respiration-induced seizures in the
adult naked mole-rat| M. Zions, T. Dzedzits,
D. McCloskey
3.051 Is more severe brain damage following
an epileptogenic insult associated with lower
seizure outcome? Interpreting data from the
post-kainic acid-induced status epilepticus
model| H. Amhaoul, D. Bertoglio, J.
Goossens, J. Verhaeghe, L. wyffels, A. Van der
linden, S. Staelens, S. Dedeurwaerdere
3.052 Time course of glutamate transporter1 (GLT1) expression in the intrahippocampal
kainic acid model of epilepsy| J. A. Hubbard,
J. Szu, J. Yonan, D. Binder
3.053 Spontaneous seizures in Kcna1-null
mice lacking voltage-gated Kv1.1 channels
activate Fos expression in select limbic
circuits| E. Glasscock, N. Gautier
3.054 Reduced GABAergic synapses in the
developing cerebellar cortex of the Scn1bnull mouse model of epileptic
encephalopathy| J. Winters, L. L. Isom
3.055 Toll-like receptor 4 signaling increases
calcium-permeable AMPA currents in the
dentate gyrus after brain injury| Y. Li, V.
Santhakumar
3.056 Neurobehavioral characteristics of a
Dravet syndrome mouse model| K. Lee, J. Qi,
I. Balzekas, J. White, S. Koh
3.057 Huperzine A confers seizure
protection in two mouse models of SCN1Aderived epilepsy| J. Wong, S. Dutton, S.
Schachter, S. Collins, A. Escayg
3.058 Interictal and ictal ECG changes in a
chronic experimental model of temporal
lobe epilepsy| A. Ashby-Lumsden, T. Lovick, J.
Jefferys
3.059 Mechanisms of epileptic
encephalopathy due to KNCT1 (Slack)
mutations| I. Quraishi, J. K. Kronengold, G.
Kim, R. Couture, M. L. Schwartz, L. K.
Kaczmarek
3.060 Acute kainic acid-induced status
epilepticus is augmented in mice lacking the
interleukin-1beta receptor type 1.| R. Leon,
S. Hewett, J. Hewett
3.061 Neonatal ischemic seizures: Age at
ischemic insult differentially modulates longterm comorbidities in a mouse model.| S.
Kang, D. Adler, S. Thodupunuri , W. C. Chan,
S. Kadam
3.062 The efficacy of the mTOR inhibitor
Torin1 on spasms in the multiple-hit rat
model of infantile spasms| T. Brima, W.
Mowrey, S. Moshé, A. S. Galanopoulou
3.063 Understanding Network Level Effects
of Calcium Channel Electrophysiology with a
Computer Model of Spike and Wave
Discharges| A. Knox, J. Tenney, K. Holland, T.
Glauser
3.064 Seizure phenotypes, natural
progression and sleep-wake patterns in
epileptic Kcna-1 null mutant mice| R.
Maganti, S. Wright, E. Wallace
human Studies
3.065 Peroxisome proliferator-activated
receptor type alpha activation as new
therapeutic approach to treat epilepsy| M.
Puligheddu, M. Melis, G. Pillolla, G. Milioli, L.
Parrino, F. Marrosu, M. Terzano, M. Pistis, A.
Muntoni
3.066 Interictal epileptogenic network
dynamics in tuberous sclerosis complex| A.
Ye, S. Wong, A. Ochi, H. Otsubo, S. Doesburg
3.067 Heightened delta during slow-wavesleep in patients with Rett syndrome
associated with poor sleep efficiency.| S.
Ammanuel, S. Kadam
3.068 Delineation of the epileptogenic zone
integrating electrocorticography with
ultrahigh field fMRI and tractography: a novel
approach| L. Marcuse, J. Young, P. Kundu, R.
O'Halloran, M. Fields, J. Yoo, R. Feldman, B.
Delman, S. Ghatan, P. Balchandani
3.069 Evaluation of the Reference Scaled
Average Bioequivalence Criteria on
Phenytoin using Population Pharmacokinetic
Modeling and Simulation Approach| H. Kim,
L. Fang, J. Yu, W. Jiang, L. Zhao, R. Lionberger
3.070 Overactivation of mTOR signaling
pathway in human therapy-resistant
temporal lobe epilepsy.| L. M. Jacobs, C.
Coto, H. Sun, T. Lucas, M. Martinez-Lage, K.
Davis, F. Jensen, D. M. Talos
3.071 Dynamics of High-frequency
Oscillations: In Emotional Memory
Processes| M. Montes de Oca Basurto, R.
Staba, A. Bragin, F. Velasco Campos, D.
Vazquez Barron, P. Saucedo Alvarado, A.
Velasco-Monroy
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
76
3.072 Characteristics of Epileptiform Activity
Recorded Using MEA from Human
Hippocampal Slices in an In-Vitro Model for
Neurostimulation and Epilepsy| M. Hsiao, P.
Yu, D. Song, T. Berger, D. Millett, C. Heck, C.
Liu
3.073 Retrospective study of lacosamide in
the elderly (≥ 60 year of age)| J. Bainbridge,
P. Wong, M. Spitz, L. Frey, A. Shrestha, L.
Strom, S. Benbadis, J. Sirven, S. Chung
3.074 Evaluating Electrocardiographic (ECG)
Changes Associated With Seizures in
Patients with Stereoelectroencephalography
(sEEG) Intracranial Electrodes as a Novel
Means to Elucidate Underlying Mechanisms
of SUDEP| S. Vadera, B. Nazer, F. P. Hsu, J. Lin
3.075 Electrocortico-thalamogram mapped
at broadband (0.01 Hz- 500 Hz) in a patient
with failed temporal lobe epilepsy surgery|
D. Pizarro, H. Deshpande, S. Deepak, L. Ver
Hoef, K. Riley, J. Szaflarski, Pati
3.076 Evidence for altered glutamate
homeostasis in human temporal lobe
epilepsy| C. A. Coto, L. M. Jacobs, R. Balu, T.
Lucas, M. Martinez-Lage, K. Davis, D. M. Talos,
F. Jensen
3.077 Localized epileptiform activity in the
dorsomedial thalamic nucleus of temporal
lobe epilepsy patients| F. C. Schmitt, S.
Rampp, J. Voges, L. Buentjen, H. B. Straub, K.
Bohlmann, H. Heinze, A. Kowski, M.
Holtkamp, C. Sweeney-Reed
3.078 Characterization of Epileptogenic
Network Using Endogenous CCEPs| S.
Karunakaran, C. Kadipasaoglu, G.
Kalamangalam, B. Aazhang, N. Tandon
3.079 Etiology determines multi-focality in
unilateral temporal lobe epilepsy syndrome|
S. Pati, A. H. Ewida, S. Deepak, A. M. Khawaja,
K. Arora, J. Miller
3.080 Autoimmune encephalitis: associated
antibodies and underlying neoplasm. - Result
from a multicenter nationwide prospective
observational registry| S. Hwang, S. Ahn, J.
Byun, J. Sunwoo, T. J. Kim, J. A. Lim, S. Lee, K.
Jung, K. Chu, K. Jung, S. Lee
3.081 Increased ratio of hippocampal ripples
during Slow Wave Sleep (SWS) in the
epileptogenic temporal lobe compared to
the normal temporal lobe| K. Birch, A. N.
Mamelak, L. Ross, J. Chung, U. Rutishauser
3.082 Electroencephalogram during
encephaloduroarteriosynangiosis and
encephalomyoarteriosynangiosis in children
with moyamoya disease| M. Goyal, C. Prince,
J. Johnston
Devices, Technologies, Stem Cells
3.083 VNS Therapy Automatic Stimulation
Mode Outcomes Study in Epilepsy Patients
Exhibiting Ictal Tachycardia| R. Fisher, P. Afra,
B. Najimipour
3.084 Seizure Detection by Multi
Extracerebral Biosignal Analysis| D. L. Cogan,
M. Nourani, J. Harvey, V. Nagaraddi
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.085 Clinical Research Use of the
NeuroPace® RNS® System| T. Tcheng, N.
Hasulak, S. Arcot Desai, T. Crowder Skarpaas,
S. Archer, J. Cao
3.086 Evaluating the effects of a new mode
of automated VNS Therapy in an EMU| K.
Eggleston, R. M. McGuire, B. Najimipour, P.
Raman, A. Jayewardene, S. Mindrebo, S.
Sabesan, J. Begnaud, O. D'Cruz
3.087 Intra-Operative Real-Time Passive
Functional Mapping of Expressive Language
Cortex| A. M. Taplin, P. Brunner, A. de
Pesters, D. Hermes, J. Dalfino, M. A. Adamo,
A. Ritaccio, G. Schalk
3.088 Automated EMG based Seizure
Detection and Quantification for the Home
and the Epilepsy Monitoring Unit: A
Prospective Multicenter Study.| J. E. Cavazos,
M. Girouard, J. Halford, M. R. Sperling, D. Nair,
W. Tatum, D. Dlugos, J. Harvey, J. French, J.
Pollard, R. Faught, K. Noe, T. R. Henry, G.
Jetter, O. V. Lie, L. Morgan, L. Whitmire
3.089 Use of Sympatho-vagal balance
derived from Heart Rate Variability during
cardiac recordings to establish "Signatures"
of different causes of seizures| P. Cooper, N.
Virag, A. Anwar, S. Crampton, M. de Melis, R.
Sutton, A. Fitzpatrick
3.090 Chronic VNS (vagus nerve stimulation)
modifies cortical excitability in man. A 2 years
prospective TMS (transcranial magnetic
stimulation) study| M. Mann, B. Gueguen, E.
Nogue, M. Picot, V. Ivanova, E. Landre, F.
Chassoux, B. Turak
3.091 Utility of TMS in Presurgical Mapping
of Eloquent Cortices in Children| S.
Narayana, K. Schiller, F. Boop, J. Wheless, A. C.
Papanicolaou
3.092 Dynamic Training of Machine-learning
Algorithm for Real-time Seizure Detection in
the Epilepsy Monitoring Unit| D. Ehrens, M.
Cervenka, G. Bergey, C. Jouny
3.093 Phase 2 StatNet EEG: validating an
important tool for reliable diagnosis of
NCSE| A. R. Voll, D. Dash, W. Sutherland, L.
Hernandez Ronquillo, J. F. Téllez Zenteno, F.
Moien-Afshari
3.094 Development and application of
inhibitory luminopsins for the treatment of
epilepsy.| J. Tung, C. A. Gutekunst, R. Gross
3.095 Dimensionality Reduction in Seizure
Prediction Studies| E. Bou Assi, D. Nguyen, S.
Rihana, M. Sawan
3.096 An improved wrist-worn convulsive
seizure detector based on accelerometry
and electrodermal activity sensors| G.
Regalia, F. Onorati, M. Migliorini, R. Picard
Biomarkers
3.097 Evaluation of epileptiform discharges
as electrographic biomarkers for
epileptogenesis| H. Ung, J. Moyer, J.
Wagenaar, A. Krieger, A. Pitkanen, B. Litt
3.098 Interictal EEG networks in pediatric
epilepsy surgery: clinical insights from graph
theory| S. Tomlinson, C. Bermudez, B. Porter,
E. Marsh
3.099 Interictal spike propagation and
connectivity: clinical relevance in pediatric
epilepsy surgery| E. Marsh, S. Tomlinson, C.
Bermudez, B. Porter
3.100 Sodium selenate retards
epileptogenesis via activating protein
phosphatase 2A| P. Zheng, S. Liu, S. Shultz,
N. Jones, T. O'Brien
3.101 A Statistical Method for the Automatic
Detection of High Frequency Oscillations in
Human Intracranial EEG| K. Charupanit, J.
Lin, B. A. Lopour
3.102 Adaptation of a Pre-clinical Biomarker
for Allopregnanolone (SAGE-547) for Use in a
Phase II Clinical Trial for Super Refractory
Status Epilepticus| G. Belfort, M. Quirk, R.
Hammond, M. Ackley, E. Christian, M. Baird,
H. Colquhoun, J. Doherty, S. Kanes, A. J.
Robichaud
3.103 Optimal sampling rate and antialiasing filter settings for the detection of
high frequency oscillations (HFOs)| S. Gliske,
W. Stacey
3.104 Magnetic resonance imaging of bloodbrain barrier dysfunction as a biomarker for
epileptogenesis| G. Bar-Klein, N. Elazary, N.
Milk, Y. Rosman, S. Lublinsky, E. Swissa, A.
Eizenkraft, L. Kamintsky, Y. Parmet, Y.
Chassidim, D. Kaufer, A. Friedman
3.105 Strong, stable neuronal networks
associated with hypsarrhythmia in infantile
spasms| V. Bajaj, D. Shrey, S. A. Hussain, B. A.
Lopour
3.106 A graphical user interface for
automated mapping of ictal and inter-ictal
high frequency oscillations (80-500 Hz)| S.
Chaibi, D. Pizarro, S. Deepak, L. Ver Hoef, K.
Riley, A. Kachouri, M. Samet, J. Szaflarski, S.
Pati
3.107 Soluble ICAM5 Plasma Concentrations
Unaltered by Status Epilepticus in Patients
with Anoxic Brain Injury| E. BurakgaziDalkilic, M. C. Strauman, U. Moghal, T. Kavi, R.
Shah, A. Shikman, P. Crino, E. Brand, J. Pollard
3.108 Cytometric analysis of the
cerebrospinal fluid of patients with NMDA
autoimmune encephalitis | S. OrozcoSuárez, L. Arriaga-Pizano, A. Vega-García, M.
Flores-Mendoza, I. A. Feria-Romero, D. RayoMares, E. Rodríguez, L. Rocha, I. Grijalva
3.109 Increased Expression of Growth
Associated Protein 43 After Seizures in
Rodent Model of Irradiation-Induced Cortical
Dysplasia| A. Nemes, K. Ayasoufi, Z. Ying, Q.
Zhou, I. Najm
neuROPhySIOlOgy
Video eeg epilepsy-Monitoring
3.110 TIRDA as an EEG marker of neocortical
involvement in mesial temporal lobe
epilepsy| A. Serafini, S. Wu, S. Rose, J. Tao
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
77
3.111 Diurnal and nocturnal patterns of
autonomic neurophysiological
measurements are related to timing of
seizures| B. Kim, A. B. Nogueira, S. ThomeSouza, K. Kapur, J. Klehm, M. Jackson, L.
St.Louis, C. Doshi, C. Papadelis, T.
Loddenkemper
3.112 Stable functional networks identified
through mutual information exhibit
significant changes during seizures| J.
Chapeton, S. Inati, K. Zaghloul
3.113 Effect of Selective Serotonin Reuptake
Inhibitor Use on Tonic Phase Duration and
Post-Ictal Generalized EEG Suppression| D.
Harris, J. Kang, M. Nei
3.114 A New Waveform Identified during
Video-EEG Monitoring| W. Tatum, B.
DiCiaccio, J. Kipta, K. Yelvington, M. Stein
ICu eeg
3.115 Utility of Continuous EEG Monitoring
Reports: A Survey of Neurointensivists| G.
Deck, M. Westover, A. Cole, L. V. Moura
3.116 Clinical and EEG Characteristics of
Preterm Neonates Undergoing Continuous
Electroencephalography in the NICU| E.
Buraniqi, A. Sansevere, J. Klehm, I. Sanchez
Fernández, A. Bergin, P. Pearl, T.
Loddenkemper
3.117 Epidemiological and etiological profiles
of patients with GPDS pattern at the Hospital
das Clinicas, Faculty of Medicine, University
of São Paulo, over a one-year period.| C.
Baise, E. Manfrim, L. Faleiros, L. Bissoli, A.
Cyrino, J. Andrade, E. Garzon
3.118 EEG Characteristics in Phases of
Therapeutic Hypothermia| K. Kim, K.
Pargeon, E. Rubens, D. Labar
3.119 Burst-Suppression Pattern in ICU
Patients in a Tertiary Health Service in São
Paulo - Brazil| C. Baise, E. Garzon, L. Bissoli,
A. Cyrino, L. Faleiros, E. Manfrim, J. Q.
Andrade
3.120 Conductive plastic electrodes reduce
EEG artifact during pediatric ECMO therapy|
J. Matsumoto, D. L. McArthur, C. Szeliga, J.
Lerner, L. Rao, S. A. Hussain, J. Wu, R. Sankar
3.121 Ictal and Nonictal Patterns in
Subarachnoid Hemorrhage :Is it a seizure or
is it vasospasm| J. Politsky, S. Iyengar, I.
Ugorec, P. Puntambekar
3.122 A 5-year retrospective study of EEG
and neurological outcomes children
undergoing ECMO at a quaternary care
center| J. Bain, J. Monteagudo, C. Schad, B.
Fallon, C. O'Brien, E. Cheung, W.
Middlesworth, J. Riviello, T. McDonough
3.123 Skin Breakdown in ICU EEG
Monitoring: Risk Factors and Time
Dependence| L. V. Moura, V. moura, D.
Kwasnik , T. Carneiro , C. Scott, M. Westover
Other Clinical eeg
3.124 Is classical mesial-temporal seizures
semiology actually perisylvian?| P.
Suwanpakdee, J. Bulacio, I. Noviawaty, J.
Gonzalez-Martinez, W. Bingaman, P. Chauvel
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.125 EEG findings in pediatric patients with
anti-NMDA encephalitis.| T. Vu, K. Ono, V.
Gonzalez Montoya, S. Gowda, L. Morton
3.126 Spike Frequency Changes with Age in
Benign Focal Epilepsy of Childhood with
Centrotemporal Spikes| M. Takeoka, K. Boyer
3.127 Identification of seizure onset zone
using electrocorticographic high-frequency
oscillation| B. Elahian, B. Mudigoudar, M.
Yeasin, A. C. Papanicolaou, J. Wheless, A.
Babajani-Feremi
3.128 Eight Channel EEG Provides Equivalent
Diagnostic Utility to Full Montage EEG in
Detecting Pathological Rhythmic Periodic
Activity| K. Gururangan, B. Razavi, J. Parvizi
3.129 REM sleep interictal fast ripples are
more specific to epileptogenic zone| R.
Sakuraba, M. Iwasaki, E. Okumura, K. Jin, T.
Tominaga, N. Nakasato
3.130 Abnormal sleep slow wave activity
topography in patients with refractory focal
epilepsy: a high-density EEG study| M. Boly,
B. Jones, A. Mensen, G. Tononi, R. Maganti
3.131 BlazeEEG: An Open-Access Webbased EEG Platform Enabling Crowd
Sourcing in Clinical Neurophysiology| J.
Peters, A. Hans, O. Ciccone, I. Titima, J.
Connolly, R. M. Hodgeman, O. Siddiqi, A.
Patel
3.132 Scalp EEG failed to record HFOs: a
study of simultaneous recording of scalp and
stereo-electroencephalography| S. Wu, S.
Rose, J. Tao
3.133 Dense-Array Electroencephalography
(dEEG) Improves Compliance And Acquisition
Without Sedation Or Restraint For Children
And Adults With Behavioral Challenges| M.
Mintz, L. Szklarski
3.134 Diagnostic Utility of Ambulatory EEG
monitoring| C. O'Donovan, J. Boggs, C.
Cornell
Animal Studies
3.135 Leaky Ryanodine Receptor-2 mutation
lowers threshold for hypoxic spreading
depolarization| I. Aiba, J. L. Noebels
3.136 Interneuronopathy in the Kcna1-null
mouse model of epilepsy| C. Gavrilovici, T. A.
Simeone, J. Rho
3.137 Prenatal Immune Insult, a Risk Factor
for Childhood Epilepsy, Promotes
Intracortical Hyperexcitability in Adult Mice|
T. Weerakkody, J. Huguenard
3.138 Postnatal expression of Arx in
GABAergic interneurons is critical for proper
network function in the mouse
hippocampus| D. J. Joseph, A. McCoy, R.
Risbud, E. Marsh
3.139 The suppression of epileptic
discharges by carbachol-induced β
oscillation in rat hippocampal slices| T.
Sawada, K. Natsume
3.140 Synaptic connectivity of transplanted
MGE interneurons within host circuits| M.
Howard, S. Baraban
3.141 Intravascular EEG in rats: proof of
concept| V. Keereman, P. van Mierlo, R.
Raedt, P. Boon
3.142 A mouse model of a human SCN8A
epileptic encephalopathy mutation exhibits
increased persistent sodium current in
bipolar and pyramidal hippocampus
neurons.| L. F. Lopez-Santiago, Y. Yuan, J.
Hull, J. Wagnon, C. R. Frasier, J. Parent, M.
Meisler, L. L. Isom
3.143 In vivo interneuron circuit dysfunction
in chronically epileptic mice| T. Shuman, M.
Javaherian, C. C. Kaba, D. Cai, D. Aharoni, K.
Cheng, R. Manavi, N. Rao, J. Daneshrad, A. A.
Fariborzi, J. Lou, S. E. Flores, C. Yang, S.
Ghiaee, M. Shtrahman, K. Bakhurin, S. C.
Masmanidis, P. Golshani
Computational Analysis &
Modeling of eeg
3.144 Analysis of Signal and Feature
Variation during Long Term iEEG
Recordings| J. D. Wilson, H. Ung, J. Wagenaar,
D. Freestone, M. Cook, B. Litt
3.145 Connectivity during passive movie
viewing tracks putative language networks in
epilepsy patients undergoing invasive
monitoring| E. J. White, A. Keller, E. Pang, T.
Valiante
3.146 The Neocortical Irritative Zone
Organization in Intracranial EEG Recording|
P. Marusic, R. Janca, P. Krsek, P. Jezdik, R.
Cmejla, M. Tomasek, V. Komarek, P. Jiruska
3.147 A Novel Approach to Spike Detection
in Hypsarrhythmia Using Matching Pursuit
Time-Frequency Domain| L. Seltzer, S.
Traitruengsakul, A. Kahn, S. Demarest, K. G.
Knupp, T. Benke, B. Ghoraani, A. Paciorkowski
3.148 Crowdsourcing Seizure Detection
Algorithms Using Kaggle and ieeg.org| T.
Blevins, A. Khambhati, J. Wagenaar, B.
Brinkmann, G. Worrell, B. Litt
3.149 Source localization in suspected extratemporal drug-resistant focal epilepsy: a
prospective high-density EEG and stereoEEG study| S. Gibbs, P. Proserpio, A. Rubino,
S. Sarasso, L. Tassi, R. Mai, S. Francione, M.
Cossu, G. Lo Russo, G. Tononi, L. Nobili
3.150 Quantitative analysis of simultaneously
recorded scalp and subdural EEGs: the
power of the gamma and omega bands (25
to 125 Hz)| O. A. Petroff, D. Spencer, H.
Zaveri
ClInICAl ePIlePSy
Classification and Syndromes
3.151 A Large Cohort of Eyelid Myoclonia
with Absences: Clinical, Electrographic and
Genetic Characteristics| C. Boelman, L.
Brunga, A. Ochi, C. Go, H. Otsubo, S. E.
Buerki, D. Andrade, B. Minassian
3.152 Characterization of a PCDH19-Related
Epilepsy Cohort| L. Smith, G. Truglio, B.
Sheidley, H. Olson, A. Poduri
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
78
3.153 In or Out: Differences between
Patients with Intracellular versus Cell-surface
Receptor Antibodies in Autoimmune
Epilepsy| C. Steriade, S. Mirsattari, D. TangWai, R. Wennberg
3.154 Development of a Predictive Model of
Seizure Events for Preadmission Screening of
Epilepsy Patients to the Seizure Monitoring
Unit| Y. Zhang, S. Hu, N. Jette, J. Engbers, S.
Macrodimitris, S. Wiebe
3.155 Electroclinical Features of epilepsy in
children with isodicentric chromosome 15: A
case series| C. Sanguansermsri, S. Buerki, C.
Boelman, L. Huh, A. Datta, M. Demos, M.
Connolly
3.156 Epilepsy and MRI findings in patients
with 22q.11 deletion syndrome.| S. L. Nune,
B. Mudigoudar, S. Fulton, E. Dayyat, A.
McGregor, J. Wheless
Cinical Diagnosis
3.157 Ripple and Fast Ripple Band Power
Correlate with Vigilance Changes in Epileptic
Brain| F. Yaghouby, A. Al-Bakrei, P. Modur, S.
Sunderam
3.158 Epilepsy and neurobehavioral
comorbidities in 1657 Tuberous Sclerosis
Complex patients: TSC Natural History
Database Study| G. de Bruyn, B. Krishnan, R.
Collier, J. Nakagawa, S. Tousseyn, L. Lagae, A.
Gupta
3.159 Do smartphone videos obviate the
need for video-EEG monitoring in diagnosing
psychogenic non-epileptic seizures?| R.
McGinty, D. Costello
3.160 Challenges in diagnosing coexisting
epilepsy and psychogenic non-epileptic
seizures| D. Costello, R. McGinty
3.161 How useful is Ictal SPECT scan for the
pre-surgical evaluation in children?| P.
Pojomovsky McDonnell, S. Jirasakuldej, A.
Mandel, D. McBrian, S. Jacob, K. Eck, E.
Gonzalez, J. Riviello, C. Akman
3.162 Is temporal lobe epilepsy with
hippocampal sclerosis a progressive
condition?| A. B. Bjørke, D. Sætre, G.
Ringstad, P. Larsson, L. Gjerstad, E. Taubøll, K.
Heuser
3.163 Proposed Montage and Clinical
Workflow for Dense Array EEG Review| M.
Dobrota, S. Herman
3.164 EEG patterns in autism with and
without epilepsy| A. Zrik, A. Namath, I.
Tuxhorn, R. Galan
3.165 Effect of Marijuana Use on Wada Test|
C. Drees, C. Domen, K. Chapman, A. Shrestha
3.166 Analysis of diagnostic motivation in the
Juvenile Myoclonic Epilepsy| I. Takumi, T.
Nozaki, Y. Kishi, A. Morita
3.167 The Spectrum of Seizures with Stroke
in Sickle Cell Disease in Children| S. Paudel,
A. Kumar, J. Yang, M. Goyal
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.168 Evaluation of Duration and Type of
Postictal Period in Geriatric Patients with
Seizure: New-onset vs. Longstanding
Epilepsy| G. Fahimi, H. Rajebi, K. Ogden, S.
Izadyar, P. Kent, A. Sanders, R. O'Dwyer
3.169 Seizure prediction models in the
Neonatal Intensive Care Unit| K. Kapur, A.
Sansevere, T. Loddenkemper, J. Peters
3.170 Cost-effectiveness of Tele-Ambulatory
EEG testing in a VA Hospital Local Network|
D. McCarthy, D. Weber, J. Berger, S. Mernoff,
J. Pathmanathan
3.171 Seizures and their Social-Psychological
Context| F. Matsuo, D. Hedges
3.172 WITHDRAWN
3.173 Unusual EEG pattern in case of
Prader-Willi Syndrome| K. Sannagowdara
3.174 Prevalence of CNS and non-CNS
related neoplasm in patients with geriatric
epilepsy| R. O'Dwyer Vourganti
3.175 EEG Patterns in the Newly Psychotic
Patient| J. Montes-Rivera, M. Fields, L.
Marcuse, J. Yoo
3.176 Hashimoto Encephalopathy causing a
cluster of atypical automotor epileptic
seizures with complex semiology. A case
report and literature review| J. Rathore, A. Ali,
F. Campanella
Clinical Treatments
3.177 Ketamine for Refractory Status
Epilepticus (RSE) in Children, A Retrospective
Cohort Study in the Pediatric Health
Information System (PHIS) database| S.
Keros, E. Buraniqi, B. Alex, A. Antonetty, H.
Fialho, B. Hafeez, M. Jackson, S. Kjelleren, J.
Klehm, E. Stewart, T. Loddenkemper, Z.
Grinspan
3.178 CBZ- or VPA-unresponsive focal
seizures in non-idiopathic and nonlesional
focal epilepsies in children and young adults
and effective antiepileptic drugs| K. Sugai, E.
Nakagawa, T. Otsuki
3.179 Treatment of intractable epilepsy with
esclicarbazepine acetate (Aptiom) as add on
therapy.| W. Mirza
3.180 Successful treatment outcome in
Lennox-Gastaut syndrome| S. Park, H. Kim
3.181 Do patients with infantile spasms (IS)
have better long term outcomes when
treated with standard therapy versus other
treatment modalities?| D. Brchan, K. Park, J.
Toler, T. Benke, K. G. Knupp
3.182 Changes in Antiseizure,
Antidepressant, and Antipsychotic
Prescribing in Elderly Nursing Home
Residents| S. Bathena , I. Leppik, A. Kanner,
A. Birnbaum
3.183 Use of Vigabatrin in Refractory Status
Epilepticus| R. Ramsay, V. Sabharwal, R.
Shumate, F. Khan, M. Irland
3.184 Vagal Nerve Stimulation for Drug
Resistant Epilepsy in Children: Puerto Rico’s
experience| M. M. Bolo-Diaz, R. Rios-Motta,
M. Rios-Motta
3.185 Sequential pneumatic compression
device prophylaxis for prevention of DVT in
Adult patients admitted to the Epilepsy
Monitoring Unit.| R. R. Sankaraneni, D.
Mudugal, S. P. Singh
3.186 Challenges Implementing a
Standardized Order Set for Status
Epilepticus in a Hospital Setting| D.
McDermott, M. Mader, C. Drees
3.187 Infantile Spasms and Injuries of
Prematurity: Short-term treatment based
response and long-term outcomes.| A.
Wallace, V. Allen, K. Park, K. G. Knupp
3.188 Neonates with acute brain injury have
low risk for ongoing seizures after hospital
discharge| C. J. Wusthoff, T. Mabud, S. Lee, C.
L. Clark
3.189 Focal neurologic deficits due to
hyponatremia in a case series of pediatric
patients with subdural grids and strips for
resective epilepsy surgery.| A. Lowden, D.
Sirsi, S. Arnold, A. Price, R. Said
3.190 Safety and effectiveness of topiramate
in medically complicated patients with
refractory status epilepticus or recurrent
convulsive seizures| W. Kim, S. Lim, Y. Shon
3.191 Seizure and Epilepsy in Stroke
Survivors.| I. Zilberman, J. Rubinstein
3.192 Managing Epilepsy With Limited
Resources: Review Of An Epilepsy Cohort In
Jamaica, 2007 – 2015.| U. Menon, M.
Williams, T. Grindley, A. Ali
3.193 “Time to Vigabatrin”: Cognitive
outcome in Tuberous Sclerosis Complex is
related to timely initiation of Vigabatrin
specifically.| A. Prohl, R. M. Hodgeman, J.
Peters, C. Harini, M. Sahin, K. Kapur
3.194 Treatment variability for seizures in
newborns: results from the multicenter
Neonatal Seizure Registry| H. C. Glass, C. J.
Wusthoff, T. Chang, N. Abend, C. Chu, M.
Cilio, S. Bonifacio, S. Massey, T. Tsuchida, F.
Silverstein, J. Soul, R. Shellhaas
Prognosis
3.195 Presentation and clinical course of
children with hypothalamic hamartoma| R.
Wilkinson, E. Caredda, S. Varadkar, H.
Spoudeas, M. Tisdall, J. Cross
3.196 The Predictive Value of EEG and MRI in
Antiepileptic Drug Response in Newly
Treated Focal Epilepsy: Interim Findings from
The Human Epilepsy Project.| M. Hegde, K.
McKenna, R. Singh, A. Boro, V. Mays, P. Klein,
J. French, D. Dlugos, B. Gidal
3.197 The Clinical Significance of Continuous
Rhythmic and Periodic EEG Patterns| J.
Cheng
3.198 Mortality in Status Eplilepticus and Its
Association with the APACHE II Score| N.
Arora, J. Cheng
3.199 Characterization of a first unprovoked
seizure during military service| D. Ekstein, A.
Tsur, A. Honig
3.200 Outcome evaluation in Status
Epilepticus: comparison between STESS and
EMSE score.| M. Pacha, E. Silva, G. Ernst, L.
Orellana, O. A. Martinez
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
79
3.201 Surgical outcome in patients with MRInegative generalized and focal epilepsy| J.
BAEK, S. Kim, H. Chung, H. Kim, J. Lee
3.202 Neuroendocrine dysregulation, periictal physiology and sleep disordered
breathing in individuals with epilepsy:
Association with SUDEP risk| N. Odom, A.
Westwood, A. Pack, B. M. Lisa
3.203 Developmental impact of total corpus
callosotomy for intractable epilepsy in early
children| N. Koide, R. Honda, T. Ono, K. Toda,
H. Baba
neuRO IMAgIng
Animal Studies
3.204 The Periaqueductal Gray and Other
Brainstem Structures are Critical Nuclei in
Seizure-Induced Sudden Death in the DBA/1
Mouse Model of SUDEP| C. Faingold, M. E.
Randall, T. J. Brozoski, B. Odintsov, S. P.
Kommajosyula
3.205 MR spectroscopic studies of a variable
rat model of epilepsy| P. Pearce-Grullon, Y.
Wu, K. M. Kelly, A. Rapuano, N. de Lanerolle, J.
Pan
3.206 Mapping of the activated areas of
brain following a single seizure or status
epilepticus using CLARITY tissue clearing
technique| S. Joshi, J. Burnsed, A.
Ksendzovsky, J. Williamson, D. Breen, S.
Oberoy, M. F. Trikantzopoulou, J. Kapur
Structural Imaging
3.207 Correlates of cognitive impairments
with hippocampal volume and T2
relaxometry in temporal lobe epilepsy| R.
Rodríguez Cruces, L. Velázquez Perez, V.
Camacho Tellez, D. Atilano Barbosa, E.
González Olvera, E. Santiago Rodríguez, D.
Trejo-Martinez, H. Barragan, L. Concha
3.208 A Potential Pitfall of FDG-PET/MRI
Coregistration in the Presurgical Evaluation
for Focal Cortical Dysplasia in Pediatric
Epilepsy Patients.| I. Orosz, V. Trinh, R. Harris,
B. Salehi, C. Geannette, J. Quiao, A. Hardy, H.
Ullman, J. Lerner, N. Salamon
3.209 Identification of Epileptogenic Lesions
Using a Template-free Framework for
Analysis of Multi-contrast Anatomical MR
Images| J. Reeves, J. Scott, Z. Saad, S. J. Inati,
S. Inati
3.210 Cortical Thickness Changes are
Associated with Anxiety and Depression in
Patients with Temporal Lobe Epilepsy| T.
Stoub, M. Sharma, C. L. Grote, A. Kanner
3.211 Diffusion Kurtosis Imaging of Juvenile
Myoclonic Epilepsy Detects Frontal White
Matter Abnormalities| T. Nowacki, E. Misaghi,
R. Stobbe, C. Beaulieu, D. Gross
3.212 T2 relaxometry in the diagnosis of
non-atrophic hippocampus in temporal lobe
epilepsy| M. Iwasaki, S. Sato, H. Suzuki, S.
Mugikura, K. Jin, N. Nakasato, T. Tominaga
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.213 Magnetic Resonance Characterization
of Hippocampus and its Correlation with
Neuropsychological Test Outcomes in Mesial
Temporal Lobe Epilepsy| H. Bagher-Ebadian,
B. Funk, F. Mahmoudi, K. Elisevich, M.
Nazem-Zadeh, J. M. Schwalb, E. Air, H.
Soltanian-Zadeh
3.214 Diffuse Brain Atrophy of LennoxGastaut Syndrome is Maximal in the Pons|
B. Newham, E. Curwood, G. Jackson, J. Archer
3.215 Frequency of Arterial Spin Labeling
(ASL) abnormalities in children with focal
seizures.| T. Zelleke, K. Khusiwilai, J. Murnick
Functional Imaging
3.216 Glial waves during seizures – coupled
or uncoupled with neurovascular activity?|
H. Ma, A. G. Daniel, P. Laffont, M. Zhao, T.
Schwartz
3.217 Hippocampal Subfield Volumetry and
Functional Connectivity on 7T MRI in
Temporal Lobe Epilepsy| K. Davis, S. Chen, P.
Yushkevich, L. Wisse, M. Geerlings, P. Hadar,
C. Coto, S. Das
3.218 The FMRI in Anterior Temporal
Epilepsy Surgery (FATES) Study| J. Binder, S.
Swanson, M. Rozman, W. Gross, C.
Humphries, R. M. Busch, E. Beall, M. Lowe, L.
Bonilha, T. Brown, J. C. Edwards, J. Langfitt, M.
Tivarus, D. Drane, D. W. Loring, J. Szaflarski, J.
Allendorfer, R. Martin, V. L. Morgan, M. L.
Jacobs, T. Grabowski, V. Phatak, J. Ojemann
3.219 Patient-specific functional connectivity
of epileptic networks in the absence of
spikes: new resting state networks in focal
epilepsy?| G. Iannotti, F. Pittau, M. Centeno,
D. Carmichael, E. Abela, A. Coito, D. van de
Ville, M. Seeck, C. Michel, F. Grouiller, S.
Vulliemoz
3.220 The Role of the Quantitative and
Qualitative PET in Patients with Temporal
Lobe Epilepsy| C. Garcia Gracia, L. Jehi, G.
Wu
3.221 Working memory in TLE patients:
correlation between cortical activity and
psychometric evaluations.| V. Camacho, L. O.
Jiménez Valverde, R. Rodríguez Cruces, M. L.
García Gomar, L. Velázquez Perez, E.
Santiago Rodríguez, D. Trejo-Martinez, H.
Barragan, E. González Olvera, D. Atilano
Barbosa, L. Concha
3.222 Correspondence between
electromagnetic (MEG) and hemodynamic
(EEG-fMRI) sources of interictal epileptic
spikes.| S. Tousseyn, B. Krishnan, Z. Wang, J.
Mosher, R. Burgess, S. Jones, A. Alexopoulos
3.223 Paroxysmal hyper-connectivity
episodes impair functional connectivity in
TLE| S. Mueller, A. Simonson, Y. Tan, R. C.
Knowlton, K. Laxer
3.224 Neurolite and Ceretec radio-isotopes:
Efficacy in acquisition of subtraction SPECTS
and there localizing value in defining the
epileptogenic zone| H. Sachdev, B. Patel, D.
F. Clarke
3.225 The role of language testing, Wada
and fMRI, in patients with left sided
hemispheric lesions considered for
hemispherectomy| D. Sieciechowicz, A.
Naduvil Valappil
3.226 Altered thalamic resting-state
functional connectivity in patients with
secondarily generalized neocortical
seizures| Y. Hsin, S. Peng
3.227 First epilepsy case of in vivo imaging of
synaptic vesicle glycoprotein 2A (SV2A) using
a novel PET radiotracer| K. Detyniecki, S.
Finnema, N. Nabulsi, T. Eid, D. Spencer, A.
Huttner, R. Carson, Y. Huang
3.228 Cognitive networks in Lennox-Gastaut
Syndrome show impaired within-network
integration and between-network
segregation| A. Warren, D. Abbott, D.
Vaughan, G. Jackson, J. Archer
3.229 Hypsarrhythmia impacts regional
cerebral metabolism in left superior lateral
temporal cortex| J. Weng, R. Ahn, D. H.
Silverman, S. A. Hussain
3.230 Alterations of sensorimotor restingstate network in patients with secondarily
generalized neocortical seizures| S. Peng, Y.
Hsin
3.231 Resting State Network Changes in
Non-lesion, Focal Epilepsy| A. S. Kurani, R. M.
Richardson, G. Ghearing, A. Popescu, M.
Baldwin, A. Antony, A. Bagic, J. Pan
COMORBIDITy (SOMATIC AnD
PSyChIATRIC)
Psychiatric Conditions
3.232 Depressive symptoms in adolescents
with Epilepsy in a Chilean Population| V.
Venegas Silva, J. Weitzler, R. Aguilera, M.
Manriquez, F. Vergara, M. Aillon, C. Fonseca
3.233 Psychiatric Comorbidities in Youth with
PNES| S. Plioplys, J. Doss, P. Siddarth, B.
Bursch, T. Falcone, M. Forgey, K. Hinman, W.
C. LaFrance, R. Laptook, R. J. Shaw, D. M.
Weisbrot, M. D. Willis, R. Caplan
3.234 The Reliability and Validity Studies of
the Korean Version of Irritability
Questionnaire in Patients with Epilepsy| H.
Moon, Y. Cho, M. Kang, M. Song
3.235 Psychiatric Complications of MRIGuided Laser Ablation of Mesial Temporal
Structures for Treatment-Resistant Temporal
Lobe Epilepsy| A. Kanner, J. Jagid, M. Lopez,
M. Lowe, M. Palomeque, G. J. Rey, R. Ribot, L.
Tornes, E. Serrano
3.236 Claustrophobia During Imaging
Studies as a Marker of Anxiety in Patients
with Psychogenic Non-Epileptic Seizures| S.
Abbas, M. Haykal, R. Fabris, B. Galdis, S.
Najamuddin, N. Zendler, D. Burdette
3.237 One year follow-up of cognitive
behavioral therapy-informed psychotherapy
treatment trial for psychogenic nonepileptic
seizures| W. C. LaFrance, R. Ranieri, G. Baird,
A. Blum, G. I. Keitner
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
80
3.238 Risk Factors Associated with
Psychiatric Comorbidity in Children with
Recent Onset Epilepsy| J. Jones, D. Almane,
D. Jackson, D. Hsu, M. Koehn, M. Seidenberg,
B. Hermann
Animal Studies
3.239 Carbamazepine and Phenytoin Inhibit
Native Sodium Currents in Murine
Osteoblasts| S. Petty, C. Milligan, M. Todaro,
K. Richards, P. Kularathna , C. Pagel, C.
French, E. Hill-Yardin, T. O'Brien, J. Wark, E.
Mackie, S. Petrou
3.240 Neurogenesis in the Lateral
Hypothalamus of a Chronically Epileptic
Mouse Mode| H. Roundtree, K. Simeone
3.241 Seizure-induced activation of the HPA
axis contributes to seizure susceptibility| J.
Maguire, K. O'Toole, S. Wakefield, A. A.
Hooper
3.242 Ontogeny of sleep disruption and
peripheral orexin levels correspond with
epilepsy onset and progression in Kv1.1KO
mice.| S. H. Iyer, H. Roundtree, K. Simeone
3.243 SSRI antidepressants accelerate
epilepsy - role for 5-HT2 receptors?| N.
Jones, G. Dezsi, E. Ozturk, D. Wong, M.
Morris, M. Salzberg, T. O'Brien
3.244 Seizures affect the signaling cascades
necessary for long-term memory formation|
A. Carter, H. A. Born, W. L. Lee, A. E.
Anderson
AnTIePIlePTIC DRugS
Mechanisms of Action
3.245 Effects of the antiepileptic drug
lacosamide on firing properties and sodium
currents in dentate gyrus granule cells of
epileptic animals| D. Holtkamp, T. Opitz, I.
Niespodziany, C. Wolff, H. Beck
3.246 Bumetanide Suppresses Kainic Acid
Induced Seizures And Prevents Development
Of Pharmacoresistance| S. Sivakumaran, J.
Maguire
3.247 2DG reduces abnormal hippocampal
network synaptic excitability without
changing membrane properties.| Y. Pan, T.
Sutula, P. Rutecki
Animal Studies
3.248 Lestaurtinib (CEP-701) Potentiates the
Anticonvulsant Effect of Phenobarbital
Against Kainic Acid-Induced Status
Epilepticus| R. Kuk, N. Kulkarni, J. Goenaga,
D. Fox, P. Adelson, D. Treiman, M. Obeid
3.249 Novel Anti-Seizure Compound ANAVEX
2-73 a Sigma-1 Receptor Agonist in Multiple
Seizure Models| C. Missling, N. Rebowe
3.250 Differentiation of AED classes in a
hippocampal slice model of electrically
induced ictogenesis| I. Niespodziany, N.
Leclère, R. Kaminski, C. Wolff
3.251 Antiepileptic effects of Perampanel in
a neonatal hypoxic seizure model| M. Handy,
H. Sun, H. Juul, J. Moyer, B. Litt, M. Dichter, F.
Jensen
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.252 WITHDRAWN
Clinical Trials
3.253 Efficacy and Safety of Adjunctive
Brivaracetam for Partial-Onset (Focal)
Seizures Overall and in Elderly Patients: A
Pooled Analysis from Three Phase III
Studies| P. Klein, Quarato, R. Mameniskiene,
E. Ben-Menachem, K. Eckhardt , M. Johnson ,
B. McDonough, J. Schiemann, J. Whitesides
3.254 Markers of Bone Turnover and Lipid
Metabolism During Eslicarbazepine Acetate
(ESL) Monotherapy, in Patients Taking or not
Taking Enzyme-Inducing Antiepileptic Drugs
(EIAEDs) at Baseline (BL)| T. Constantino, B.
Gidal, S. Mintzer, T. Grinnell, D. Blum, H.
Cheng
3.255 Efficacy of High-Dose Clobazam
Treatment on Seizures, Epileptiform Activity,
and Cognition in CSWS| C. Vega, I. Sanchez
Fernández, J. Klehm, J. Peters, S. Thome, M.
Jackson, C. Harini, M. Takeoka, G. Wilkening,
K. Chapman, T. Loddenkemper
3.256 A randomized double-blind, placebocontrolled study to evaluate the efficacy and
safety of perampanel as adjunctive therapy
in patients with refractory partial-onset
seizures from the Asia-Pacific region| T.
Nishida, S. Kaneko, Y. Inoue, S. Lee, K. Saeki,
K. Ishikawa
3.257 Development of Unique Dosage Form
and Differentiating Features of USL255,
Qudexy® XR (Topiramate) Extended-Release
Capsules| S. Chung, R. E. Hogan, M. Holmay,
V. Yu, H. Nguyen, I. Blatt, M. Halvorsen
3.258 Neurocognitive Adverse Event Profile
of USL255 (Qudexy® XR; Topiramate
Extended-Release Capsules): Phase III
PREVAIL and PREVAIL OLE Studies| I. Blatt, S.
Chung, B. Lawson, H. Nguyen, M. Holmay, V.
Yu, M. Halvorsen, R. E. Hogan
3.259 Long-Term Efficacy of USL255
(Qudexy® XR; Topiramate Extended-Release
Capsules) by Refractory Status and Age:
PREVAIL OLE| R. Hogan, I. Blatt, M. Holmay,
H. Nguyen, V. Yu, M. Halvorsen, S. Chung
3.260 Long-term cognitive effects of
adjunctive perampanel (PER) in adolescents
for treatment of partial-onset seizures (POS):
randomized, double-blind and open-label
extension (OLE) study| R. Fain, K. J. Meador,
L. Lagae, H. Yang, B. Williams, D. Kumar, A.
Laurenza
3.261 Efficacy of Long-Term Adjunctive
Brivaracetam Treatment for Partial-Onset
Seizures| M. Johnson, M. Toledo, P. Kwan, B.
McDonough, S. Borghs , K. Eckhardt , J.
Schiemann, J. Whitesides
3.262 Effect of adjunctive perampanel on
growth and development in adolescents with
inadequately controlled partial-onset
seizures (POS): randomized, double-blind
and open-label extension (OLE) study| D.
Kumar, L. Lagae, J. Piña-Garza, H. Yang, B.
Williams, A. Laurenza
3.263 Intravenous Immunoglobulins in
Infantile Spasm| P. Maertens, S. Landry, M.
Bramhall
3.264 Status of a double-blind, randomized,
active-controlled study to investigate the
efficacy and safety of eslicarbazepine acetate
as monotherapy in patients with newly
diagnosed partial-onset seizures.| J. Moreira,
E. Trinka, R. Pinto, F. Rocha, P. Soares-da-Silva
3.265 Results of Phase I/II Trial of Sage-547
for Super-Refractory Status Epilepticus (547SSE-201) Response and Relationship to
Underlying Patient Characteristics.| S. Kanes,
E. Rosenthal, H. Vaitkevicius, J. Claassen, E.
Hoffman, M. Baird, M. Quirk, H. Colquhoun
3.266 Antiepileptic Drug Levels in Tuberous
Sclerosis Complex Patients Taking
Everolimus| C. Talley, C. Kam, M. Messinger,
D. Krueger, M. Mays, A. Wilfong
3.267 Biopharmaceutic Risk Assessment of
Brand and Generic Lamotrigine Tablets| S.
Vaithianathan, S. Raman, W. Jiang, T. Ting, M.
Kane, J. Polli
Other
3.268 Efficacy and tolerability of perampanel:
3 year experience in a tertiary epilepsy
centre| K. A. Sieradzan
3.269 Are All Antiepileptic Drugs (AED)
Narrow Therapeutic Index (NTI) Drugs: FDA’s
perspective| E. C. Chow, L. Fang, J. Fan, X.
Zhang, H. Lin, N. Zheng, W. Cai, L. Zhao, W.
Jiang
3.270 Is a Single Dose Bioequivalence Study
in Healthy Subjects Sufficient for Drugs that
Auto-induce their Own Metabolism:
Population Physiologically Based
Pharmacokinetic (PBPK) Simulation with
Carbamazepine| J. Fan, L. Fang, E. C. Chow, L.
Zhao, W. Jiang
3.271 Do Anti-Epileptic Drugs follow the FDA
definitions for Narrow Therapeutic Index
Drugs?| E. Dahmane, J. Gobburu, M.
Gopalakrishnan, V. Ivaturi
3.272 Safety and efficacy analysis of
Perampanel use in a clinical setting in two
Spanish hospitals| G. Garcia-Martin, I. M.
Sladogna, M. Chamorro Muñoz , I. Carrera
Muñoz, J. Romero Godoy, M. Romero Acebal,
J. Ruiz Gimenez
3.273 Health related quality of life and
tolerability in patients under add-on
treatment with eslicarbazepine| A. Oliveros
Cid, A. Oliveros Juste, I. Pagola Lorz, M. Cid
Lopez, F. Jarauta Salvador
3.274 Surveillance of clinical use of
lacosamide in Norway: Patient and
population aspects| T. Svendsen, M. Burns,
A. Baftiu, S. Johannessen, C. J. Landmark
3.275 Clinical experience with perampanel in
the adjunctive treatment of partial-onset
seizures.| A. Oliveros Juste, A. Oliveros Cid, I.
Pagola Lorz, M. Cid Lopez, F. Jarauta Salvador
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
81
nOn-AeD/nOn-SuRgICAl
TReATMenTS
Adult
3.276 Investigating the Effects of ClosedLoop Vagus Nerve Stimulation on EEG and
ECG Signals during Seizures| M. Ravan, S.
Sabesan, O. D'Cruz
3.277 Central mechanisms of Electrodermal
Biofeedback in reducing seizure frequency in
patients with epilepsy: Neuroimaging Study|
Y. Nagai, J. Aram, S. Sisodiya, M. Koepp, L.
Lemieux, M. Cercignani
3.278 Treatment Choices of Women within
the Epilepsy Treatment Gap in Kerala, South
India: A Qualitative Study| J. Von Gaudecker,
A. Keeling, A. G. Taylor, R. H. Steeves
3.279 Stress Management Intervention for
Living With Epilepsy: A Pilot Double-Blind
Randomized Controlled Trial| S. Haut, A.
Dwivedi, S. Cornes, M. Privitera
3.280 Diet therapy as an alternative to
antiepileptic drugs in adult epilepsy.| M.
Cervenka, B. Henry, E. Kossoff
3.281 Efficacy of rituximab as a second-line
immunotherapy in autoimmune encephalitis
and factors associated with favorable
outcomes| S. Ahn, S. Hwang, J. Byun, J.
Sunwoo, T. J. Kim, J. A. Lim, J. Moon, S. Lee, K.
Jung, D. Jeon, K. Jung, S. Lee
3.282 Seizure protection in different murine
ketogenic diets| P. Santos, A. Dolce, C. Sing,
F. Ladha, C. Pardo, A. Hartman
SuRgeRy
Adult
3.283 Single cell firing patterns in the
anterior thalamic nucleus relate to therapy
response in deep brain stimulation for
refractory epilepsy| R. Rouhl, Y. Zhao, G.
Wagner, E. Gommer, M. L. Janssen, L.
Ackermans, C. Heida, Y. Temel, V. van KranenMastenbroek
3.284 Lateral transorbital endoscopic access
to the mesial temporal lobe| H. Chen, L.
Bohman, L. Emery, M. Martinez-Lage, A.
Richardson, K. Davis, J. Pollard, B. Litt, R.
Gausas, T. Lucas
3.285 Reappraisal of the Role of Video-EEG
for the Presurgical Evaluation of Patients with
Temporal Lobe Epilepsy Due to Mesial
Temporal Sclerosis| C. Huang, D. Steven, R.
McLachlan, J. G. Burneo
3.286 Vagus nerve stimulation during
pregnancy and delivery: three cases
experience.| X. Rodriguez Osorio, Á. Prieto, J.
rumia, A. Donaire Pedraza, A. Pato, G. Pérez
Lorenzo, F. L. Gonzalez, M. Carreno
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.287 Factors associated with post-operative
seizures after tumor resection with
intraoperative cortical stimulation| J.
Templer, J. Gavvala, M. Tate, J. Raizer, S.
Schuele
3.288 MRI-guided stereotactic laser ablation
of mesial temporal structures for the
treatment of refractory temporal lobe
epilepsy.| R. Ribot, J. jagid, M. Lopez, M.
Lowe, M. Palomeque, G. J. rey, E. Serrano, L.
Tornes, A. Kanner
3.289 Clinical utility of simultaneous scalp
and intracranial EEG in surgical evaluation
patients with intractable focal epilepsy| S.
Abramovici, M. Baldwin, A. Popescu, G.
Ghearing, J. Pan, R. Hendrickson, C. Plummer,
M. Richardson, A. Bagic, A. Antony
3.290 Stereotactic Laser Ablation in a Typical
Epilepsy Center| G. Petito, R. Wharen, W.
Tatum
3.291 Stereotactic Laser
Amygdalohippocampotomy for Mesial
Temporal Lobe Epilepsy: 12 Month Outcome
is Comparable to Open Resective Surgery| R.
Gross, J. Willie, D. Drane, B. Soares, A. M.
Saindane
Pediatrics
3.292 Efficacy and safety of Vagus Nerve
Stimulator in individuals with chromosome
15q duplication and refractory epilepsy| D.
Arkilo, R. L. Thibert, N. Agarwal, K. Luchsinger,
M. D. Frost, J. Young, O. Devinsky
3.293 Phenotypic variation in the SturgeWeber syndrome: Illustration of 3 cases| W.
Gump, R. Debski, M. Thompson
3.294 The combined 10 year experience with
corpus callosotomy at two children’s
hospitals| D. Graham, D. Gill, R. C. Dale, M.
Tisdall
3.295 Obstruction of the foramen of Monro
is a cause of hydrocephalus after
hemispherotomy| H. Sugano, M. Nakajima,
T. Higo, Y. Iimura, H. Arai
3.296 The outcome of VNS therapy for
pediatric patients with intractable epilepsy|
T. Yamazoe, T. Yamamoto, A. Fujimoto, T.
Yokota, T. Okanishi, H. Enoki
3.297 Outcomes following intraoperative
magnetic resonance imaging (iMRI) guided
surgical resection of Focal Cortical Dysplasia
in Pediatric Subjects| C. Oluigbo, M. Sacino,
T. DeFreitas, S. Magge, C. Ho, R. Keating, W. D.
Gaillard
3.298 Invasive Monitoring after Resection of
Epileptogenic Frontal Lesions in Children| E.
Hidalgo, H. Frankel, B. Grobelny, D. Friedman,
H. Weiner
3.299 Baseline Developmental Status and
Postoperative Outcome in Children with
Focal Cortical Dysplasia| L. Wong-Kisiel, A.
Mrelashvili, L. D. Vázquez-Figueroa, M.
Zaccariello, K. Nickels, E. Wirrell
3.300 Multiple lobe resections required in
drug-resistant epilepsy children with
increased subcortical oligodendroglia-like
cells| S. Sakuma, W. Halliday, K. Okanari, S.
Baba, M. Nakajima, Y. Sato, A. Ochi, H.
Otsubo
3.301 Temporal lobe epilepsy and focal
cortical dysplasia in children: MRI findings
and pathology| L. Bartolini, M. Whitehead, C.
Ho, L. Sepeta, C. Oluigbo, K. Havens, E.
Freilich, J. Schreiber, W. D. Gaillard
All Ages
3.302 Stereotactic radiofrequency
thermocoagulation for hypothalamic
hamartoma| H. Shirozu, H. Masuda, Y. Ito, Y.
Nakayama, T. Higashijima, S. Kameyama
3.303 Stereotactic laser ablation in the
management of lesion induced Frontal Lobe
Epilepsy: Safety and Efficacy| M. Moustafa,
M. Lee, B. Patel, J. Titus, N. Nussbaum, F.
Perkins, K. Keough, D. F. Clarke
3.304 A retrospective cohort of patients with
parietal lobe epilepsy attended in a tertiary
center focusing on clinical and laboratory
characterization and long term outcome| F.
N. Nakano, T. R. Velasco, A. Sakamoto
3.305 Complete callosotomy: more than
atonic seizures| L. Rios, A. Zuniga-Fajuri, L.
Fabres, M. Campos
3.306 Resective surgery for epileptogenic
lesion adjacent to the pyramidal tract -7
cases report-| N. Ikegaya, T. Otsuki, T. Kaido,
Y. Kaneko, A. Takahashi, T. Saito, E. Nakagawa,
K. Sugai, M. Sasaki
3.307 Technical aspects of rolandic area
surgery in patients with refractory epilepsy|
J. A. Burattini, C. M. Cukiert, A. Cukiert
3.308 Encephalocele as a Complication of
Intracranial EEG Monitoring: Case Report| S.
Williams, K. Davis, J. Pollard
3.309 Minimally invasive localization and
treatment of focal epilepsy: a paradigm shift|
N. Tandon, J. Johnson, O. Hope, M. Thomas,
S. Thompson, J. Slater, G. Kalamangalam
BehAVIOR/neuROPSyChOlOgy/
lAnguAge
Adult
3.310 Why is your quality of life better than
mine? The role of positive illusions in
adjusting to drug-resistant epilepsy| S.
Wilson, G. Rayner, J. Lawrence
3.311 Comparative study of screening tests
for suicidality in people with epilepsy| J. Seo,
S. Hong
3.312 Relation between memory impairment
and neuronal cell density of the hippocampal
subfields in patients with hippocampal
sclerosis| S. M. Comper, A. P. Jardim, J. T.
Corso, L. B. Gaça, M. D. Noffs, R. Centeno, E.
Yacubian
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
82
3.313 The Relationship Between Selfreported and Objective Measures of AED
adherence: Exploring the Role of Episodic
Memory| L. Nakhutina, S. A. Margolis, J. S.
Gonzalez, A. Medina, K. Davidoff, A. Grant
3.314 Adherence in patients with epilepsy|
V. Donath
3.315 Atypical language dominance is
associated with better object naming in
patients with left medial temporal sclerosis|
B. Martins-Castro, J. de Almeida, C. Listik, K. T.
Chaim, J. R. Sato, E. Amaro Jr, L. M. Castro
3.316 Choosing to receive information about
SUDEP: Impact on an epilepsy patient’s selfreported mood, general health and quality of
life - A preliminary study.| N. Duncan, Y.
Leavy, D. Ahearn, S. Duncan
3.317 Determining the Relationship between
Depression and Anxiety Neuro-Quality of Life
Measures and the Personality Assessment
Inventory in Patients with Epilepsy| J. J.
Mahoney III, A. P. De Marco, S. D. Bajo, A. J.
Reno, J. Langer, P. Aduen, D. K. Broshek
3.318 Prospective Memory in Epilepsy:
Preliminary Findings| S. D. Bajo, A. P. De
Marco, J. J. Mahoney III, A. J. Reno, P. Aduen,
D. Broshek, N. Fountain
3.319 Hispanics Born and Raised in the U.S.
Show Poor Confrontation Naming:
Implications for Interpreting Lateralization|
K. Perrine, L. Myers, M. Lancman, M.
Lancman
3.320 Predictors of Quality of Life and Social
Functioning Among Adults with Temporal
Lobe Epilepsy| M. Fujikawa, Y. Nishio, H.
Iwaki, Y. Kitazawa, K. Kato, Y. Kakisaka, M.
Iwasaki, K. Jin, N. Nakasato
3.321 Cognitive Outcome Following
Supplemental Motor Area Resection in
Patients with Frontal Lobe Epilepsy| A.
Mullane, D. P. Floden, R. M. Busch
Pediatrics
3.322 Academic Outcome Following Epilepsy
Surgery in Children Using Reliable Change
Indices| J. Haut, L. Ferguson, T. Lineweaver, P.
Klaas, W. Bingaman, D. Lachhwani, R. M.
Busch
3.323 Consanguinity and Neurobehavioral
Problems in Children with Epilepsy, their
Siblings, and First-Degree Cousins| D.
Almane, J. Jones, Q. Zhao, P. Rathouz, D.
Jackson, D. Hsu, M. Koehn, M. Seidenberg, B.
Hermann
3.324 Adolescent Changes in Verbal Memory
and Strategic Organization in Children with
Temporal Lobe Epilepsy| T. Snyder, J.
Urlacher, D. B. Sinclair, R. Tang-Wai, M.
Wheatley, J. Pugh
3.325 Executive Function following Pediatric
Epilepsy Surgery| A. Martin, J. Facella-Ervolini,
M. Sady, W. D. Gaillard, L. Sepeta, M. Berl
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.326 ADHD and Involvement in Sports and
Activities among Children with Epilepsy.| R.
Trobliger, K. Lebeau, M. Lancman, M.
Lancman
3.327 Reorganization of Cognitive Functions
Following Right Hemispherectomy in
Adolescence: Parallel Findings in Two Cases|
K. Boyer, J. Madsen M. Libenson
3.328 The presence of epilepsy increases the
burden of occasional but not frequent
epileptiform discharges among children with
autism.| V. Lee, O. Hayward, P. Hung, T. Cao,
T. Hutman, S. A. Hussain, P. Sharifi
3.329 Treatment of electrical status
epilepticus in sleep (ESES) with pulse dose
prednisone: Language, behavioral and EEG
outcomes| A. Hempel, C. P. Brown, M. Frost
3.330 The Influence of Seizures on Language
and Adaptive Functioning in Children with
the Isodicentric Variation of Chromosome
15q Duplication Syndrome| A. Laffer, C. L.
Evans, L. M. Evans, A. Morgan, A. Prasad, R. L.
Thibert
3.331 Executive Functioning Profile of Youth
with ASD and Epilepsy without Intellectual
Disability| Y. Granader, L. Sepeta, J. FacellaErvolini, M. Berl, L. Kenworthy
geneTICS
3.332 Genome-wide association analysis of
treatment-resistant epilepsy in children| B.
Almoguera, E. Robbins, H. Hakonarson, D.
Dlugos
3.333 Reversible Retinopathy and Systemic
Manifestations in P5P Dependent Epilepsy|
R. Guerriero, A. A. Patel, F. Baumer, J. Peters,
L. Rodan, A. Shah, P. Pearl, M. Takeoka
3.334 Diagnostic yield and clinical utility of
genetic testing in a cohort of patients with
epileptic encephalopathy| B. Gonzalez
Giraldez, R. Guerrero-Lopez, L. OrtegaMoreno, V. Soto-Insuga, R. Losada, M.
Rodrigo, G. Sánchez, J. Serratosa
3.335 EPIPX gene panel for epileptic
encephalopathy| X. L. Bozarth, G. Mirzaa, H.
Mefford, J. Bennettt, F. Hisama, W. Dobyns, K.
Tsuchiya, E. Novotny
3.336 Epilepsy in Patients with Tuberous
Sclerosis Complex and No Mutations
Identified in TSC1 or TSC2| A. Vignoli, A.
Peron, F. La Briola, E. Morenghi, V. Chiesa, E.
Zambrelli, M. Canevini
3.337 KCNQ2 p.Arg198Gln, a gain-offunction variant presenting recurrently as
West syndrome without preceding neonatal
seizures| J. Millichap, F. Miceli, B. Tran, C.
Keator, N. Joshi, M. Soldovieri, E. C. Cooper,
M. Taglialatela
3.338 Progressive Myoclonus Epilepsy
caused by SACS mutations| F. A. Nascimento
e Silva, M. Muona, D. Aljaafari, M.
Tarnopolsky, A. Lehesjoki, H. Faghfoury, M.
McAndrews, B. Minassian, S. Berkovic, D.
Andrade
3.339 Identifying genetic variants underlying
sudden unexpected death in epilepsy
(SUDEP)| D. E. Crompton, R. Bagnall, S.
Petrovski, B. Regan, S. I. Garry, S. Berkovic, C.
Semsarian, I. Scheffer
3.340 A teenage girl with 18p deletion
syndrome (18pDS) and epilepsy: A Case
Report| E. Cruz, G. Kaur , Y. Krutoshinskaya,
M. Andriola, L. N. Manganas
3.341 Differential Timing of Genetic Risk in
the Spectrum of Sudden Death Disorders is
Lifestage-Dependent| C. Troskie, T. L.
Klassen
3.342 The phenotypic and genetic spectrum
of DNM1 encephalopathy| I. Helbig, D.
Shinde, R. Huether, C. Lourenço, K. L. Helbig,
S. von Spiczak, M. Pendziwiat, M. Nunes, D.
Sarco, R. Kaplan, D. Dlugos, H. Kirsch, M.
Cervenka, L. Hernandez-Hernandez, B.
Maher , S. Weckhuyse, R. S. Møller, S. Pena, S.
Sisodiya
3.343 Identification of KCNQ2 mutation in
neonates with refractory seizures| N.
Wiwattanadittakun, T. Tsuchida
3.344 Using next generation genetic
sequencing in children with treatment
resistant epilepsy| E. Segal, H. Pedro, E.
Fertig, J. Sabri, S. Iyengar, K. Valdez-Gonzalez,
S. Parisotto, F. Gliksman
3.345 De novo nonsense mutation of HDAC8
and haploinsufficiency of HDAC4 confirmed
by whole exome sequencing| J. Yu, S. Heo, E.
Nam, S. Lee, K. Han, M. Choi
3.346 Mutations of the sonic hedgehog
pathway underlie hypothalamic hamartoma
and gelastic epilepsy| M. S. Hildebrand, N. G.
Griffin, J. Damiano, E. J. Cops, R. Burgess, B.
Darbro, E. Ozturk, N. Jones, R. Leventer, J. L.
Freeman, A. S. Harvey, I. Scheffer, D.
Goldstein , J. Kerrigan, S. Berkovic, E. Heinzen
3.347 Identification Of TRPM6
Channelopathy In Intractable Epilepsy
Responsive to Magnesium
Supplementation| M. Mintz
heAlTh SeRVICeS
3.348 Safety and Outcomes For Patients
Admitted to a Level 4 Epilepsy Monitoring
Unit| C. Ledo, H. Morris, J. Croom, R. Fields
3.349 Nontraditional health providers:
Untapped opportunities in epilepsy care| E.
Tomaschek, R. Kobau, C. Begley, K. Elam, R.
Guerrero-Luera
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
83
3.350 The Effectiveness of the Psychogenic
Non-Epileptic Seizure Clinic In Reducing
Emergency Department Visits| A. Patel, J. K.
Sale, D. Terry, Z. Grinspan
3.351 The Single-Seizure Clinic Model is a
Superior Paradigm of Care: Analysis and
Evidence| S. A. Rizvi, J. Tellez-Zenteno, F.
Moien-Afshari, G. Hunter, K. Waterhouse, L.
Hernandez Ronquillo
3.352 Effectiveness of epilepsy surgery in
reducing health care costs, utilization, and
mortality| N. Schiltz, K. Kaiboriboon, S.
Koroukian, M. E. Singer, T. E. Love
3.353 Radiology utilization before and after
diagnosis of psychogenic seizures| M.
Kellogg, M. Salinsky
3.354 A Mobile Health-Intensive Care
Delivery Model for Amplifying Outreach for
Refractory Epilepsy and Co-Morbid Mood
Disorders| M. A. Rossi, N. Monica, K. Babiarz,
L. Cendejas Zaragoza, M. Caicedo, J. Endres
3.355 Identifying Areas for Quality and Safety
Improvement During Phase II Monitoring in a
Veteran Population| Y. Bukovskaya, V.
Nguyen, C. Saipetch, N. Kan, G. Minassian, S.
Dergalust
3.356 Improving the Process of Ordering
STAT Electroencephalograms in one
Hospital| S. Krish, J. Yoshi, T. Nguyen, J. D.
Slater, O. Hope
neuROPAThOlOgy OF ePIlePSy
Animal Studies
3.357 Suppression of Postischemic Seizure
by Rapamycin is Associated With
Deactivation of mTOR and ERK1/2 Signaling
Pathways| P. A. Li, P. Liu, X. Yang, C. Hei, Y.
Meli
3.358 Rapamycin has Limited Effects on
Abnormal Granule Cell Development
following Pilocarpine-Induced Status
Epilepticus| B. Hosford, M. Hester, S. Danzer
3.359 A Kcnq2 mutation facilitates firing and
GABA release of GABAergic interneurons in
the neonatal hippocampus| T. Uchida, M.
Deshimaru, Y. Yanagawa, S. Koyama, S.
Hirose
3.360 WITHDRAWN
3.361 Genetic and pharmacological targeting
of α2δ-1 prevents pathological
synaptogenesis and epileptogenic circuit
reorganization following neonatal cortical
insult| L. Andresen, D. Croker, D. Hampton,
C. Dulla
3.362 Changes in expression of
synaptosomal receptors in a mouse model
of viral-induced epilepsy| T. Hanak, A.
DePaula-Silva, D. J. Doty, J. E. Libbey, K. S.
Wilcox, R. S. Fujinami
DECEMBER 4 - 8, 2015 www.AeSnet.org
MONDAY, DECEMBER 7, 2015: POSTER SESSION 3
3.363 Infiltration of Leukocytes into the Brain
of Epileptic Kcna1-null Mice| A. Aggarwal, M.
Deodhar, K. Simeone, T. Simeone
3.364 Ventilatory arrest is the primary
initiating event that leads to sudden death
after heat-induced seizures in a Dravet
mouse model| E. Bravo, Y. Kim, G. Richerson
ePIDeMIOlOgy
3.365 Clinical Aspects of First Convulsive
Attack| D. Fujii, H. Mori, K. Shindo
3.366 Epilepsy surgery: the yield of
comprehensive work-up| J. Tomás, F. Pittau,
S. Momjian, F. Sales, A. Rossetti, C. Korff, E.
Roulet Perez, K. Schaller, S. Vulliemoz, M.
Seeck
3.367 Life Expectancy in Adult Epilepsy
Patients: A Surprising Outcome.| C.
Granbichler, G. Zimmermann, W. Oberaigner,
G. Kuchukhidze, J. Ndayisaba, A. Bathke, E.
Trinka
3.368 Disparity in mortality in people with
epilepsy by race/ethnicity, South Carolina,
2000-2013| D. A. Wilson, A. Selassie
3.369 Social Support in Caregivers of Urban
Pediatric Epilepsy| S. Shih, M. E. Ardini, A.
Bumbut, B. Kroner, W. Gaillard
3.370 Impact of exposure to neurological
specialist care on mortality in epilepsy in a
Canadian population| M. Lowerison, J.
Engbers, T. Sajobi, C. Josephson, N. Jette, S.
Wiebe
3.371 Durability of Outcomes in Mesial
Temporal Lobe Epilepsy| P. Tseng, M. Liu, M.
Quigg, U. Uysal, W. Elias, N. Fountain
3.372 Prevalence of Febrile Seizures in
Korean Children using the Big Data| J. Byeon,
G. Kim, S. Eun, B. Eun
3.373 WITHDRAWN
3.374 Predictors of quality of life among
people with epilepsy in Bhutan| A. Saadi, S.
Deki, L. Tshering, D. Nirola, B. Patenaude, S.
Clarke, E. Wolper, F. Mateen
3.375 Temporal trends of post stroke early
seizures or epilepsy during stroke
hospitalizations in United States.| V. Jani, A.
Patel, M. Kassab
PuBlIC heAlTh
3.376 A Survey on the Public Knowledge,
Attitude and Practice towards Patients with
Epilepsy (PWEs) in the city of Al Ain, UAE| T. I.
El-Azzabi, H. H. Al Hashemi, K. M. Al Zarooni,
L. S. Al Mansoori, R. Ravindran, H. Narchi
3.377 Hospitalizations for Uncontrolled
Epilepsy in US: a National Perspective| G.
Singh, V. Lingala, A. Mithal
3.378 Implication of the Current Level of
Evidence for Therapeutic In-equivalence
Between Brand and Generic Anticonvulsant|
E. N. Kitabi, V. Ivaturi, J. Gobburu, M.
Gopalakrishnan
3.379 Decreasing Unplanned Healthcare
Utilization for Pediatric Epilepsy Patients with
a Preferred Language other than English| J.
Pacheco-Phillips
3.380 Extension for Community Healthcare
Outcomes (ECHO) experience in a level 4
pediatric epilepsy center| A. Abdelmoity, M.
Gustafson
3.381 Care Coordination in Pediatric
Refractory Epilepsy - A Pilot Study| A. May, N.
Zaeemfar, Z. Grinspan
CASe STuDIeS
3.382 The effect of Vagus Nerve Stimulator
in controlling Status Epilepticus| S. Gedela,
B. Sitwat, Y. Sogawa
3.383 Clinical and electrographic spectrum
of seizures in anti-NMDA receptors
encephalitis| A. Lekoubou-Looti, E. Kutluay,
B. Pakoz, J. Chalela
3.384 Variable clinical phenotypes in patients
with mutations in genes with a known link to
epilepsy| M. La Vega-Talbott, C. GonzalezRojas, H. Feenstra, M. Kokoszka
3.385 Intractable myoclonic seizures in
allogeneic stem cell transplant recipient: a
rare case of myoclonic epilepsy| A. Robuccio,
P. Ssentongo, M. Sather, F. Claxton, F. Gilliam
3.386 Case of Encephalocraniocutaneous
lipomatosis and epileptic spasms| M.
Gustafson, E. Fecske
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
84
3.387 Case report: Atypical EEG findings in
infant with pyridoxine-dependent epilepsy|
L. E. Fried, C. Akman
3.388 Epilepsy of Intermediate Sialic Acid
Storage Disorder| R. Morse, D. Gardner, S. E.
Gaelic, J. Filiano
3.389 Febrile Infection-Related Epilepsy
Syndrome in children: our experience at
Children’s Hospital of Alabama.| A. Kumar, T.
A. Ireland, J. Ness, P. Kankirawatana
3.390 Musical hallucinations as presenting
symptom in left-temporal glioma: case report
and review of literature| P. Martinez, M.
Herrera, L. Mayor, E. Jimenez-Hakim
3.391 The long lasting focal seizures arising
from left frontal lobe evaluated by subdural
electrodes| N. Akamatsu, S. Tsuji, S. Ohara,
H. Shigeto, T. Kamada
3.392 Large displasias in patients with
Tuberous Sclerosis Complex can be
considered as biomarkers of worse
prognosis?| E. Caetano, P. B. Cerqueira , M.
G. Manreza , U. C. Reed, L. B. Sampaio, F. A.
Costa, P. S. Mendes , E. C. Miotto
3.393 Zonisamide in Women with Epilepsy:
Pharmacokinetic changes in a Singleton and
a Twin Pregnancy| P. Wong, J. Bainbridge, A.
Shrestha
3.394 Unusual Clinical Presentation of
Herpes Simplex Virus Encephalitis after
cranioplasty eight years ago| A. anand, Y.
Zhou, F. Najibi, S. Dunlap, R. Weir, A. Trouth
3.395 Two children with Shigella infection
and provoked seizures: a case presentation
and review of the literature| J. Ziobro, J.
Reese, A. Abo
DECEMBER 4 - 8, 2015 www.AeSnet.org
TUESDAY, DECEMBER 8, 2015
neurostimulation/epilepsy and engineering:
neurostimulation Mechanisms
7:00 a.m. – 8:30 a.m.
Special Interest group Meetings
Convention Center - Room 105
Ictal Semiology: looking Carefully at Seizure
Semiology to Deduce Onset and Spread of Ictal
Discharges
Coordinators: Cristopher DeGiorgio, M.D., Catherine
Schevon, M.D., Ph.D. and Steven J. Schiff, M.D., Ph.D.
Basic mechanisms of vagal nerve and deep brain stimulation;
new paradigms for stimulation to control seizures.
Convention Center - Room 108
Coordinators: Philippe Kahane, M.D, Ph.D. and Andrew
Bleasel, Ph.D., M.B.B.S., FRACP
Antiepileptic and Antidepressant Effects of VNS mediated
via Locus Coeruleus
Kristl Vonck, M.D., Ph.D.
Speakers: Andrew Bleasel, Ph.D., M.B.B.S., FRACP, Philippe
Kahane, M.D., Ph.D., Hans. O. Lüders, M.D., Ph.D. and Felix
Rosenow, M.D.
Disease modifying Effects of Long Term DBS of the
Hippocampus
Paul Boon, M.D., Ph.D.
The main idea of this session — as in previous years — is to
figure out ictal semiology based on patient's history and video
documentation of four to six typical or unusual seizures. The
coordinators and speakers will show videos of typical or
unusual seizures. After showing each video, members of the
audience will be invited to describe and analyze seizure
semiology, and to make hypotheses on the seizure onset and
spread. The faculty members will then give their opinion, and
the final explanation will be given by the presenter at the end
of each case presentation, based on intracranial EEG and/or
surgical result. The format of the session is interactive, with
the main aim to show the audience how to use subjective and
observable clinical elements to localize the seizure onset and
to reconstruct the propagation pattern of the ictal discharge.
Post-traumatic epilepsy: Biomarkers,
Prevention and novel Surgical Approaches to
the Treatment of Post-traumatic epilepsy
Convention Center - Room 103 C
Coordinators: Joe Drazkowski, M.D. and Enrique A. Feoli, M.D.
Speakers: Robert Goodman M.D. and Andrew Cole, M.D.
Traumatic brain injury (TBI) is a major cause of acquired
epilepsy accounting for 20% of symptomatic epilepsies in the
general population. The mechanisms that underlie posttraumatic epilepsy (PTE) are sundry and complicated and
consensus is lacking both in terms of cause and therapeutic
approach, this year will discuss potential biomarker of PTE, like
EEG, Brain MRI, Head CT or other modalities that might help
us predict who will develop epilepsy. We will also discuss
whether or not epilepsy could be prevented, we will go over
the animal models, looking for prevention strategies. Lastly we
will talk/discuss surgical approaches, and how to approach
these cases with usually challenging refractory epilepsy, large,
complex areas of encephalomalacia, where would the
implants go? Can that be narrowed down by current
technology, like MEG among others and are there other
surgical options besides resection?
neonatal Seizures: A Menagerie of Models —
A Tour of Animal Models of neonatal Seizures
Convention Center - Room 103 A
Coordinators: Courtney Wusthoff, M.D. and Tim Benke, M.D.,
Ph.D.
Speakers: TBA
We will divide the session into two sections:
1. Data Blast — The organizers will screen accepted
abstracts and invite the authors of 3 of the most relevant
papers to present their work and accept questions and
comments from the audience.
Practice Management Course
Convention Center - Room 104 A
2. Tour of Animal models — A panel of respected basic
science researchers will present their unique animal
models for neonatal seizures. Concepts will be reviewed at
a level appropriate for the clinician seeking to enhance
their understanding of the literature in this area. EEG
examples from specific models will then be used to
illustrate individual strengths and limitations, culminating
in a dialogue amongst the panel and with the audience.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Coordinator: Gregory Barkley, M.D.
Annual update on ICD and CPT codes plus an open forum to
discuss Electronic Health Record (EHR) issues, tips and tricks.
Participants are encouraged to submit suggestions of
problems and tips from their own practices ahead of time.
This year, in addition to the 2016 Medicare Physician Fee
Schedule and the new ICD-10-CM codes, there will be a
discussion on MACRA and Alternative Payment Models (APMs)
as well as the possible impacts on providers of epilepsy care.
Time will be given for questions and answers.
85
DECEMBER 4 - 8, 2015 www.AeSnet.org
TUESDAY, DECEMBER 8, 2015
Quality, Value and Safety in epilepsy: Improving
eeg Quality and Access to eeg Services
PROgRAM
Chair: Michael Sperling, M.D.
Convention Center - Room 104 B
When Should Genetic Testing Be Performed?
Annapurna Poduri, M.D.
Coordinator: Katherine Noe, M.D., Ph.D.
Speakers: Susan Agostini, REPT, REEGT, Janice Walbert, REEGT
and Sydney Cash, M.D.
When Should Autoantibody Testing Be Performed?
Christian Bien, M.D.
This year’s SIG will focus on current challenges impacting
quality and value of routine outpatient EEG studies. Susan
Agostini, President Elect of ASET and Clinical Neurophysiology
practice manager at Mayo Clinic Arizona, will discuss the
training and certification of EEG technologists as it pertains to
quality of care. Janice Walbert, Executive Director of ABRET, will
review the ongoing challenges of a national shortage in
qualified technologists and strategies to address this problem.
Finally we will discuss emerging technologies that may allow
improved access to EEG services. Dr. Sydney Cash, Assistant
Professor of Neurology, Harvard Medical School, will discuss a
wireless device for long-term recording that could replace
standard ambulatory units. Ample time will be available for
audience questions and discussion amongst participants
regarding their institution’s experiences and strategies for
improvement in the outpatient EEG laboratory.
Should Valproate be Prescribed to Women and Girls of
Childbearing Potential?
Torbjörn Tomson, M.D., Ph.D.
Cannabis Update
Kelly Knupp, M.D.
eDuCATIOn CReDIT
2.0 CME Credits
Nurses may claim up to 2.0 contact hours for this session.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.0 contact hours (0.20 EUs).
UAN 0077-9999-15-040-L01-P. Initial Release Date: 12/8/2015.
The American Board of Psychiatry and Neurology has
reviewed the Hot Topics Symposium: Epilepsy Updates and
has approved this program as part of a comprehensive
program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
8:45 a.m. – 10:45 a.m.
hot Topics Symposium: epilepsy updates
Convention Center - Room 201
8:45 a.m. – 10:45 a.m.
OVeRVIeW
This program will provide information to enable physicians
and other health care providers to improve diagnostic and
patient management skills. The topics include practical
approach to ordering and interpreting genetic testing for
epilepsy, a practical approach to diagnosing and treating
autoimmune epilepsy, a review of indications and use of
valproate for women with epilepsy and an update on
cannabis and cannabinoid use in epilepsy.
Scientific Symposium: Personalized Medicine
in epilepsy — A Brave new World
Convention Center - Room 204
OVeRVIeW
Tremendous advances in our understanding of the genetic
mutations that underlie different types of epilepsy have left
the epilepsy research and clinical world reeling. How to take
this knowledge to the next level so that treatments can be
identified for these patients in, some of whom exist in only
small numbers, is being wrestled with at many levels. At the
same time President Obama’s recent Precision Medicine
Initiative represents a bold new research effort to
revolutionize how we improve health and treat disease. This
symposium will address these issues, from mutation to
bedside in a precision medicine fashion.
leARnIng OBJeCTIVeS
Following participation in this symposium, learners should be able to:
·
·
·
Utilize diagnostic testing for genetic and autoimmune
disorders more effectively, to better diagnose and treat
these conditions
Prescribe valproate more effectively to improve medical
management of women with epilepsy
Discuss the latest information regarding cannabis and
epilepsy to provide better advice for patients
leARnIng OBJeCTIVeS
Following participation in this symposium, learners should be able to:
•
TARgeT AuDIenCe
Intermediate and Advanced (See page 132 for details)
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
86
Recognize identified genetic causes of epilepsy and is
familiar with the literature on emerging genetic causes of
epilepsy
DECEMBER 4 - 8, 2015 www.AeSnet.org
TUESDAY, DECEMBER 8, 2015
•
•
•
•
11:00 a.m. – 12:30 p.m. Session One
12:45 p.m. – 2:15 p.m. Session Two
Counsel families regarding prognosis and treatment using
a personalized medicine approach
Skills Workshops
Participate in counseling families regarding genetic
epilepsies
Pre-registration and tickets are required for these sessions. An
additional $50 registration fee applies for each workshop;
maximum of 30 people per session.
Assist in treating genetic epilepsies through a better
understanding of emerging personalized medicine findings
Basic eeg in epilepsy: Fundamentals and
Interpretation
Recognize the neuropsychological and developmental
impact of genetic epilepsies
Convention Center - Room 107
TARgeT AuDIenCe
Basic, Intermediate and Advanced (see page 132 for details)
moderator: Gregory D. Cascino, M.D.
The routine EEG recording remains essential in the care and
management of individuals with seizures and suspected
epilepsy. The EEG is used for diagnosis, classification of
seizure type and identification of a specific epileptic
syndrome. EEG findings may be of prognostic importance and
be used to assess the efficacy of treatment. Use of
appropriate EEG methodology and recognition of artifact and
benign variant patterns are essential for satisfactory clinical
studies. This workshop will review basic methodologies of EEG
for the evaluation and treatment of pediatric and adult
patients with seizure disorders. This will include use of
appropriate EEG techniques and fundamentals of EEG
recordings. Recognition of benign variant alterations and ictalinterictal epileptogenic discharges will be addressed. The
presentations will also discuss the importance of EEG to
identify characteristics of specific epilepsies and epileptic
syndromes.
PROgRAM
Co-Chairs: Scott Baraban, Ph.D. and Daniel Lowenstein, Ph.D.
Introduction
Daniel Lowenstein, M.D.
Defining the Target: mutation Discovery in Human
Epilepsy
Heather Mefford, M.D., Ph.D.
Precision medicine in Zebrafish: A Primer Using SCN1
mutants
Scott C. Baraban, Ph.D.
Patient-derived IPS Cells to Understand Epileptic
Encephalopathy and SUDEP
Lori Isom, Ph.D.
Application of Precision medicine in Patients with a KCNT1
mutation
Ethan Goldberg, M.D., Ph.D.
Basics of neuroimaging Acquisition and
Processing: What the Clinician needs to know
Conclusions
Daniel Lowenstein, M.D.
Convention Center - Room 103 C
moderator: R. Edward Hogan, M.D.
eDuCATIOn CReDIT
2.0 CME Credits
Basic principles of image acquisition and post-imageacquisition processing have important implications for
correlation with clinical history and EEG findings in the
diagnosis and treatment of epilepsy. The workshop will focus
on pertinent basic principles of acquisition and processing of
MRI, PET and SPECT, focusing on important factors in clinical
correlations and interpretation of test results.
Nurses may claim up to 2.0 contact hours for this session.
Nurse Practitioners may claim 2.0 hours of pharmacology for
this session.
PhARMACy CReDIT
AKH Inc., Advancing Knowledge in Healthcare approves this
knowledge-based activity for 2.0 contact hours (0.20 CEUs).
UAN 0077-9999-15-036-L01-P. Initial Release Date: 12/8/2015.
genetics Testing in epilepsy Patients
Convention Center - Room 103 B
moderators: Alica M. Goldman, M.D., Ph.D. and Annapurna
Poduri, M.D.
The American Board of Psychiatry and Neurology has
reviewed the Personalized Medicine in Epilepsy -- A Brave New
World Symposium and has approved this program as part of a
comprehensive program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Description: Novel detection platforms have accelerated
scientific discoveries of genes relevant to patients with
epilepsy of all ages. These research findings are being
87
DECEMBER 4 - 8, 2015 www.AeSnet.org
TUESDAY, DECEMBER 8, 2015
neurostimulation/VnS
adapted by clinical diagnostic laboratories in academic
institutions and commercial laboratories. Selection of patients
that would most benefit from the genetic investigations,
identification of the appropriate tests, and reporting of results
are increasingly complex. This skills workshop will review
available testing platforms and outline case scenarios driven
testing algorithms. The aim is to provide practical clinical guide
in selecting patients, testing methods, and the workflow
involved in ordering, submitting, and reporting genetic tests.
Convention Center - Room 103 A
moderator: Mohamad Koubeissi, M.D.
Neurostimulation is now an accepted treatment option for
patients with refractory epilepsy. Two devices are approved by
the FDA for patients with epilepsy: the vagus nerve stimulation
(VNS) and the responsive neurostimulator (RNS). This
workshop will discuss and instruct on how to use these
devices effectively. After the workshop, participants should be
able to identify appropriate patients, understand how
implantation is carried out and how to program the devices.
Side effects and how to practically manage them will be
discussed as well.
The workshop is designed to be an interactive, case driven
discussion and a practical guide for clinical care. Participants
are encouraged to submit questions and cases to Drs.
Goldman and Poduri. The goal is to address pressing
questions and discuss real life cases within the context of
genetic testing driven diagnostics and care.
Optimal use of neuroimaging in Diagnosing
and Treating epilepsy
Intracranial electrode Studies: how Do you
Choose a Technique for Optimum localization
Convention Center - Room 104
Convention Center - Room 105
moderators: John Stern, M.D. and David Millett, M.D., Ph.D.
moderator: Dennis Spencer, M.D.
Neuroimaging is an essential tool in the diagnosis and
treatment of epilepsy. It has opened a window on the
pathological substrate underlying epilepsy, ranging from
subtle gliotic lesions and cortical malformations to larger,
more extensive structural disturbances. This workshop will
review the techniques used to diagnose epilepsy, emphasizing
both basic MRI customized for epilepsy and advanced
neuroimaging techniques. We will review a rational approach
to the use of neuroimaging, highlight specific techniques that
enhance diagnostic ability, along with newer fMRI and other
functional imaging methods. Interpretation of scans and
various findings will be reviewed in this practical session.
Over the past thirty years, resection for medically intractable
epilepsy has become a standard treatment option. However,
in many instances successful surgery is not possible without
defining the potential respective volume by intracranial
electrophysiology. Imaging and stereotactic navigation have
made great strides since the 1990s and epilepsy centers have
many choices regarding types of electrodes, number of
contacts needed and how they are delivered. This workshop
will look at three centers with different solutions to intracranial
studies. Common problematic cases will be presented and
each of the three surgeons will provide a rationale for their
solution to a standard study.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
88
DECEMBER 4 - 8, 2015 www.AeSnet.org
LOOKING FORWARD
See you next year at the
70TH AES Annual Meeting in Houston, TX
at the George R. Brown Convention Center.
Mark your calendar for December 2 - 6, 2016.
FUTURE ANNUAL MEETING DATES
Houston, TX
December 2 - 6, 2016
George R. Brown Convention Center
Washington, DC
December 1 – 5, 2017
Washington Convention Center
New Orleans, LA
November 30 – December 4, 2018
Ernest N. Morial Convention Center
Baltimore, MD
December 6 – 10, 2019
Baltimore Convention Center
Seattle, WA
December 4 - 8, 2020
Washington State Convention Center
EXHIBITOR LOCATIONS
BOOTH/TABLE
BOOTH/TABLE
The Jack Pribaz Foundation ......................................................................334
John Libbey Eurotext ..................................................................................332
LGS Foundation ..............................................................................................22
Lifelines Neurodiagnostic Systems, Inc. ................................................ 226
LivaNova ..........................................................................................................719
Lundbeck ...................................................................................................... 711
Mallinckrodt Pharmaceuticals, Inc. ................................................315, 412
Managing Epilepsy Well Network ................................................................2
Medical Neurogenetics ..............................................................................200
Medtech Surgical ........................................................................................301
Medtronic........................................................................................................209
Microprobes for Life Science ....................................................................141
MOBĒ ..............................................................................................................309
Moberg ICU Solutions ................................................................................327
Monteris Medical, Inc. ................................................................................127
Multi Channel Systems - A Division of Harvard Bioscience ..............834
National Association of Epilepsy Centers ............................................613
National Institute of Neurological Disorders & Stroke (NINDS) ......326
Natus Neurology Incorporated ................................................................617
Neuralynx, Inc. ..............................................................................................831
Neurology Reviews ......................................................................................106
NeuroPace, Inc. ............................................................................................534
NeuroQuest LLC ..........................................................................................304
Neurotech ......................................................................................................115
Neurovirtual ..................................................................................................114
Nexstim, Inc. ..................................................................................................201
Nihon Kohden America, Inc. ....................................................................727
Oxford University Press ..............................................................................735
PCDH19 Alliance..............................................................................................20
Penn State Hershey Medical Center ......................................................102
Persyst Development Corporation..........................................................212
Pinnacle Technology, Inc.............................................................................839
PMT Corporation ..........................................................................................408
Practical Neurology ......................................................................................242
Rhythmlink International LLC ..................................................................214
Ring14 USA ......................................................................................................12
Ripple LLC ......................................................................................................739
Rogue Research Inc./Rogue Resolutions Inc. ......................................100
RSC Neuro ......................................................................................................340
Sage Therapeutics ........................................................................................300
SeizureTracker.com ........................................................................................21
Smart Monitor Corp.....................................................................................532
South Carolina Advocates For Epilepsy ....................................................13
SUDEP Aware ....................................................................................................5
Sunovion Pharmaceuticals Inc. ................................................................701
Supernus Pharmaceuticals, Inc. ..............................................................401
Taylor & Francis ............................................................................................643
Texas Children’s Hospital............................................................................434
Transgenomic Inc ........................................................................................110
Tuberous Sclerosis Alliance ............................................................................1
UCB, Inc. ..........................................................................................................601
UCBCares ......................................................................................................104
UCSF Medical Center ..................................................................................335
United Diagnostics ......................................................................................145
University of Pennsylvania IEEG.org Portal ............................................11
Upsher-Smith Laboratories, Inc. ....................................................124, 217
VA Epilepsy Centers of Excellence .............................................................. 8
Wiley ................................................................................................................235
Wolters Kluwer ..............................................................................................227
ABRET Neurodiagnostic Credentialing & Accreditation ......................17
Acorda Therapeutics....................................................................................543
Ad-Tech Medical Instrument Corp. ........................................................206
AED Pregnancy Registry..............................................................................233
Ambry Genetics ............................................................................................103
Ambu, Inc. ......................................................................................................210
American Board of Clinical Neurophysiology ........................................16
American Board of Psychiatry and Neurology ....................................213
American Clinical Neurophysiology Society ............................................18
American Epilepsy Society ........................................................................317
American Clinical Magnetoencephalography Society (ACMEGS) ......19
Angel Wings Foundation .............................................................................. 7
The Anita Kaufmann Foundation ................................................................3
ANT North America ......................................................................................116
Aprecia Pharmaceuticals Company ........................................................107
Ark Diagnostics, Inc. ....................................................................................339
ASET – The Neurodiagnostic Society ........................................................14
Athena Diagnostics, Inc. ............................................................................312
Batten Disease Support and Research Association ..........................740
BIOPAC Systems, Inc. ..................................................................................239
Blackrock NeuroMed, LLC ..........................................................................519
Brain Sentinel, Inc. ......................................................................................333
Brain Vision LLC ..........................................................................................113
Cadwell Industries, Inc. ..............................................................................513
Cambrooke Therapeutics ..........................................................................142
captureproof..................................................................................................111
Carle Physician Group ................................................................................647
Cascade Survey Research ..........................................................................245
Child Neurology Foundation ..........................................................................9
Citizens United for Research in Epilepsy (CURE) ......................................4
Compumedics ..............................................................................................427
CortiCare ........................................................................................................140
Courtagen Life Sciences, Inc. ....................................................................130
CREmedical Corp. ........................................................................................246
Demos Medical Publishing ........................................................................132
DigiTrace Care Services, Inc. ....................................................................128
Dravet Syndrome Foundation ....................................................................15
Eisai Inc. ..........................................................................................................501
Electrical Geodesics, Inc. ..........................................................................433
ELEKTA, Inc. ....................................................................................................413
ELSEVIER ........................................................................................................229
emka TECHNOLOGIES Inc. ........................................................................432
Empatica ........................................................................................................338
Epilepsy Foundation................................................................................6, 712
Epilepsy Foundation of New Jersey ........................................................742
Everyday Excellence in Epilepsy ..............................................................443
Executive Communication System ..........................................................101
The FamilieSCN2a Foundation ................................................................744
FHC ..................................................................................................................108
Fulgent Diagnostics......................................................................................205
g.tec Guger Technologies OG ..................................................................838
GeneDx ..........................................................................................................308
Global Neuro-Diagnostics, LP ..................................................................438
Glut1 Deficiency Foundation ......................................................................10
Greenwood Genetic Center ......................................................................241
GW Pharmaceuticals ..................................................................................827
Ideal Health Careers, Inc.............................................................................344
INSYS Therapeutics ......................................................................................138
Integra ............................................................................................................112
Invitae ..............................................................................................................134
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
90
DECEMBER 4 - 8, 2015 www.AeSnet.org
GES Service
Center
EXHIBITOR FLOOR PLAN
245 344
143 244
243 342
141 242
241 340
F&B
132
239 338
339 438
235 334
335 434
433 534
18
233 332
333 432
532
19
15 14
127 226
21
326
327
427
227
124
119
217
739 838
10
735 834
For more information,
see page 92
8
7
6
2
3
4
727
827
5
617
317
831
9
22
519
AES
839
13 12
11
1
Cyber
Café
F&B
Epilepsy
Resource
Center
20
229
744
742
740
17
130
128
Poster Boards
643
16
F&B
Pavilion E
645
543
Everyday
Excellence 443
140
138
134
Pavilion
D
Office 3
145 246
Pavilion C
719
114
115 214
112
113 212
413
213 312
513
613 712
315
Exhibitor Offices
116
711
412
110
111 210
209 308
108
309
406
107 206
106
104
100
401
205 304
103
200
101
201 300
501
Office 2
Pavilion B
Office 1
142
Pavilion A
Campfire
Discussion
Exhibitor
Lounge
Exhibit
Manager’s
Office
601
701
301
Poster Information Table
HALL A
Entrance
To Registration
exhibit hall hours
Saturday, December 5
Noon - 6:00 p.m.
Poster Session Entrance when exhibits are closed
Sunday, December 6
10:00 a.m. - 4:00 p.m.
Monday, December 7
10:00 a.m. - 2:00 p.m.
To ensure safety and security, no children under 12 years of age, strollers, carriages, wheeled luggage or wheeled briefcases are allowed in the
Exhibit Hall during exhibit hours.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
91
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
Acorda Therapeutics
Booth #543
Ms. Brenda Weaver
420 Saw Mill River Rd
Ardsley NY 10502
Phone: 914-326-5843
Fax: 914-606-9608
Email: bweaver@acorda.com
www.acorda.com
Acorda Therapeutics develops therapies that
restore function and improve the lives of people
with neurological disorders. Acorda markets three
FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg,
and has one of the leading neurology pipelines in
the industry that addresses disorders including
epilepsy, post-stroke walking deficits, Parkinson’s
disease and MS.
Ad-Tech Medical Instrument Corp.
Booth #206
Ms. Angie Bouwma
1901 William St
Racine WI 53404
Phone: 262-634-1555
Fax: 262-634-5668
Email: abouwma@adtechmedical.com
www.adtechmedical.com
For over 25 years, Epilepsy Centers have made
Ad-Tech their choice for invasive electrodes for
brain mapping and epilepsy monitoring. We offer
a large variety of electrodes and accessories to
meet you and your patients needs. Visit our booth
to discover why Ad-Tech is your best choice.
software solutions to offer the most
comprehensive genetics services in the industry.
The North American AED Pregnancy Registry is
dedicated to determine the safety of
anticonvulsant medications that can be taken by
women during pregnancy. The primary goal is to
determine the frequency of major malformations
in the infants exposed during pregnancy to
anticonvulsant drugs. Please visit our booth to
learn more about our findings, and to obtain
materials for use in your office.
Ambry genetics
Booth #103
Ms. Colleen Garcia
15 Argonaut
Aliso Viejo CA 92656
Phone: 949-900-5500
Fax: 949-900-5501
Email: cgarcia@ambrygen.com
www.ambrygenetics.com
Ambry Genetics is College of American
Pathologists (CAP)-accredited and Clinical
Laboratory Improvement Amendments (CLIA)certified. Together with its subsidiary Progeny
Genetics, Ambry leads in clinical diagnostics and
Ambu, Inc.
Booth #210
Mr. Brett Alpaugh
6740 Baymeadow Dr
Glen Burnie MD 21060
Phone: 410-768-6464
Fax: 800-262-8673
Email: balp@ambu.com
www.ambuusa.com
Ambu manufactures and sells quality electrodes
that optimize workflow, reduce costs and
improve patient care. Ambu offers innovative
products such as our Neuroline 100% disposable
cups. We also specialize in a full line of needles
and electrodes for IOM, EMG, NCS, EP, Sleep and
EEG studies.
American Board of Clinical neurophysiology
Table #16
Janice Walbert
2908 Greenbriar Dr. - Ste A
Springfield IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abcn@att.net
abcn.org
The ABCN promotes excellence in Clinical
Neurophysiology by offering subspecialty
examinations with added competency in Epilepsy
Monitoring, Critical Care EEG Monitoring and
Intraoperative Monitoring for physicians.
International testing available. Stop by the booth
to learn about eligibility changes for 2016!
Visit the epilepsy Resource Center
A special feature of the AES
Exhibit Hall is the Epilepsy
Resource Center (ERC).
Network with non-profit
organizations doing
important work in advocacy,
patient outreach, patient
services and research
funding.
Many Epilepsy Resource
Center exhibitors will be
offering mini-workshops and
presentations: a daily
schedule will be posted near
the entrance.
744
742
741
740
Entrance
16
15 14
13 12
17
11
18
10
19
9
20
Entrance
ABRET® is the national credentialing board for
Neurodiagnostic Technologists, offering REEGT,
REPT, Intraoperative Monitoring (CNIM), Long
Term Monitoring (CLTM) and Certification for
Autonomic Testing Professionals (CAP)
credentials. ABRET also oversees three
laboratory accreditation programs, LAB-EEG,
LAB-NIOM, and LAB-LTM for Epilepsy/Critical
Care EEG Monitoring Programs.
AeD Pregnancy Registry
Booth #233
Dr. Lewis Holmes, M.D.
121 Innerbelt Rd - Ste 220
Massachusetts General Hospital
Somerville MA 02143
Phone: 888-233-2334
Fax: 617-726-1911
Email: holmes.lewis@mgh.harvard.edu
www.aedpregnancyregistry.org
Entrance
ABReT neurodiagnostic Credentialing &
Accreditation
Table #17
Janice Walbert
2908 Greenbriar Dr. - Ste A
Springfield IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abreteo@att.net
abret.org
8
Presentation
Area
21
7
22
6
1
2
3
4
5
Entrance
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
92
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
American Board of Psychiatry and
neurology
Booth #213
Ms. Karen Back
2150 E Lake Cook Rd - #900
Buffalo Grove IL 60089
Phone: 847-229-6500
Fax: 847-229-6600
Email: kback@abpn.com
www.abpn.com
The American Board of Psychiatry and Neurology
serves the public interest and the professions of
psychiatry and neurology by promoting
excellence in practice through its certification and
maintenance of certification processes. ABPN
also oversees the certification process for
physicians seeking certification in child and
adolescent psychiatry.
American Clinical neurophysiology Society
Table #18
Ms. Megan Hille
555 E. Wells St - Ste 1100
Milwaukee WI 53202
Phone: 414-918-9803
Fax: 414-276-3349
Email: info@acns.org
www.acns.org
The American Clinical Neurophysiology Society
(ACNS) is a professional association dedicated to
fostering excellence in clinical neurophysiology
and furthering the understanding of central and
peripheral nervous system function through
education, research, and the provision of a forum
for discussion and interaction. Register now for
the ACNS Annual Meeting & Courses - Feb. 1014, 2016 in Orlando!
American epilepsy Society
Booth #317
Keri Kramer
135 S. LaSalle St - Ste 2850
Chicago IL 60603
Phone: 312-883-3800
Fax: 312-896-5784
Email: membership@AESnet.org
www.AESnet.org
The American Epilepsy Society is dedicated to
eradicating epilepsy and its consequences. For
more than 75 years, AES has provided a forum
where professionals from academia, private
practice, not-for-profit, government and industry
can learn, share and grow. Visit the AES booth to
learn more, get help with the Annual Meeting
app, or purchase an official AES tie or scarf.
American Clinic Magnetoencephalography
Society (ACMegS)
Table #19
Ms. Megan Hille
555 E. Wells St - Ste 1100
Milwaukee WI 53202
Phone: 414-918-9804
Email: info@acmegs.org
www.acmegs.org
The American Clinical MEG Society is a 501(c)6
trade association whose membership includes
clinical MEG facilities in the United States.
Founded in 2006 by physicians committed to
high quality care of patients with epilepsy,
ACMEGS advocates for individuals who would
benefit from MEG by educating policymakers and
regulators about current and recommended
standards of care.
ANT Neuro specializes in providing high
performance EEG systems and accessories for
use in neuroscience and neurodiagnostics. ANT's
eego line of EEG products was developed to
allow collection of high density EEG data in
unconventional environments, and ANT's
waveguard EEG caps lead the industry in
comfort, reliability, and usability.
Aprecia Pharmaceuticals Company
Booth #107
Jennifer Zieverink
10901 Kenwood Rd
Blue Ash OH 45242
Phone: 513-864-4114
Email: Jennifer.Zieverink@aprecia.com
www.aprecia.com
Angel Wings Foundation
Table #7
Ms. Debbie Flader
2134 Baldwin Court
Hanover Park IL 60133
Phone: 630-550-1049
Email: dflader@angelwingsfoundation.net
www.angelwingsfoundation.net
Aprecia is committed to enhancing customers'
experience with highly prescribed high-dose
medications. We are the first and only
pharmaceutical company using threedimensional printing (3DP) to manufacture
FDA-approved medicines. Our first 3DP
innovation is ZipDose® Technology, a
formulation platform designed to make
medicines easy for caregivers to administer and
patients to take.
The Anita kaufmann Foundation
Table #3
Ms. Debra Josephs
PO Box 11 New Milford NJ 07646
Phone: 201-655-0420
Fax: 866-303-3219
Email: debra@akfus.org
www.akfus.org
ARK Diagnostics Inc. designs, manufactures, and
distributes in vitro diagnostic products. ARK’s
proprietary Therapeutic Drug Monitoring (TDM)
assays measure drug levels accurately in
biological fluids. Clinicians use these
measurements to guide dosing decisions for
safe, effective, and personalized drug therapy.
ARK’s TDM assays are unique assays for 2nd and
3rd generation anti-epileptic drugs.
AnT north America
Booth #116
K.C Chelette
437 S Yellowstone Dr - Ste 216
Madison WI 53719
Phone: 608-204-0878
Fax: 608-204-0874
Email: kchelette@ant-neuro.com
www.ant-neuro.com
ASET – The Neurodiagnostic Society represents
nearly 5,000 allied health professionals who
perform neurodiagnostic procedures. ASET
provides education and advocacy, creates
greater awareness of the profession, and
establishes standards and best practices to
ensure quality patient care. Stop by the ASET
booth to see our newest publications and
educational offerings.
Angel Wings Foundation is dedicated to
enhancing the lives of adults with epilepsy,
allowing them to reach their full potential
through independent living in the community.
Angel Wings will create home where adults with
epilepsy can lead person-centered lives, with
supports in place. Angel Wings will offer
recreational, vocational and educational
opportunities for adults with epilepsy.
AKF is a 501©3 charity with a grassroots mission
to educate the public not to fear people with
epilepsy, seizures or brain trauma. We offer our
5th Grade Education Program, our Heads Up For
Vets Program & free awareness materials for
public use. As the global sponsor for Purple
Day® - World Epilepsy Day™, we & our
Advocates organize awareness events around
the globe.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
93
Ark Diagnostics, Inc.
Booth #339
Mr. Ryan Olandria
48089 Fremont Blvd
Fremont CA 94538
Phone: 510-270-6282
Fax: 510-270-6298
Email: ryan@ark-tdm.com
www.ark-tdm.com
ASeT – The neurodiagnostic Society
Table #14
Ms. Sarah Ecker
402 E Bannister Rd - Ste A
Kansas City MO 64131-3019
Phone: 816-931-1120
Fax: 816-931-1145
Email: sarah@aset.org
www.aset.org
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
Athena Diagnostics, Inc.
Booth #312
Ms. Shari Williams
200 Forest St - 2nd Fl
Marlborough MA 01752
Phone: 508-756-2886
Fax: 508-753-5601
Email: shari@mma-inc.com
www.athenadiagnostics.com
Brain Sentinel, Inc.
Booth #333
Mr. Jeffrey Jung
8023 Vantage Dr - Ste 216
San Antonio TX 78230
Phone: 855-275-5424
Fax: 855-275-5424
Email: jeff.jung@brainsentinel.com
www.brainsentinel.com
Batten Disease Support and Research
Association
Table #740
Noreen Murphy
1175 Dublin Rd
Columbus OH 43215
Phone: 614-768-1159
Email: nmurphy@bdsra.org
www.bdsra.org
Brain Vision llC
Booth #113
Mr. Florian Strelzyk
2500 Gateway Centre Blvd
Morrisville NC 27560
Phone: 919-460-2510
Fax: 214-224-0829
Email: travel@brainvision.com
www.brainvision.com
Athena Diagnostics combines cutting-edge
diagnostic technologies, fast turn-around, and
Athena Insight™ to offer a uniquely powerful
diagnostic toolset that can make a difference in
the care of your patients.
BDSRA is dedicated to funding research for
treatments and cures, providing family support
services, advancing education, raising awareness,
and advocating for legislative action. Founded by
parents seeking to build a network around
Batten disease, BDSRA is now the largest support
and research organization dedicated to Batten
disease in North America.
BIOPAC Systems, Inc.
Booth #239
Mr. Brenton Pyle
42 Aero Camino
Goleta CA 93117
Phone: 805-685-0066
Fax: 805-685-0067
Email: brentonp@biopac.com
www.biopac.com
Human and animal wireless EEG systems with
AcqKnowledge analysis automation & scoring:
small animal seizure detection, EPOCH 2-ch longterm wireless EEG/neural signals, B-Alert X10
wireless EEG & Cognitive State Metrics, Mobita
32-ch wireless EEG system with water electrodes,
BioNomadix Wireless Physiology amplifiers,
Stellar telemetry interface for multiple animals,
Developer Scripting, and more!
Blackrock neuroMed, llC
Booth #519
Ms. Shanna Ryan
630 Komas Dr - Ste 200
Salt Lake City UT 84108
Phone: 801-994-5661
Fax: 877-623-6027
Email: sryan@blackrockneuromed.com
www.blackrockneuromed.com
Blackrock NeuroMed offers the Cervello® Family
of EEG systems, ranging from a basic routine EEG
video system to a powerful, high-end LTM system
(up to 256 channels) with high sampling rates. For
more information: www.blackrockneuromed.com.
Brain Sentinel, Inc. is a privately held medical
device start-up based in San Antonio, Texas,
preparing to launch a new Generalized TonicClonic (GTC) Seizure Detection and Warning
System.
Brain Vision LLC offers market-leading hardware
and software for EEG/ERP/BCI, and fNIRS. We
integrate EEG and fNIRS with fMRI, TMS,
tDCS/HDtDCS, MEG, and eye-tracking. Our
solutions are offered for research on infants and
adults that include wired and wireless systems
with passive, active, or dry electrodes.
Cadwell Industries, Inc.
Booth #513
Ms. Lori Kaufman
909 N Kellogg St
Kennewick WA 99336
Phone: 509-735-6481
Fax: 509-783-6503
Email: lorik@cadwell.com
www.cadwell.com
Cadwell proudly introduces the second member
in our new ARC EEG product family, the Essentia.
Available in 3 variations to solve whatever EEG
needs you have, whether routine EEG, long term
monitoring EEG or continuous EEG in the ICU, we
have the right solution. See the new Essentia and
the Arc Alterna ambulatory EEG with USB Photic
system, both available with Q-Video Mobile in our
booth.
Cambrooke Therapeutics
Booth #142
Ms. Susan Gingrich, RD
4 Copeland Drive Ayer MA 01432
Email: sgingrich@cambrooke.com
www.cambrooketherapeutics.com
Cambrooke Therapeutics is a leader and global
innovator in the field of advanced medical
nutrition. We are passionate in our pursuit of
improving the lives of patients by bringing new
therapeutic options to those with therapeutic
and chronic medical needs.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
94
captureproof
Booth #111
Ms. Beth Boyer
650 Townsend - Ste 317
San Francisco CA 94103
Phone: 917-435-9200
Email: beth@captureproof.com
www.captureproof.com
Never organize PHOTOS or VIDEOS again.
captureproof is the leading PHOTO and VIDEO
management/communication platform for the
healthcare industry. Our HIPAA-compliant
platform helps create better doctors by allowing
them to simply, quickly and securely do what
matters most: monitor progress, compare data
in historical context, and decide on an optimal
approach.
Carle Physician group
Booth #647
Katie Schroeder
611 West Park Street Urbana IL 61801
Phone: 217-326-2572
Fax: 217-326-1214
Email: katie.schroeder@carle.com
www.carle.org
Carle is the leading healthcare system in east
central Illinois serving a patient base of more
than 1.5 million. Carle Physician Group, the
outpatient practice serving nearly 170,000
unique patients annually, is comprised of more
than 400 physicians dedicated to providing
patient-focused care in 80 specialties located in
14 communities across central Illinois.
Cascade Survey Research
Booth #245
D. James Hindle III
PO Box 122 Virginia City NV 89440
Phone: 775-847-0796
Email: sales@cascade-research.com
www.cascade-research.com
Cascade Survey Research conducts fast and easy
SurveyStation Touchscreen Computer based
Market Research Intercept Surveys at
Professional Meetings and Events. We collect the
valid and accurate data required for the effective
development of marketing, sales, and new
product development strategies in your dynamic
markets.
Child neurology Foundation
Table #9
Ms. Stacia Grace
201 Chicago Ave # 200
Minneapolis MN 55415
Phone: 612-928-6326
Fax: 612-454-2744
Email: sgrace@childneurologyfoundation.org
www.childneurologyfoundation.org
Child Neurology Foundation’s mission is to
improve the lives of children with neurologic
disorders by strengthening connections between
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
patients and their families, physicians, other
healthcare professionals, and advocacy and
industry partners, creating a community of
support so that each child may reach her full
potential. Stop by table 9 to support Infantile
Spasms Awareness Week, December 1-7.
Citizens united for Research in epilepsy
(CuRe)
Table #4
Ms Elizabeth Higgins
430 W Erie St - Ste 210
Chicago IL 60654
Phone: 312-255-1801
Email: info@CUREepilepsy.org
www.cureepilepsy.org/
CURE's mission is to cure epilepsy, transforming
and saving millions of lives. We identify and fund
cutting-edge research, challenging scientists
worldwide to collaborate and innovate in pursuit
of this goal. As the leading private funder of
epilepsy research, CURE offers 2 grant cycles per
year. Please come visit us to learn more about
what we do and the funding opportunities we
offer.
Compumedics
Booth #427
Mr. Joseph Polantz
6605 W WT Harris Blvd - Ste F
Charlotte NC 28269
Phone: 704-749-3200
Fax: 704-749-3299
Email: jpolantz@compumedicsusa.com
www.compumedics.com.au
Compumedics Neuroscan is a world-leader of
complete systems for neurophysiology,
neuroimaging, and neurodiagnostics.
Compumedics Neuroscan systems provide
solutions for scientists and clinicians interested in
recording EEG from 32-512 channels, with
integrated signal processing to evaluate and
identify the cortical origins of this activity, all
powered by the Curry 7 NeuroImaging software.
CortiCare Booth #140
Mr. Tim Innes
6120 Paseo Del Norte Carlsbad CA 92011
Phone: 760-500-8055
Email: info@corticare.com
www.corticare.com
CortiCare provides continuous EEG Services
using a robust infrastructure of monitoring
personnel and reading neurophysiologists. The
first nationwide network of on-call registered
electroencephalographic technologists (R.EEG.T
and CLTM) and neurophysiologists available 24/7
and 365 days a year. Our clinical team provides
immediate notification of patient events so
physicians can interpret neurocritical care data in
real-time.
Courtagen life Sciences, Inc.
Booth #130
Mr. Daniel Kimball
12 Gill St - Ste 3700
Woburn MA 01801
Phone: 410-299-6479
Fax: 617-892-7191
Email: daniel.kimball@courtagen.com
www.courtagen.com
Courtagen Life Sciences, Inc. offers diagnostic
testing on blood or saliva for neurological
conditions such as epilepsy. Courtagen also
handles insurance pre-authorization and limits
out-of-pocket expenses for families to $100 or
less. Test ordering is available through our secure
online portal and results are available in a
number of weeks.
CRemedical Corp.
Booth #246
Rachel Bartels
110 Bean Farm Dr
Kingston RI 02881
Phone: 401-782-7997
Email: rachel@cremedical.com
www.cremedical.com
At CREmedical, we invent new technologies that
help us understand the brain, and diagnose &
treat brain disorders. We are the pioneer of
tripolar concentric ring electrodes (TCRE), which
offer significant improvement over existing
electrode configurations in applications like
TCRE-based electroencephalography (tEEG) and
TCRE-based transcranial focal electrical
stimulation (TFS) for neuromodulation.
Demos Medical Publishing
Booth #132
Ramon Simmons
11 W 42nd St
New York NY 10036
Phone: 212-804-6316
Email: RFAMANILA@SPRINGERPUB.COM
www.demosmedical.com
For more than 25 years, Demos Medical
Publishing has served the information needs of
medical professionals. Visit us in Booth #132 to
see our latest print and digital titles in epilepsy.
DigiTrace Care Services, Inc.
Booth #128
Mr. Dan Martin
200 Corporate Pl - Ste 5
Peabody MA 01960
Phone: 978-536-7400
Fax: 978-535-9778
Email: dmartin@sleepmedinc.com
www.sleepmed.md
Dravet Syndrome Foundation
Table #15
Mary Anne Meskis
PO Box 16536
West Haven CT 06516
Phone: 203-392-1950
Email: info@dravetfoundation.org
www.dravetfoundation.org
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
95
The mission of Dravet Syndrome Foundation
(DSF) is to aggressively raise research funds for
Dravet syndrome and related epilepsies; to
increase awareness of these catastrophic
conditions; and to provide support to affected
individuals and families.
eisai Inc.
Booth #501
Ms. Shirley Hunt
100 Tice Blvd
Woodcliff Lake NJ 07677
Phone: 201-692-1100
Fax: 201-692-1804
Email: shirley_hunt@eisai.com
www.eisai.com
As the U.S. pharmaceutical subsidiary of Tokyobased Eisai Co., Ltd., we are a fully integrated
pharmaceutical business with discovery, clinical,
manufacturing and marketing capabilities. Our
key areas of commercial focus include oncology
and specialty care (Alzheimer’s disease, epilepsy
and metabolic disorders). To learn more about
Eisai Inc., please visit us at www.eisai.com/US.
electrical geodesics, Inc.
Booth #433
Ms. Dee Dee Nunes
500 E 4th Ave - Ste 200
Eugene OR 97401
Phone: 541-687-7962
Fax: 541-687-7963
Email: dnunes@egi.com
www.egi.com
EGI offers a broad range of neuromonitoring
systems for advanced clinical and research use.
EEG systems feature the Geodesic Sensor Net
for unprecedented patient comfort, with 32
channels for routine EEG, or 64, 128, or 256
channels for source estimation and applications
requiring high spatial resolution. EGI also offers
products for 10-20 montage EEG, ambulatory
EEG, LTM, NICU, EMG/NCV, and EP.
elekta, Inc.
Booth #413
Ms. Doris AuBuchon
400 Perimeter Center Terrace - Ste 50
Atlanta GA 30346
Phone: 770-670-2409
Fax: 770-448-6338
Email: doris.aubuchon@elekta.com
www.elekta.com
Elekta is a human care company pioneering
significant innovations and clinical solutions for
brain disorders. Our magnetoencephalography
system, Elekta Neuromag® TRIUX moves beyond
conventional imaging and clinical
neurophysiology tools to provide clinicians and
researchers with precise millisecond resolution
and accurate localization to open a revolutionary
new window on human brain activity.
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
elSeVIeR
Booth #229
Ms. Diane Stanton
1600 John F. Kennedy Blvd - Ste 1800
Philadelphia PA 19103
Phone: 215-239-3900
Fax: 215-239-3642
Email: d.stanton@elsevier.com
www.elsevierclinicalsolutions.com
ELSEVIER is a leading publisher of health science
publications, providing superior reference
information, decision support tools to doctors,
nurses, health practitioners and students. Our
media spectrum — print, online and handheld,
provides information in the most convenient
format.
emka TeChnOlOgIeS Inc.
Booth #432
Ms. Virginie Brechet
307 Annandale Rd - Ste 203
Falls Church VA 22042
Phone: 703-237-9001
Fax: 703-237-9006
Email: emkatech@emkatech.com
www.emkatech.com
Check-out our latest Tether-less monitoring
solutions for rodents, featuring: rodentPACKv2
head-mounted, tetherless radio-telemetry device
for recording EEG, EMG, ECG, temp, and/or
activity from up to 32 subjects 5 meter
transmission range 150 hours of recording
EPITEL wireless EEG recording for Mice! 2 EEG
per mouse options for 2 or 6 months continuous
recording data acquisition and analysis software
empatica
Booth #338
Mr. Daniel Bender
488 Main St Medford MA 02155
Phone: 617-999-3380
Email: db@empatica.com
www.empatica.com
epilepsy Foundation
Table #6, Booth #712
Ms. Temi Aregbesola
8301 Professional Pl
Ardmore MD 20785
Phone: 301-918-3739
Email: taregbesola@efa.org
www.epilepsy.com
The Epilepsy Foundation, a national non-profit
with more than 47 affiliated organizations
throughout the United States, has led the fight
against seizures since 1968. The Foundation is
an unwavering ally for individuals and families
impacted by epilepsy and seizures. The
Foundation works to ensure that people with
seizures have the opportunity to live their lives to
their fullest potential.
epilepsy Foundation of new Jersey
Table #742
Ms. Jenna Andolora
35 Beaverson Blvd Bldg 11
Brick NJ 08723
Phone: 800-336-5843 x218
Fax: 732-262-4373
Email: jandolora@efnj.com
www.efnj.com
EFNJ is dedicated to helping improve the quality
of life for people affected by epilepsy. We will
ensure that people with seizures are able to
participate in all life experiences. We provide
services, education, advocacy & research; as well
as comprehensive support, personalized services
& advocacy for individuals & their families in
order to maximize their participation in society.
everyday excellence in epilepsy
Booth #443
Ms. Keri Kramer
American Epilepsy Society
135 S LaSalle St - Ste 2850
Chicago IL 60603
Phone: 312-883-3800
Email: kkramer@aesnet.org
www.aesnet.org
Every day your efforts advance clinical care and
research, improving the lives of those living with
epilepsy. Come to Booth #443 and share your
story — both daily work and meaningful career
moments — with AES. A professional interviewer
will be on hand to assist. Select member stories
will be shared in upcoming AES communications.
Supported by Sunovion Pharmaceuticals Inc.
executive Communication Systems
Booth #101
Ms. Carol Sabory
1445 Donlon St - Ste 1
Ventura CA 93003
Phone: 800-644-9525
Fax: 888-644-6979
Email: sales@tvps.com
www.tvps.com
Dragon Medical Practice Edition 2 Speech
Recognition, Dictation/Transcription equipment
and accessories. Digital Portable Recorders, PC
Hand Held Microphones, Telephone Dictation
Systems, Foot pedals, Headsets, Accessories, etc.
available at www.TVPS.com. Network Dictation
Systems available at www.WinScribeUSA.com.
Contact us at sales@tvps.com, or (800) 6449525, ext. 101 for more details.
The FamilieSCn2a Foundation
Tables #744
Carla Forbes
P.O. Box 75
Granby MA 01033
Phone: 413-330-3116
Email: carla.forbes@scn2a.or
www.scn2a.og
The FamilieSCN2a Foundation is an organization
created by parents of children diagnosed with a
mutation of the SCN2a gene, many of whom
have epilepsy. We are working to coordinate and
collaborate with researchers around the world to
to find a cure.
FhC
Booth #108
Ms. Sarah Favreau
1201 Main St
Bowdoin ME 04287
Phone: 207-666-8190
Fax: 207-666-8292
Email: sfavreau@fh-co.com
www.fh-co.com
Planning System, watch our Distance Expert®–
Neurophysiology software, WayPoint™
Stereotactic System, and microTargeting™
Multioblique Platform in action, and learn why
surgeons rely on our systems for positioning
Monteris and Visualase Ablation technologies.
Fulgent Diagnostics
Booth #205
Mr. Jakub Sram
4978 Santa Anita Ave
Temple City CA 91780
Phone: 626-350-0537
Fax: 626-454-1667
Email: jakubsram@gmail.com
www.fulgentdiagnostics.com
Fulgent Diagnostics, a CLIA certified high
complexity molecular diagnostics lab, offers
4,600+ single gene tests, and 170+ preset
(Epilepsy) panels, including a Clinical and Whole
Exome sequencing and deletion/duplication. In
addition, Fulgent enables customers to easily
order custom NGS panels. Most importantly,
Fulgent provides flexibility, high quality testing,
and affordable pricing.
g.tec guger Technologies Og
Booth #838
Mrs. Michaela Pichler
Sierningstrasse 14
Schiedlberg 4521 Austria
Phone: + 43 7251 22240-0
Email: office@gtec.at
www.gtec.at/
g.tec produces hard- and software for biosignal
processing since more than 15 years. The
products are used for research and clinical
applications like neurorehabilitation (stroke
patients) and assessment of coma patients. The
new cortiQ system was developed for rapid
functional mapping of the cortex using the ECoG.
It can be used to identify functional brain regions
in real-time.
geneDx
Booth #308
Ms. Marianne Sansing
481 Edward H Ross Dr
Elmwood Park NJ 07407
Phone: 301-519-2100
Fax: 301-519-2892
Email: msansing@bioreference.com
www.genedx.com
global neuro-Diagnostics, lP
Booth #438
Mr Nolan Shock
1278 Justin Rd
Lewisville TX 75077
Phone: 214-532-3757
Fax: 877-290-1544
Email: janice.shock@globalneuro.com
www.globalneuro.net
Come try forty-plus year innovative neuroscience
partner FHC’s latest WayPoint™ Navigator DBS
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
96
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
glut1 Deficiency Foundation
Table #10
Glenna Steele
PO Box 943
Westfield IN 46074
Phone: 859-585-2538
Email: gsteele@g1dfoundation.org
www.g1dfoundation.org
The Glut1 Deficiency Foundation is a volunteer,
non-profit family organization dedicated to
increasing awareness of and advocacy for Glut1
Deficiency, educating others, and supporting and
funding researchers as they work for better
treatments and an ultimate cure.
greenwood genetic Center
Booth #241
Kellie Walden
106 Gregor Mendel Circle Greenwood SC 29646
Phone: 864-941-8110
Email: kwalden@ggc.org
www.ggc.org
The Greenwood Genetic Center is a nonprofit
institute organized to provide clinical genetic
services, diagnostic laboratory testing, educational
resources, and research in the field of medical
genetics. Our laboratory offers biochemical,
cytogenetic, and molecular diagnostic testing. We
strive to ‘Give Greater Care’ by combining state-ofthe-art diagnostics with exceptional service.
gW Pharmaceuticals
Booth #827
Dr. Kelly Simontacchi
5800 Armada Dr - Ste 210 Carlsbad CA 92008
Phone: 760-795-2200
Email: ksimontacchi@gwpharm.com
www.gwpharm.com
With more than 17 years of cannabinoid
research experience, GW is a world leader in
development of novel cannabinoid prescription
medicines for people living with severe diseases.
Our portfolio includes Epidiolex® (cannabidiol)
currently in Phase III trials for Dravet and LennoxGastaut Syndromes as well as a pipeline of other
cannabinoid candidates. For more information,
please visit gwpharm.com.
Ideal health Careers, Inc.
Booth #344
Mr. David Cruz
3455 Peachtree Rd NE - Ste 500 Atlanta GA 30326
Phone: 404-816-9988
Email: dcruz@idealhealthcareers.com
www.idealhealthcareers.com
Executive search firm focused on clinical
neurophysiology and neuromodulation, with a
success rate of 96%. Due to our industry focus
and ability to deliver talent with a sense of
urgency, clients view us as strategic partners
rather than "vendors." Clinicians and business
professionals seeking opportunities in the neuro
space are welcome to contact us at anytime.
InSyS Therapeutics
Booth #138
Ms. Anna Marzahl
1333 S Spectrum #100
Chandler AZ 85286
Phone: 602-910-2617
Fax: 602-910-2627
Email: amarzahl@insysrx.com
www.insysrx.com
Insys Therapeutics is a specialty pharmaceutical
company that develops and commercializes
innovative drugs and novel drug delivery systems
of therapeutic molecules, including its
proprietary sublingual spray technology, to help
improve patient quality of life. Focused on
pharmaceutical cannabinoids development, the
company is evaluating its pharmaceutical
cannabidiol (CBD) for epilepsy treatment.
Integra
Booth #112
Ms. Kristen Fahrman
311 Enterprise Dr
Plainsboro NJ 08536
Phone: 609-275-0500
Fax: 609-799-3297
Email: kristen.fahrman@integralife.com
www.integralife.com
Integra is a leader in neurosurgery, offering a vast
portfolio of implants, devices, instruments and
systems used in neurosurgery, neuromonitoring,
neurotrauma, and critical care.
Invitae
Booth #134
Ms. Jamie Raymond
458 Brannan St
San Francisco CA 94107
Phone: 415-374-7782
Email: jamie.raymond@invitae.com
www.invitae.com
Invitae, a genetic information company, is
aggregating the world’s genetic tests into a single
service with better quality, faster turnaround time
and a lower price than most single-gene
diagnostic tests today. Please visit
www.invitae.com.
The Jack Pribaz Foundation
Booth #334
Ms. Angela Cherry
PO Box 813
Wheaton IL 60187
Phone: 630-485-9986
Email: angelacherry86@gmail.com
KCNQ2.org
The Jack Pribaz Foundation is a 501(c)(3) charity
established in Illinois in 2011. Named for a boy
diagnosed with one of the first known cases of
KCNQ2 epileptic encephalopathy in North
America, its mission is to support research for
this condition by raising funds and awareness.
We believe that increasing understanding of this
uncommon pediatric epilepsy aids other epilepsy
research and accelerates progress toward a cure.
Visit www.kcnq2.org and www.jacksarmy.org.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
97
John libbey eurotext
Booth #332
Mr. Cahn Gilles
127 Avenue de la Republique
92120 Montrouge
France
Phone: (+33)146730679
Fax: (+33)140840999
Email: gilles.cahn@jle.com
www.jle.com
For decades, John Libbey Eurotext is The
Publisher of both world-renowned specialists
and new authors in Epilepsy. Through Epileptic
Disorders now became the Educational Journal
of the ILAE and moreover through our huge
book series, we are devoted to provide first class
knowledge in the field of Epilepsy. Visit
www.epilepticdisorders.com, The Real Forum for
The Worldwide Epilepsy Community.
lgS Foundation
Table #22
Christina SanInocencio
192 Lexington Ave - Ste 212
New York NY 10016
Phone: 718-374-3800
Email: christina@lgsfoundation.org
www.lgsfoundation.org
The LGS foundation is a nonprofit organization
dedicated to improving the lives of individuals
living with Lennox-Gastaut Syndrome through
research, programs, and education.
lifelines neurodiagnostic Systems, Inc.
Booth #226
Ms. Elizabeth Thompson
411 Edwardsville Rd
Troy IL 62294
Phone: 618-667-6445
Fax: 618-667-1982
Email: elizabeth@lifelinesneuro.com
www.lifelinesneuro.com
Visit LifeLines Neurodiagnostic Systems, Inc. at
AES Booth #226 and see the new Lifelines iEEG
Portable—the first ever, true virtual EMU. The
iEEG Portable revolutionizes EEG in your patients’
homes with features like day & night IR video
capability, real-time remote monitoring, and
immediate access to critical data from anywhere!
Impact your practice and enhance patient care
with the iEEG Portable.
livanova
Booth #719
Ms. Renee Adams
100 Cyberonics Blvd
Houston TX 77058
Phone: 281-228-7200
Fax: 281-218-9332
Email: renee.adams@livanova.com
www.livanova.com
As pioneers of the VNS (Vagus Nerve Stimulation)
Therapy® system, we continue to advance
medical device solutions for people affected by
treatment-resistant epilepsy. We strive to help
where it really counts, where it truly matters the
most. Sharp, responsive and effective – at
LivaNova we serve health and improve lives. Day
by day. Life by life.
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
lundbeck
Booth #711
Ms. Lisa Berry
Four Parkway North
Deerfield IL 60015
Phone: 847-282-1000
Fax: 847-282-1001
Email: lerr@lundbeck.com
www.lundbeckus.com
Lundbeck, a global pharmaceutical company
based in Copenhagen, Denmark, was founded in
1915. As one of the world’s leading companies
specializing in brain disorders, Lundbeck’s key
focus is to address disorders such as depression,
anxiety, schizophrenia, epilepsy, and
Huntington’s, Alzheimer’s and Parkinson’s
diseases.
Mallinckrodt Pharmaceuticals, Inc.
Booth #315, Booth #412
Mr. J.T. Thomas
26118 Research Rd
Hayward CA 94545
Phone: 510-400-0743
Fax: 510-400-0710
Email: jt.thomas@questcor.com
www.mallinckrodt.com
Mallinckrodt Pharmaceuticals is a global specialty
biopharmaceutical and medical imaging
company. The company’s Autoimmune and Rare
Diseases business includes H.P. Acthar® Gel
(repository corticotropin injection), indicated for
use in multiple specialties including neurology,
rheumatology, nephrology and pulmonology. To
learn more, visit Exhibit #315 or #412 or
www.mallinckrodt.com.
Managing epilepsy Well network
Table #2
Dr. Yvan Bamps
1518 Clifton Rd NE
Rollins School of Public Health
Atlanta GA 30322
Phone: 404-727-7043
Fax: 404-727-1369
Email: yvan.bamps@emory.edu
web1.sph.emory.edu/ManagingEpilepsyWell/
The Managing Epilepsy Well (MEW) Network is a
team of people who care about the health of
people with epilepsy. MEW Network members
come from U.S. universities, community-based
organizations and the Centers for Disease
Control and Prevention (CDC). We work together
to promote epilepsy self-management research
and improve the quality of life for people with
epilepsy. The MEW Network is non-profit.
Medical neurogenetics
Booth #200
Ms. Juliann Kowalski
5424 Glenridge Dr NE
Atlanta GA 30322
Phone: 678-225-0222
Fax: 678-381-2553
Email: jkowalski@mnglab.com
www.mnglab.com
MNG Laboratories provides expert diagnostics
through clinical services, complex biochemical
testing and Next Generation Sequencing. Our
panels are the most cost effective and
comprehensive available, particularly for
cardiomyopathy, cellular energetics, muscular
dystrophies, and epilepsy. A major focus is to
provide rapid sequencing /metabolic diagnostics
for immediate impact on patient treatment.
Medtech Surgical
Booth #301
Mr. Lee Gillett
211 Warren St - Ste 306
Newark NJ 07103
Phone: 612-251-6698
Fax: 855-329-7672
Email: l.gillett@medtechsurgical.com
www.medtechsurgical.com
Medtech designs, develops and markets ROSA™,
the latest generation of robotic assistance for
minimally-invasive neurosurgery. ROSA™
represents a new milestone for SEEG
procedures, offering increased efficiency, security
and flexibility compared to traditional framebased surgery. ROSA™ has already been
successfully adopted by several leading US
Epilepsy Centers.
Medtronic
Booth #209
Ms. Sara Hanson
4620 N Beach St
Ft Worth TX 76137
Phone: 713-275-2063
Fax: 713-741-0122
Email: sara.g.hanson@medtronic.com
www.visualaseinc.com
The Visualase Thermal Therapy System is an MRIguided, minimally invasive laser ablation system
which allows for continuous monitoring of an
ablation in real-time. The system is FDA-cleared
for the ablation of soft tissue, including for use in
neurosurgical procedures. More than 60 US
centers have performed >1,500 neurosurgical
cases.
Microprobes for life Science
Booth #141
Ms. Claudia Tsas
18247-D Flower Hill Way
Gaithersburg MD 20879
Phone: 301-330-9788
Email: Claudia.tsas@microprobes.com
www.microprobes.com
MOBĒ
Booth #309
Ms. Julie Thompson
4190 Vinewood Ln N #111-305
Plymouth MN 55442
Phone: 855-739-5994
Email: Julie.Thompson@mobeforlife.com
mobeforlife.com/pages/seizure
Working to Detect, Predict and Prevent Seizures.
Focusing on the detection, prediction and
prevention of seizure events, the MOBĒ Seizure
Disorder Initiative is a comprehensive approach
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
98
that will change forever our understanding and
management of this debilitating chronic
condition. Our mission consists of a long-term,
integrated program that benefits patients, their
families, and caregivers.
Moberg ICu Solutions
Booth #327
Miranda Pruitt
224 S. Maple St
Ambler PA 19002
Phone: 215-283-0860
Fax: 215-283-0859
Email: info@moberg.com
www.moberg.com
The Moberg CNS Monitor is the only solution for
continuous ICU EEG and comprehensive
physiological data integration. Integrated data
improves understanding of cerebral
pathophysiology and enhances providers’
abilities to personalize care, potentially
contributing to better patient outcomes. This
advanced combination of EEG and other
physiology is the future of neurological
monitoring and care.
Monteris Medical
Booth #127
Ms. Lauren Bichsel
16305 36th Ave N - Ste 200
Plymouth MN 55446
Phone: 204-272-2220
Fax: 732-399-8070
Email: lauren.bichsel@bichselconsulting.com
www.monteris.com
Monteris Medical is a privately held company
developing devices for minimally-invasive, MRguided, robotically controlled neurosurgery.
Monteris markets the NeuroBlate® system for
controlled, volumetric ablation of brain lesions.
Monteris also offers the various Stereotactic
anchoring devices for image-guided trajectory
alignment, and the AtamA™ Stabilization System.
Multi Channel Systems - A Division of
harvard Bioscience
Booth #834
Ms. Karla Bellack
Markwiesen Strasse 55
D-72770 Reutlingen
Germany
Phone: 497-121-5030-10
Fax: 497-121-5030-11
Email: bellack@multichannelsystems.com
www.multichannelsystems.com
Harvard Bioscience divisions Triangle BioSystems
International (TBSI) and Multi Channel Systems
(MCS) are the ideal partner for in vivo
electrophysiology. Complete wireless or tethered
recording systems from headstage to software,
options for optical and electrical stimulation, and
the possibility for parallel recordings make them
the perfect solution for studies of
behavior/learning and memory.
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
national Association of epilepsy Centers
Booth #613
Ms. Johanna Gray
600 Maryland Ave SW - Ste 835W
Washington DC 20024
Email: jgray@dc-crd.com
www.naec-epilepsy.org
national Institute of neurological Disorders
& Stroke (nInDS)
Booth #326
Ms. Natalie Frazin
9000 Rockville Pike
Bethesda MD 20892
Phone: 301-496-5751
Fax: 301-402-2186
Email: frazinn@ninds.nih.gov
www.ninds.nih.gov
The National Institute of Neurological Disorders
and Stroke (NINDS), part of the National
Institutes of Health, supports basic, translational,
and patient-oriented research on epilepsy
prevention, diagnosis and treatment, including
mechanisms of epileptogenesis, gene discovery,
epidemiology, psychosocial and behavioral
consequences, and development of new
therapies. Free patient information.
natus neurology Incorporated
Booth #617
Mr. Steven Stump
3150 Pleasant View Rd
Middleton WI 53562
Phone: 800-356-0007
Email: neurology.marketing@natus.com
www.natus.com
Natus Neurology is a leading provider of
instrumentation for the diagnosis and
monitoring of neurological conditions: epilepsy,
sleep disorders, cerebral vascular disorders and
stroke, neuropathies, neuromuscular diseases,
myopathies; neurosurgical procedures;
neurophysiologic research; and offers a
complete line of supplies and accessories for use
in settings from private practice to hospital.
neuralynx, Inc
Booth #831
Mrs. Susan Stengel
105 Commercial Dr
Bozeman MT 59715
Phone: 406-585-4542
Fax: 406-585-9034
Email: susan@neuralynx.com
nlxneuro.com/
Neuralynx provides high-end clinical research
systems which are used in top-tier hospitals
worldwide. The ATLAS system is the only DC
capable, high-density EEG, EcOG, and Human
Single-Unit system designed to operate as a
research LTM while providing full clinical
compatibility as a stand-alone system or in
parallel with your existing clinical system. Also see
our full line of animal products.
neurology Reviews
Booth #106
Lynne Kalish
7 Century Drive, Suite 302
Parsippany NJ 07054
Phone: 973-290-8228
Email: lkalish@frontlinemedcom.com
www.neurologyreviews.com
NEUROLOGY REVIEWS is a clinical news
publication with articles and timely department
features that keep neurologists, primary care
physicians, and other healthcare professionals
informed of the latest news affecting their
practice. NEUROLOGY REVIEWS covers major
medical conferences and monitors the peer
review literature to report the latest research
findings.
neuroPace, Inc.
Booth #534
Ms. Janet Greenwood
455 N Bernardo Ave
Mountain View CA 94043
Phone: 650-237-2700
Fax: 650-237-2701
Email: info@neuropace.com
www.neuropace.com
NeuroPace, Inc. develops and produces medical
device solutions for the treatment of neurological
disorders. NeuroPace, Inc. has FDA approval for
the RNS® System, the world’s first and only
neurostimulator that provides targeted,
responsive therapy for patients with medically
refractory epilepsy.
neuroQuest llC
Booth #304
Ms. Christy Norton
S75 W17317 Janesville Rd
Muskego WI 53150
Fax: 855-777-8378
Email: cnorton@neuroquestllc.com
www.neuroquestllc.com
neurotech
Booth #115
Ms. Vickie Wolfe
626 W. Moreland Blvd.
Waukesha WI 53188
Phone: 262-754-0898
Email: vwolfe@neurotecheeg.com
www.neurotecheeg.com
Neurotech is a leading service provider in
Monitored Long Term EEGs in patients’ homes.
Working with both academic and private practice
institutions we have office in 7 states. Neurotech
provides EEG technical services to physicians to
enhance their Routine or LTM EEG services.
Neurotech is JCAHO accredited and a clinical
training site for EEG students with the Institute of
Health Sciences.
neurovirtual
Booth #114
Mr. Sergio Solis
2315 NW 107th Avenue Suite 1M27
Doral FL 33172
Phone: 786-693-8200
Email: info@neurovirtual.com
www.neurovirtual.com
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
99
Neurovirtual specializes in the development,
manufacturing, marketing, and servicing of hightech, premium-quality medical devices used in
the fields of Neurology and Sleep Medicine. Our
mission is to provide the highest-quality medical
equipment at a fair price. Our corporate culture
promotes a humanized experience with access
to live service and support throughout the
ownership cycle.
nexstim, Inc.
Booth #201
Mr. John Hardin
875 N. Michigan Ave - Ste 3100
Chicago IL 60611
Phone: 312-373-3704
Fax: 312-794-7801
Email: dana.wolski@nexstim.com
www.nexstim.com
Nexstim Plc. Is a medical technology company
aiming to improve Neurosurgery and
Rehabilitation for stroke patients. Nexstim is a
pioneer in brain diagnostics with its Navigated
Brain Stimulation (NBS) system as the first and
only FDA-cleared and CE-marked navigated
Transcranial Magnetic Stimulation (nTMS) device
for pre-surgical mapping of the eloquent areas of
the cortices.
nihon kohden America, Inc.
Booth #727
Ms. Jeannie Callahan
15353 Barranca Pkwy
Irvine CA 92618
Phone: 949-580-155
Fax: 949-271-5319
Email: jeannie_callahan@nkusa.com
www.nkusa.com
For over 60 years Nihon Kohden has been the
trusted Neurology solution for Epilepsy
Monitoring, Electroencephalography, EEG & PSG
Wireless & Ambulatory Recording,
Polysomnography, Out of Center Sleep
Testing/PSG, Electromyography, Evoked
Potentials, Intra-operative and cEEG ICU
monitoring. Serving the Best Minds in Neurology
for Over Sixty Years. http://www.nkusa..com
Oxford university Press
Booth #735
Mr. Greg Bussy
198 Madison Ave
New York NY 10016
Phone: 212-726-6000
Fax: 919-677-1303
Email: greg.bussy@oup.com
www.oup.com/us
Featuring: Asadi-Pooya Antiepileptic Drugs, 2nd ed.;
Engel Epilepsy Board Quick Review; Morris
Mannual of Neurological Signs; LaFrance Treating
Nonepileptic Seizures, and much more from the
Oxford University Press neurology list.
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
PCDh19 Alliance
Table #20
Leslie Henkel
6 Wisteria Ct
Novato CA 94945
Phone: 563-676-3044
Email: leslie@pcdh19info.com
www.pcdh19info.org
Our mission is to improve the lives of children
and families who are affected by PCDH19
Epilepsy. The PCDH19 Alliance focuses on raising
and directing funds to scientific research with the
goal of finding better, more effective treatments
and, ultimately, a cure; providing information and
support to affected families; and assisting the
efforts of the medical community.
Penn State hershey Medical Center
Booth #102
Maddie Hertzog
90 Hope Dr
Hershey PA 17033
Phone: 717-531-5065
Email: mhertzog@hmc.psu.edu
www.pennstatehershey.org
Persyst Development Corporation
Booth #212
Ms. Ann Shambo
12625 High Bluff Dr - Ste 213
San Diego CA 92130
Phone: 858-461-4542
Fax: 858-461-4531
Email: sales@persyst.com
www.persyst.com
Persyst is the world’s leading supplier of EEG
software for clinical applications. Persyst Seizure
Detection, Spike Detection, Trending and Artifact
Reduction is integrated and sold by every leading
EEG manufacturer. Visit Persyst to see the future
of EEG software.
Pinnacle Technology, Inc.
Booth #839
Ms. Linda Lane
2721 Oregon St
Lawrence KS 66046
Phone: 785-832-8866
Fax: 785-749-9214
Email: mjohnson@pinnaclet.com
www.pinnaclet.com
Pinnacle provides preclinical research tools for
recording seizure-related activity and behavior.
Optogenetics and biosensors can be integrated
into our EEG/EMG monitoring systems, making
our turn-key platforms applicable to a variety of
research models. Our analysis software identifies,
marks, and analyzes seizure events. Synchronized video can be incorporated into any
Pinnacle system.
PMT Corporation
Booth #408
Ms. Amanda Bammert
1500 Park Rd
Chanhassen MN 55317
Phone: 952-470-0866
Fax: 952-470-0865
Email: abammert@pmtcorp.com
www.pmtcorp.com
For over 30 years PMT® has been designing and
producing quality neurosurgical products for
epilepsy procedures and research. Our extensive
line of neurosurgical products include: Cortac®
cortical electrodes, Depthalon® depth
electrodes, sEEG depth electrodes, stereotactic
placement kits and accessories. We are on-site to
work with you defining products which match
your specific requirements.
Practical neurology
Booth #242
Mr Steve Farrell
1008 Upper Gulph Rd
Wayne PA 19087
Phone: 973-768-8681
Email: sfarrell@bmctoday.com
practicalneurology.com
Practical Neurology™ readers trust its straightforward clinical and practice management advice.
Pressed for time and faced with multiple
information sources, readers favor Practical
Neurology™ magazine’s unique editorial style
that cuts to the heart of the issues with
authoritative content and summary points.
Published 9 times per year.
PracticalNeurology.com
Rhythmlink International, llC
Booth #214
Ms. Lori Melton
1140 First St S
Columbia SC 29202
Phone: 816-429-5931
Fax: 803-252-1111
Email: lmelton@rhythmlink.com
www.rhythmlink.com
Rhythmlink International is a medical device
manufacturing company specializing in devices
that help connect patients to machines to record
or elicit physiologic information. Rhythmlink
offers an array of monitoring devices including
the first and only FDA cleared Disposable MRI
Conditional EEG electrodes and the new artifact
free CT imaging electrodes.
feeding difficulties and severe, intractable
epilepsy which presents early in life. Ring14 USA
is a nonprofit dedicated to funding critical
research, raising awareness, and providing a
supportive community to those affected by the
rare syndromes of the 14th chromosome, in
particular Ring14.
Ripple llC
Booth #739
Mr. Mitch Frankel
2015 S 1100 E
Salt Lake City UT 84106
Phone: 801-413-0139
Fax: 801-413-2874
Email: sales@rppl.com
www.rppl.com
Ripple provides high performance
electrophysiology data acquisition systems for
neurophysiology recording and stimulation. Our
systems are compact, portable, and heavily
optimized for real-time, closed-loop control
applications with up to 512 channels of EMG,
EEG, and microelectrode data. Our software is
cross platform, and can be run on Windows, Mac
OS X, and Linux.
Rogue Research Inc./Rogue Resolutions Inc.
Booth #100
Ms. Diane Gariepy
4398 Boul. St-Laurent, #206
Montreal Quebec H2W 1Z5
Canada
Phone: 514-284-3888
Email: info@rogue-research.com
www.rogue-research.com
RSC neuro
Booth #340
Ms. Jami Jackson
101 East Park Blvd - Ste 910
Plano TX 75074
Phone: 877-333-2575
Fax: 877-333-2575
Email: jjackson@rscdiagnosticservices.com
rscdiagnosticservices.com
RSCNeuro specializes in In-Home Video AEEG
and REEG for physician practices, multi-specialty
clinics, and hospitals. Our unique approach and
technology empowers physicians by increasing
the diagnostic yield to evaluate, diagnose and
treat a variety of seizure disorders. RSCNeuro is
committed to insuring quality EEG
interpretations and Redefining Seizure Care.
Ring14 uSA
Table #12
Yssa DeWoody
2501 Homeland Dr
Midland TX 79707
Phone: 765-491-6910
Fax: 765-491-6910
Email: yssa@ring14usa.org
www.ring14usa.org
Ring14 is a rare cytogenetic syndrome
characterized by global delays, hypotonia,
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
100
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
Sage Therapeutics
Booth #300
Ms. Kelly Linehan
215 First St
Cambridge MA 02142
Phone: 617-299-8380
Fax: 617-299-8379
Email: kelly@sagerx.com
www.sagerx.com
SAGE Therapeutics is a clinical-stage
biopharmaceutical company committed to
developing and commercializing novel medicines
to treat life-altering central nervous system (CNS)
disorders. SAGE's lead program, SAGE-547, is in
Phase 3 development for super-refractory status
epilepticus and is the first of several compounds
the Company is developing in its portfolio of
potential CNS medicines.
SeizureTracker.com
Table #21
Mr. Robert Moss
PO Box 10738
Alexandria VA 22310
Phone: 703-339-8448
Fax: 703-339-8430
Email: rob@seizuretracker.com
www.seizuretracker.com
SeizureTracker.com is dedicated to providing
people living with epilepsy and their care
providers with free comprehensive tools to help
understand relationships between seizure
activity and anti-epileptic treatments.
Smart Monitor Corp.
Booth #532
Ms. Sheri Becker
6203 San Ignacio Ave #112
San Jose CA 95119
Phone: 408-505-1976
Fax: 408-351-0154
Email: sheri.becker@smart-monitor.com
www.smart-monitor.com
Smart Monitor provides monitoring solutions for
people with chronic health conditions. Founded
in 2009 and headquartered in San Jose, CA,
Smart Monitor fuses together sensor, mobile
and cloud technologies with big-data analytics in
a seamless environment. Our patent protected
solutions foster autonomy and enhance
safety,while offering significant peace-of mind to
their families and care providers.
South Carolina Advocates For epilepsy
Table #13
Ms. Karen St Marie
105 Main Ridge Blvd
Goose Creek SC 29445
Phone: 843-991-7144
Email: Karen@scepilepsy.org
www.scepilepsy.org
As the only epilepsy organization in SC, we strive
to raise awareness and remove the stigma
associated with seizures and epilepsy. Our
mission is to ADVOCATE on behalf of patients,
families/caregivers; EDUCATE people from all
walks of life about epilepsy and seizure first aid;
INSPIRE patients, families, and others to make a
difference for themselves and others who deal
with epilepsy every day.
SuDeP Aware
Table #5
Ms. Tamzin Jeffs
Ste 350 - 283 Danforth Ave
Toronto ON M4K 1N2
Canada
Phone: (001) 416 556 8770
Email: tcjeffs@gmail.com
www.sudepaware.org
Sunovion Pharmaceuticals Inc.
Booth #701
Ms. Susan Mahoney
84 Waterford Dr
Marlborough MA 01752
Phone: 888-866-6500
Fax: 508-357-7490
Email: susan.mahoney@sunovion.com
www.sunovion.com
Sunovion is a leading pharmaceutical company
dedicated to discovering, developing and
commercializing therapeutic products that
advance the science of medicine in the
Psychiatry, Neurology and Respiratory disease
areas to improve the lives of patients and their
families. Sunovion is a subsidiary of Sumitomo
Dainippon Pharma Co., Ltd. Visit
www.sunovion.com for more information.
Supernus Pharmaceuticals, Inc.
Booth #401
Mr. Tilton Conner
1550 E Gude Dr
Rockville MD 20850
Phone: 301-838-2500
Email: tconner@supernus.com
www.supernuspharma.com
Texas Children’s hospital
Booth #434
Ms. Karen Wilkinson
1919 S Braeswood - Ste 6226
Houston TX 77030
Phone: 832-824-2100
Fax: 832-825-8892
Email: kcwilkin@texaschildrens.org
texaschildrens.org/neuroscience
Ranked #2 in Neurology and Neurosurgery by
U.S.News & World Report in 2015, the
Neuroscience Center at Texas Children’s Hospital,
along with the Texas Children’s Jan and Dan
Duncan Neurological Research Institute, is a
leader in the research, treatment and surgical
intervention for the full continuum of neurological
conditions in children.
Transgenomic Inc
Booth #110
Scott Stremick
12325 Emmet St
Omaha NE 68164
Phone: 402-452-5439
Email: sstremick@transgenomic.com
www.transgenomic.com
Transgenomic, Inc. specializes in genetic testing
for cardiology (FAMILION), neurology,
mitochondrial disorders and oncology.
Transgenomic develops assays and offers testing
with the goal to overall improve medical diagnosis
and outcomes for patients.
Tuberous Sclerosis Alliance
Table #1
Jaye Isham
801 Roeder Rd - Ste 750
Silver Spring MD 20910-4487
Phone: 301-562-989
Fax: 301-562-9870
Email: info@tsalliance.org
www.tsalliance.org
Supernus Pharmaceuticals, Inc. is a specialty
pharmaceutical company focused on developing
and commercializing products for the treatment
of CNS diseases. The company has two marketed
products for epilepsy, Oxtellar XR®
(oxcarbazepine) extended-release tablets and
Trokendi XR® (topiramate) extended-release
capsules.
The Tuberous Sclerosis Alliance is the only U.S.based non-profit organization dedicated to
finding a cure for tuberous sclerosis complex
(TSC) while improving the lives of those affected.
TSC is a rare genetic disorder that causes tumors
to form in vital organs. It is also the leading
genetic cause of both epilepsy and autism.
For two centuries, Taylor & Francis has been fully
committed to the publication of scholarly
research. We are pleased to now publish The
Neurodiagnostic Journal on behalf of ASET. Stop
by our booth for FREE journal sample copies and
browse the wide variety of journals we have
available.
At UCB, we have a passionate, long-term
commitment to discovering and developing
innovative medicines that transform the lives of
people living with severe immunological diseases
and central nervous system disorders. With 8,500
employees in 40 countries, we invest
approximately 28% of revenue in cutting-edge
scientific research to meet unmet patient needs.
Taylor & Francis
Booth #643
Kayla Daniel
530 Walnut St - Ste 850
Philadelphia PA 19106
Phone: 215-625-8900
Fax: 215-606-0050
www.tandfonline.com
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
101
uCB, Inc.
Booth #601
1950 Lake Park Dr
Smyrna GA 30080
Phone: 844-599-2273
Email: UCBCares@ucb.com
www.ucb-usa.com/ucbcares
DECEMBER 4 - 8, 2015 www.AeSnet.org
EXHIBITORS
uCBCares
Booth #104
1950 Lake Park Dr
Smyrna GA 30080
Phone: 844-599-2273
Email: UCBCares@ucb.com
www.ucb-usa.com/ucbcares
uCSF Medical Center
Booth #335
Ms. Cheryl Hardin
3360 Geary Blvd - Ste 301
San Francisco CA 94118
Phone: 212-999-9230
Email: cheryl.hardin@ucsfmedctr.org
www.ucsfhealth.org
If you are looking to take your career in the END
field to the next level then UCSF Medical Center
Neurodiagnostics Program is for you! UCSF has
one of the largest, most comprehensive epilepsy
surgery programs in the Western United States.
united Diagnostics
Booth #145
Mr. Michael Glynn
50 Rose Place Garden City Park NY 10040
Phone: 516-873-6500
Fax: 516-873-6501
Email: Michael@unitedsleepd.com
www.unitedsleepd.com
United Diagnostics is New York’s leading provider
of Video EEG services, specializing in ambulatory
in-home studies. Our team delivers
comprehensive service to patients and the most
accurate testing and results to healthcare
providers. United currently manages its
Ambulatory Video EEG (AVEEG) services from its
multiple locations throughout Long Island, New
York, Rockland and Orange Counties, as well as
Boston MA and Providence RI.
university of Pennsylvania Ieeg.org Portal
Table #11
Ms. Carolyn Wilkinson
Room 301 Hayden Hall
240S 33rd St
Philadelphia PA 19104
Phone: 215-746-4850
Fax: 215-573-8393
Email: wilkinsc@seas.upenn.edu
www.ieeg.org
EEG.org is a web-based epilepsy database
funded by the National Institutes of Neurological
Disorders and Stroke to facilitate sharing data
from humans and animal models of epilepsy, to
promote collaboration on projects where
algorithms, common annotation and “gold
standard” data sets are vital to moving epilepsy
research and translation to patient care forward.
Please visit https://www.ieeg.org/
upsher-Smith laboratories, Inc.
Booth #124, Booth #217
Ms. Becky Bouley
6701 Evenstad Dr
Maple Grove MN 55369
Phone: 763-315-200
Fax: 763-315-2244
Email: becky.bouley@upsher-smith.com
www.upsher-smith.com
Upsher-Smith Laboratories, Inc., founded in 1919,
is a growing, fully integrated pharmaceutical
company dedicated to its mission of delivering
high-value, high-quality therapies and solutions
which measurably improve individuals’ lives. For
more information, visit www.upsher-smith.com.
VA epilepsy Centers of excellence
Table #8
Mr. Ryan Rieger
4150 Clement St (127E)
San Francisco CA 94121
Phone: 415-221-4810-411
Fax: 415-379-5666
Email: ryan.rieger@va.gov
www.epilepsy.va.gov
The VA Epilepsy Center of Excellence (ECoE) aims
to improve the health and well being of Veteran
patients with epilepsy and other seizure
disorders through the integration of clinical care,
outreach, research, and education.
Wiley
Booth #235
Taryn Walsh
350 Main St
Malden MA 02148
Phone: 781-388-8361
Fax: 781-338-8361
Email: twalsh@wiley.com
www.wiley.com
Wiley is a global provider of knowledge and
knowledge-enabled services that improve
outcomes in areas of research, professional
practice, and education. Visit www.wiley.com or
Booth #235 for more information.
Wolters kluwer
Booth #227
Ms. Joey-Rose Jester
Two Commerce Sq, 2001 Market St
Philedelphia PA 19103
Phone: 215-521-830
Fax: 215-521-849
Email: joey-rose.jester@wolterskluwer.com
www.lww.com
Wolters Kluwer Health is a global provider of
information, business intelligence and point-ofcare solutions for the healthcare industry,
including: Lippincott Williams & Wilkins Books and
Journals, Lippincott Solutions and Ovid, online
information search, discovery and management
solutions.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
102
Innovation Pavilions
Convention Center - Exhibit Hall A,
200 Level
Visit the Innovation Pavilions to
experience in-depth education and
training from exhibitors — featuring
some of the latest research and
technology related to the treatment and
prevention of epilepsy.
Saturday, December 5
noon - 6:00 p.m.
Sunovion Pharmaceuticals Inc. Pavilion A
Lundbeck - Pavilion B
NeuroPace, Inc. - Pavilion C
LivaNova - Pavilion D
UCB, Inc. - Pavilion E
Sunday, December 6
10:00 a.m. - 4:00 p.m.
Sunovion Pharmaceuticals Inc. Pavilion A
Lundbeck - Pavilion B
NeuroPace, Inc. - Pavilion C
LivaNova - Pavilion D
UCB, Inc. - Pavilion E
Monday, December 7
10:00 a.m. - 2:00 p.m.
Sunovion Pharmaceuticals Inc. Pavilion A
Tuberous Sclerosis Alliance Pavilion B
Eisai Inc. - Pavilion C
#AeSmtg15
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
A
A, A 2.321
Aaron, G 2.088
Aazhang, B 3.078
Abbas, S 3.236
Abbott, D 3.228
Abdelmoity, A 1.007, 2.294, 2.295, 3.380
Abdelmoity, S 2.294, 2.295
Abdennadher, M 2.388
Abdulsattar, A 1.106
Abela, E 3.219
Abella Corral, J 2.275
Abend, N 1.123, 1.137, 2.183, 3.194
Abo, A 3.395
Abokhamis, 1.097
Abou-Khalil, B 1.088, 1.103, 1.186, 1.218,
2.201, 2.248
Abrahamsen, R 1.317
Abramian, A M. 3.023
Abramovici, S 3.289
Abrams, E 3.004
Abubakr, A 1.081
Achkar, C 2.189
Ackermans, L 3.283
Ackley, M 3.102
Adam, S 1.311
Adamo, M A. 2.121, 3.087
Adams, E 1.176, 1.295, 2.342, 2.346
Adduchio, S 1.120
Adelson, P 2.241, 3.248
Adlard, P 1.313
Adler, D 3.061
Aduen, P 3.317, 3.318
Afra, P 3.083
Aftab, H 2.058
Afzal, B 2.369
Agarwal, N 3.292
Agarwal, P 2.300
Agarwal, R 1.136, 2.142
Aggarwal, A 3.363
Aghaei-Lasboo, A 2.104
Agler, W 1.163
Agostini, M 1.105, 2.172
Agrawal, D 1.115
Agricola, K 1.251
Aguilera, R 3.232
Aharoni, D 3.143
Ahearn, D 3.316
Ahmad, G 2.317
Ahmed, M M. 3.009
Ahn, R 3.229
Ahn, S 3.080, 3.281
Aiba, I 3.135
Aillon, M 3.232
Aimola, S 2.289
Air, E 1.144, 3.213
Aizenman, E 3.015
Ajay, G 1.086
Ajwad, A 2.038
Akalan, N 1.344
Akamatsu, N 3.391
Akcakaya, M 2.054, 2.082
Akdag, G 2.169
Akhtar, N 1.089
Akin, B 2.339
Akiyama, T 1.067
Akiyama, Y 1.253
Akman, C 3.161, 3.387
Akman, C 1.040
Alam, J 2.333
Alarcon-Martinez, L 3.020
Al-Bakrei, A 3.157
Albaugh, D 1.164
Albert, D V. 1.037
Albert, H 2.319
Alberto, G 2.035
Alcantara, J 2.357
Alessi, R 2.357
Alex, B 3.177
Alexander, J 2.056
Alexopoulos, A 1.055, 1.140, 2.064,
2.217, 3.222
Al Hail, H 1.089
AlHashemi, H 2.149
Al Hashemi, H H. 3.376
Alhourani, A 1.043, 1.049
Ali, A 3.176
Ali, A 2.376
Ali, A 3.192
Ali, I 2.246
Ali, W 2.074, 2.074
Aljaafari, D 3.338
Al Jurdi, A 1.089
Al-Kaylani, M 1.088
Allen, C P. 2.366
Allen, V 1.241, 2.134, 3.187
Allendorfer, J 1.165, 3.218
Alloway, R 2.267
Almajano, J 1.230
Almane, D 3.238, 3.323
Al Mansoori, L S. 3.376
Almazán-Alvarado, S 2.029
Almoguera, B 1.316, 3.332, C.02
Alomar, S 1.170
Alonso, M E. 2.354, 2.356
Alonso-Vanegas, M 2.070, 2.071
Al-Otaibi, A 2.390
Alqadi, K 2.185, 2.217
Al-Said, Y 2.185
Al-Sharif, N 1.140
Al-Shehri, E 2.185
Alsherbini, K 1.387
Alter, E 2.351
Althaus, A 2.117
Alvarado-Rojas, C 2.061
Alvim, M K. 1.351, 2.299
Al Zarooni, K M. 3.376
Amaro Jr, E 3.315
Ambrosino, P 3.018
Amhaoul, H 3.051
Amiri, M 2.122
Ammanuel, S 3.067
Anadani, M 1.258
Anand, A 3.394
Anand, B 1.125
Andermann, E 2.243
Andersen Becser, N 2.281
Anderson, A E. 3.032, 3.244
Anderson, A 2.074
Anderson, C T. 1.051
Anderson, G 2.049
Anderson, L L. 3.035
Anderson, W 1.028
Andrade, D 3.151, 3.338
Andrade, J 3.117
Andrade, J Q. 3.119
Andrade, R 1.325
Andresen, L 2.056, 3.361
Andrews, N 2.245
Andriola, M 1.216, 3.340
Anisman, D 1.337
Antinew, J 1.127
Antoine, D 2.014
Antonetty, A 3.177
Antonio, Z 2.238
Antony, A 1.043, 2.054, 2.082, 3.231,
3.289
Antwi, P 3.030
Anwar, A 3.089
Aparicio, J 2.288
Appavu, B 1.246, 2.146, 2.241, 2.383
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Appendino, J P. 2.103
Aragón, E 1.230
Arai, H 1.072, 1.149, 1.384, 3.295
Arain, A 1.044, 1.088, 2.248
Arakawa, Y 1.281
Aram, J 3.277
Aranda, J 1.042
Araújo, M S. 2.020
Archer, J 3.214, 3.228
Archer, S 3.085
Arcot Desai, S 1.045, 1.046, 1.121, 3.031,
3.085
Ardini, M E. 1.370, 3.369
Arias-Montaño, J 2.071
Arif, H 1.034
Arif, M A. 2.149
Arita, K 2.013
Arkilo, D 1.122, 2.163, 3.292
Armacost, M 2.331
Arnett, A 2.337
Arnold, S 1.038, 3.189
Aronica, E 2.003
Arora, K 2.077, 3.079
Arora, N 3.198
Arriaga-Pizano, L 3.108
Arruda, F 2.139, 2.357
Arthur, T 2.127
Arya, R 1.123, 1.137, 2.127, 2.183
Asadi-Pooya, A 1.074, 2.320
Asano, E 1.017, 1.070, 2.128, 2.199
Asato, M 1.336
Asato, M R. 1.293
Ashby-Lumsden, A 3.058
Ashwal, S 2.344
Assirati, J A. 2.231
Atilano Barbosa, D 3.207, 3.221
Atkinson, J 2.307
Atkinson, M J. 2.302
Atmaca, M 2.096
Aung, T 1.005, 2.190
Auvin, S 2.044, 2.292
Averill, K 1.099
Avery, K 1.386
Avery, R 2.238
Ayasoufi, K 3.109
Ayer, T 1.034
Aygok, G 1.132
Azar, N 1.044, 1.088, 2.248
Aziz, A 1.357, 2.350
Azuma, Y 1.142
B
Ba-Armah, D 1.039
Baba, H 1.359, 2.188, 3.203
Baba, H 1.250
Baba, S 2.155, 2.312, 3.300
Babajani-Feremi, A 1.162, 3.127
Baber, J 1.348
Babiarz, K 3.354
Baccon, J 2.053
Bae, E 1.210
Baeesa, S 2.185
Baek, J 2.293, 3.201
Baek, J H. 1.288
Baftiu, A 2.285, 2.377, 3.274
Bagher-Ebadian, H 1.144
Bagher-Ebadian, H 3.213
Bagic, A 1.043, 1.049, 2.054, 2.082,
3.231, 3.289
Bagliella, E 2.197
Bagnall, R 3.339, C.01
Bahari, F 2.027, 2.053
Bai, D 2.356
Baierlipp, T 1.231
Bailey, J 1.310, 2.354, 2.356
103
Bain, J 1.099, 3.122
Bainbridge, J 1.342, 3.073, 3.393
Baird, G 3.237, B.01
Baird, M 3.102, 3.265
Baise, C 3.117, 3.119
Bajaj, V 3.105
Bajo, S D. 3.317, 3.318
Bakhurin, K 3.143, 3.143
Baki, S A. 1.042
Balachandar, S 2.227
Balchandani, P 3.068
Baldassano, S 2.060
Baldini, S 2.110
Baldwin, M 2.054, 2.082, 3.231, 3.289
Baldwin, R 2.022
Balena, T 2.008, 3.007
Balestri, M 1.312, 2.343
Balicka-Adamik, L 2.094
Ball, M 2.370
Balosso, S 2.014, 3.024, 3.024
Balu, R 3.076
Balzekas, I 2.033, 3.056
Bammler, T 2.049
Bangash, I 2.353, C.03
Bannout, F 1.390
Banuelos-Cabrera, I 2.071
Bao, Y 2.052, A.08
Baraban, S 2.023, 3.017, 3.049, 3.140
Baram, T 2.006, 3.005
Baranano, K 1.317
Barba, C 1.275
Barba, D 1.022
Barbara, H 2.344
Bardakjian, B 2.086
Barghout, V 1.335
Barkan, H 1.269, 1.337, 2.370
Barker, B S. 2.364
Barker, G 1.153
Barker-Haliski, M 3.047
Bar-Klein, G 3.104
Barkley, G L. 1.060, 2.172
Barnard, S 2.197
Barnes, N J. 2.391
Barnoski, E 1.125
Barr, P 2.272
Barragan, H 3.207, 3.221
Barros, M T. 1.382
Barry, F 1.339
Barry, J 3.044
Barry, J 2.206
Bartlett, V 1.082
Bartolini, L 3.301
Basha, M 1.044, 1.240, 1.352, 2.177,
2.279
Bashir, M 1.389
Baslet, G 2.236
Bassett, D S. 2.016, 2.019
Bastin, M 1.143
Bastos, A 2.139
Bathena, S 2.271, 3.182
Bathke, A 3.367
Baumer, F 2.189, 3.333
Baumgartner, J 1.048
Bautista, J 2.066, 2.335, 2.379
Bayat, A 2.031
Bazil, C 2.172
Bazil, C W. 1.121
Beach, R 1.383
Beall, E 3.218
Beattie, J 1.244, 2.334
Beaulieu, C 3.211
Bebin, M 2.375
Beck, H 3.245
Becker, D 1.111
Becker, F 2.362
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Bedner, P 3.041
Beers, C 1.158
Begley, C 1.003
Begley, C 1.376, 3.349
Begnaud, J 3.086
Behari, M 2.300
Behnke, E 2.061
Beimer, N J. 2.133
Belfort, G 2.240, 3.102
Bell, R Z. 2.115
Bellini, G 1.312
Bello-Espinosa, L 1.267
Bellows, S 1.313, 2.359
Belousova, E 2.148
Beltramini, G C. 2.203
Bena, J 2.245
Benbadis, S 2.165, 3.073
Benedik, M 2.148
Beniczky, S 2.362
Benke, T 2.067, 3.147, 3.181
Ben-Menachem, E 1.116, 3.253
Bennettt, J 3.335
Benquet, P 1.057
Bensalem-Owen, M 1.393, 2.154
Benson, J 3.021
Ben-Zeev, B 2.386
Benzinger, T 1.174
Berdichevsky, Y 1.229, 2.051
Berenyi, A 2.062
Berg, A K. 2.256, 2.259
Berg, A 1.085, 1.091, 1.110, 1.122, 1.339,
2.163
Berg, K 1.295
Berg, K 2.342
Berg, M 1.060, 2.172, 2.267
Berger, J 3.170
Berger, T 3.072
Bergey, G 1.060, 1.121, 2.172, 3.092
Bergin, A 2.286
Bergin, A 3.116
Bergo, F 2.203
Berk, A 1.374
Berkovic, S 1.313
Berkovic, S 2.359, 3.338, 3.339, 3.346,
C.01, C.04
Berl, M 1.150, 1.151, 2.219, 3.325, 3.331
Bermudez, C 3.098, 3.099
Bernasconi, A 1.145, 1.147, 2.102, 2.145,
2.202
Bernasconi, N 1.145, 1.147, 2.102, 2.145,
2.202
Bernhardt, B 1.145, 1.147, 2.202
Bernhardt, M 2.351
Berry, J 1.322
Bertoglio, D 3.051
Berube, A 2.322
Besio, W 2.029, 2.104
Bessone, S 1.249
Betzler, C 2.361
Beydoun, A 2.253
Bezerra, D 1.266
Bhardwa, V 1.309
Bhuyan, P 2.021
Bibbiani, F 1.189, 1.190, 1.191, 1.194,
1.195, 1.211, 1.214, 2.250
Bican, O 2.180
Biche, W 2.034
Bickel, S 1.071
Bien, C 1.102, 2.320
Bilevicius, E 1.304
Bilginer, B 1.344
Billakota, S 1.025
Billard, M W. 2.027, 2.053
Billeaud, N 1.165, 2.077
Binder, D 3.052, 3.252
Binder, J 3.218
Binelli, S 2.132
Bingaman, W 1.290, 2.081, 2.318, 3.124,
3.322, A.06
Biraben, A J. 1.057, 1.084
Birch, K 3.081
Birnbaum, A 2.271, 3.182
Birot, G 1.073, 2.110
Biskup, S 2.152
Bissoli, L 3.117, 3.119
Bjornson, B 1.311, 1.311
Bjursell, M K. 2.353, C.03
Bjørke, A B. 3.162
Blackmon, K 1.146
Blatt, I 3.257, 3.258, 3.259
Blazer, T 1.113
Bleasel, A 1.059, 2.218
Blevins, T 3.148
Blount, J 2.314
Blum, A 3.237, B.01
Blum, D 1.182, 1.183, 1.185, 1.186,
1.202, 2.243, 2.246, 2.249, 2.252,
2.254, 3.254
Blumcke, I 3.037
Blumenfeld, H 2.034, 2.160, 3.030
Blumkin, L 1.302
Boatman, D 1.028
Boelman, C 1.311, 3.151, 3.155
Boes, A 1.064
Boggs, J 2.171, 3.134
Bohlmann, K 3.077
Bohman, L 3.284
Bolger, P 2.267
Bolo-Diaz, M M. 3.184
Bolton, J 1.263, 2.097, 2.306, 2.310
Boly, M 3.130
Bond, T 1.182, 1.202, 2.249
Bone, M E. 1.293
Bonifacio, S 3.194
Bonilha, L 1.044, 2.208, 3.218
Bonito, J 2.380
Bonno, D M. 1.228
Bonpietro, F 1.389
Boon, P 2.085, 2.216, 2.225, 3.141
Boop, F 3.091
Boosalis, 2.242
Boreale, K 1.001
Borggraefe, I 2.361
Borghs, S 1.199, 1.203, 3.261
Borkowska, J 1.124
Born, H A. 3.244
Boro, A 3.196
Borowsky, R 2.058
Bortnik, K 2.327
Bosworth, M 3.031
Bou Assi, E 3.095
Bouet, R 2.065
Boulogne, S 2.065
Bourdillon, P 1.276
Bouthillier, A 2.322
Bower, T 1.035
Bower Baca, C 1.339
Boyce, E 2.144
Boyer, K 1.263, 3.126, 3.327
Boyle, M 2.336
Boyle, R 1.336
Bozarth, X L. 3.335
Bradley, S 1.353
Braga, B 2.203
Bragin, A 2.061, 3.071
Braksick, S A. 1.133
Bramhall, M 3.263
Brand, E 3.107
Brandon, N J. 2.017, A.09
Brandt, T 2.349
Brautbar, C 2.264
Bravo, E 2.032, 2.120, 3.364
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Brchan, D 3.181
Brebesh, B 2.103
Breen, D 3.206
Brennan, G P. 2.006, 3.005
Brenner, L 1.263
Brenner, R 3.011
Brenton, J 2.183
Brenton, J N. 1.123, 1.137
Brewer, M K. 3.012
Briggs, D 2.125
Brightwell, S 1.241
Brilstra, E H. 1.303, 2.361
Brima, T 3.062
Brinkmann, B 3.148
Brinyiczki, K 2.062
Britton, J W. 1.035, 1.133, 1.356
Brook, R A. 1.201
Brooks, B 1.181
Brooks, L 1.355
Brooks-Kayal, A 3.009
Broshek, D K. 3.317
Broshek, D 3.318
Brouwer, C 2.007
Brown, A 1.213
Brown, C P. 3.329
Brown, E C. 1.070, 2.128
Brown, S N. 1.036
Brown, S 2.329
Brown, S 2.291
Brown, S 2.144
Brown, T 3.218
Brozoski, T J. 3.204
Bruder, J C. 1.021
Brunga, L 3.151
Brunner, P 3.087
Bruton, M 2.245
Bruun, D A. 2.242
Bruzzo, C 2.323
Brywczynski, J 1.094
Bu, L 2.085
Bubolz, B 2.074
Bubrick, E 2.333
Buchanan, G F. 2.036
Buchanan, R 2.125
Buchhalter, J 1.245, 1.358, 2.068
Buchsbaum, R 1.223, 1.234, 2.270
Buck, L 1.125
Buckley, S 2.131
Buckley, S 2.191
Buckmaster, P 3.004
Buelow, J 1.328
Buelow, J 2.223, B.03
Buelow, J 1.329, 1.330, 2.059
Buentjen, L 3.077
Buerki, S E. 1.311, 3.151
Buerki, S 3.155
Bukovskaya, Y 3.355
Bulacio, J 2.081, 3.124, A.06
Bulloch, A G. 2.373
Bumbut, A 1.370, 3.369
Bunker, M 1.250
Bunker, M T. 2.174
Burakgazi-Dalkilic, E 3.107
Buraniqi, E 2.143, 3.116, 3.177
Buraniqui, E 2.136
Burattini, J A. 1.266, 3.307
Burd, J 2.332
Burdette, D 3.236
Burgess, R 1.055, 1.140, 2.137, 3.222
Burgess, R 1.313, 3.346, C.04
Burke, K 2.241
Burkholder, D B. 1.133
Burneo, J G. 1.147, 2.140, 2.144, 3.285
Burns, H 2.115
Burns, M 2.285, 3.274
104
Burnsed, J 3.206
Burre, J 3.014, A.04
Burroughs, S 2.108
Bursch, B 3.233
Busatto, G 2.324, 2.325, 2.326, 2.357
Busch, R M. 1.289, 1.290, 3.218, 3.321,
3.322
Bussing, R 1.365
Butler, I 1.391
Buyse, G M. 1.306, C.05
Buzsaki, G 2.062
Byeon, J 1.090, 3.372
Byram , L 1.203
Byrnes, W 2.244
Byun, J 1.209, 2.372, 3.080, 3.281
C
Cabrera, F 1.230
Cabrera Kang, C M. 2.109
Caciagli, L 1.154
Caetano, E 3.392
Cahill, K E. 2.192, 2.194
Cai, D 3.143, 3.143
Cai, W 3.269
Caicedo, M 2.368, 3.354
Caldairou, B 1.145, 2.102
Caller, T 1.286
Camacho, V 3.221
Camacho Tellez, V 3.207
Camarata, P 1.255
Camerone, J 1.050
Camfield, C 1.110, 1.296, 2.371
Camfield, P 1.110, 2.371
Campanella, F 3.176
Campos, M 3.305
Can, A 2.181, 2.286
Cances, C 2.292
Candrilli, S D. 2.282
Canevini, M 3.336
Cansino, C 2.195
Cao, J 3.085
Cao, T 3.328
Caplan, R 1.339, 2.099, 3.233
Cappa, R 1.243
Cappell, J 1.040
Carapetian, S 2.395
Cardoza, C 2.363
Caredda, E 3.195
Carlen, P 2.086
Carlotti, C G. 2.231
Carlson, C 1.051
Carlson, H 3.045
Carmant, L 2.345
Carmichael, D 3.219
Carneiro, T 3.123
Carney, P 1.365, 2.119
Carney, P W. 1.024
Carpenter, J 1.123, 1.137, 2.183
Carrel, A 3.009
Carreno, M 2.252, 2.288, 2.320, 3.286
Carrera Muñoz, I 3.272
Carrette, E 2.216
Carson, R 3.227
Carter, A 3.244
Carter, T 2.148
Carvalho, B S. 1.304
Carver, C 2.011, 3.011
Carvill, G L. 2.355
Cascino, G 1.238
Cash, S 1.060
Cassady, M 2.235, B.09
Cassese, A 2.215
Castagna, C 1.204, 1.205
Castellana, R 2.148
Castillo, A 1.233
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Castillo, E 1.048
Castro, L M. 1.382, 3.315
Castro, O W. 2.020
Catenoix, H 1.276
Cavazos, J E. 3.088
Cavitt, J 2.063
Cayabyab, F S. 2.058
Ceballos, M 1.230
Cendejas Zaragoza, L 2.078, 2.080,
2.084, 2.368, 3.354
Cendes, F 1.304, 1.351, 2.203, 2.252,
2.299
Centeno, M 1.154, 3.219
Centeno, R 1.345, 3.312
Cercignani, M 3.277
Ceronie, B 2.073
Cerqueira, P B. 3.392
Cervenka, M C. 1.249
Cervenka, M 1.028, 3.092, 3.280, 3.342,
C.08
Ceulemans, B 2.262, 2.266
Chadwick, E 2.055
Chae, J 1.075
Chaibi, S 3.106
Chaim, K T. 3.315
Chaim, T 2.357
Chalela, J 3.383
Chamnanphol, M 2.352
Chamorro Muñoz, M 3.272
Chan, J 1.203
Chan, V 1.248, 2.289
Chan, W C. 3.061, 3.061
Chang, E F. 1.252, 1.256, 1.270, 1.271,
1.362
Chang, T 3.194
Chanlaw, T 2.274
Chapeton, J 3.112
Chapman, K 1.112, 1.123, 1.137, 1.241,
2.183, 3.165, 3.255
Chari, G 1.042
Charupanit, K 3.101
Charyton, C 2.230, 3.021
Chassidim, Y 3.104
Chassoux, F 3.090
Chatterjee, P 1.014
Chaturvedi, J 2.321
Chaudhry, N 2.317
Chauvel, P 2.081, 3.124, A.06
Chavez, G 2.012
Chelaru, M 1.069
Chen, B 1.223, 1.234, 2.270
Chen, H 3.284
Chen, J W. 2.105
Chen, M 2.195
Chen, M 2.396, 3.010
Chen, P 1.048
Chen, S 1.171, 3.217
Chen, W 3.013, 3.015
Chen, W 2.160
Chen, Y 2.006
Cheng, H 1.182, 1.183, 1.185, 2.243,
2.246, 2.254, 3.254
Cheng, J 3.197, 3.198
Cheng, K 3.143
Cheng, W 1.077, 1.372
Chern, J 1.031
Cheung, E 3.122
Cheyuo, C 1.132
Chez, M 2.164
Chi, C 1.101
Chi, X 1.347, 2.015
Chiang, S 2.215
Chiesa, V 3.336
Chikkannaih, M 2.161
Chin, R 1.340
Chin, R 1.143, 2.341
Chinvarun, Y 1.155, 2.347
Chiriboga, C 1.099
Chiriboga, N 1.064
Chmielewski, D 1.124
Cho, A 2.274
Cho, K 2.130
Cho, K 2.091
Cho, M 2.293
Cho, Y 2.130
Cho, Y 3.234
Choezom, T 2.380
Choi, H 1.223, 1.234, 2.270
Choi, J 1.075
Choi, M 3.345
Choi, S 1.075
Chong, J 1.376
Chong, S 3.024
Choudhri, A F. 1.162
Choudry, S 1.106
Chow, E C. 3.269, 3.270
Chowdhury, F 1.259
Chowdhury, R 2.214
Chowdhury, R A. 1.169
Christian, E 3.102
Christie, M 1.099
Chu, C 1.085, 1.091, 1.110, 1.122, 2.163,
3.194
Chu, K 1.209, 2.372, 3.080
Chuang, S 2.011
Chugani, H 1.117, 1.156, 2.199, 2.209
Chung, H 1.299, 2.293, 3.201
Chung, J 3.081
Chung, S 1.309
Chung, S 1.197, 1.380, 2.257, 3.257,
3.258, 3.259
Chung, S S. 3.073
Chung, W 1.099
Chung, W K. 1.341
Ciccone, O 2.159, 3.131
Cid Lopez, M 3.273, 3.275
Cilio, M R. 2.343
Cilio, M 1.312, 2.296, 2.386, 3.194
Cines, B 2.290
Cios, J 2.176
Ciumas, C 2.065
Claassen, J 3.265
Clancy, R 1.096
Clark, C L. 3.188
Clark, S 1.238
Clarke, D F. 1.054, 1.126, 1.265, 2.125,
3.224, 3.303
Clarke, M 1.003
Clarke, S 3.374
Claus, R 1.186
Claxton, F. 3.385
Claycomb, K I. 2.036
Cleary, D R. 2.075
Cloyd, J C. 1.200
Cloyd, J 2.026
Cmejla, R 3.146
Coan, A 2.203, 2.233
Cogan, D L. 3.084
Cohen, D 1.332, 1.375, 2.366, 2.367
Cohen, G 1.334
Cohen, J 1.317
Cohen, M 1.109
Cohen-Wolkowiez, M 2.284
Coimbra, E 2.325, 2.326
Coito, A 1.160, 3.219
Cole, A J. 2.243
Cole, A 1.060, 2.172, 2.213, 3.115
Cole, J H. 1.146
Cole, J R. 2.328
Cole, J 1.375
Coles, L 2.026
Collier, R 3.158
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Collins, S 3.045, 3.057
Colquhoun, H 3.102, 3.265
Colson, A 1.224
Comper, S M. 1.345, 3.312
Compton, R 1.076
Concha, L 3.207, 3.221
Condie, J 1.246
Connelly, L 1.279
Connolly, J 3.131
Connolly, M J. 2.030
Connolly, M 1.245, 1.311, 1.361, 3.155
Conrad, B 2.201
Conry, J 1.262, 1.307
Consortium, E 1.315, C.06
Constantinidis, C 2.035
Constantino, T 3.254
Cook, M 3.144
Cook, R 2.345
Cooper, E C. 1.308, 1.346, 2.386, 3.018,
3.337, C.07
Cooper, P 3.089
Coorg, R 1.381
Coppola, G 2.132
Cops, E J. 3.346, C.04
Corbett, B 1.363
Cornell, C 3.134
Cornely, S 2.197
Cornes, S 1.256, 2.157, 3.279
Cornett, K 3.010
Corredera, E 2.275
Corso, J T. 1.345, 3.312
Coryell, J 1.085, 1.091, 1.110, 1.122,
1.179, 2.163
Cossette, P 2.322
Cossu, M 3.149
Costa, F A. 3.392
Costa, M A. 2.020
Costantini, J 2.016
Costello, D 3.159, 3.160
Costinas, S 2.024
Coto, C 1.166, 1.171, 3.070, 3.217
Coto, C A. 3.076
Cottin, V 2.148
Cottler, L 1.365
Coughlin, F R. 1.029
Coulter, D 2.076, 2.113, 2.118, A,05
Coumans, B 3.026
Couture, D 2.171
Couture, R 3.059
Cowen, S 2.079
Cracco, J 1.042
Cramer, J 1.182, 2.249
Crampton, S 3.089
Creinin, M 2.195
Crepeau, A Z. 1.322
Crepeau, D 2.026
Crino, P 3.107
Crippa, S 2.148
Cristofaro, S 1.282, 2.206
Criteser, S 1.241
Croker, D 3.361
Crompton, D E. 2.359
Crompton, D E. 3.339, C.01
Crone, N 1.028, 1.070, 2.128
Croom, J 2.332, 3.348
Cross, J 1.275, 2.308, 3.195
Crowder Skarpaas, T 1.045, 2.172, 3.031,
3.085
Crunelli, V 3.037
Cruz, E 1.098, 3.340
Cuellar-Herrera, M 2.071
Cui, W 1.366
Cukiert, A 1.266, 3.307
Cukiert, C M. 1.266, 3.307
Cull, A 1.158
Cunningham, C E. 2.336
105
Curatolo, P 2.148
Curiel, J 3.019, A.01
Curry, D 1.268, 2.305
Curwood, E 1.159, 3.214
Cutter, G 1.208
Cyrino, A 3.117, 3.119
D
D'Alfonso, S 1.245
d’Augères, G B. 2.148
D'Cruz, O 3.086, 3.276
D'Giano, C 1.008
D'Souza, J 2.253
Daab, A 3.014, A.04
Dadkhah, M 2.086
Daga, A 2.354
Dahl, H 1.317, 2.152, 2.361
Dahl, I T. 2.226, B.06
Dahle, E 2.021
Dahmane, E 3.271
Dale, R C. 3.294
Dalfino, J 3.087
Dallara, A 1.040
Dalmau, J 2.320
Dalton, S 2.238
Damiano, J 1.313, 3.346, C.04
Damoiseaux, J 1.104
Damron, J 1.077
Daneshrad, J 3.143
Dang, L 1.020
Daniel, A G. 3.216
Danoun, O 2.279
Danzer, S 2.039, 3.358
Darbro, B 3.346, C.04
Darby, D 1.282
Das, K 2.353, C.03
Das, K 2.391
Das, S 1.171, 3.217
Dash, D 3.093
Datta, A 1.311, 3.155
Daunais, J 2.035
Davey, M 2.229, B.08
Davidoff, K 3.313
Davidson, L 2.330
Davis, A M. 2.336
Davis, A R. 2.192, 2.194, 2.197
Davis, J 1.096
Davis, K 1.111, 1.166, 1.171, 2.019,
3.070, 3.076, 3.217, 3.284, 3.308
Davis, R C. 1.333
Davis, R 1.184, 1.327
Davis, T 2.297
Day, B K. 1.174
Dayyat, E 3.156
Dazzo, E 1.343, 2.132
Deale, A C. 1.180
de Almeida, J 3.315
Dean, B 1.044
De Biase, D 1.343
de Bruyn, G 3.158
Debski, M 2.060
Debski, R 3.293
Decima, G 1.008
Deck, G 2.213, 3.115
de Curtis, M 2.323
Dedeken, P 1.203
Dedeurwaerdere, S 3.051
Deeb, T Z. 2.017, A.09
Deepak, S 1.258, 3.075, 3.079, 3.106
DeFreitas, T 1.307, 2.311, 3.297
DeGiorgio, C M. 1.130
de Jonghe, P 1.313
Deki, S 3.374
Delamont, R 1.180
de Lanerolle, N 3.205
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
de la Pena, C B. 2.196
Del Campo, M 2.086
Deleo, F 2.323
Deleu, D 1.089
Delgado-Escueta, A 1.310, 2.354, 2.356,
3.026
Del Gaizo, J 2.208
Del Giudice, E 2.014
de Lima, M T. 2.135
Delisle, B P. 2.041
DellaValle, D 1.247
Delman, B 3.068
DeLorenzo, R 2.040
De Los Reyes, E 1.037
Del Pozzo, B 2.144
De Marchi, L R. 1.345
De Marchi Capeletto, C 2.135
De Marco, A P. 3.317, 3.318
Demarest, S 2.067, 3.147
De Maria, M 3.018
Demarque, R 2.233, 2.357
de Melis, M 3.089
Demos, M 1.311, 3.155
Dengler, C 2.113
de Nijs, L 2.354, 2.356, 3.026
Denoyer, Y 1.057
Dente, J 2.160
Deodhar, M 2.057, 3.363
DePaula-Silva, A 3.362
de Pesters, A 2.121, 3.087
Depienne, C 1.303
Depositario-Cabacar, D 1.262
Depositario-Cabacar, D 2.313
Derera, I 2.041
Dergalust, S 3.355
De Ribaupierre, S 1.147
Derry, C 2.330
de Saint Martin, A 2.292
Deshimaru, M 3.359
Deshpande, H 3.075
Deshpande, L 2.040
de Toledo, M 1.230
Detre, J 1.171
Detyniecki, K 1.223, 1.234, 2.138, 2.270,
2.380, 3.227
de Vincentiis, S 2.233, 2.324, 2.326,
2.357
Devinsky, O 2.174, 2.348, 3.292
Devlin, J J. 1.321
de Vries, P 2.148
Dewar, S 2.298, 2.316
de Witte, P A. 1.306, 3.039, C.05
DeWolfe, J 1.165, 2.077
Dey, D 3.005, 3.005
Dezsi, G 3.243, B.05
Dhamne, S 2.025, 2.055
Dhulekar, N 2.392
Diaz, F 2.267
DiBonaventura, M D. 1.236
Di Bonaventura, C 2.132
DiCarlo, S 1.231, 2.351
Dichter, M 2.076, 3.251, A,05
DiCiaccio, B 3.114
Dicker, L 1.096
Didato, G 2.323
Dieguez, D 2.059
Diehl, B 1.259
Dierkhising, R 1.238
Dietrichs, E 2.301
Dike, C R. 1.242, 1.243
Dike, N 1.066
Dill, E 2.291
Dinday, M T. 3.017, 3.049
Ding, K 1.105
Diosy, D 2.140
Dispoto, S 1.184, 1.187
e
Dittman, J 3.014, A.04
Divine, G 1.144
Dlugos, D 1.122, 1.316, 2.163, 3.088,
3.196, 3.332, 3.342, C.02, C.08
Dobrinsky, C 1.189, 1.190, 1.192
Dobrota, M 3.163
Dobyns, W 3.335
Doerrer, S C. 1.249
Doesburg, S 1.039, 1.041, 2.155, 3.066
Doherty, C 1.003
Doherty, J 3.102
Doherty, J 2.240
Doja, A 1.357, 2.350
Dolatshahi, M 2.141
Dolce, A 3.282
Dolzany Rosales, FE 2.143
Domanska-Pakiela, D 1.124
Domen, C 3.165
Dominese, A 2.323
Domínguez, M 1.230
Dominski, M 1.353
Donaire Pedraza, A 2.320, 3.286
Donath, V 3.314
Donner, E 1.248, 1.331, 2.289, 2.312
Dority, L 1.247
Dorn, T 2.152
Doshi, C 2.097, 3.111
Doshi, H 2.280
Doss, J 1.176, 1.295, 2.342, 2.346, 3.233
Doty, D J. 3.362
Doucet, G 2.222
Drabek, J 1.301
Drake, J 2.312
Drane, D 1.058, 2.234, 3.218, 3.291, B.07
Drazkowski, J 1.322
Drees, C 3.165, 3.186
Dressel, A 1.102
Drew, P J. 2.027, 2.053
Driwech, W 2.024
Du, X 2.087, A.03
Dubeau, F 2.102, 2.111, 2.145, 2.214
Dubovec, K 1.093
Duchowny, M 1.060
Duckrow, R 1.060, 2.075, 2.172
Dudek, F 2.158
Dudek, F E. 1.229
Dudley, R W. 2.307
Duempelmann, M 1.021
Dufresne, D 1.093
Duignan, K 1.320
Dulla, C 2.056, 3.361
Duncan, J 1.154, 1.349
Duncan, J 1.259
Duncan, N 3.316
Duncan, S 2.330, 3.316
Dunlap, S 3.394
Dunlop, J 2.017, A.09
Dunn, E 2.024
Duong, T Q. 1.152
Dupuis, N 2.044
Durai, K 2.082
Duran, F 2.324
Durgin , T 1.225, 1.226
Duron-Martinez, R M. 1.310, 2.354, 2.356
Dustin, I 2.007
Dutton, S 3.057
Dwivedi, A 3.279
Dworetzky, B 2.236, 2.267, 2.333
Dyment, D 2.350
Dzedzits, T 3.050
Dzhala, V 2.004, 2.008
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Eberly, K 1.100
Ebersole, J S. 1.050
Echauz, J 2.060
Eck, K 3.161
Eckert, A 2.026
Eckhardt, K 3.253
Eckhardt, K 3.261
Edwards, J C. 2.172, 3.218
Edwards, S 2.255
Egawa, K 1.052, 2.008
Egge, A 2.301
Egger, K 2.200
Eggleston, K 3.086
Ehrenberg, J 1.058
Ehrens, D 3.092
Eid, T 3.227
Einstadter, D 1.175
Eisch, A 2.091
Eizenkraft, A 3.104
Ekstein, D 2.264, 3.199
Ekstrom, A 2.079
Elahian, B 3.127
Elam, K 3.349
Elazary, N 3.104
El-Azzabi, T I. 3.376
Elder, E 2.267
Elger, C 2.085
Elias, W 3.371
Eliashiv, D 2.316
Elisevich, K 1.144, 3.213
Elkay, M 2.319
Elkins, K 1.161
Elledge, D 2.305
Elliott, M 1.171
Elliott, N 1.003
Ellis, M 1.348
Elmore, B E. 2.049
Elmoufti, S 1.199, 2.253
El Tahry, R 2.072, 2.085
Elwes, R 2.073
Elwood, M 2.158
Emery, E 2.219
Emery, L 3.284
Enatsu, R 1.253
Endoh, F 1.067
Endres, J 2.368, 3.354
Engbers, J 1.135, 2.265, 3.154, 3.370
Engel Jr., J 2.061
Enger, R 3.041
Englot, D J. 1.252, 1.270, 1.271, 1.362
Enoki, H 1.198, 3.296
Eom, S 1.299
Epstein, C 1.058
Epstein, L 3.010
Erbayat Altay, E 2.106
Erdinc, O O. 2.169
Ernst, G 3.200
Escayg, A 3.057
Eschbach, K 2.134
Esfahanizadeh, A 1.002
Espinera, A R. 2.193
Esplin, B 2.066
Ettinger, A 1.189, 1.190
Eun, B 3.372
Eun, B 1.090
Eun, S 3.372
Evans, C L. 3.330
Evans, D 1.311
Evans, L M. 3.330
Evans, P 1.038
Ewert, K A. 1.135
Ewida, A H. 1.258, 2.077, 2.142, 3.079
Ewing, K 2.153
106
Eyal, S 1.235, 2.264
Eydoux, P 1.311
Eysturoy, A 1.317
F
Fabres, L 3.305
Fabris, R 3.236
Facella-Ervolini, J 1.150, 1.151, 3.325,
3.331
Faghfoury, H 3.338
Fahimi, G 2.187, 3.168
Fain, R 3.260
Faingold, C 3.048, 3.204
Falcone, T 1.009, 3.233
Faleiros, L 3.117, 3.119
Falip, M 1.128
Falip Centellas, M 2.288, 2.320
Fallon, B 3.122
Fan, J 3.269, 3.270
Fang, L 3.069
Fang, L 3.269, 3.270
Fantaneanu, T 1.386
Farabella, I 2.353, C.03
Faramand, A M. 2.308
Fariborzi, A A. 3.143
Farin, F M. 2.049
Farmer, J 2.307
Farooque, P 1.223, 2.101
Farrer, M 1.311
Farwell, K 1.303
Fasano, R 1.058
Fasano, R E. 2.109
Faught, R 1.213, 1.225, 1.226, 3.088
Faustin, A 2.348
Fayed, N 2.336
FEBSTAT Study Team, 2.396
Fecske, E 1.007
Fecske, E 3.386
Federico, P 1.158, 1.158, 1.167
Feenstra, H 3.384
Feet, S 2.377
Feldman, R 3.068
Fellner, M 2.123
Feng, H 3.048
Feng, L 2.034
Fenger, C 1.317
Ferastraoaru, V 2.381
Ferguson, L 1.289, 1.290, 3.322
Feria-Romero, I A. 2.070, 3.108
Fernandes, F 2.357
Fernandez, S 1.128
Fernández Lebrero, A 2.275
Fernández-Mas, R 2.029
Ferrao Santos, S 2.072
Ferrari, P 1.054
Ferraro, L 1.111
Ferreira, J 1.184
Ferreira, J 2.148
Ferri, R 2.395
Ferro, M 1.294, 1.296, 1.361
Ferry, J 1.187, 1.211, 1.212
Fertig, E 2.196, 2.269, 3.344
Fessler, A 1.228
Feucht, M 2.148
Feyissa, A M. 1.035
Feyma, T 1.303
Fialho, H 3.177
Ficker, D 1.387
Fields, M 2.393, 3.068, 3.175
Fields, R 2.332, 3.348
Fields, T 2.061
Fiest, K 2.373
Fifer, M S. 1.028
Filiano, J 3.388
Fine, A 1.392
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Fine, A 2.088
Finet, P 2.322
Finnegan, S 2.369
Finnegan, T 1.012, 1.013, 1.014
Finnema, S 3.227
Firouztale, E 1.125
Fisher, G 2.115
Fisher, J 2.158
Fisher, R 1.082, 2.104, 3.083
Fisher, T 1.333
Fisher, T L. 2.319
Fisher, W G. 2.384
Fishman, J 1.334
Fitzpatrick, A 3.089
Fladrowski, C 2.148
Fleck, D 2.018
Flecknell, P 3.037
Fleming, M E. 1.132
Flinker, A 1.028
Floden, D P. 1.289, 3.321
Flores, J 1.233
Flores, R 2.374
Flores, S E. 3.143, 3.143
Flores-Mendoza, M 3.108
Foerch, P 2.003
Foldvary-Schaefer, N 2.137, 2.137, 2.245
Fonseca, C 3.232
Forcadela, M 1.024
Ford, P 2.066
Forgey, M 3.233
Fountain, N B. 1.036, 1.368
Fountain, N 1.060, 2.172, 3.318, 3.371
Fowler, K 1.366
Fowler, K M. 2.192, 2.194
Fox, C K. 1.367
Fox, D 2.241, 3.248
Fox, J 2.146, 2.241
Fox, N 1.349
Foxworth, P K. 2.378
Francione, S 3.149
Frank, A 1.179
Frank, L 3.010
Frank, M 2.396
Frankel, H 3.298
Frankel, W 1.320
Franz, D 1.251
Frasch, B 1.006
Frasier, C R. 2.052, 3.142, A.08
Frauscher, B 2.102, 2.111, 2.122, 2.145
Frederick, F 2.159
Freedman, D 2.174
Freeman, J L. 3.346, C.04
Freestone, D 3.144
Freier, K 2.344
Freilich, E 3.301
French, C 3.239
French, J 2.063, 2.138, 2.197, 2.206,
2.223, 3.088, 3.196, B.03
Frenguelli, B 3.037
Frey, L 3.073
Fried, I 2.061
Fried, L E. 3.387
Friedman, A 3.104
Friedman, D 2.348, 3.298
Friedman, L K. 2.001, 2.093
Frigerio, F 2.003
Frontera, A 2.165, 2.378
Frost, M 3.329
Frost, MD 3.292
Frucht, M 1.353
Fu, X 3.019, A.01
Fuentes, A 1.291
Fujii, D 3.365
Fujikawa, M 2.173, 3.320
Fujimoto, A 1.198, 3.296
Fujinami, R S. 2.021, 3.362
Fujita, M 2.007
Fujiwara, H 1.163, 2.127, 2.340
Fukasawa, T 1.138
Fullerton, H J. 1.367
Fulton, R 3.017
Fulton, S 1.162, 1.355, 3.156
Fung, E 1.245
Funk, B 3.213
Funke, M 1.269
Funkhouser, E 1.213
Furlan, S 1.343
g
Gaça, L B. 3.312
Gaddam, A 2.166
Gaelic, S E. 3.388
Gago, A 1.230
Gaillard, W 3.019, A.01
Gaillard, W 1.150, 1.172, 1.262, 1.298,
2.163, 2.219, 2.311, 2.313, 3.369
Gaillard, W D. 1.085, 1.091, 1.110, 1.122,
1.123, 1.137, 1.151, 1.307, 1.370,
2.183, 3.297, 3.301, 3.325
Galan, R 3.164
Galanopoulou, A S. 1.071, 2.048, 3.062
Galdis, B 3.236
Gale, J 1.278
Galiano, L 1.230
Gallentine, W 2.396, 3.010
Galluzzi, H 1.008
Gama, H 1.186, 2.243, 2.252
Gammaitoni, A 2.262
Gao, F 1.314
Gao, J 2.012
Gao, K 1.314
Gao, Y 1.314
Garbelli, R 2.323
Garces, M 1.233
Garcia, E 1.388
Garcia-Cairasco, N 3.038
García Estevez, D 2.275
García Gomar, M L. 3.221
Garcia Gracia, C 3.220
Garcia-Gracia, C 2.318
Garcia-Martin, G 3.272
García Morales, I 2.288
Garcia-Ramos, C 2.338
Gardella, E 1.317, 2.152, 2.362
Gardiner, K J. 3.009
Gardner, D 3.388
Garg, M 2.274
Gargaro, A 2.325, 2.326
Garibay Pulido, D 2.080
Garic, I 2.193
Garry, S I. 3.339, C.01
Garzon, E 3.117, 3.119
Garzon Mrad, C 2.060
Gaspard, N 1.034
Gattaz, W F. 2.357
Gausas, R 3.284
Gauthier, A 2.363
Gautier, N 3.053
Gavrilovici, C 3.136
Gavvala, J 3.287
Gaxiola Valdez, I 1.158, 1.167
Geannette, C 3.208
Gebre, R 2.160
Gedela, S 3.382
Geerlings, M 3.217
Geevasinga, N 1.059
Geider, K 2.360, C.09
Geller, E 2.172
Gellert, P 2.362
Genetti, M 1.160, 2.110
Gennaro, E 1.312
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Genov, R 2.083
Gentry, M 3.012
George, A L. 3.035
Gerard, E 2.063, 2.193, 2.195
Gerke, J 1.322
Germeyan, S C. 2.219
Geronimo, A 2.053
Gerrard, J 2.034
Gerrard, J L. 2.075
Gershen, L 2.007
Gersner, R 1.063, 1.064, 1.065, 3.045
Geyer, S 3.016
Gezalian, M 2.022
Ghatan, S 1.260, 2.393, 3.068
Ghearing, G 2.054, 2.082, 3.231, 3.289
Ghiaee, S 3.143
Ghizoni, E 1.351, 2.299
Ghoraani, B 3.147
Ghuman, A 1.049
Giallonardo, A 2.132
Gibbons, M 2.067
Gibbs, S 3.149
Gibson, K M. 1.099
Gidal, B 1.211, 1.212, 1.214, 2.267,
3.196, 3.254
Gidal, B E. 1.200
Gierbolini, J 2.165
Giguere-Duval, P 1.077, 1.372
Gil, F 2.320
Gill, F J. 2.288
Gill, D 3.294
Gilliam, F 2.027, 2.053, 3.385
Gilmore, E 1.034
Gil-Nagel, A 2.288
Giner, P 1.233
Giraldez, B 1.233
Girard, H 1.168
Girgis, F 2.302
Girgis, S 2.227
Girouard, M 3.088
Gislimberti, G 2.148
Gissen, P 2.353, C.03
Gjerstad, L 3.162
Gladden, M 1.366
Glanowska, K 2.087, A.03
Glass, H C. 3.194
Glasscock, E 3.053
Glauser, T 1.123, 1.137, 1.163, 2.183,
2.340, 3.063, 3.063
Glaze, D 1.301
Gliksman, F 3.344
Gliske, S 3.103
Gluckman, B 2.027, 2.053
Glykys, J 3.003
Go, C 2.312, 3.151
Gobburu, J 3.271, 3.378
Gober, L 2.160
Godek, M 2.094
Godge, Y 2.315
Godin, J 3.026
Godoy, L D. 3.038
Godwin, D 2.035
Goenaga, J 2.241
Goenaga, J 3.248
Goldenholz, D M. 1.018, 2.381
Goldfarb, M 1.306, C.05
Goldman, A 1.301
Goldsmith, J 1.341
Goldstein, J 1.123, 1.137, 2.183
Goldstein, L 1.180
Goldstein, D 3.346, C.04
Golla, S 1.038
Gollwitzer, S 2.123
Golshani, P 3.143
Gomez-Ibanez, A 1.233
107
Gommer, E 3.283
Gong, Y 1.318
Gonzalez, A 2.382
Gonzalez, D 2.284
Gonzalez, E 3.161
Gonzalez, F L. 2.275, 3.286
Gonzalez, J S. 3.313
Gonzalez, M 1.128
Gonzalez, R 2.086
Gonzalez, S 2.088
Gonzalez Giraldez, B 3.334
Gonzalez-Martinez, J 1.170, 1.273, 1.278,
2.064, 2.081, 2.318, 3.124, A.06
Gonzalez Montoya, V 3.125
González Olvera, E 3.207, 3.221
Gonzalez-Rojas, C 3.384
Gooding, A L. 2.328
Goodkin, H 1.123, 1.137, 2.183
Goodman, J 3.031
Goodman, R 2.172
Goodwin, S 1.294, 1.294
Goossens, J 3.051
Gopalakrishnan, M 3.271, 3.378
Gordon, C M. 2.174
Gorin, B 1.197
Gostelow, M 2.284
Gotay, K 1.058
Gotman, J 2.102, 2.111, 2.122
Gotterer, L 2.335
Gottshall, J 3.014, A.04
Goubran, M 1.147
Govil Dalela, T 1.156, 2.209
Gowda, S 3.125
Goyal, M 1.244, 3.082, 3.167
Goyal, V 2.300
Grabowski, J A. 1.331
Grabowski, T J. 3.218
Graham, D 3.294
Granader, Y 3.331
Granbichler, C 3.367
Grant, A 3.313
Grant, E 2.097
Graus, F 2.320
Gravel, J 2.345
Gray, W 3.037
Greenberg, R 2.284
Greentree, D 2.001
Gregory, A M. 2.334
Greiner, H 2.127
Grieb, P 2.094
Griffin, N G. 3.346, C.04
Grijalva, I 3.108
Grimes, K 2.235, B.09
GRIN1 study group, c 2.360, C.09
Grindley, T 3.192
Grinenko, O 2.064
Grinnell, T 1.183, 1.185, 1.186, 2.243,
2.246, 2.252, 2.254, 3.254
Grinspan, Z 1.085, 1.091, 1.110, 1.323,
3.177, 3.350, 3.381
Grisar, T 2.354, 2.356, 3.026
Grishaber, T 1.023
Grobelny, B 3.298
Grollnek, A K. 2.159
Grone, B P. 2.023
Grosenbaugh, D 3.022
Gross, D 2.203, 3.211
Gross, R 1.058, 1.060, 1.228, 2.030,
2.172, 3.094, 3.291, A.07
Gross, W 3.218
Grote, C L. 3.210
Grouiller, F 3.219
Grova, C 1.053, 1.169, 2.214, 2.322
Grover, E 2.160
Gruenewald, A 2.028
Gu, F 3.006
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Guaranha, M B. 1.345
Guduru, Z 1.115
Gueguen, B 3.090
Guekht, A 2.228
Guella, I 1.311
Guénot, M 1.276
Guerreiro, C 2.233
Guerrero-Lopez, R 3.334
Guerrero-Luera, R 3.349
Guerriero, R 2.089, 2.136, 2.143, 2.186,
3.333
Guerrini, R 1.275, 2.152
Guger, C 1.157
Guilfoyle, S 1.292, 2.337
Guilhoto, L M. 1.310, 2.354, 2.356
Guillamon, E 1.233
Guirgis, M 2.086
Gulsen, G 1.173
Gultekin, E 2.283
Gulyaeva, N 2.228
Gummadavelli, A 2.034
Gump, W 3.293
Gunbey, C 1.344
Gunning, B 2.262
Gunter, S A. 3.016
Guo, A 1.119, 2.168
Gupta, A 1.009, 1.055, 2.137, 3.158
Gupta, J 2.088
Gupta, R 1.087
Gupta, S 1.374
Guptill, J T. 2.284
Gurbani, S 2.099
Gurkoff, G 2.079
Gurses, R 2.096
Gururangan, K 3.128
Gusev, E 2.228
Gustafson, M 3.380, 3.386
Gutekunst, C A. 3.094, A.07
Gutierrez, C 1.354
Gutierrez, R 2.112
Güvelioğlu, L 2.106
Gwinn, R 1.060, 2.172
h
Ha, R 1.223
Haas, K 1.094, 2.248
Habtke, B 1.261
Hadar, P 1.171, 3.217
Haddad, N 1.089
Hader, W 1.267, 2.302
Haegelen, C 1.057, 1.084
Hafeez, B 1.323, 3.177
Hagen, D 1.009
Hagge, M 2.123
Haginoya, K 1.302
Hajek, M 2.036
Hakonarson, H 1.316, 3.332, C.02
Halford, J 1.044, 1.193, 3.088
Hall, A 3.005, 3.005
Hall, A 2.294
Hall, C 3.021
Hall, J 2.214
Hallak, J E. 2.231
Halliday, W 3.300
Halvorsen, M 3.257, 3.258, 3.259
Hamandi, K 1.309
Hamberger, M J. 1.297, 1.300, 2.327,
2.328
Hameed, M 2.009, 2.055, 2.089
Hamer, H 2.123
Hamling, K 2.023
Hammen, T 2.200
Hammock, B 2.242
Hammond, R 1.147
Hammond, R 2.240, 3.102
Hampton, D 3.361
Han, K 3.345
Hanada, T 2.239
Hanak, T 3.362
Hanaya, R 2.013
Hancock, E 2.255
Handler, M 1.261
Handy, M 2.028, 3.008, 3.251
Haneef, Z 2.215
Hani, A J. 1.062
Hanrahan, D 1.247
Hans, A 3.131
Hansen, B 2.375
Hanslmayr, S 2.123
Hantus, S 1.092
Hara, K 1.254
Harada, K 2.013
Harden, C 1.132, 1.192, 2.197
Harden, J 1.340
Hardies, K 1.313
Hardy, A 3.208
Haridas, B 1.323
Hariharan, H 1.171
Harini, C 2.159, 2.286, 3.193, 3.255
Harris, D 3.113
Harris, R 3.208
Harris, S 1.223, 2.270
Harris, T J. 2.084
Harrison, C 2.391
Hartman, A 1.085, 1.091, 1.110, 1.122,
2.163, 3.282
Harvey, A S. 3.346, C.04
Harvey, J 2.254, 3.084, 3.088
Harvey, R J. 2.353, C.03
Hasegawa, H 1.083
Hashim, A 1.242, 1.243
Hashizume, A 1.272, 2.013
Hassnain, K 1.362
Hasulak, N 3.031, 3.085
Haugaa, K H. 2.226, B.06
Hauser, W 2.192, 2.194, 2.228
Haut, J S. 1.290
Haut, J 3.322
Haut, S 1.013, 2.138, 2.381, 3.279
Havens, K 1.307, 3.301
Havens, K 1.262
Havens, K 1.172, 2.313
Hawkins, N 1.319
Hayashi, K 2.162
Haykal, M 3.236
Hays, R 1.105
Hayward, O 3.328
Hayyat, U 1.038
He, B 2.045, 2.212
He, X 2.222
Heck, C 2.172, 3.072
Hedges, D 3.171
Hedrich, T 1.053, 2.214
Hedrick, T 2.116
Hegazy, M 2.318
Hegde, M 2.157, 3.196
Heguy, A 2.348
Hei, C 3.357
Heida, C 3.283
Heinze, H 3.077
Heinzen, E 3.346, C.04
Helbig, I 2.360, 2.361, 3.342, C.08, C.09
Helbig, K L. 1.303, 1.317, 2.360, 3.342,
C.08, C.09
Helm, P 3.041
Helmers, S 1.225, 1.226, 1.374
Helseth, A 1.123, 1.137, 2.183
Helvaci Yilmaz, N 2.106
Heminghyt, E 2.301
Hempel, A 3.329
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Henderson, G 1.386
Hendrick, R 1.313
Hendrickson, R 3.289
Hennessy, R 2.138
Hennig, J 2.339
Henning, O 1.221, 2.377
Henry, B J. 1.249
Henry, B 3.280
Henry, K 2.179
Henry, T R. 3.088
Hensch, T 2.089
Heo, K 2.129, 2.130
Heo, S 3.345
HEP Investigators, O 2.138
Herekar, A 1.060, 1.121, 2.172
Herman, J P. 2.039
Herman, S 3.163
Hermann, B 1.298, 2.338, 3.238, 3.323
Hermes, D 3.087
Hernandez, J 2.033
Hernandez-Hernandez, L 3.342, C.08
Hernandez Ronquillo, L 2.131, 2.191,
3.093, 3.351
Hernandez-Ronquillo, L 2.058
Hernando, K 1.165
Herrera, M 3.390
Herrman, H 2.301
Hertzberg, C 2.148
Herzog, A 2.192, 2.194
Hesdorffer, D 1.341, 1.366, 2.059, 2.168,
2.174, 2.206, 2.223, 2.396, 3.010, B.03
Hester, M 3.358
Hetherington, H 2.204
Heuser, K 3.041, 3.162
Hewett, J 1.318, 3.060
Hewett, S 3.060
Heyne, H O. 2.360, C.09
Hidalgo, E 3.298
Higashijima, T 3.302
Higgins, A 1.003
Higgins, J. 1.321
Higo, T 1.072, 1.149, 1.384, 3.295
Higuchi, E 2.156
Hiken, M 2.058
Hildebrand, M S. 3.346, C.04
Hildebrand, M 1.313
Hill, K D. 2.284
Hill, T 3.034
Hill-Yardin, E 3.239
Hilmarsson, A 1.228
Hinman, K 3.233
Hintz, M 2.147
Hirata, H 2.353, C.03
Hirose, S 2.356, 3.359
Hiroshima, S 1.157
Hirsch, E 1.275
Hirsch, L 1.034, 1.223, 1.234, 2.270,
2.380
Hirvonen, J 2.007
Hisama, F 3.335
Hixson, J 2.138
Hjalgrim, H 2.152, 2.362
Ho, A 2.305, 2.305
Ho, C 2.311, 3.297, 3.301
Hoane, M R. 2.049
Hoch, D 1.325
Hocker, S 1.238
Hodgeman, R M. 1.099, 2.135, 2.159,
2.286, 3.131, 3.193
Hodgson, N 2.089
Hoerth, M 1.322
Hoffman, E 3.265
Hogan, R E. 1.174, 3.257, 3.258
Hogan, R 3.259
Holder, C 1.162
108
Holland, K 2.127, 3.063
Holland, S 1.163
Höller, Y 1.160
Holmay, M 3.257, 3.258, 3.259
Holmes, G 1.312
Holmes, M D. 2.126, 2.210
Holtkamp, D 3.245
Holtkamp, M 2.258, 2.261, 2.268, 3.077
Holzheimer, Q 1.353
Honda, R 1.359, 2.188, 3.203
Hong, J 2.007
Hong, S 2.202
Hong, S 1.145
Hong, S 1.257
Hong, S 3.311
Hong, S 1.257
Hong, Z 2.251
Honig, A 3.199
Honma, S M. 1.271
Hooper, A A. 3.043, 3.241, B.04
Hope, O 3.309, 3.356
Hopp, J 2.235, B.09
Hornik, C P. 2.284
Horvath, G 1.311
Hosford, B 3.358
Hou, J 2.210
Hou, M 2.195
Houitte, P 2.090
Hounshell, J A. 2.364
House, P 2.297
Howard, M 3.140
Hsiao, M 3.072
Hsieh, J 2.091
Hsin, Y 3.226, 3.230
Hsu, D 3.238, 3.323
Hsu, F P. 3.074
Hsu, F 2.118
Hsu, S 2.134
Hu, S 2.001, 2.093
Hu, S 3.154
Huang, B 2.040
Huang, C 1.347, 2.015
Huang, C 2.144, 3.285
Huang, S 2.079
Huang, S 1.374
Huang, W 1.296
Huang, Y 3.227
Hubbard, A 2.024
Hubbard, J 3.252
Hubbard, J A. 3.052
Huether, R 1.303, 3.342, C.08
Hughes, D 2.353, C.03
Hughes, S 1.013
Hughes-Scalise, A 1.176, 2.342
Huguenard, J 3.023, 3.023, 3.137
Huh, L 1.311, 3.155
Hull, J 3.142
Humphries, C 3.218
Hung, P 3.328
Hunter, E 1.279
Hunter, G 3.351
Hunter, M 1.143
Hunter, M B. 2.341
Huntley, M A. 2.018
Huntsman, M M. 3.019, A.01
Huntsman, R 2.058
Hur, E 2.272
Husain, A 1.062, 2.378
Hussain, S 1.122, 2.163
Hussain, S A. 2.273, 2.274, 3.105, 3.120,
3.229, 3.328
Hussein, Z 1.187, 1.211, 1.214
Hutman, T 3.328
Huttner, A 3.227
Huynh, L 1.197
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Hwang, H 1.075
Hwang, J 1.141
Hwang, S 3.080, 3.281
Hwang, Y 1.075
Hwnag, W 1.257
I
Iannotti, G 1.160, 3.219
Ibrahim, Z 1.042
Ido, K 2.239
Iida, K 1.272, 2.013
Iimura, Y 1.072, 1.149, 1.384, 3.295
Ikeda, A 1.281
Ikegaya, N 2.309, 3.306
Ilhan Algin, D 2.169
Inada, T 1.281
Inagaki, M 2.047
Inaji, M 1.254
Inano, R 1.281
Inati, S 1.018, 2.007, 3.112, 3.209
Inati, S J. 3.209
Innis, R 2.007
Inoue, N 2.047
Inoue, Y 1.250, 2.356, 3.256
Inoue, Y 2.251
Inoyama, K 2.104
Ippolito, D 2.063
Iragui-Madoz, V 1.022, 1.076, 1.168
Ireland, T A. 3.389
Irland, M 1.131, 2.394, 3.183
Ishihara, K 2.013
Ishihara, N 1.142
Ishikawa, K 3.256
Isnard, J 1.276
Isojarvi, J 1.077, 1.197, 1.200, 1.372
Isom, L L. 2.052, 2.087, 2.114, 3.054,
3.142, A.03, A.08
Israel, S 2.264
Isrie, M 1.306, C.05
Issa, N 2.384
Ito, Y 3.302
Ito, Y 1.142
Ivanova, V 3.090
Ivanyi, B 2.062
Ivaturi, V 3.271, 3.378
Iwaki, H 3.320
Iwasaki, M 2.173, 2.304, 3.129, 3.212,
3.320
Iwuchukwu, I 1.131
Iyengar, S 1.033, 1.285, 3.121, 3.344
Iyengar, S S. 2.196
Iyer, S H. 3.242
Iyer, V 2.315
Izadi, A 2.079
Izadyar, S 1.287, 2.187, 3.168
J
Jack, S M. 1.338
Jackson, C 2.024
Jackson, D 3.238, 3.323
Jackson, G D. 1.159
Jackson, G 3.214, 3.228
Jackson, M 1.123, 1.137, 2.181, 2.183,
2.276, 3.111, 3.177, 3.255
Jacob, M 2.056
Jacob, S 3.161
Jacob, T 3.027
Jacobs, J 1.021, 2.339
Jacobs, L M. 3.070, 3.076
Jacobs, M L. 3.218
Jacobson, M 1.354
Jafarpour, S 2.135, 2.276, 2.286
Jagid, J 1.284, 3.235, 3.288, B.02
Jain, S 2.127
Jain, N 2.315
Jaiser, N 2.339
Janca, R 3.146
Jang, W 2.129
Jani, V 3.375
Jansen, A 2.148
Jansen, F E. 1.303
Jansen, L 1.122, 2.163, 3.016
Janssen, M L. 3.283
Jantararoungtong, T 2.352
Jara-Prado, A 1.310, 2.354, 2.356
Jarauta Salvador, F 3.273, 3.275
Jardim, A P. 1.345, 1.348, 3.312
Jarrar, R 1.246
Javaherian, M 3.143
Javed, A 1.223, 1.234
Jayabal, V 1.056
Jayakar, A 2.143, 2.310
Jayewardene, A 3.086
Jefferys, J 3.037, 3.058
Jehi, L 1.092, 1.134, 2.137, 2.318, 3.220
Jehle, R 1.071
Jenko, K 2.007
Jensen, F 2.028, 3.008, 3.070, 3.076,
3.251
Jensen, V 3.041
Jenson, K 2.126, 2.210
Jeon, D 3.281
Jeong, J 2.199
Jepsen, B 2.362
Jesus, J D. 1.325
Jette, N 1.135, 1.324, 2.265, 2.302, 2.373,
3.154, 3.370
Jetter, G 3.088
Jezdik, P 3.146
Jiang, A 1.223, 1.234
Jiang, M 1.216
Jiang, W 2.267, 2.284, 3.069, 3.267,
3.269, 3.270
Jiang, Y 1.314
Jicha, G 2.154
Jimenez, N 2.331
Jimenez, X F. 2.066, 2.379
Jimenez-Hakim, E 3.390
Jiménez Valverde, L O. 3.221
Jin, J 1.079
Jin, K 2.173, 2.304, 3.129, 3.212, 3.320
Jin, X 2.012
Jiong, Q 2.148
Jirasakuldej, S 1.040, 3.161
Jirsch, J 2.237
Jiruska, P 3.146
Jo, K 2.129
Jobst, B C. 1.036, 1.286
Jobst, B 1.060, 2.172, 2.221
Joel, M 1.353
Johannesen, K 1.317, 2.152
Johannesen, K M. 2.362
Johannessen, S 2.377
Johannessen, S 1.221, 2.285, 3.274
Johnson, A 2.255
Johnson, E 1.032, 3.030
Johnson, J 1.004, 3.309
Johnson, M 2.092
Johnson, M 3.261
Johnson, P 1.323
Johnson, M 1.224, 3.253
Johnston, J 3.082
Johnstone, J 3.045
Jonathan, M 1.109
Jones, A 2.085
Jones, B 3.130
Jones, J 1.285
Jones, J 1.278
Jones, J 3.238, 3.323
Jones, N 3.034
Jones, N 3.100, 3.243, 3.346, B.05, C.04
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Jones, S 1.140, 2.081, 3.222, A.06
Joo, E 1.257
Jorge, C L. 1.382
Jose, S 1.309
Joseph, D J. 3.138
Josephson, C 1.135, 2.265, 2.302, 3.370
Joshi, A 1.140
Joshi, C 1.122, 2.163
Joshi, N 1.308, 3.337, C.07
Joshi, R 2.380
Joshi, S 1.091, 1.122, 2.163
Joshi, S 3.206
Joshua, D 1.389
Jouny, C 3.092
Jovic, N J. 1.371
Jozwiak, S 1.124, 2.148
Juarez, L 1.213
Juhasz, C 1.017, 2.199
Juhl, S 1.220
Jules, B 1.071
Jung, K 2.372, 3.080, 3.281
Jung, K 1.209, 3.080, 3.281
Jung, S 1.283
Junger, K 2.337
Juul, H 2.076, 3.251, A,05
Juusola, J 2.349
k
Kaba, CC. 3.143
Kachouri, A 3.106
Kaczmarek, L K. 3.059
Kadakia Bhalla, P 2.060
Kadam, S 3.061, 3.067
Kaddurah, A 1.117
Kadipasaoglu, C 3.078
Kadiwala, H 1.105
Kagawa, K 1.272, 2.013
Kahn, A 3.147
Kaiboriboon, K 3.352
Kaido, T 2.309, 3.306
Kaimovsky, I 2.228
Kakisaka, Y 2.173, 3.320
Kakita, A 1.305
Kalamangalam, G 1.044, 1.069, 3.078,
3.309
Kalayjian, L 2.063
Kalilani, L 1.225, 1.226
Kalynchuk, L 2.058
Kam, C 3.266
Kamada, K 1.157
Kamada, T 3.391
Kamal, H 1.097
Kameyama, S 1.250, 1.305, 3.302
Kaminski, R 2.003, 3.024, 3.037, 3.250
Kamintsky, L 3.104
Kan, N 3.355
Kandipalli, D 2.280
Kandratavicius, L 2.231
Kane, M 3.267
Kaneko, S 1.250, 2.356, 3.256
Kaneko, Y 2.309, 3.306
Kanemoto, K 2.389
Kanes, S 3.102, 3.265
Kang, H 1.264, 1.299
Kang, J 1.114, 2.175, 3.113
Kang, M 3.234
Kang, S 3.061
Kankirawatana, P 2.314, 3.389
Kannan, K 2.348
Kanner, A 1.284, 2.170, 2.206, 3.182,
3.210, 3.235, 3.288, B.02
Kanno, A 1.253
Kansal, L 1.022
Kantor, E D. 2.049
Kao, A 1.262, 1.307, 2.290
109
Kapeller, C 1.157
Kaplan, R 3.342, C.08
Kapoor, S 1.326, 1.393
Kapur, K 2.181
Kapur, J 3.022, 3.022, 3.206
Kapur, K 2.135, 2.159, 3.111, 3.169,
3.193
Kapur, R 1.060, 1.121, 2.172
Karajannis, M 2.348
Karakis, I 2.109
Karia, S 1.247
Karkar, K 1.152
Karli Oguz, K 1.344
Karlsson, C 2.258, 2.261
Kartagiri, M 1.272
Karunakaran, S 3.078
Kasradze, S 1.206
Kassab, M 3.375
Kassiri, H 2.083
Kaszynski, K 2.346
Katagiri, M 2.013
Kato, A 1.250
Kato, K 2.173, 3.320
Kato, K 1.223, 2.270
Kato, M 1.302, 1.305
Katz, A D. 1.223, 1.234
Kaufer, D 3.104
Kaufman, K R. 1.002
Kaur, G 1.383
Kaur, H 2.104
Kaur, M 1.144
Kaur, G 3.340
Kaushal, R 1.323
Kavak, K 1.087
Kavi, T 3.107
Kawahara, A 2.353, C.03
Kawai, K 1.250
Kawara, T 1.061
Kaye, H L. 1.063, 1.064
Kearney, J A. 1.319, 2.116, 3.035
Keating, R 2.311, 3.297
Keator, C 1.085, 1.091, 1.110, 1.122,
2.163, 3.337, C.07
Keeling, A 3.278
Keereman, V 3.141
Keitner, G I. 3.237, B.01
Keller, A 3.145
Kellermann, T 1.181
Kelley, M R. 2.017, A.09
Kelli, G 1.353
Kellogg, M 3.353
Kelly, K M. 1.280, 3.205
Kennedy, C 2.255
Kennedy, J 2.195
Kenneth, L 1.394
Kenney, D 1.277
Kent, P 2.187, 3.168
Kenworthy, L 3.331
Keough, K 3.303
Kern, L M. 1.323
Keros, S 3.177
Kerr, D 2.357
Kerr, E 2.312
Kerrigan, J 2.146, 3.346, C.04
Kessler, C 1.102
Kestle, J 1.269
Kevill, J W. 2.153
Khambhati, A 3.148
Khambhati, A N. 2.019
Khan, A 1.147
Khan, F 1.131, 2.394, 3.183
Khan, H 2.392
Khawaja, A M. 1.208, 2.077, 3.079
Khoshkhoo, S 3.042
Khozein, R 2.160
Khusiwilai, K 1.172, 3.215
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Kidokoro, H 1.142
Kiernan, M 1.059
Kija, E 2.159
Kijsanayotin, P 2.347
Kikuchi, K 1.212
Kikuchi, T 1.281
Kim, B 3.111
Kim, D 2.372
Kim, D 2.129
Kim, D 1.264
Kim, D 1.079, 2.247, 2.372
Kim, E 1.139
Kim, G 3.059
Kim, G 1.090, 3.372
Kim, H 1.264, 1.299, 2.293, 3.180, 3.201
Kim, H 1.075
Kim, H 2.130
Kim, H 3.069
Kim, H 2.372
Kim, H 1.023, 1.031, 1.225, 1.226, 2.314
Kim, J 2.372
Kim, J 2.247
Kim, J 2.198
Kim, J 2.205
Kim, J 2.198
Kim, K 1.075
Kim, K 2.372
Kim, K 2.247
Kim, K 1.118, 1.141
Kim, K 3.118
Kim, M 1.139, 2.167
Kim, R 1.042
Kim, S 1.059
Kim, S 1.075
Kim, S 2.293, 3.201
Kim, S 2.205
Kim, T J. 1.209, 3.080, 3.281
Kim, W 2.205, 3.190
Kim, Y 1.141
Kim, Y 1.118, 1.141
Kim, Y 2.372
Kim, Y 2.032, 3.364
Kim, Y 2.120
King-Stephens, D 1.060, 1.121, 2.172
Kingswood, J C. 2.148
Kini, L 1.166
Kinoshita, M 2.162
Kipta, J 3.114
Kiri, V 1.203
Kirmani, B 1.191
Kirsch, H E. 1.252, 1.270, 1.271
Kirsch, H 3.342, C.08
Kishi, Y 3.166
Kistner, B M. 2.271
Kitabi, E N. 3.378
Kitaura, H 1.305
Kitazawa, Y 2.173, 3.320
Kjelleren, S 3.177
Klaas, P 3.322
Klaas, P 1.290
Klassen, T L. 2.043, 3.341
Klehm, J 1.029, 2.181, 2.186, 2.276,
3.111, 3.116, 3.177, 3.255
Klein, P 1.186, 2.196, 3.196, 3.253
Klima, P 1.086
Kline, J 1.332
Klöcker, A 2.072
Klorig, D 2.035
Kluger, G 2.361, 2.362
Kluin, K 2.133
Knoth, I 2.345
Knoth, R L. 1.374
Knowlton, R C. 1.148, 1.252, 1.256, 1.270,
1.271, 3.223
Knox, A 3.063
Knupp, K G. 1.085, 1.091, 1.110, 1.122,
2.134, 2.163, 3.147, 3.181, 3.187
Ko, D Y. 2.272
Ko, T 1.075, 1.139, 2.167
Kobau, R 1.366, 3.349
Kobayashi, E 1.053, 1.169, 2.214
Kobayashi, J 1.248, 2.289
Kobayashi, K 1.067
Kobayashi, Y 1.302
Kobylarz, E J. 2.108
Koehler, A 2.291
Koehn, M 2.179, 3.238, 3.323
Koeleman, B P. 1.303
Koenig, M 1.099
Koepp, M 1.153, 1.154, 1.349, 3.277
Kogure, S 2.047
Koh, S 2.033, 3.056
Koide, N 1.359, 2.188, 3.203
Kokoszka, M 1.260, 3.384
Komaragiri, A 1.223, 1.234, 2.380
Komarek, V 3.146
Komatsubara, T 1.302
Kommajosyula, S P. 3.204
Kondoker, M 1.180
Kondylis, E 1.043
Kong, W 1.314
Konka, P 1.156, 2.209
Koo, Y 2.372
Koomdee, N 2.352
Koontz, E 1.177
Korff, C 3.366
Korostenskaja, M 1.048
Koroukian, S 3.352
Korsnes, J S. 2.282
Korzeniewska, A 1.028, 1.070, 2.128
Kosobucki, G 3.015
Kossoff, E 1.122, 1.249, 2.163, 3.280
Kotagal, P 1.009, 1.055, 1.093, 2.137,
2.217
Kotani, S 2.239
Kotloski, R 2.046
Kotsenas, A 1.277
Kotulska, K 1.124
Koubeissi, M Z. 1.360
Koubeissi, M 2.031
Koudijs, S 1.104
Kovitch, E 1.023
Kowski, A 2.268, 3.077
Koyama, S 3.359
Krauss, G 1.196, 1.211, 1.214
Krebill, R 2.267
Krecke, K 1.277
Kreiselmeyer, G 2.123
Krempel, R 2.024
Krieger, A 3.097
Krish, S 3.356
Krishnan, B 1.140, 1.170, 2.064, 3.158,
3.222
Kriz, D 1.179
Kronengold, J K. 3.059
Kroner, B 1.370, 2.059, 2.223, 3.369, B.03
Krsek, P 3.146
Krueger, D 1.251, 3.266
Kruer, M C. 1.303
Krutoshinskaya, Y 1.098, 3.340
Ksendzovsky, A 3.206
Kubota, M 1.047
Kubota, T 1.138
Kubova, H 2.050
Kuchukhidze, G 3.367
Kucukboyaci, N 1.168
Kuk, R 2.241, 3.248
Kularathna, P 3.239
Kulkarni, N 3.248
Kullmann, D 2.353, C.03
Kumar, A 1.117, 1.156, 2.209
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Kumar, A 3.167, 3.389
Kumar, D 1.184, 1.192, 2.263, 3.260,
3.262
Kumar, G 1.120, 1.122, 2.161, 2.163
Kumar, M 3.017
Kundishora, A J. 2.034, 3.030
Kundu, P 3.068
Kunieda, T 1.281
Kuo, C 2.210
Kuo, J 1.019
Kupsky, W 1.352
Kurani, A S. 3.231
Kurian, M A. 2.353, C.03
Kurisu, K 1.272, 2.013
Kurukumbi, M 1.100
Kurzbuch, K 2.123
Kutluay, E 1.044, 3.383
Kuzniecky, R 1.146, 2.204, 2.206
Kuzum, D 2.076, A,05
Kvarta, M 2.235, B.09
Kwan, P 3.261
Kwan, P 2.359
Kwasnik, D 3.123
Kwon, O 1.283
l
Laban-Grant, O 2.196
Labar, D 3.118
Labiner, D 1.376
La Briola, F 3.336
Lach, L 2.336
Lachaux, J 2.065
Lachhwani, D 1.290, 3.322
Lachner, D 1.021
Lacuey Lecumberri, N 1.394
Ladha, F 3.282
Laffer, A 3.330
Laffont, P 3.216
LaFrance, W C. 3.233, 3.237, B.01
Lagacé, M 2.345
Lagae, L 1.306, 2.262, 2.266, 3.039,
3.158, 3.260, 3.262, C.05
Lai, A 2.054
Lai, Y 2.074
Lakaye, B 2.354, 2.356, 3.026
Lakshminrusimha, S 2.369
Lalonde, J W. 3.033
Lamb, N 2.286
Lammers, S 2.055
Lancman, M 1.285, 2.196, 2.269, 3.319,
3.326
Lancman, M 1.285, 2.196, 3.319, 3.326
Landazuri, P 1.255
Landmark, C J. 1.221, 2.285, 2.377, 3.274
Landre, E 3.090
Landry, S 3.263
La Neve, A 2.132
Lang, J 2.123
Lange, J 1.102
Langer, J 3.317
Langfitt, J 3.218
Lankford, J 1.391
Laoprasert, P 1.261
LaPalme-Remis, S 2.140
Laptook, R 3.233
LaRoche, S 1.044
Laroche, S 1.034, 2.109
Larsen, J 2.362
Larsen, L 1.317, 2.152, 2.361
Larsson, P 2.377
Larsson, P 2.226, 3.162, B.06
Laska, E 2.260
Lassonde, M 2.322
Lau, C 2.197
Laube, B 2.360, C.09
110
Lauer, J R. 2.314
Laurenza, A 1.184, 1.187, 1.188, 1.189,
1.190, 1.191, 1.192, 1.193, 1.194,
1.195, 1.196, 2.250, 2.263, 3.260,
3.262
Lauriault, V 2.238
La Vega-Talbott, M 1.260, 3.384
Lavorato, D 2.373
Lawrence, J 3.310
Lawson, B 3.258
Lawson, J 2.148
Lax, D 2.396
Laxer, K 1.148, 3.223
Laxton, A 2.171
Lay, J 2.273
Lazo-Langner, a 2.144
Le, S 1.082
Leahy, R 1.140
Leake, D 2.388
Leal-Campanario, R 3.020
Leavy, Y 3.316
Lebeau, K 1.285, 3.326
Lebedeva, A 2.228
Leclercq, K 2.003
Leclère, N 3.250
Ledo, C 2.332, 3.348
Ledoux, D 1.132
Lee, B 2.130
Lee, D J. 1.022
Lee, D 1.168
Lee, H 2.150
Lee, J 1.264, 1.299, 2.293, 3.201
Lee, J 1.034, 1.386
Lee, J 3.172
Lee, K 2.153
Lee, K 1.048
Lee, K 3.056
Lee, L 1.236
Lee, M 1.054, 1.126, 1.265, 2.125, 2.388,
3.303
Lee, M 2.129
Lee, S 1.209, 2.372, 3.080, 3.256, 3.281
Lee, S A. 1.288
Lee, S 1.079
Lee, S 3.188
Lee, S 2.372
Lee, S 3.345
Lee, S 1.209
Lee, V 3.328
Lee, W L. 3.244
Lee, Y 1.075, 1.139, 2.167
Lee, Y 1.118, 1.141
Leger, P 2.044
Legge, A 1.234
Legge, A W. 1.223, 2.270
Lehesjoki, A 3.338
Lehmkuhle, M 2.158
Lehnhoff, L 1.005
Leibner, J 1.026
Lein, P J. 2.242
Leister, E 1.122, 2.163
Leite, J 2.231, 2.325, 2.326
Lekoubou-Looti, A 3.383
Leloux, M 1.238
Lemieux, L 3.277
Lemke, J 2.152, 2.360, 2.361, 2.362, C.09
Lenck-Santini, P 2.221
Leon, R 3.060
Leppik, I 1.194, 2.026, 2.271, 3.182
Lerche, H 2.362
Lerche, H 2.152, 2.361
Leri, D 2.060
Lerman-Sagie, T 1.302
Lerner, J 3.120, 3.208
Leroux, J 2.322
Lesko, N 2.353, C.03
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Lesser, H J. 2.016
Lesser, R 2.016
Leupold, C 2.123
Lev, D 1.302
LeVan, P 2.339
Leventer, R 3.346, C.04
Levin, S 1.296
Levisohn, P M. 2.291
Levitt, J 2.099
Lewis, D 2.396, 3.010
Leyden, K 1.168
Leydon, G 2.101
Leymon-Porter, B 1.334
Lhatoo, S 1.394
Li, E 1.167
Li, J 1.347, 2.015
Li, L 1.346
Li, P 3.019, A.01
Li, P 1.087, 2.317
Li, P A. 3.357
Li, T 3.002
Li, X 2.095
Li, Y 1.185
Li, Y 1.256
Li, Y 3.055
Li, Y 2.095
Li, Z 1.051
Liao, W 2.218
Liao, W 2.251
Libbey, J E. 3.362
Libenson, M 3.327
Liberati, G 2.072
Licheni, S H. 2.229, B.08
Lidster, K 3.037
Lie, O V. 1.152, 2.069, 3.088
Lilenbaum, R 2.160
Lillis, K 2.008, 3.001
Lim, B 1.075
Lim, J A. 1.209, 3.080, 3.281
Lim, S 2.205, 3.190
Lima, E 2.324, 2.325, 2.326
Limwongse, C 2.347
Lin, A 2.089
Lin, H 3.269
Lin, J 1.173, 2.338, 3.074, 3.101
Lin, Y 1.310, 2.354, 2.356
Lina, J 1.053, 1.169, 2.214
Lineweaver, T T. 1.290
Lineweaver, T 3.322
Lingala, V 3.377
Lionberger, R 3.069
Liow, J 2.007
LippÃ, S 2.345
Lippman Bell, J 2.028
Lipski, W J. 1.043
Liranso, T 2.272
Lisa, B M. 3.202
Lispi, M 2.343
Listik, C 3.315
Litt, B 2.019, 2.060, 2.076, 3.097, 3.144,
3.148, 3.251, 3.284, A,05
Little, R 2.146
Liu, C 3.072
Liu, C 2.331
Liu, J 1.127
Liu, J 2.051
Liu, J 1.348
Liu, J 3.019, A.01
Liu, L 1.228
Liu, M 2.034
Liu, M 1.368, 3.371
Liu, M 1.145
Liu, P 3.357
Liu, S 3.100
Liu, X 1.314
Liu, X 1.365
Liu, Y 1.248, 2.289
Liu, Y 1.306, C.05
Liu, Z 1.078
Lizardo, M 1.178
Llewellyn, N 2.197
Lockhart, R 2.010
Loddenkemper, T 1.029, 1.085, 1.091,
1.110, 1.122, 1.123, 1.137, 2.097,
2.135, 2.136, 2.143, 2.163, 2.181,
2.183, 2.186, 2.276, 2.286, 3.111,
3.116, 3.169, 3.177, 3.255
Loeb, J 2.002
Logan, J 1.203
Lohmann, E 2.152
Loiselle, K 2.337
Lojszczyk, B 1.124
Long, P 2.353, C.03
Long, X 3.048
Longo, D 2.343
Lopes-Cendes, I 1.304
Lopez, M 1.284, 2.170, 2.378, 3.235,
3.288, B.02
Lopez-Baquero, R 2.105
López Ferreiro, A 2.275
López Gallardo, S 1.230
Lopez-Gomariz, E 1.233
Lopez-Gonzalez, F 1.233
López González, J 2.288
Lopez-Santiago, L F. 2.114, 3.142
Lopez-Santiago, L 2.087, A.03
Lopour, B A. 3.101, 3.105
Loring, D W. 3.218
Lo Russo, G 3.149
Losada, R 3.334
Losey, T 1.390
Lou, J 3.143
Lourenço, C 3.342, C.08
Love, T E. 3.352
Lovick, T 3.058
Lowden, A 3.189
Lowe, M 1.284
Lowe, H 1.248, 2.289
Lowe, M 2.204, 3.218
Lowe, M 3.235, 3.288, B.02
Lowenstein, D 1.367
Lowerison, M 2.265, 3.370
Lowy, D V. 2.369
Lu, K 1.229
Lu, Y 2.212
Lubin, F 2.010
Lublinsky, S 3.104
Lucas, T 2.076, 3.070, 3.076, 3.284, A,05
Lucero, R D. 3.033
Luchsinger, K 3.292
Luders, H 2.142
Luikart, B 2.088
Luisi, C 2.132
Luke, R 1.023
Lundeberg, J 2.353, C.03
Lunney, M 2.265, 2.302
Luo, Y 1.369
Lupton, P 1.356
Luu, P 2.127, 2.210
Lux, A 2.255
Ly, C 2.006
Lynch, T M. 2.121
Lyu, S 1.118, 1.141
M
Ma, C 2.034, 2.380
Ma, H 3.216, 3.216
Ma, K 3.005, 3.005
Ma, T 1.188, 1.193, 1.194, 1.196
Mabud, T 3.188
MacAllister, W 1.297, 1.300
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Macaulay, D 1.119, 2.168
Macaya, A 2.148
MacDonald, J W. 2.049
MacEachern, S 2.068
Machado-Salas, J 2.354
Maciver, S 2.165
Mackay, M T. 2.255
Macken, M 2.193
Mackie, E 3.239
Macknik, S 3.020
MacLean, J 2.156
Macrodimitris, S 1.324, 3.154
Mader, M 1.021
Mader, M 3.186
Madsen, J 1.263, 2.097, 3.327
Maehara, T 1.254
Maertens, P 3.263
Maganti, R 3.064, 3.130
Magara, S 1.302
Magdaleno-Madrigal, V M. 2.029
Magge, S 1.262, 2.311, 2.313, 3.297
Maglalang, P 2.026
Magnetta, E J. 3.005
Maguire, J 3.043, 3.241, 3.246, B.04
Mahadevan, A 2.321
Mahaffey, C 1.320
Maher, B 3.342, C.08
Maheshwari, A 2.100
Mahfooz, N 2.369
Mahfoud, Z 1.089
Mahmood, B 2.317
Mahmoudi, B 2.030
Mahmoudi, F 1.144, 3.213
Mahoney III, JJ. 3.317, 3.318
Mahulikar, A 1.240
Mai, R 3.149
Maideniuc, C 2.278
Maier, O 2.152
Mailo, J A. 2.178
Majidi, S 1.360
Majoie, M 1.104
Makeig, S 1.017
Makinson, C 3.023
Malhotra, K 1.115
Malik, M 2.196, 2.269
Maljevic, S 2.152, 2.361
Malla, B 2.321
Mallick, A 2.255
Maloney, N 1.223
Maloney, T 2.340
Mamelak, A N. 3.081
Mameniskiene, R 3.253
Manavi, R 3.143
Mancuso, J 2.093
Mandel, A 1.040
Mandel, A 3.161
Mandle, H 2.192, 2.194
Mandrekar, J 1.035, 1.133
Manfrim, E 3.117, 3.119
Mang, Y 2.361
Manganas, L N. 1.108, 3.340
Manganas, L 2.363
Mangano, F 2.127
Mangum, T 2.383
Mani, R 1.002, 2.227
Manjila, S 1.109
Mann, D 1.127
Mann, K 1.292
Mann, M 1.379, 3.090
Manreza, M G. 3.392
Manriquez, M 3.232
Mantle, M 1.271
Marafie, D 1.301
Marandi, E 1.117
Marashly, A 1.258, 2.142
111
Marchau, F 2.266
Marchese, M 2.023
Marcuse, L 2.392, 2.393, 3.068, 3.175
Mares, P 2.050
Margolis, S A. 3.313
Marincek, M E. 1.008
Marini, C 2.152
Marks, R 2.100
Marlangue, C 2.044
Marrosu, F 3.065, 3.065
Marsch, S 1.129
Marsh, E 3.098, 3.099, 3.138
Marsh, R 2.172
Marsh, S 2.257
Marsh, S T. 2.042, 2.098, A.02
Marson, T 1.309
Marti, C 2.286
Martin, A 3.325
Martin, B 3.019, A.01
Martin, R 1.213, 2.334, 3.218
Martín-Araguz, A 1.230
Martineau, L 1.133
Martinez, A 1.128
Martinez, G 2.240
Martinez, O A. 1.239, 3.200
Martinez, P 3.390
Martinez, R 1.131
Martinez-Conde, S 3.020
Martinez-Juarez, I 2.354, 2.356
Martínez-Juárez , I E. 1.310
Martinez-Lage, M 3.070, 3.076, 3.284
Martínez Martínez, M 1.230
Martínez-Vargas, D 2.029
Martins-Castro, B 3.315
Martyniuk, A 2.094
Martz, G 1.044
Maruoka, E 1.250
Marusic, P 2.320, 3.146
Masmanidis, S C. 3.143
Massey, C 2.120
Massey, S 3.194
Masuda, H 1.305, 3.302
Mateen, F 3.374
Mathews, E A. 1.222
Mathias, S V. 2.154
Matsumoto, J 3.120
Matsumoto, N 1.302, 1.305
Matsumoto, R 1.281, 2.162
Matsuo, F 3.171
Matsushima, E 1.061
Matsuura, M 1.061
Matthews, S A. 2.057
Mattson, R 2.363
Mau, M 3.047
Maurer-Morelli, C V. 1.304
Maurey, H 2.292
May, A 3.381
May, R 2.063
Mayerson, E 2.223, B.03
Mayor, L 3.390
Mays, M 3.266
Mays, V 3.196
McAndrews, M 3.338
McArthur, D L. 3.120
McAuley, J 2.176
McBee, N 2.267
McBrian, D 3.161
McBrian, D 1.040
McCafferty, C 2.034, 3.030
McCarren, H 2.024
McCarthy, D 1.015, 1.016, 3.170
McCloskey, D 3.050
McConathy, J 1.174
McCoy, A 3.138
McDermott, D 3.186
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
McDonald, C 1.168
McDonough, B 1.224, 3.253, 3.261
McDonough, J 2.024
McDonough, T 3.122
McElveen, W 1.195
McEvoy, A 1.259
McFarland, E 2.024
McGarr, T 1.320
McGinty, R 3.159, 3.160
McGoldrick, P 1.260
McGowin, I 2.035
McGrade, H 1.131, 2.394
McGrady, M 2.337
McGregor, A 1.355, 3.156
McGuire, R M. 3.086
McGuire, R 2.085
McHugh, D C. 1.108
McIntosh, A 2.359
McKenna, K 1.282, 2.206, 3.196
Mckenzie, M 1.311
McKnight, D 2.349
McLachlan, R 2.140, 3.285
McLellan, A 1.143, 2.330, 2.341
McMahon, J 2.355
McMahon, J 1.313, 1.315, 2.229, B.08,
C.06
Mcmanis, M 1.126
McManis, M 1.054
McMicken, C 1.197
McMurray, R 2.258, 2.261
McNulty, M L. 1.183
McPhillips, M 1.143
McSween, T 1.042
McTague, A 2.353, C.03
McTiernan, M 1.232
Meador, K J. 1.282, 3.260
Meador, K 2.063
Mecarelli, O 2.132
Medard, L 3.026
Medaugh, E 1.120
Medel, R 2.385
Medina, A 3.313
Medina, M 1.310, 2.354, 2.356
Mefford, H 1.315, 2.355, 2.361, 3.335,
C.06
Mei, D 2.152
Mei, S 2.095
Mei, Y 3.005
Meisler, M 2.052, 2.114, 2.364, 3.142,
A.08
Meli, Y 3.357
Melikyan, G 1.089
Melis, M 3.065
Mellers, J D. 1.180
Melo, I S. 2.020
Melo, J 2.195
Melo-Souza, S E. 2.139
Memon, A 1.097
Mendes, P S. 3.392
Mendez, D 1.325
Mendonça, L O. 1.382
Mendoza, M 2.233
Mendoza, M 1.383
Meng, H 2.251
Menon, P 1.059
Menon, U 3.192
Mensen, A 3.130
Merlin, L 2.037
Mernoff, S 3.170
Mesraoua, B 1.089
Messina, S A. 2.153
Messinger, J 3.014, A.04
Messinger, M 1.231, 2.351, 3.266
Meurs, A 2.216
Mevaag, M 1.221
Monaco, L 1.354
Monga, P 1.038
Monibi, A 1.113
Monica, N 3.354
Montavont, A 1.276
Monteagudo, J 3.122
Monteiro, M 2.231
Montes, J L. 2.307
Montes de Oca Basurto, M 3.071
Montes-Rivera, J 3.175
Montouris, G 1.077, 1.200, 1.372, 1.380
Moon, B 2.287
Moon, H 2.372, 3.234
Moon, J 1.209, 2.372, 3.281
Moore, E 2.063
Moore, J 2.230
Moore, S 2.117
Moosa, A N. 1.086, 1.140
Moravineni, K 1.106
Morawo, A 3.030
Moreira, C H. 1.382
Moreira, J 3.264
Morenghi, E 3.336
Moreno, R 2.357
Morgan, A 3.330
Morgan, L 3.088
Morgan, S 1.309
Morgan, V L. 2.201, 3.218
Mori, H 3.365
Moriarty, J 1.180
Morin, L 2.044
Morita, A 3.166
Morita, D 2.127, 2.340
Morita, M 1.351, 2.203, 2.299
Morrell, M 1.045, 1.046, 1.060, 1.121,
2.172, 3.031
Morris, H 2.332, 3.348
Morris, M 3.243, B.05
Morrison, C 1.282
Morrison, I 1.232
Morrison, S 2.245
Morse, C 2.007
Morse, E 2.160
Morse, R 2.108, 3.388
Morton, L 3.125
Morton, W 1.030
Mosca, I 3.018
Moschetta, S 2.233
Moseley, B D. 1.130, 2.224
Moshe, S 1.071, 2.396, 3.010
Moshé, S 2.048, 3.062
Mosher, J 1.055, 1.140, 3.222
Moss, R 2.381
Moss, S 2.017, A.09
Motte, J 2.292
Moura, V 3.123
Moura, L V. 1.325, 3.115, 3.123
Mouraux, A 2.072
Moustafa, M 3.303
Mowrey, W 2.048, 3.062
Moyer, J 3.097, 3.251
Mrelashvili, A 3.299
Mudigoudar, B 1.355, 3.127, 3.156
Mudugal, D 3.185
Mueller, M 1.181
Mueller, S 1.148, 3.223
Mueller, W 1.051
Mugikura, S 3.212
Muhle, H 2.361
Mukaida, S 1.302
Mukharesh, L 2.031
Muldoon, S F. 2.016
Mulkey, S B. 2.386
Mullane, A 3.321
Mullatti, N 2.085
Mevåg, M A. 2.285
Meyer, E 2.353, C.03
Meyer, M 2.025
Miceli, F 3.018, 3.337, C.07
Michalak, Z 1.348
Michaud, J 2.360, C.09
Michel, C 1.073
Michel, C 1.160, 2.110, 3.219
Michelhaugh, S 2.277
Michelucci, R 1.343, 2.132
Michoulas, A 1.245, 1.311
Mickleborough, M 2.058
Middlesworth, W 3.122
Migliorini, M 3.096
Miguel, J 2.241
Mihaylova, T 2.133
Mikati, M 1.123, 1.137, 2.183
Mikuni, N 1.253, 1.281
Milburn, J 2.394
Milioli, G 3.065
Milk, N 3.104
Miller, A 1.204, 1.205
Miller, I 1.060
Miller, J 2.063
Miller, J 1.258, 3.079
Miller-Horn, J 1.216
Millett, D 2.331, 3.072
Millichap, J 1.122, 2.163, 3.337, C.07
Milligan, C 3.239
Mims, K 1.026
Minassian, B 2.107, 3.151, 3.338
Minassian, G 3.355
Mindrebo, S 3.086
Mintz, M 1.187, 3.133, 3.347
Mintzer, S 3.254
Miotto, E C. 3.392
Mir, K 1.268
Miraglia del Giudice, E 1.312
Miro Llado, J 1.128
Mirro, E A. 1.036
Mirsattari, S 1.147, 2.140, 3.153
Mirza, W 3.179
Mirzaa, G 3.335
Misaghi, E 3.211
Miserocchi, A 1.259
Mishra, U 2.026
Misra, S N. 1.381, 3.046
Missling, C 3.249
Mitchell, W 1.122, 1.327, 2.163
Mithal, A 3.377
Mittal, S 1.352, 2.277
Miura, K 1.142
Miyajima, M 1.061
Miyake, N 1.305
Miyakoshi, M 1.017
Miyamoto, S 1.281
Mizrahi, E 2.172
Mizuiri, D 1.271
Modat, M 1.350
Modi, A 1.292, 2.337
Modolo, J 2.090
Modur, P 2.125, 2.388, 3.157
Moeller, J 2.101
Mofrad, N 2.208
Moghal, U 3.107
Mohamed, I 2.322
Mohammed, A 2.300
Mohanarangan, K 2.166
Moien-Afshari, F 2.058, 3.093, 3.351
Moineddin, R 1.373
Molano, J 2.224
Molina, Y 1.310, 2.354
Molins Albanell, A 1.128, 1.207, 1.233,
2.288
Momjian, S 3.366
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
112
Mullen, S 1.024, 1.313
Mullin, J 1.170, 1.273, 1.278
Munger-Clary, H 2.171
Munian Govindan, R 1.117
Muntoni, A 3.065, 3.065
Muona, M 3.338
Murai, T 2.162
Murnick, J 1.172, 3.215
Muro, V L. 1.008
Murphy, G 2.115, 2.117
Murro, A 1.060
Murro, A M. 2.172
Muthaffar, O 2.107, 2.312
Muzumdar, D 2.315
Myers, C 1.315, 2.355, 2.361, C.06
Myers, L 1.178, 1.285, 2.269, 3.319
Myers, T 2.294
Myrvik, M J. 2.256, 2.259
Myseros, J 2.311
Mytinger, J 1.085, 1.091, 1.122
Mytinger, J R. 2.163
Møller, R S. 1.315, 2.355, C.06
Møller, R S. 1.317, 2.152, 2.361, 2.362,
3.342, C.08
n
Nabbout, R 2.148, 2.292
Nabi, A 2.027
Nabulsi, N 3.227
Nadasdy, Z 2.125
Nadkarni, S 2.206
Naduvil- Valapil, A 1.009
Naduvil Valappil, A 2.137, 3.225
Naegele, J 2.088
Nagai, Y 3.277
Nagaraddi, V 3.084
Nagaraj, V 3.040
Nagarajan, S S. 1.252, 1.270, 1.271
Nagasawa, T 1.047
Nagelhus, E A. 3.041
Naik, S 1.097
Nair, D 1.060, 2.081, 2.172, 3.088, A.06
Najamuddin, S 3.236
Najibi, F 3.394
Najimipour, B 3.083, 3.086
Najm, I 1.134, 1.289, 2.064, 2.081, 3.109,
A.06
Nakae, T 1.281
Nakagawa, E 2.309, 3.178, 3.306
Nakagawa, J 3.158
Nakagawa, J 2.200
Nakajima, M 1.072, 1.149, 1.384, 3.295
Nakajima, M 2.155, 3.300
Nakamura, M 1.061
Nakano, F N. 3.304
Nakasato, N 2.173, 2.304, 3.129, 3.212,
3.320
Nakashima, M 1.302, 1.305
Nakayama, Y 3.302
Nakhutina, L 3.313
Nam, E 3.345
Nam, G 2.091
Nam, S 1.118, 1.141
Nam, W 1.283
Namath, A 3.164
Nanga, R 1.171
Naranjo, B 2.374
Narayana, S 1.162, 3.091
Narayanan, J 1.095, 1.107, 2.384
Narchi, H 3.376
Nariai, H 1.071
Nascimento e Silva, F A. 3.338
Nashef, L 2.073
Natsume, J 1.142
Natsume, K 3.139
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Nava, C 1.303
Nava Lagunes, A 2.080
Navarrete-Modesto, V 2.070
Nayak, T 2.097
Nazem-Zadeh, M 1.144, 3.213
Nazer, B 3.074
Ndayisaba, J 3.367
Nearing, B 2.225
Negoro, T 1.138, 1.142
Nei, M 2.175, 3.113
Neider, J 1.337, 2.370
Nelson, T 1.311
Neme-Mercante, S 2.245
Nemes, A 3.109
Nenert, R 1.165
Ness, J 3.389
Netoff, T I. 3.040
Newham, B 3.214
Newton, M 2.359
Newton, R 2.255
Ng, M 2.141
Ngo, L 1.333
Nguyen, D 2.322, 3.095
Nguyen, H 3.257, 3.258, 3.259
Nguyen, L 3.032
Nguyen, L 2.074
Nguyen, T 3.356
Nguyen, V 1.310, 3.355
Nica, A 1.057, 1.084
Nickels, K 1.122, 1.277, 1.392, 2.163,
3.299
Nielsen Kromann, M 2.281
Niespodziany, I 3.024, 3.245, 3.250
Nikanorova, M 2.152, 2.361, 2.362
Nikkhah, G 2.123
Niquet, J 2.022
Niranjan, A 1.049
Nirola, D 3.374
Nishida, M 1.070, 2.128
Nishida, S 1.281
Nishida, T 3.256
Nishio, Y 3.320
Njau, A 2.159
Noam, Y 2.006
Nobile, C 1.343, 2.132
Nobili, L 3.149
Noe, K 1.060, 1.322, 2.172, 3.088
Noebels, J L. 3.135
Noebels, J 2.100, 3.033
Noffs, MD. 3.312
Nogue, E 3.090
Nogueira, A B. 3.111
Nolan, M 2.255
Nome, C 3.041, 3.041
Nonoda, Y 1.017
Noor, M 2.369
Nordli, D R. 1.085, 1.091, 1.110, 1.122,
2.163, 2.396, 3.010
Normand, C 1.003
Norris, G 2.280
Nourani, M 3.084
Noviawaty, I 3.124
Novotny, E 1.110, 3.335
Nowack, W 1.279
Nowacki, T 3.211
Nowell, M 1.259
Nozaki, F 1.302
Nozaki, T 3.166
Nozawa, T 1.250
Numis, A L. 1.367
Nune, S L. 3.156
Nunes, M 3.342, C.08
Nunley, S 1.375
Nussbaum, N 3.303
Nuttall, G 1.035
O
Orellana, L 1.239, 3.200
Organizations, R 2.223, B.03
Orlandi, R 1.337
Orosz, I 3.208
Orozco-Suarez, S 2.070
Orozco-Suárez, S 3.108
Ortega-Moreno, L 3.334
Ortiz, F 2.112
Osada, Y 2.239
Osawa, M 1.250, 2.356
Osborn, M 1.218
Osborne, J 2.255
Osnes, K 2.301
Osorio, I 1.279
Otoul, C 1.219
Otsubo, H 1.039, 1.041, 2.155, 2.312,
3.066, 3.151, 3.300
Otsuki, T 1.250, 2.309, 3.178, 3.306
Ottman, R 1.341
Ourselin, S 1.350
Overman, L 1.009
Owen, C 1.174
Oyegbile, T 1.298
Ozturk, E 3.243, 3.346, B.05, C.04
O'Boyle, B 2.253
O'Brien, C 3.122
O'Brien, M 1.386
O'Brien, T 1.282, 2.206, 2.250, 2.359,
3.036, 3.100, 3.239, 3.243, B.05
O'Callaghan, F 2.148, 2.255
O'Donovan, C 2.171, 3.134
O'Dwyer, R 2.187, 3.168
O'Dwyer Vourganti, R 1.287, 3.174
O'Halloran, R 3.068
O'Hara, B 2.038
O'Muircheartaigh, J 1.153, 1.154
O'Neal, W 2.272
O'Toole, K 3.241, B.04
Obaid, S 1.242, 1.243
Obeid, M 2.241, 2.383, 3.248
Oberaigner, W 3.367
Oberman, L 1.064, 1.065
Oberoy, S 3.206
Ochi, A 1.039, 1.041, 2.155, 2.312, 3.300
Ochi, A 3.066, 3.151
Ochi, S 1.253
Ochoa, A 1.310, 2.354, 2.356
Odgen, K 3.015
Odintsov, B 3.204
Odom, N 3.202
Oelze, J 2.241
Ofen, N 1.070, 2.128
Ofer, I 2.339
Oganisian, A 1.077
Ogata, K 1.302, 1.305
Ogawa, C 1.142
Ogawa, H 1.157
Ogden, K 2.187, 3.168
Oguni, H 2.356
Oguro, K 2.207, 2.211
Oh, A 1.031
Oh, S J. 2.287
Ohara, S 3.391
Ohba, C 1.302, 1.305
Ohta, K 1.061
Ohtaki, S 1.253
Ojeda, A 1.017
Ojeda, J 1.230
Ojemann, J 3.218
Oka, M 1.067
Okamoto, N 1.302
Okanari, K 3.300
Okanishi, T 1.198, 3.296
Okazaki, K 1.302
Okumura, E 3.129
Okumura, M 1.061
Oldham, M 1.312, 2.296
Olin, B 2.174, 2.225
Oliva, A 2.062
Oliver, H 2.285
Oliver, J 1.112, 1.241
Oliveros Cid, A 3.273, 3.275
Oliveros Juste, A 3.273, 3.275
Ollier, S 1.292
Olson, D 2.156
Olson, H 2.358, 3.152
Olson, L 1.031, 1.161, 2.220
Oluigbo, C 1.262, 1.307, 2.311, 2.313,
3.019, 3.297, 3.301, A.01
Omidvarnia, A 1.159
Ono, K 3.125
Ono, T 1.359, 2.188, 3.203
Onorati, F 3.096
Onuma, A 1.302
Oommen, B 2.060
Opitz, T 3.245
Oppel, C 2.024
Opperman, C 1.176, 1.295
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
P
Pacha, M 1.239, 3.200
Pacheco, A 2.020
Pacheco, V H. 1.301
Pacheco-Phillips, J 3.379
Paciorkowski, A 3.147
Pack, A 2.063
Pack, A 3.202
Paelinck, B 2.266
Pagel, C 3.239
Pagola Lorz, I 3.273, 3.275
Paige, A 2.267
Pakoz, B 3.383
Palau, J 1.233
Palmese, C 1.260
Palomeque, M 1.284, 3.235, 3.288, B.02
Pan, J 2.054, 2.082, 2.204, 3.205, 3.231,
3.289
Pan, Y 3.247
Panchal, K 2.315
Pang, E 3.145
Panov, F 1.256
Paolicchi, J M. 1.321
Papadelis, C 2.097, 3.111
Papanicolaou, A C. 1.162, 3.091, 3.127
Pappalardo, I 2.323
Paquette, E 2.088
Parada, I 3.006, 3.006
Pardo, C 3.282
Pardo, M 2.275
Pardoe, H R. 1.146, 2.204, 2.206
Parent, J 2.052, 2.087, 2.114, 2.117,
3.142, A.03, A.08
Parent, R 2.115
Pargeon, K 3.118
Parikh, P 2.195
Paris, A 2.286
Parisotto, S 3.344
Park, E 2.097
Park, J 1.109
Park, K 2.195
Park, K 3.181, 3.187
Park, K 1.229, 3.007
Park, S 3.180
Park, S 1.283
Parker, D 2.280
Parks, P 1.244
Parmet, Y 3.104
Parrent, A 1.147
Parrino, L 3.065
113
Parrish, R R. 2.010
Parry, R E. 1.340
Parthasarathi, S 2.321
Parviz, M 1.099
Parvizi, J 3.128
Paschoal, N 1.351
Pascual, F 1.385
Pascual-Leone, A 1.064
Pasini, E 1.343, 2.132
Passarelli, V 1.382
Pastore, A 2.014
Patel, A, 3.375
Patel, A 1.110, 1.323, 1.332, 1.375, 2.366,
2.367, 3.350
Patel, A A. 2.159, 3.131, 3.333
Patel, B 3.224, 3.303
Patel, D 2.021
Patel, M 2.021, 3.017
Patel, M 2.364
Patel, V 1.335
Patenaude, B 3.374
Pathmanathan, J 1.015, 1.016, 2.109,
3.170
Pati, S 3.079
Pati, 1.165, 1.258, 2.077, 3.075, 3.106
Patil, N 2.332
Pato, A 3.286
Patodia, S 1.350
Patroneva, A 2.238, 2.260
Patten, A 1.189, 1.190, 1.191, 1.194,
1.195, 1.211, 1.214, 2.250
Patten, S B. 2.265, 2.302, 2.373
Patterson, A 1.355
Patterson, C 1.310, 2.354, 2.356
Patterson, E 2.026
Patterson, K P. 2.006, 3.005
Patterson, R 1.030
Paudel, S 3.167
Pauletti, A 2.014
Pavlova, M 2.333
Pawar, K 2.294
Pawley, A D. 2.073
Pazdera, L 2.254
Peace, T 1.213
Pearce-Grullon, P 3.205
Peariso, K 1.123, 1.137, 2.183
Pearl, P 1.029, 1.099, 2.089, 2.097, 2.136,
2.143, 2.186, 2.189, 2.365, 3.116,
3.333
Pearson, C M. 1.255
Pedersen, B 1.217
Pedersen, M 1.159
Pedro, H 3.344
Pelisch, N 1.239
Pellegrino, G 1.053, 1.169, 2.214
Pellock, J 2.396
Peltzer, J 1.279
Pena, S 3.342, C.08
Pendziwiat, M 2.361, 3.342, C.08
Peng, G 1.200
Peng, S 3.048
Peng, S 3.230
Peng, S 3.226
Pennell, P 2.063, 2.197, 2.333
Penovich, P 1.282, 1.328, 1.329, 1.330,
2.063, 2.252
Pereira, F 2.325
Pérez Lorenzo, G 3.286
Perez Velazquez, J 2.083
Perkins, F 1.054, 1.126, 3.303
Peron, A 3.336
Perrine, K 1.132
Perrine, K 2.269, 3.319
Perrotte, G 2.044
Persson, B 2.353, C.03
Perucca, P 2.359
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Perzynski, A T. 1.175
Pestana Knight, E M. 1.086, 2.137
Pestana-Knight, E 1.009, 1.009
Peters, J 2.159, 2.189, 3.131, 3.169,
3.193, 3.255, 3.333
Peters, T 1.147
Petito, G 3.290
Petroff, O A. 3.150
Petrou, S 1.313, 3.239
Petrovski, S 3.339, C.01
Petsko, G 3.014, A.04
Pett, N 1.180
Petton, M 2.065
Petty, S 3.239
Peugh, J 2.337
Pevzner, A 2.079
Pfeffer, S 2.152
Pflaster, N 1.125
Pham, K 2.287
Phatak, V 3.218
Phelan, J C. 1.341
Phelps, M 2.232
Phillips, A 1.313
Phillips, K 2.040
Piantino, J 2.395
Picard, R 3.096
Pichat, J 1.350
Pichon, P 2.344
Pickersgill, M 1.340
Pickrell, W O. 1.309
Picot, M 3.090
Pieters, H 2.298
Pike, V 2.007
Pillai, J 2.180
Pilli, V 2.209
Pillolla, G 3.065
Pimentel, J 2.320
Pina-Garza, J 1.077, 1.372, 1.380
Piña-Garza, J 3.262
Pinchin, G 2.043
Ping, X 2.012
Pinnick, L 1.241
Pinto, R 3.264
Piper, L 1.213
Pirone, A 2.056
Pistis, M 3.065
Pisu, M 1.213
Pitkanen, A 3.037, 3.097
Pitman, V 1.127
Pittau, F 1.160, 2.110, 3.219, 3.366
Pittman, D J. 1.158
Pizarro, D 3.075, 3.106
Plancher, J 1.387
Plante Anastassopoulos, K 1.182, 1.202,
2.249
Plioplys, S 3.233
Plomp, G 1.160
Ploof, D 1.336
Plueger, M 1.005
Plummer, C 2.082, 3.289
Pochettino, A 1.035
Poduri, A 2.025, 2.286, 2.353, 2.358,
3.152, C.03
Pohl, D 1.357, 2.350
Pojomovsky McDonnell, P 1.040, 3.161
Polat, B 2.106
Politsky, J 1.033, 1.050, 3.121
Pollard, J 2.267, 3.088, 3.107, 3.284,
3.308
Polli, J 3.267
Pomerantz, D 1.236
Pontillo, A 1.382
Poolos, N 1.204, 1.205
Popescu, A 2.054, 2.082, 3.231, 3.289
Popli, G 2.035, 2.171
Porter, B 1.222, 3.098, 3.099
Potter, B 1.162
Powell, K 3.036
Prager, K 1.010
Prasad, A 3.330
Prasad, A 1.363
Prescott, M 3.037
Pressler, R M. 2.255
Price, A 3.189
Price, E C. 2.027, 2.053
Prieto, Á 3.286
Prince, C 3.082
Prince, D 3.006
Pritchard, J 1.027
Pritchard, P 1.177
Privitera, M 1.387, 2.267, 3.279
Pro, S 2.343
Proddutur, A 3.025
Prohl, A 3.193
Prommas, S 2.352
Proserpio, P 3.149
Prueckl, R 1.157
Puangpetch, A 2.352
Puckett, O 1.168
Pugh, J 3.324
Puka, K 1.373
Puligheddu, M 3.065
Pulitano, P 2.132
Punia, V 1.092
Puntambekar, P 1.033, 3.121
Pushchinska, G 1.098
Puy Núñez, A 2.275
Rao, L 3.120
Rao, N 3.143
Rapuano, A 3.205
Rathod, J 2.165
Rathore, J 3.176
Rathouz, P 3.323
Raththagala, M 3.012
Rating, D 2.255
Rausch, J 1.292
Ravan, M 3.276
Ravat, S H. 2.315
Ravindran, R 3.376
Ravizza, T 2.014
Rawal, P 1.088
Rayner, G 3.310
Raynes, H 1.260
Rayo-Mares, D 3.108
Razavi, B 3.128
Read, A F. 2.027, 2.053
Rebecca, G 1.332
Rebowe, N 3.249
Reddy, D 2.011, 3.011
Reddy, R 1.171
Reddy, S 2.305
Reed, U C. 3.392
Rees, M 1.309
Reese, J 3.395
Reeves, C 1.348
Reeves, J 3.209
Regalia, G 3.096
Regan, B 3.339, C.01
Rege, B 1.187, 1.211
Rehman, R 2.378
Reid, C 1.313
Reisert, M 2.200
Reith, M A. 2.353, C.03
Rejdak, K 2.094
Ren, G 2.095
Renfroe, B 1.187, 1.189, 2.263
Reno, A J. 3.317, 3.318
Resnick, T 1.380
Retterer, K 2.349
Revesz, D 1.116
Rey, GJ. 1.284, 3.235, 3.288, B.02
Rey, G 1.284
Rezaie, R 1.162
Reznikov, A 1.042
Rheims, S 1.276, 2.065
Rho, J 3.136
Rho, J M. 1.245
Ribeiro Vaz, J 2.072
Ribot, R 1.284, 3.235, 3.288, B.02
Richard, G 2.349
Richards, K 3.239
Richardson, A 2.076, 3.284, A,05
Richardson, M 1.043, 1.049, 2.054, 2.082,
3.289
Richardson, M P. 1.153, 1.154, 2.073
Richardson, R M. 3.231
Richerson, G 2.032, 2.120, 3.364
Richert, M 2.235, B.09
Richman, J 1.213
Ricordeau, C 1.084
Rieiro, H 3.020
Rihana, S 3.095
Riley, C L. 2.151
Riley, D 2.378
Riley, K 2.010, 3.075, 3.106
Ringstad, G 3.162
Rios, L 3.305
Rios-Motta, M 3.184
Rios-Motta, R 3.184
Rioux, E 2.145
Risbud, R 3.138
Ritaccio, A 2.121, 3.087
Q
Qaiser, F 2.077
Qi, J 3.056
Quach, M 2.124
Quarato, 3.253
Queiroz, L 1.351
Quiao, J 3.208
Quigg, M 1.036, 1.368, 2.184, 3.371
Quintana, M 1.128, 1.207
Quirk, M 3.102, 3.265
Quraishi, I 3.059
Qureshi, A I. 1.360
R
Rabiei, A 2.175
Rabinstein, A 1.133
Radell, J 2.088
Radhakrishnan, R 2.149
Radtke, R 1.380
Raedt, R 3.141
Raftopoulos, C 2.072
Ragan, I 3.037
Ragazzo, P C. 2.139, 2.357
Raghavan, M 1.051
Rahman, T 2.144
Rahman, Z 1.059
Raizer, J 3.287
Rajaraman, R 2.273
Rajebi, H 2.187, 3.168
RamachandranNair, R 1.331, 1.338
Raman, P 3.086
Raman, S 3.267
Ramanathan, S 1.115
Ramey, P 1.218
Ramon, C 2.126
Rampp, S 2.123, 3.077
Ramsay, R 2.394, 3.183
Ramsay, R 1.131
Randall, M E. 3.204
Randazzo, M J. 1.043, 1.049
Ranieri, R 3.237, B.01
Ranjan, M 1.267
Rao, L M. 2.274
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
114
Ritter, F 1.295, 2.346
Ritzl, E K. 1.032
Riviello, J 1.099, 3.122, 3.161
Rizvi, S A. 3.351
Robbins, E 1.316, 3.332, C.02
Robert, M 2.322
Robert, W 1.277
Roberts, C 1.179
Robichaud, A J. 2.240, 3.102
Robinson, C 2.058
Robles, C A. 2.165
Robuccio, A 2.027, 2.053, 3.385
Rocha, F 1.185, 1.186, 2.243, 2.252,
3.264
Rocha, L 2.070, 2.071, 3.108
Rodan, L 3.333
Rodionov, R 1.259
Rodrigo, M 3.334
Rodrigues Velasco, T 2.325, 2.326
Rodriguez, A 1.034
Rodriguez, D 1.331
Rodríguez, E 3.108
Rodríguez Castro, E 2.275
Rodríguez Cruces, R 3.207, 3.221
Rodriguez Osorio, X 2.275, 3.286
Rodriguez Ruiz, A A. 2.109
Rodriguez Uranga, J 1.233, 2.320
Roessler, K 2.123
Rogawski, M 2.242
Rogerio, F 1.351
Rogers, B P. 2.201
Rogin, J B. 2.252
Rohena, L O. 1.303
Rollins, C 2.136
Rolston, J D. 1.271
Romero Acebal, M 3.272
Romero Godoy, J 3.272
Ronen, G 2.336
Rose, D 1.163, 2.127
Rose, S 3.110, 3.132
Rosenbaum, P L. 2.336
Rosenfeld, W 1.190, 2.252
Rosenthal, E 2.213, 3.265
Rosenthal, J 1.132
Rosman, Y 3.104
Ross, D 2.010
Ross, L 3.081
Ross, L 1.273
Rossetti, A 1.133, 3.366
Rossi, M A. 1.060, 2.078, 2.080, 2.084,
2.368, 3.354
Roten, A 1.024
Rotenberg, A 1.063, 1.064, 1.065, 2.009,
2.025, 2.055, 2.089, 2.306, 3.045
Roth, R 1.286
Rouhl, R 1.104, 3.283
Roulet Perez, E 3.366
Roundtree, H 3.240, 3.242
Rowland, B 2.089
Rowley, S 3.017
Roy, P L. 2.131
Rozhkov, L 1.163
Rozman, M 3.218
Rozzelle, C 2.314
Rubboli, G 1.317, 2.152, 2.361, 2.362
Rubens, E 3.118
Rubin, P 1.293
Rubinchik-Stern, M 1.235
Rubino, A 3.149
Rubinstein, J 3.191
Rubio-Nazábal, E 2.275
Rueda, S 1.376
Rueegg, S 1.129
Ruiz, A 2.353, C.03
Ruiz Gimenez, J 3.272
Rumia, J 2.320, 3.286
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Runge, U 1.102
Rutecki, P 1.060, 2.046, 2.172, 3.247
Rutishauser, U 3.081
Rutka, J 2.312
Ryan, C 2.365
Ryan, J 2.337
Ryan, J 1.337, 2.370
Ryan, J 2.241
Ryan, N 1.085, 1.085, 1.091, 1.110, 1.122,
2.163
Rydenhag, B 1.116
Rydjeski, S 2.108
Ryvlin, P 1.186, 1.276, 2.065, 2.174,
2.243
Rzezak, P 2.233, 2.324, 2.325, 2.326,
2.357
S
Saad, A 2.058
Saad, Z 3.209
Saadi, A 3.374
Saavedra Piñeiro, M 2.275
Sabaz, M 1.294, 1.294
Sabesan, S 3.086, 3.276
Sabharwal, V 1.131, 2.394, 3.183
Sabri, J 1.285, 2.269, 3.344
Sachdeo, R 1.183
Sachdev, H 3.224
Sacino, M 2.311, 3.297
Sadowski, K 1.124
Sady, M 3.325
Saeki, K 3.256
Saenz, M 2.067
Sætre, D 3.162
Sætre, E 2.377
Safronova, M 2.072
Saghyan, A 3.031
Sahin, M 2.055, 3.193
Said, R 3.189
Saignavongs, M 2.065
Saindane, A M. 3.291
Saint-Martin, C 2.307
Saipetch, C 3.355
Saito, T 3.306
Saitsu, H 1.302, 1.305
Sajan, S 2.378
Sajatovic, M 1.175
Sajobi, T 1.135, 2.302, 3.370
Sakaguchi, Y 1.142
Sakamoto, A 3.304
Sakhuja, A 1.136
Sakuma, S 3.300
Sakuraba, R 3.129
Salam, M 1.242, 1.243
Salam, M T. 2.083, 2.086
Salamon, N 2.316, 3.208
Salanova, V 2.172
Salas Puig, J 1.128, 1.207
Salas-Puig, J 1.233
Sale, J K. 3.350
Salehi, B 3.208
Sales, F 3.366
Salinas, F 1.152
Salinsky, M 3.353
Salorio, C 2.232
Salpekar, J 2.232
Salzberg, M 3.243, B.05
Sam, M 2.171, 2.246
Samet, M 3.106
Sampaio, L B. 3.392
Sampognaro, J 3.030
Sanchez, M J. 1.064
Sanchez, R 2.010
Sánchez, G 3.334
Sánchez, O 1.230
Sanchez Fernández, I 1.123, 2.135,
2.186, 3.116, 3.255
Sánchez Fernández, I 1.029, 1.137, 2.183
Sander, V 2.148
Sanders, N 2.370
Sanders, A 2.187, 3.168
Sandok, E 2.179
Sands, T T. 1.312
Sandy, S 1.167
Saneto, R 1.085, 1.091
Sanguansermsri, C 3.155
Sankar, R 1.200, 2.273, 2.274, 3.120
Sankaraneni, R R. 2.217, 3.185
Sannagowdara, K 3.173
Sansevere, A J. 1.029, 2.136, 2.143
Sansevere, A 2.186, 3.116, 3.169
Santamarina, E 1.128, 1.207
Santhakumar, V 3.025, 3.025, 3.055
Santiago Rodríguez, E 3.207, 3.221
Santon, S 2.352
Santos, P 3.282
Santos, Y O. 2.020
Saponjian, Y 1.229, 2.004, 3.007
Sarasso, S 3.149
Sarco, D 3.342, C.08
Sarkis, R 2.333
Sasaki, M 2.309, 3.306
Sasaki-Adams, D 2.319
Sasano, T 1.061
Sather, M 3.385
Sato, J R. 3.315
Sato, K 1.198
Sato, S 3.212
Sato, T 2.304
Sato, T 1.305
Sato, Y 1.041, 2.155, 3.300
Saucedo Alvarado, P 3.071
Sauro, K 1.324, 2.302
Sauter, M 2.148
Savard, M 1.133
Sawada, T 3.139
Sawan, M 3.095
Scandiuzzi, R C. 2.231
Schachter, S 2.225, 3.045, 3.057
Schad, C 3.122
Schaeffer, M 2.292
Schalk, G 2.121, 3.087
Schaller, K 3.366
Schaper, F 1.104
Scheffer, I 1.275, 1.313, 1.315, 2.229,
2.353, 2.355, 2.359, 3.339, 3.346, B.08,
C.01, C.03, C.04, C.06
Scheldeman, C 1.306, C.05
Schembri, A 1.282
Scherzer, D 1.332
Schiemann, J 3.253, 3.261
Schiff, S 1.068, 2.027, 2.053
Schildt, C 2.038
Schiller, K 3.091
Schiltz, N 3.352
Schmitt, B 2.255
Schmitt, F C. 3.077
Schmitt, S 1.111, 2.092
Schneider, A 1.315, 2.229, 2.355, B.08,
C.06
Schoemaker, R 1.227, 1.237
Schooley, D E. 2.098, A.02
Schoonjans, A 2.262, 2.266
Schorge, S 2.353, C.03
Schrader, D 2.202
Schramke, C J. 1.280
Schreiber, J 1.262, 1.307, 3.301
Schubert, J 2.362
Schubert, R 1.317
Schuele, S 2.193, 3.287
Schultz, L 2.166
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
115
Schulze-Bonhage, A 1.021, 2.085, 2.147,
2.200, 2.339
Schusse, C 2.190
Schwab, S 2.123
Schwalb, J 1.144, 2.166
Schwalb, J M. 3.213
Schwartz, M 2.101
Schwartz, M L. 3.059
Schwartz, T 3.216
Schwarz, M 2.123
Schweiger, S 1.317
Scirica, B 1.386
Scott, C 1.259
Scott, C 3.123
Scott, J 3.209
Scott, R 2.353, C.03
Secolin, R 1.304
Secore, K 1.286
Seeck, M 1.073, 1.160, 2.110, 3.219,
3.366
Segal, E 3.344
Segal, R 1.365
Segalovich, M 1.008
Seidel, W T. 1.300
Seidenberg, M 3.238, 3.323
Seinfeld, S 2.396, 3.010
Selassie, A 3.368
Selby, K 1.311
Selioutski, O 1.228
Sell, E 1.357, 2.350
Seltzer, L 3.147
Semah, F 2.253
Semsarian, C 3.339, C.01
Sen, S 1.265
Sen-Gupta, I 2.105
Seo, D 1.257
Seo, J 3.311
Seo, J 1.048
Sepeta, L 1.150, 1.151, 2.219, 3.301,
3.325, 3.331
Sepulveda, R 1.376
Serafini, A 3.110
Serafini, R 2.002
Seraji-Bozoergzad, N 1.240, 2.279
Serge, V 1.073, 2.110
Serioli, E 2.132
Serpa, M 2.357
Serrano, E 1.284, 3.235, 3.288, B.02
Serrano, J 2.348
Serrano, P 2.288
Serratosa, J 1.233, 2.356, 3.334
Seyal, M 1.019, 2.195
Shah, A 1.186, 1.240, 1.352, 2.177, 2.277
Shah, A 2.177
Shah, A 3.333
Shah, K 1.255
Shah, L 1.280
Shah, M 3.037
Shah, R 3.107
Shah, V 1.287
Shahid, A 1.109, 2.387
Shahlaie, K 2.079
Shandra, O 2.048
Shanmugasundaram, B 2.027, 2.053
Shannon, R 3.036
Shanungu, S 2.159
Shao, L 2.005
Shapiro, J S. 1.323
Shapiro, M 3.011
Sharan, A 2.222
Sharifi, P 3.328
Sharma, A 2.224
Sharma, M 3.210
Shashipadme, A 3.016
Shattuck, D 1.140
Shaw, R J. 3.233
Shaw, S 2.331
Shegog, R 1.376
Sheidley, B 2.358
Sheidley, B 3.152
Shella, T 2.329
Shellhaas, R 1.020, 1.085, 1.085, 1.110,
1.122, 2.163, 3.194
Shelton, L 1.336
Shen, J 2.125, 2.388
Shen, V 1.077, 1.200, 1.372
Sheng Duh, M 1.077, 1.197, 1.372
Sheppard, E 2.345
Shetty, J 1.143
Shibata, S 1.055, 1.281
Shields, D 2.172
Shiffman, D 1.321
Shigeto, H 3.391
Shih, S 1.370, 3.369
Shih, Y 1.164
Shiina, M 1.302, 1.305
Shikman, A 3.107
Shim, W 1.139
Shin, D 3.029
Shin, H 1.333, 2.319
Shin, W 2.204
Shinde, D 3.342, C.08
Shindo, K 3.365
Shinnar, R 2.396, 3.010
Shinnar, S 1.071, 2.396, 3.010
Shiraishi, H 2.008
Shiraisi, H 1.052
Shirozu, H 1.305, 3.302
Shmuel, M 1.235
Shokri, S 1.144
Shon, Y 2.205, 3.190
Short, K W. 2.053
Shostak, S 1.341
Shpak, A 2.228
Shrestha, A 1.342, 3.073, 3.165, 3.393
Shrey, D 3.105
Shroff, S 2.348
Shtrahman, M 3.143
Shukla, G 2.300
Shultz, S 3.100
Shuman, T 3.143
Shumate, R 1.131, 2.394, 3.183
Si, Y 3.030
Siddarth, P 3.233
Siddarth, P 2.099
Siddiqi, O 3.131
Siddiqui, K 2.149
Siddiqui, R K. 2.149
Siddiqui, R S. 2.149
Siddu, M 2.031
Sideridis, G 2.159
Sidney, S 1.367
Sidovar, M 1.119, 2.168
Sieciechowicz, D 3.225
Siehr, M S. 3.033
Siekierska, A 1.306, C.05
Sieradzan, K A. 3.268
Sills, G 1.309
Silva, E 3.200
Silva, M S. 1.304
Silva, N T. 2.020
Silva, R 2.020
Silveira, D C. 1.389, 2.385
Silverman, D H. 3.229
Silverstein, F 3.194
Silvia, M 2.171
Sim, D G. 2.027, 2.053
Simeone, K 3.240, 3.242, 3.363
Simeone, T 2.057, 3.363
Simeone, T A. 3.136
Simonato, M 3.037
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Simonson, A 3.223
Sinasac, D 1.245
Sinclair, D B. 3.324
Sinclair, G 1.311
Sing, C 3.282
Singer, M E. 3.352
Singer, R 1.245
Singh, G 3.377
Singh, N 1.245
Singh, N 2.300
Singh, P 1.088, 2.248
Singh, R 3.196
Singh, S 3.036
Singh, S P. 1.378, 3.185
Singh, S 1.167, 2.302
Singhal, N 2.296
Sinha, S 2.321
Sinha, S 1.025, 1.026
Sinha, S 2.149
Sirsi, D 1.038, 3.189
Sirven, J 1.014, 1.322, 1.328, 1.329,
1.330, 3.073
Sisodiya, S 1.275, 1.348, 1.350, 3.277,
3.342, C.08
Sitwat, B 3.382
Sivakumaran, S 3.246
Sivaraaman, K 1.002, 2.227
Sivaraju, A 2.160
Skidmore, C 1.060, 2.172
Skinner, H 2.153
Skopin, M 2.031
Slade, E 1.311
Sladogna, I M. 3.272
Slater, J D. 1.069, 1.197, 3.356
Slater, J 3.309
Slomko, A 2.001, 2.093
Smart, S 1.026
Smeeding, J E. 1.201
Smith, A 2.043
Smith, B 2.041
Smith, D M. 1.096
Smith, G 1.181
Smith, H 2.353, C.03
Smith, J 2.331
Smith, J D. 1.245
Smith, L 2.358, 3.152
Smith, M 1.291, 1.296, 1.297, 1.300,
1.361, 1.373
Smith, M 1.183, 2.172
Smith, M D. 1.215
Smith, N 3.030
Smith, P 1.309
Smith, S 2.238
Smith, S S. 2.037
Smithason, S 1.170, 1.278
Smolders, I 3.039
Snead, C 1.361, 1.373, 2.312
Snead, O 1.039
Snuderl, M 2.348
Snyder, T 3.324
So, E 1.277, 2.174
So, N 1.093
Soares, B 3.291
Soares-da-Silva, P 1.185, 3.264
Sofat, P 1.087
Sogawa, Y 1.071, 3.382
Sohal, V 3.042, 3.042
Sohrabpour, A 2.045, 2.212
Soldovieri, M 3.018, 3.337, C.07
Soltanian-Zadeh, H 1.144, 3.213
Song, D 3.072
Song, H 3.029
Song, J 2.210
Song, M 3.234
Song, Y 2.028
Soomro, A 1.152
Sopelana, D 1.230
Sorg, R 1.119, 2.168
Sorge, S 1.341
Sorokin, J 3.023, 3.023
Sorrell, J 2.066
Soto-Insuga, V 3.334
Soul, J 3.194
Sourbron, J 3.039
Sousa, R 1.182, 1.202, 2.249, 2.258,
2.261
Soylemezoglu, F 1.344
Spanaki, M 2.166
Specchio, L M. 1.186
Speechley, K 1.294, 1.296, 1.361
Spencer, C 2.340
Spencer, D 1.036, 1.060, 2.172
Spencer, D 3.150, 3.227
Sperling, M R. 1.074, 1.114, 1.188, 3.088
Sperling, M 2.174, 2.222, 2.254, 2.320
Spinelli, E 2.178
Spitz, M 3.073
Spoudeas, H 3.195
Spreafico, R 2.323
Spritzer, S 1.322
Squillacote, D 1.119, 2.168
Srikanth Mysore, C 1.027
Srivastava, A 2.300
Ssentongo, P 2.027, 2.053, 3.385
St.Louis, L 2.181, 3.111
StÃdberg, T 2.353, C.03
Staab, D M. 2.179
Staba, R 2.061, 3.071
Stacey, W 3.103
Staelens, S 3.051
Stafstrom, C 2.005
Staley, K 1.229, 2.004, 2.008, 3.001,
3.003, 3.007, 3.027
Staljanssens, W 1.073
Staniskyte, M 1.009
Stapleton-Kotloski, J 2.035
Steeves, R H. 3.278
Stein, J M. 1.166
Stein, M 3.114
Steinhaeuser, C 3.041
Stenger, E 2.292
Steriade, C 3.153
Stern, J 2.215
Steven, D 1.147, 3.285
Stevenson, M 1.241
Stewart, E 3.177
Stickgold, R 2.333
Stillman, C 1.112, 1.241
Stivaros, S 2.353, C.03
Stobbe, R 3.211
Stockis, A 1.219, 1.224, 1.227, 1.237
Stoeckel, M 1.179
Stolfi, A 2.161
Storb, R 1.203
Story, T 1.204, 1.205
Stosser, M 2.349
Stott, C 3.034
Stoub, T 3.210
Stoute, J A. 2.053
Stranneheim, H 2.353, C.03
Straub, H B. 3.077
Strauman, M C. 3.107
Streiner, D L. 2.336
Streletz, L 1.089
Striano, P 1.317, 2.132, 3.018
Striano, S 2.132
Strobbe, G 1.073, 2.216
Strobl, K 1.275
Strom, L 1.183, 3.073
Struck, A 2.213
Stuber, G 1.164
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Suchdev, K 2.280
Suchy, S 2.349
Sudachan, P 2.137
Sugai, K 2.309, 3.178, 3.306
Sugano, H 1.072, 1.149, 1.384, 3.295
Sukasem, C 2.347, 2.352
Sukumar, D 2.227
Sullivan, J 1.085, 1.091, 1.110, 1.122,
1.367, 2.163, 2.296
Suls, A 1.313
Sultan, F 1.326
Sumpter, R 2.341
Sun, F 1.036, 1.045, 1.046, 1.121
Sun, H 2.028, 3.008, 3.070, 3.251
Sun, S 2.396, 3.010
Sunderam, S 2.038, 3.157
Sunwoo, J 1.209, 2.372, 3.080, 3.281
Sureja, P 2.165
Suter, B 1.301
Sutherland, W 3.093
Sutter, R 1.129
Sutton, R 3.089
Sutula, T 2.046, 3.247
Suwanpakdee, P 3.124
Suzuki, H 1.072, 1.149
Suzuki, H 3.212
Suzuki, T 2.354, 2.356
Suzuki, Y 1.061
Sveberg, L 2.382
Svendsen, T 3.274
Swaminathan, A 1.393
Swann, J 3.046
Swanson, G 2.116
Swanson, S 3.218
Swartz, B E. 1.113
Sweeney-Reed, C 3.077
Sweet, J 1.109
Sweitek, B 3.025
Swiercz, W 1.229, 3.027
Swissa, E 3.104
Sy, H 1.132
Synowiec, A 1.066, 1.115, 1.280
Syrbe, S 2.360, 2.362, C.09
Szabo, C 1.152, 1.327
Szaflarski, J 1.165, 1.208, 1.213, 2.077,
2.267, 2.334, 2.340, 2.375, 3.075,
3.106, 3.218
Szaflarski, M 2.375
Szeliga, C 3.120
Szklarski, L 3.133
Szu, J 3.052, 3.252
T
Tachrount, M 1.350
Tadevosyan, A 2.108
Tadokoro, Y 2.389
Taghibiglou, C 2.058
Taglialatela, M 1.308, 1.312, 3.018, 3.337,
C.07
Tai, X 1.349
Takahashi, A 2.309, 3.306
Takahashi, D 3.006
Takahashi, R 1.281
Takahashi, Y 2.148
Takahashi, Y 1.281
Takano, H 2.076, 2.113, 2.118, A,05
Takebayashi, H 1.305
Takei, N 1.305
Takeoka, M 3.126, 3.255, 3.333
Takeuchi, T 1.142
Takumi, I 3.166
Talley, C 1.251, 1.268, 2.305, 2.305, 3.266
Talos, D M. 3.070, 3.076
Talvik, I 2.361
Talvik, T 2.361
116
Tan, Y 1.148, 3.223
Tanaka, F 2.173
Tanaka, M 1.310, 2.354, 2.356
Tanaka, T 1.250
Tandon, N 1.004, 3.078, 3.309
Tang, B 2.230
Tang, S 1.303
Tang, W 3.041, 3.041
Tangen, R 1.109
Tang-Wai, D 3.153
Tang-Wai, R 2.178, 3.324
Tankovic, A 3.013, 3.015
Tao, J 2.376, 3.110, 3.132
Taplin, A M. 2.121, 3.087
Taraschenko, O 1.058
Tarnopolsky, M 3.338
Tasker, R 1.123, 2.186
Tasker, R 1.137, 2.183
Tassi, L 3.149
Tate, M 3.287
Tatsuoka, C 1.175, 1.394
Tatum, W 1.060, 3.088, 3.114, 3.290
Tauboll, E 2.226, 2.382, 3.041, B.06
Taubøll, E 2.301, 3.162
Taurin, G 1.084
Tayah, T 2.322
Taylor, A G. 3.278
Taylor, C 3.011
Tcheng, T 1.046, 3.031, 3.085
Tecoma, E 1.022, 1.168
Tecoma, E 1.076
Tedeschi, H 1.351
Tedeschi, H 2.299
Teeter, B 1.087
Telci, A 2.096
Tellez-Zenteno, J 2.058, 3.351
Téllez Zenteno, J F. 2.131, 2.191, 3.093
Temel, Y 3.283
Templer, J 3.287
Tenga, M 3.019, A.01
Tenney, J 1.163, 2.127, 2.340, 3.063
Tennigkeit, F 2.251
Terashima, H 1.047
Terrill, M 2.127
Terrone, G 2.014
Terry, D 1.332, 3.350
Terzano, M 3.065
Tesar, G 1.134, 2.379
Thanaviratananich, S 2.387
Theerannaew, W 1.394
Theodore, W H. 1.018
Theodore, W 2.007, 2.219
Therriault, S 2.244
Thesen, T 1.146
Thibert, R L. 3.292, 3.330
Thieffry, S 1.203
Thodeson, D 1.038
Thodupunuri, S 3.061
Thom, M 1.348, 1.349, 1.350
Thomas, A 3.009
Thomas, A 1.165, 2.077
Thomas, C 2.348
Thomas, G P. 2.221
Thomas, M 3.309
Thomas, R 1.309
Thome, S 3.255
Thome, U 1.086, 2.217
Thome-Souza, S 2.276, 3.111
Thompson, L 2.294
Thompson, M 1.244, 3.293
Thompson, N 1.279
Thompson, P 1.349
Thompson, P 1.154, 1.348
Thompson, S 2.235, B.09
Thompson, S 3.309
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Thomschewski, A 1.160
Thornton, N 2.068
Thuku, G 2.053
Thurman, D 1.225, 1.226
Tian, N 1.366
Tibbetts, L 1.223, 2.270
Tidball, A 2.087, A.03
Tigerschiöld, S 2.353, C.03
Tilahun, B 2.066
Tillema, J 1.392
Tilton, N 2.296
Timmler, T 2.179
Timmons-Mitchell, J 1.009
Ting, T 3.267
Tisdall, M 2.308, 2.391, 3.195, 3.294
Titima, I 3.131
Titiz, A 2.221
Titus, J 3.303
Tivarus, M 3.218
Toda, K 1.359, 2.188, 3.203
Todaro, M 3.239
Togo, O 2.251
Tohyama, J 1.302, 1.305
Tolaymat, a 1.078
Tolchin, B 1.010, 2.236
Toledano Delgado, R 2.288
Toledo, M 1.128, 1.207, 1.233, 3.261
Toler, J 3.181
Tom, M B. 2.248
Tomás, J 3.366
Tomaschek, E 3.349
Tomasek, M 3.146
Tomescu, M I. 2.110
Tominaga, T 2.304, 3.129, 3.212
Tomko, S R. 1.381
Tomlinson, S 3.098, 3.099
Tommerup, N 1.317, 2.361
Tong, C 1.321
Tong, F 1.080
Tononi, G 3.130, 3.149
Topcu, M 1.344
Topf, M 2.353, C.03
Topjian, A 1.123, 1.137, 2.183
Torello, A 2.003
Tornes, L 1.284, 3.235, 3.288, B.02
Torres, N 1.233
Tosun, D 2.099
Touloumes, G 2.160
Touraine, R 2.148
Tousseyn, S 3.158, 3.222
Tovar Quiroga, D F. 1.356
Toyoda, G 1.070, 2.128
Toyota, E 1.311
Tracy, J 2.222
Traitruengsakul, S 3.147
Tran, B 3.337, C.07
Trandafir, C C. 1.391
Traynelis, S 3.013, 3.015
Treiman, D 3.248
Treiman, D M. 2.042, 2.098, 2.241, A.02
Treiman, L 2.098, A.02
Trejo-Martinez, D 3.207, 3.221
Tremblay, G 1.335
Trevelyan, A 3.037
Trikantzopoulou, M F. 3.206
Tringali, G 2.323
Trinh, V 3.208
Trinka, E 1.160, 2.243, 3.264, 3.367
Triplett, R 1.293
Trobliger, R 1.285, 2.269, 3.326
Troskie, C 3.341
Trouth, A 3.394
Trudeau, P 2.179
Truglio, G 3.152
Truong, A 1.100
Van de Ville, D 3.219
Vanegas, F 3.047
Van Esch, H 1.306, C.05
Van Ess, P J. 2.256, 2.259
Van Gassen, K 2.361
Van Grunderbeek, W 2.085
Van Holen, R 1.073, 1.164
Vanhove, C 1.164
Van Karnebeek, C 1.311
Van Kranen-Mastenbroek, V 3.283
VanMeter, J W. 1.298
Van Mierlo, P 1.073, 2.069, 2.216, 3.141
Van Ness, P 1.121, 2.172
Van Vliet, E 2.003
Vandenplas, C 2.003
Vannest, J 1.163, 2.340, 3.218
Van Orman, C 1.269
Van Poppel, K 1.355
Van Rijckevorsel, K 2.085
Van Roost, D 2.216
Vanthillo, N 1.306, C.05
Varadkar, S 2.391, 3.195
Varley, J 1.003
Vassallo, G 2.353, C.03
Vaughan, D 3.228
Vazquez, B 1.119, 2.168
Vazquez, B 1.192
Vazquez Barron, D 3.071
Vázquez-Figueroa, L D. 3.299
Vega, C 1.263, 3.255
Vega-García, A 3.108
Vekeman, F 1.077, 1.372
Velasco, A 2.071
Velasco, T R. 3.304
Velasco Campos, F 2.071, 3.071
Velasco-Monroy, A 3.071
Velázquez Perez, L 3.207, 3.221
Velez, F 1.182, 1.201, 1.202, 1.236, 2.249,
2.282
Velez, M 1.082
Velez-Ruiz, N 2.063
Venegas Silva, V 3.232
Venkateswaran, S 2.350
Veras Rocha de Moura, L M. 2.109
Vergara, F 3.232
Verhaeghe, J 3.051
Ver Hoef, L 1.165, 2.077, 3.075, 3.106
Verity, C 2.255
Verity, K 2.341
Verrier, R L. 2.225
Vervaeke, K 3.041
Vezina, G 2.313
Vezyroglou, K 1.275
Vezzani, A 2.003, 2.014, 3.024
Vickrey, B 1.325, 1.339
Vidaurre, J 1.037
Vidhya, K 2.344
Vigevano, F 1.312, 2.343
Vignoli, A 3.336
Villalobos, A P. 2.374
Villalobos-Nieto, R 2.374
Villani, F 2.323
Villanueva, V 1.233, 2.263
Villanueva, V 2.253
Villar, M 1.230
Villasana-Salazar, B 2.029
Ville, D 2.292
Vincentiis, S 2.325
Virag, N 3.089
Vitkovskiy, P 3.030
Vlachy, J 1.034
Vlooswijk, M 1.104
Vogel, S 2.290
Voges, J 3.077
Volk, H 3.037
Tsai, J 2.238, 2.260
Tschudin-Sutter, S 1.129
Tseng, P 3.371
Tsetsou, S 1.133
Tshering, L 3.374
Tsuchida, T 1.262, 3.019, 3.194, 3.343,
A.01
Tsuchiya, K 3.335
Tsuchiya, K 2.047
Tsuji, S 1.250, 3.391
Tsur, A 3.199
Tsurusaki, Y 1.305
Tucker, D 2.127, 2.210
Tumkur, A 1.026
Tung, J 3.094, A.07
Turak, B 3.090
Turanli, G 1.344, 2.283
Turchi, R 1.336
Turco, L 1.378
Turlington, K 2.235, B.09
Turner, Z 1.249
Tuttle, E 1.077, 1.372
Tuxhorn, I 1.109, 3.164
Tworek, D M. 1.200
Tzingounas, A 1.320
u
Uchida, T 3.359
Udayasankar, U 1.140
Ueda, A 2.047
Uematsu, M 1.302
Ueno, T 1.212
Ugorec, I 1.033, 3.121
Uldall, P 1.317
Ulker, B 2.148
Ullah, A 1.223, 1.234
Ullah, G 1.068
Ullman, H 3.208
Umeoka, E H. 3.038
Umetsu, Y 1.187
Underwood, T 3.047
Ung, H 3.097, 3.144
Urbach, H 2.200
Urbain, K 2.303
Urlacher, J 3.324
Uthman, B 1.089
Uysal, U 1.255, 1.368, 3.371
Uzuner, G 2.169
V
Vadera, S 3.074
Vaher, U 2.361
Vaidya, U 1.178
Vaithianathan, S 3.267
Vaitkevicius, H 3.265
Vakorin, V 2.312
Valdés-Cruz, A 2.029
Valdez, G 3.019, A.01
Valdez, J 2.287
Valdez-Gonzalez, K 3.344
Valença, M 1.129
Valencia, I 1.085, 1.091, 1.110, 1.122,
2.163
Valente, K 2.233, 2.324, 2.325, 2.326,
2.357
Valeriano, J P. 1.280
Valiante, T 3.145
Van Allen, M 1.311
Vanatta, L 1.246
Van Den Berge, N 1.164
Vandenberghe, S 1.073, 2.216
Van den Bos, M 1.059
Vander Kooi, C 3.012, 3.012
Van der linden, A 3.051
Van der Linden Jr, H 2.139, 2.357
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
117
Voll, A R. 2.191, 3.093
Vollmar, C 1.153, 1.154
Vonck, K 2.085, 2.216
Von Ellenrieder, N 1.053, 2.102, 2.111
Von Gaudecker, J 3.278
Von Podewils, F 1.102
Von Spiczak, S 3.342, C.08
Voroslakos, M 2.062
Vossler, D G. 1.183
Vossler, D 1.195, 2.244
Vrbancic, M 2.058
Vu, T 3.125
Vucic, S 1.059
Vulliemoz, S 3.219
Vulliemoz, S 1.160, 3.366
Vuppala, A 1.051
Vuu, I 2.026
W
Waber, D P. 1.263
Wagenaar, J 2.060, 3.097, 3.144, 3.148
Wagner, E 2.234, B.07
Wagner, G 2.085, 3.283
Wagner, J L. 1.181
Wagner, M L. 2.227
Wagnon, J 2.052, 2.114, 2.364, 3.142,
A.08
Waheed, R 2.177
Wainwright, M 1.123, 1.137, 2.183
Wakefield, S 3.241, B.04
Walker, M 3.037
Wallace, A 3.187
Wallace, E 3.064
Walsh, K 1.297
Walz, J 1.159
Wandschneider, B 1.154
Wang, C 3.031
Wang, D 2.095
Wang, D 2.119
Wang, D D. 1.271
Wang, G 1.208
Wang, J 2.237
Wang, J 1.314
Wang, L 2.245
Wang, M 3.008
Wang, S 2.218
Wang, W 2.251
Wang, X 2.095
Wang, X 2.251
Wang, X 1.182, 2.249
Wang, Y 2.048
Wang, Y 1.028
Wang, Z 1.335
Wang, Z 1.140, 3.222
Wang, Z I. 1.170, 2.064, 2.217
Ward, M J. 1.049
Ward-Mitchell, R 1.393
Wark, J 3.239
Warren, A 3.228
Warren, K 1.097
Warsi, N 2.307
Wasade, V S. 1.144, 2.166
Wasterlain, C 2.022
Watanabe, E 1.250, 2.207, 2.211
Watanabe, K 1.142
Watanabe, K 1.305
Waterhouse, K 3.351
Waters, C 1.044
Watson, R 1.277
Webber, W 2.016
Weber, D 1.015, 1.016, 3.170
Weber, Y 2.362
Wechsler, R 1.200, 1.211, 1.214, 1.380,
2.244, 2.246
DECEMBER 4 - 8, 2015 www.AeSnet.org
ABSTRACT AUTHOR INDEX
Weckhuysen, S 1.308, 1.313, 3.018,
3.018, 3.342, C.08
Wedell, A 2.353, C.03
Weedon, J 1.042
Weerakkody, T 3.137
Wehner, T 1.259, 2.320
Wei, Y 1.068
Weiner, H 3.298
Weinstein, S 1.262, 2.027
Weinstock, A 2.317, 2.369
Weir, R 3.394
Weisbrot, D M. 3.233
Weisman, J 1.327
Weiss, B 2.380
Weiss, S A. 2.061
Weissinger, F 2.268
Weissman, J 1.325
Weistein, S L. 2.053
Weitzler, J 3.232
Welter, E 1.175
Welty, T 2.267
Wendling, F 2.090
Weng, J 3.229
Wennberg, R 3.153
Westover, M 2.109, 3.115, 3.123
Westover, M B. 2.213
Westwood, A 3.202
Wharen, R 1.060, 2.172
Wharen, R 3.290
Wheatley, M 3.324
Wheeler, J 2.158
Wheless, J 1.162
Wheless, J 1.328, 1.329, 1.330, 1.355,
3.091, 3.127, 3.156
Wheless, M 1.355
White, E J. 3.145
White, H 2.021, 3.047
White, J 2.033, 3.056
White, K 1.232
White, M 1.003
White, S 1.200, 1.215
White, T 1.132
Whitehead, M 3.301
Whitesides, J 1.199, 1.224, 3.253, 3.261
Whiting, S 1.331, 1.357, 2.350
Whitmire, L 3.088
Widjaja, E 1.361, 1.373, 2.155
Wiebe, N 1.324
Wiebe, S 1.135, 1.296, 1.324, 2.265,
2.302, 3.154, 3.370
Wiest, R 1.160
Wiggs, E 2.219
Wight, J 1.310, 2.354, 2.356
Wilberger, J 1.280
Wilcox, K S. 1.215, 2.021, 3.362
Wilfong, A 1.123, 1.137, 1.231, 1.251,
1.268, 1.381, 2.183, 2.305, 2.305,
2.351, 3.266
Wilkening, G 2.291, 3.255
Wilkinson, R 3.195
Willey, J 1.010
Williams, A 1.300
Williams, B 1.188, 1.189, 1.190, 1.191,
1.192, 1.193, 1.194, 1.195, 1.196,
1.211, 1.214, 2.250, 2.263, 3.260,
3.262
Williams, J 2.373
Williams, K 1.123, 1.137, 2.183
Williams, M 3.192
Williams, P 2.244
Williams, S 3.308
Williams, S 1.204, 1.205
Williamson, J 3.206
Willie, J 1.058, 3.291
Willis, M D. 3.233
Wilson, D A. 3.368
Yalnizoglu, D 1.344
Yamakawa, K 2.354, 2.356
Yamamoto, H 1.052, 1.142
Yamamoto, H 1.011
Yamamoto, T 1.198, 3.296
Yamao, Y 1.281
Yamazoe, T 1.198, 3.296
Yampayon, K 2.347
Yan, J 2.095
Yanagawa, Y 3.359
Yang, C 3.143
Yang, H 1.184, 1.187, 1.188, 1.189, 1.190,
1.191, 1.192, 1.193, 1.196, 1.211,
1.214, 2.250, 2.263, 3.260, 3.262
Yang, J 3.167
Yang, L 2.037
Yang, X 3.357
Yang, X 2.095
Yasuda, C 1.351, 2.203
Yasuda, C L. 2.299
Yates, E 2.066
Yates, N 3.037
Yaun, A 3.019, A.01
Ybot, I 1.230
Ye, A 1.039, 3.066
Yeasin, M 3.127
Yee, K 2.093
Yeh, S J. 2.215
Yelvington, K 3.114
Yener, B 2.392
Yeon, G 1.118, 1.141
Yim, M 2.287
Yin, H 1.037
Yin, S 2.235, B.09
Ying, Z 3.109
Yokoi, S 1.142
Yokota, H 2.207, 2.211
Yokota, T 1.198, 3.296
Yonan, J 3.052
Yoo, I 1.075
Yoo, J 2.393
Yoo, J 3.068, 3.175
Yoon, H 1.139
Yoong, M 1.143, 2.341
Yoshi, J 3.356
Yoshida, N 1.061
Yoshinaga, H 1.067
You, X 1.150, 1.151
Younes, K 2.142
Young, J 3.292
Young, J 3.068
Youroukos, S 2.148
Yousry, T 1.350
Yozawitz, E 1.122, 2.163
Yu, J 3.345
Yu, J 3.025, 3.025
Yu, J 3.069
Yu, K 2.100
Yu, P 3.072
Yu, R 1.264
Yu, V 3.257, 3.258, 3.259
Yu, Y J. 2.140
Yu, Z 2.095
Yuan, H 3.013, 3.015
Yuan, Y 2.114, 3.142
Yue, C 2.113
Yum, A 1.002
Yum, M 1.139, 2.167
Yun, S 2.091
Yushkevich, P 3.217
Wilson, J D. 3.144
Wilson, S 3.310
Winawer, M 1.341, 2.206
Winesett, S P. 1.249
Wingenbach, D D. 1.201
Winslow, J 1.134
Winters, J 3.054
Winterstein, A 1.365
Wirrell, E 1.085, 1.091, 1.110, 1.122,
1.277, 1.356, 1.392, 2.163, 3.299
Wisniewski, T 2.348
Wisse, L 3.217
Witek, N 2.157
Wiwattanadittakun, N 3.343
Wolf, S 1.260
Wolff, C 3.024, 3.245, 3.250
Wolper, E 3.374
Wong, C 1.059, 2.218
Wong, D 3.243, B.05
Wong, J 3.057
Wong, M 2.171
Wong, P 3.073
Wong, P 1.342, 3.393
Wong, R 1.223, 1.234
Wong, S 1.041, 3.066
Wong, S M. 2.155
Wong, S 1.002
Wong, V S. 1.036
Wong, V S. 1.377
Wong-Kisiel, L 1.122, 1.277, 2.163, 3.299
Wongvravit, J 2.001
Wood, E G. 2.367
Woodard, V 2.171
Worrell, G 1.060, 2.026, 2.172, 2.212,
3.148
Wozny, T A. 1.043, 1.049, 2.054, 2.082
Wragg, R 3.014, 3.014, A.04
Wray, C 1.179, 2.395
Wright, C 1.362
Wright, S 3.064
Wright, S 3.034
Wu, A 2.058
Wu, E 1.119, 2.168
Wu, G 2.217, 3.220
Wu, H 2.284
Wu, J 3.120
Wu, S 3.110, 3.132
Wu, T 2.239
Wu, X 1.314
Wu, Y 1.314
Wu, Y 3.205
Wu, Y 2.120
Wulsin, A C. 2.039
Wusthoff, C 1.085, 1.091, 1.110, 1.122
Wusthoff, C J. 2.163, 3.188, 3.194
Wuttke, T V. 2.361
Wyffels, L 3.051
Wyllie, E 1.009, 2.137
X
Xiang, J 1.163
Xie, H 1.314
Xiong, W 2.012
Xu, M 1.106, 2.303
Xu, S 2.303
y
Yaakub, S 1.153
Yacubian, E 1.310, 1.345, 2.354, 2.356,
3.312
Yaghouby, F 2.038, 3.157
Yagyu, K 1.052
Yakovlev, A 2.228
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
118
Z
Zaccariello, M 3.299
Zachwieja, N 1.319, 2.116
Zack, M 1.366
Zaeemfar, N 3.381
Zaghloul, K 3.112
Zagzag, D 2.348
Zaher, N 1.103
Zaiderman, M 2.290
Zak, M 1.248, 2.289
Zaki, T 2.274
Zambrelli, E 3.336
Zanelli, S 3.022
Zangen, A 1.065
Zanotti-Fregonara, P 2.007
Zapfe, W 2.112
Zaveri, H 2.075, 2.380, 3.150
Zawadzki, L 1.122, 2.163
Zechner, U 1.317
Zelano, J 3.028
Zelleke, T 1.172, 1.262, 3.215
Zemba, D 1.009
Zendler, N 3.236
Zeng, C 3.048
Zhai, F 1.274
Zhang, H 2.117
Zhang, L 2.251
Zhang, S 2.380
Zhang, X 3.269
Zhang, Y 1.314
Zhang, Y 1.314
Zhang, Y 3.154
Zhang, Y 2.182
Zhao, L 3.069, 3.269, 3.270
Zhao, M 3.216, 3.216
Zhao, Q 3.323
Zhao, Y 3.283
Zhao, Z 2.218
Zhen, J 2.353, C.03
Zheng, N 2.284, 3.269
Zheng, P 3.100
Zheng, Y 1.305
Zhou, D 1.347, 2.015
Zhou, J 2.119
Zhou, L 2.251
Zhou, Q 3.109
Zhou, Y 3.394
Ziemann, A 1.197
Zilberman, I 3.191
Zimmermann, G 3.367
Zinser, J 2.236
Ziobro, J 3.395
Zions, M 3.050
Zoghbi, S 2.007
Zolkowska, D 2.242
Zombori, T 2.062
Zonjy, B 1.394
Zonnenberg, B 2.148
Zou, G 1.296
Zrik, A 3.164
Zuniga-Fajuri, A 3.305
Zutshi, D 2.177
Zutshi, D 1.352, 2.279, 2.280
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Benefactor Level
Sunovion
Pharmaceuticals Inc.
Special thanks to
• Buffet Lunch in Exhibit Hall
(Saturday)
• Exhibit Booth
• Innovation Pavilion
• Coffee Breaks in Exhibit Hall
(Sunday and Monday)
• office on Exhibit Floor
• Scientific Exhibit
• Coat Check Sponsorship
• Everyday Excellence in Epilepsy
Booth #443
• Exclusive Door Drop (Friday)
• Campfire Sessions (Saturday,
Sunday and Monday)
• Annual Meeting Mobile App
• Program Book Advertising
• Epilepsy Currents Advertising
• Footprints to Booth
• AES Fellows/EpiPoRT Program
Support
• Airport Baggage Carousel
Advertising
• General Annual Meeting Support
• Media Wall Advertising
• Poster Breakfasts (Sunday
and Monday)
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
119
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Leader Level
eisai Inc.
Special thanks to
• Exhibit Booth
• Innovation Pavilion
• office on Exhibit Floor
• Scientific Exhibit
• Premier Sponsorship of Passport
to Prizes
• Program Book Advertising
• Footprints to Booth
• CME Grant: Pediatric State of the
Art Symposium
• CME Grant: Epilepsy Therapies
Symposium
• CME Grant: Professional in
Epilepsy Care (PEC) Symposium
• AES Fellows/EpiPoRT Program
Support
• Door Drops (Saturday)
• Epilepsy Currents Advertising
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
120
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Leader Level
lundbeck
Special thanks to
• Exhibit Booth
• Innovation Pavilion
• Scientific Exhibit
• Passport to Prizes
• Program Book Advertising
• Door Drop (Saturday)
• Hotel Key Card Sponsorship
• Epilepsy Currents Advertising
• CME Grant: Professionals in
Epilepsy Care (PEC) Symposium
• CME Grant: Pediatric State of the
Art Symposium
• CME Grant: Annual Fundamentals
of Epilepsy Symposium
• AES Fellows/EpiPoRT Program
Support
• CME Grant: Epilepsy Therapies
Symposium
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
121
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Leader Level
uCB, Inc.
Special thanks to
• Exhibit Booths
• Innovation Pavilion
• Scientific Exhibit
• Passport to Prizes
• Program Book Advertising
• Media Wall Advertising
• Cyber Café Sponsorship
• CME Grant: Professionals in
Epilepsy Care (PEC) Symposium
• AES Fellows/EpiPoRT Program
Support
• Epilepsy Currents Advertising
• Mobile Charging Station
Sponsorship
• CME Grant: Epilepsy Therapies
Symposium
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
122
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Partner Level
upsher-Smith
laboratories, Inc.
Special thanks to
• Exhibit Booths
• Judith Hoyer Lecture Support
• Scientific Exhibit
• Epilepsy Currents Advertising
• Program Book Advertising
• AES Fellows/EpiPoRT Program
Support
• Passport to Prizes
• Door Drops (Saturday)
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
• Seed Grant
123
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Partner Level
Supernus
Pharmaceuticals, Inc.
Special thanks to
• CME Grant: Epilepsy Therapies
Symposium
• Exhibit Booth
• Passport to Prizes
• CME Grant: Presidential
Symposium
• Program Book Advertising
• Door Drop (Saturday)
• AES Fellows/EpiPoRT Program
Support
• Water Cooler Sponsorships
Supernus
R
Pharmaceuticals
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
124
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Supporter Level
Supporter Level
livanova
Cadwell
Industries, Inc.
Special thanks to
Special thanks to
• Exhibit Booth
• Exhibit Booth
• CME Grant: Pediatric State of
the Art Symposium
• Epilepsy Currents Advertising
• Program Book Advertising
• Innovation Pavilion
• Passport to Prizes
• CME Grant: Annual
Fundamentals Symposium
• Named Fellowship
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
125
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Supporter Level
Supporter Level
Acorda
Therapeutics
gW
Pharmaceuticals
Special thanks to
Special thanks to
• Exhibit Booth
• Exhibit Booth
• Passport to Prizes
• CME Grant: Annual Course
• office on Exhibit Floor
• Program Book Advertising
• Investigator Workshop
• CME Grant: Professionals in
Epilepsy Care Symposium
• AES Fellows/EpiPoRT
Program Support
• CME Grant: Presidential
Symposium
• AES Fellows/EpiPoRT
Program Support
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
126
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Supporter Level
Pfizer, Inc.
Special thanks to
• General Annual Meeting
Support
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
127
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Contributor Level
Contributor Level
Special thanks to
Special thanks to
nihon kohden
America, Inc.
• Exhibit Booth
•
•
•
•
•
• Donation of Proceeds from
Equipment Sale
• Passport to Prizes
Contributor Level
Aprecia
Pharmaceuticals
Company
Exhibit Booth
Program Book Advertising
Water Cooler Sponsorship
Coffee Break in Exhibit Hall (Saturday)
Media Wall Advertising
Contributor Level
Special thanks to
Special thanks to
Compumedics
Sage Therapeutics
• Exhibit Booth
• Exhibit Booth
• Program Book Advertising
• Epilepsy Currents Advertising
• Epilepsy Currents Advertising
• Passport to Prizes
• Media Wall Advertising
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
128
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Advocate Level
Special thanks to
Medtronic
neuroPace, Inc.
• Exhibit Booth
• Exhibit Booth
• Scientific Exhibit
• Innovation Pavilion
• young Investigator Awards
elekta, Inc.
natus neurology
Incorporated
• Exhibit Booth
• Exhibit Booth
Moberg ICu Solutions
Blackrock neuroMed, llC
• Exhibit Booth
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
• Exhibit Booth
129
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Advocate Level
Medtech Surgical
Special thanks to
electrical geodesics, Inc.
• Exhibit Booth
• Exhibit Booth
• Epilepsy Currents Advertising
lifelines neurodiagnostics
Systems, Inc.
Marinus
Pharmaceuticals, Inc.
• Scientific Exhibit
• Exhibit Booth
• Door Drop (Saturday)
• Epilepsy Currents Advertising
Rhythmlink
International, llC
• Exhibit Booth
• Epilepsy Currents Advertising
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
130
DECEMBER 4 - 8, 2015 www.AeSnet.org
SUPPORTER RECOGNITION
Patron Level
Special thanks to
Mallinckrodt Pharmaceuticals, Inc.
Ad-Tech Medical Instrument Corp.
Persyst Development Corporation
Tuberous Sclerosis Alliance
Athena Diagnostics, Inc.
geneDx
Brain Sentinel, Inc.
MOBÉ
PMT Corporation
Medical neurogenetics, llC
neuralynx, Inc.
Monteris Medical, Inc.
nexstim, Inc.
The Jack Pribaz Foundation
Texas Children's hospital
Transgenomic, Inc.
Based on Annual Meeting support as of October 25, 2015.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
131
DECEMBER 4 - 8, 2015 www.AeSnet.org
GENERAL INFORMATION
AeS 2015 Annual Meeting
The American Epilepsy Society (AES) is one of 108 Chapters of
the International League Against Epilepsy (ILAE). The AES
Annual Meeting is the largest meeting and exhibition in the
world for those who share the common scientific and clinical
interests of epilepsy and neurophysiology. The meeting
attracts nearly 5,000 attendees dedicated to improving the
quality of life for those dealing with epilepsy.
Content Categories
The AES Annual Meeting offers high-quality educational
content across diverse work settings, professional roles and
experience levels:
Basic: Those new to epilepsy treatment or whose background
in the specialty is limited, e.g., students, residents, general
physicians, general neurologists and neurosurgeons, other
professionals in epilepsy care, administrators.
Annual Course — Allows in-depth exploration of important
topics related to epilepsy, focused on clinical care, including
review of the science underlying the topics, reviews of clinical
research and discussion of the associated clinical implications.
The Annual Course utilizes a mixture of educational lectures,
clinical vignettes and panel discussions.
Investigator Workshops — Provide exploration and
discussion of the science underlying epilepsy, with focus on
basic science research, but clinical and translational research
also. While the target audience is primarily scientists, some
workshops provide insight into the scientific basis of clinical
epilepsy.
Skills Workshops — Deliver hands-on and interactive
learning opportunities in focused clinical areas. Attendance at
each workshop is limited to a small number of participants to
allow for optimal interaction. Advanced registration and an
additional fee are required.
Intermediate: Epilepsy fellows, epileptologists, epilepsy
neurosurgeons, and other providers with experience in
epilepsy care (e.g., advanced practice nurses, nurses,
physician assistants), neuropsychologists, psychiatrists, basic
and translational researchers.
Poster Sessions
educational Sessions
The Exhibit Hall is an integral part of the learning experience.
Meeting participants will have an ideal opportunity to learn
about the latest in pharmaceuticals, publications, scientific
equipment and technology relevant to the fields of epilepsy
and neurophysiology.
Advanced: Address highly technical or complex topics (e.g.,
neurophysiology, advanced imaging techniques or advanced
treatment modalities, including surgery.)
From illuminating lectures to hands-on learning. the AES
Annual Meeting offers a comprehensive program:
Symposia — Provide the major educational activities at the
Annual Meeting. Topics range from clinically oriented
presentations reviewing common issues in epilepsy to more
complex topics combining basic sciences and clinical
neurology. While target audiences differ, all symposia include
discussion of clinically relevant information.
Special Interest Groups (SIGs) — Offer a less formal
opportunity for attendees with similar interests to explore
specific topics, through brief educational sessions and open
discussion. Although the sizes of SIG sessions vary, all lend
themselves to active participation and dialogue.
General Lectures — Recognize distinguished leaders in
clinical epilepsy and research. At the Hoyer Lecture, an AES
past-president honors contributions by leading members. An
invited member whose scholarly work has greatly enhanced
the collective understanding of epilepsy gives the Lennox and
Lombroso Lecture.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Providing a forum for cutting edge research, Poster Sessions
encourages interaction among presenters and attendees.
exhibit hall
Included in the Exhibit Hall is the Epilepsy Resource Center -non-profit organizations doing important work in advocacy,
patient outreach, patient services and research funding.
To ensure safety and security, no children under 12 years of
age, strollers, carriages, wheeled luggage or wheeled
briefcases are allowed in the Exhibit Hall during exhibit hours.
Scientific exhibits
AES has approved guidelines for industry-sponsored Scientific
Exhibits at the Annual Meeting. Scientific Exhibits differ from
traditional poster presentations in that a broad range of
material can be presented as a collection of topics, such as
results of various clinical trials or a thematic presentation of
one aspect of drug development.
#AeSmtg15
132
DECEMBER 4 - 8, 2015 www.AeSnet.org
GENERAL INFORMATION
Accreditation
The American Epilepsy Society is accredited by
the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical
education for physicians.
Credit Designation
Physicians
The American Epilepsy Society designates this live activity for a
maximum of 30.75 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of
their participation in the activity.
Physician Assistant
AAPA accepts certificates of participation for educational
activities certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state
medical society. Physician assistants may receive a maximum
of 30.75 hours of Category 1 credit for completing this
program.
Jointly provided by AKH Inc., Advancing
Knowledge in Healthcare and the American
Epilepsy Society.
International Credits
The American Medical Association has determined that nonU.S. licensed physicians who participate in this CME activity are
eligible for AMA PRA Category 1 Credits™.
CMe/Ce Certificates
For those attendees who wish to claim CME or CE, there is an
additional fee. Registrants can pay this fee as part of the
registration process. Those who do not pre-purchase the
credit will also have the ability to pay this fee at the time they
attempt to claim credit. Fees for CME increase after January
16 and are a one-time charge per annual meeting.
The evaluation system will remain open through Friday,
February 26, 2016. Evaluations must be completed by this
date in order to record and receive your CME/CE certificate.
member Fees:
$50 through January 15, 2016
$75 January 16 – February 26, 2016
Non-member Fees: $75 through January 15, 2016
$100 January 16 – February 26, 2016
Attendance Certificate/International
Attendees
Nursing
AKH Inc., Advancing Knowledge in Healthcare is accredited as
a provider of continuing nursing education by the American
Nurses Credentialing Center’s Commission on Accreditation.
A meeting attendance certificate will be available at the
registration desk for international meeting attendees on
Tuesday, December 8.
Nurse Practitioners
AKH Inc., Advancing Knowledge in Healthcare is accredited by
the American Association of Nurse Practitioners as an
approved provider of nurse practitioner continuing education.
Provider Number: 030803. This program is accredited for
30.75 contact hours which includes 8 hours of pharmacology.
Program ID #21547
The AES maintains a policy on the use of commercial support,
which assures that all educational activities sponsored by the
AES provide in-depth presentations that are fair, balanced,
independent and scientifically rigorous. All faculty, planning
committee members, moderators, panel members, editors,
and other individuals who are in a position to control content
are required to disclose relevant relationships with
commercial interests whose products relate to the content of
the educational activity. All educational materials are reviewed
for fair balance, scientific objectivity and levels of evidence.
Disclosure of these relationships to the learners will be made
through syllabus materials and the meeting app.
This activity is awarded 30.75 contact hours.
This program was planned in accordance with AANP CE
Standards and Policies and AANP Commercial Support
Standards.
Pharmacy
AKH Inc., Advancing Knowledge in Healthcare is
accredited by the Accreditation Council for
Pharmacy Education as a provider of continuing
pharmacy education.
Select portions of this Annual Meeting are approved for
pharmacy CE credit. Specific hours of credit for approved
presentations and Universal Activity Numbers assigned to
those presentations are found in the educational schedules.
Criteria for success: nursing and pharmacy credit is based on
program attendance and online completion of a program
evaluation/assessment.
Policy on Commercial Support and
Conflict of Interest
Disclosure of unlabeled/unapproved uses
This educational program may include references to the use
of products for indications not approved by the FDA. Faculty
have been instructed to disclose to the learners when
discussing the off-label, experimental or investigational use of
a product. Opinions expressed with regard to unapproved
uses of products are solely those of the faculty and are not
endorsed by the AES.
If you have any questions about this CE activity, please contact
AKH Inc. at service@akhcme.com.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
133
DECEMBER 4 - 8, 2015 www.AeSnet.org
GENERAL INFORMATION
language
Safety and Security Information
Meeting Attire
•
The following security measures have been designed to
further enhance your personal and professional safety.
The official language of the Annual Meeting is English.
Dress for the Annual Meeting is business casual. Consider
bringing a light jacket or sweater with you since meeting room
temperatures and personal comfort levels vary.
.
no Smoking Policy
For the comfort and health of all attendees, smoking is not
permitted at any AES function. This includes educational
sessions, meetings and all food functions. Both the
Pennsylvania Convention Center and the official meeting
hotels are smoke-free facilities. Please note: smoking is not
permitted in public buildings, restaurants or bars.
•
•
Symposia handouts
•
Handout materials for the educational symposia will be
available via the Annual Meeting App.
•
Audience Response System
AES will be utilizing an Audience Response System (ARS) in
several of the symposia. Faculty will have ARS questions
throughout their presentations with multiple choice answers.
To participate, you will use your cell phone to text your
answer. When a question appears in a presentation, simply
text your answer (a 5 or 6 digit code) to “22333”. Standard text
rates will apply. The ARS allows the learner to participate in
real time. Responding to these questions enhances the
learning environment and provides feedback to the speaker
to assure that the symposium learning objectives are met.
•
•
•
Program Changes
•
gratuities
•
AES cannot assume liability for any changes in the program
due to external or unforeseen circumstances.
Uniformed Convention Center employees have
radios and are ready to assist you. Advise the
dispatcher of the exact location within the
Convention Center. We respectfully request that you
do NOT call 911 directly
An EMT will be on duty in the Convention Center
throughout the meeting
A government-issued photo identification is required
to receive a badge and to replace a lost badge
Convention Center Security may randomly check
packages and bags at the Convention Center
entrances, meeting rooms and in the Exhibit Hall
You will be asked to always clearly display your name
badge and to use only approved Convention Center
entrances and exits
Appropriate badges will be required to enter all
educational sessions, Poster Sessions, Exhibit Hall and
meetings. Due to safety and fire regulations, doors will
be closed to session rooms that fill to capacity
Throughout the meeting, you will notice security staff
presence to monitor the safety of all participants
Do not leave unattended packages (i.e., briefcases,
laptops, purses, etc.) in any area of the Convention
Center or hotel
Please report any suspicious activity to security staff
or to the AES registration desk staff
general Safety Tips
Gratuities are not automatically added to the bill, except in
some cases for large groups. Waiters and waitresses are
usually given 15% to 20% of the bill. Taxi drivers typically
receive 15% of the fare, doorman $2 per service and $2 per
night for hotel housekeeping. Skycaps and porters are
normally tipped $1 per bag.
•
•
•
•
•
•
•
•
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
Pick up any Convention Center house phone in the
facility and dial the Command Station at extension
4911. Or call 215.418.4911 from a cell phone.
134
Take all items with you when leaving a session.
Rooms are cleaned and items left behind are
discarded
Remove your badge once you leave the meeting
facilities
Carry important telephone numbers with you
Do not display or carry large amounts of cash
Walk in groups, especially at night
Lock your hotel room door
Always verify hotel room repair or service calls
Do not disclose your room number to anyone
Never give your personal information (credit card,
room number, etc.) over the phone; instead, go to the
front desk if the hotel calls with questions
DECEMBER 4 - 8, 2015 www.AeSnet.org
GENERAL INFORMATION
Photography and Recording of Programs
The AES strictly prohibits all photography (flash, digital, or
otherwise), audio, videotaping and live-streaming during the
Annual Meeting. Equipment will be confiscated.
Press Room
Convention Center - Room 303, 300 Level
Material presented at the AES Annual Meeting is not to be
reproduced in any format without the express written consent
of the AES. Attendees acknowledge and agree that
commercial or promotional distribution, publishing or
exploitation of speaker sessions, content, or materials from
the AES Annual Meeting is strictly prohibited unless you have
received the express prior written permission from AES or the
otherwise applicable rights holder.
Photograpy Release
When you attend an approved AES event or program, you
enter an area where photography, audio, and video recording
may occur. By entering the event premises, you consent to
photography and its release, publication, exhibiting, or
reproduction to be used for news, newsletters, promotional
purposes, advertising, inclusion on websites, or any other
purpose by AES and its representatives. You release AES, its
officers and employees, and each and all persons involved
from any liability connected with the taking, digitizing, or
publication of photographs and computer images. You have
been fully informed of your consent, waiver of liability, and
release before entering the event.
Insurance/liabilities
AES cannot be held responsible for any personal injury, loss,
accident, damage to private property or additional expenses
incurred as a result of delays or changes in air, rail, sea, road,
or other services, strikes, sickness, weather, acts of terrorism
and any other cause. All participants are encouraged to make
their own arrangements for health and travel insurance.
Faculty Ready Room
Convention Center – Room 203 B, 200 Level
All faculty PowerPoint presentations have already been
uploaded through the AES Faculty Development Room. All
faculty must stop by to reconfirm their presentation with an
audiovisual technician.
Thursday, December 3 ................................4:00 p.m. – 8:00 p.m.
Friday, December 4 ......................................8:00 a.m. – 6:00 p.m.
Saturday, December 5 ................................8:00 a.m. – 6:00 p.m.
Sunday, December 6 ....................................8:00 a.m. – 6:00 p.m.
Monday, December 7 ..................................8:00 a.m. – 6:00 p.m.
Tuesday, December 8 ..................................8:00 a.m. – 11:00 a.m.
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
AES offers meeting information and assistance for journalists
reporting on epilepsy studies, educational presentations, and
special reports at this meeting. The AES on-site Press Room
staff works with journalists to develop stories, research facts
and information, and connect with experts and presenters.
The on-site Press Room is also available to sponsors and
exhibitors for the display and distribution of relevant press
releases and media kits. For more information, contact Natalie
Judd at (203) 605-9515 and natalie@bigvoicecomm.com.
Friday, December 5 ......................................11:00 a.m. - 6:30 p.m.
Saturday, December 6 ....................................7:30 a.m. - 6:30 p.m.
Sunday, December 7 ......................................7:30 a.m. - 6:30 p.m.
Monday, December 8 ....................................7:30 a.m. - 6:30 p.m.
Tuesday, December 9. ....................................7:30 a.m. - 1:00 p.m.
A series of media briefings on a select number of topics will
be held in the press room from Friday, December 4 through
Monday, December 7. Embargoed copies of all press releases
and press room details will be posted in advance on the AES
website at aesnet.org/meetings_events/press
Business Centers
Two full-service FedEx Office business centers are
conveniently located in Philadelphia for Annual Meeting
attendees. Both offer a variety of services that include
shipping, mailing, faxing and photocopying. Please contact the
office directly for details.
Pennsylvania Convention Center
200 Level, between Exhibit Halls B & C
FedEx Office
Phone: 215.925.1218
Email: usa5530@fedex.com
Philadelphia marriott Downtown
Located off main lobby on the First Floor
FedEx Office
1201 Market Street
Phone: 215.923.2520
Email: usa0669@fedex.com
135
DECEMBER 4 - 8, 2015 www.AeSnet.org
AREA MAP OF PHILADELPHIA AND HOTELS
The AES 69th Annual meeting is being held at:
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, Pennsylvania 19107
NP
AR
KW
AY
WINTER ST.
VINE ST.
FRANKLIN
SQUARE
LOGAN
SQUARE
CHINATOWN
3
OLD CITY
RACE ST.
LOGAN SQUARE
PENNSYLVANIA
CONVENTION
CENTER
CHERRY ST.
ARCH ST.
W
JFK BLVD.
2
MARKET ST.
H
ARCH ST.
FILBERT ST.
1
INDEPENDENCE
MALL
JEFFERSON
STATION
MARKET ST.
6
LUDLOW ST.
MARKET EAST
CHESTNUT ST.
SANSOM ST.
SANSOM ST.
7TH ST.
CHESTNUT ST.
RITTENHOUSE SQUARE WEST
WALNUT ST.
H
hotels
1
l
2
l
3
l
4
Philadelphia marriott Downtown
(Headquarter Hotel)
1201 Market Street
Philadelphia, Pennsylvania 19107
Adjacent to Convention Center
Phone: 215.625.2900
l
5
Courtyard Philadelphia Downtown
21 Juniper Street
Philadelphia, Pennsylvania 19107
Phone: 215.496.3200
l
6
Hampton Inn Center City
1301 Race Street
Philadelphia, Pennsylvania 19107
Phone: 215.665.9100
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
136
SPRUCE ST.
8TH ST.
9TH ST.
10TH ST.
11TH ST.
12TH ST.
13TH ST.
BROAD ST.
15TH ST.
16TH ST.
17TH ST.
18TH ST.
19TH ST.
20TH ST.
21ST ST.
PHILADELPHIA
INTERNATIONAL
AIRPORT
WASHINGTON
SQUARE
LOCUST ST.
WASHINGTON SQUARE WEST
5TH ST.
RITTENHOUSE SQUARE EAST
RITTENHOUSE
SQUARE
6TH ST.
WALNUT ST.
LOCUST ST.
SPRUCE ST.
E
S
4
5
AMTRAK
30TH STREET
STATION
N
WASHINGTON SQUARE EAST
Hilton Garden Inn Center City
1100 Arch Street
Philadelphia, Pennsylvania 19107
Phone: 215.923.0100
Home2 Suites Convention Center
1200 Arch Street
Philadelphia, Pennsylvania 19107
Phone: 215.627.1850
Loews Philadelphia
1200 Market Street
Philadelphia, Pennsylvania 19107
Phone: 215.627.1200
DECEMBER 4 - 8, 2015 www.AeSnet.org
PENNSYLVANIA CONVENTION CENTER
Race Street
FE
FE
R
R
RR
C
F
F
11th Street
12th Street
13th Street
Street level
100 level
RR
F
Exhibit Hall F
104
TAXI STAND
R
R
105
F
F
F
107
108
T
E
R
FE
R
R
R
R R
S T
R R
R R
E
S
S
Arch Street
Race Street
FE
FE
R R
R R
Exhibit Hall C
C
C
C
Exhibit Hall A
&
Poster Sessions
Exhibit Hall B
R
R R
11th Street
200 Level at the
Convention Center
goes to Level 3
at the Marriott
13th Street
200 level
C
R
R
R
R
R
S
Business Center
Bridge Area
Arch Street
Registration
R
R
R
R
R
R
R
R
Grand
Ballroom A/B
grand
Ballroom
located
above 200
level
R
Ballroom
Foyer
R
E
R
R
E
Grand Hall
200 level
Meeting
Rooms
Grand Hall
CORRIDOR TO
MARRIOTT HOTEL
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
137
DECEMBER 4 - 8, 2015 www.AeSnet.org
PHILADELPHIA MARRIOTT DOWNTOWN
level Three
level Three
STAIR
EXIT
STAIR
STAIR
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
138
DECEMBER 4 - 8, 2015 www.AeSnet.org
PHILADELPHIA MARRIOTT DOWNTOWN
level Four – Franklin hall
level Five
AMERICAN EPILEPSy SoCIETy 69Th AnnuAl MeeTIng
139
DECEMBER 4 - 8, 2015 www.AeSnet.org
Exploring Critical Advances
in Brain Connection Research
Brain Connectivity is the premier peer-reviewed journal for cutting-edge
research in the expanding area of systems neuroscience.
’
Critical advancements in the
diagnosis and treatment of
neurodegenerative diseases
and psychiatric disorders
’
Vital information on brain
mapping, new imaging
modalities, and translating
research discoveries from
lab to clinic
’
Accepted in MEDLINE®
in its first year
Founding and Co-Editors-in-Chief:
Christopher P. Pawela, PhD
and Bharat B. Biswal, PhD
Sign Up for Free Email Alerts
www.liebertpub.com/brain/connect
THE MOST WIDELY READ AND HIGHLY
CITED PEER-REVIEWED NEUROLOGY JOURNAL
The Official Journal o
of the
American Acadeemy of
o Neurology
GET IT ON
One subscription ... four ways to access
Neurrology brings you:
ǦŠŠ—ǂ—Š›ŽŠœŠ‰—™Žˆ‘Š˜†“‰
Clinical/Scientific Notes
ǦŽŠœ˜ʮŠ›ŽŠœ˜ǩŽ“ˆ‘š‰Ž“Œ
Medical Hypothesis papers)
ǦŽ˜™”—Žˆ†‘Šš—”‘”Œž
Ǧ”“™Š’•”—†—ž˜˜šŠ˜
in Neurologic Practice
ǦŠš—”Images
Ǧ”‰ˆ†˜™˜
Ǧš’†“Ž™ŽŠ˜
Ǧ—Ž™Š‘ŽˆȎ†•Ž‰“‘Ž“Š”——Š˜•”“‰Š“ˆŠ
ǦŠ˜Ž‰Š“™ʮŠ‘‘”œŠˆ™Ž”“
Ǧ
‘”‡†‘Š—˜•Šˆ™Ž›Š˜
Ǧ”˜Ž™Ž”“•†•Š—˜†“‰ŒšŽ‰Š‘Ž“Š˜
from the AAN
Enjoy full-text online access, including expedited e-pub, presentation downloads, search functions,
topic alerts, e--TTOC service, RSS feeds of current issues and podcasts, mobile device downloads, and a
Resident & Fellow subsite. Plus, access Neurology on your iPad® and Android™ devices for a print-like
reading experience enhanced with article-sharing features, links, and more!
Neurology.org
Visit Booth #227 for Meeting Discounts
5-Q607
Neu
urology® Cliinical Prracti
actic
ice
An Offficial
ficcial Journal of the Amerrican Academ
my of Neurrology
o
GET IT
T ON
Ǧ
Addittional Series Sections:™†™Ž˜™Žˆ˜Ž“‘Ž“Žˆ†‘
—†ˆ™ŽˆŠ†“‰—†ˆ™ŽˆŠˆ—”˜˜”—‰Š—˜
Ǧ••—”†ˆŠ˜™”•†™ŽŠ“™˜œŽ™›†—Ž”š˜“Šš—”‘”ŒŽˆ
ˆ”“‰Ž™Ž”“˜
Ǧ†˜Šǂ‡†˜Š‰†—™Žˆ‘Š˜”“Š™Žˆ†‘Ž˜˜šŠ˜
Ǧ ǒŽ›ŠŠœŽ“Œ˜Ǔš•‰†™Š˜”“‰Ž˜Š†˜Š˜†“‰‰Ž˜”—‰Š—˜
Ǧ‹ʬˆŠǂ‡†˜Š‰Ž˜˜šŠ˜†“‰’†“†ŒŠ’Š“™™Ž•˜
ǦŠ†‘™•”‘Žˆž‰Ž˜ˆš˜˜Ž”“˜
Š’‡Š—˜”‹™Š’Š—Žˆ†“ˆ†‰Š’ž
”‹Šš—”‘”Œž—ŠˆŠŽ›ŠNeurology:
Clinical Prractic
actice†˜†‡Š“Šʬ™”‹
’Š’‡Š—˜Ž•ǀ“™Š—“†™Ž”“†‘Š’‡Š—˜
—ŠˆŠŽ›Š”“‘Ž“Šǂ”“‘ž†ˆˆŠ˜˜ǀ
”™†’Š’‡Š—lj
Š†—“’”—Š†‡”š™™Š†™
AAN.com/Membersship.
Neurologyy.or
org/cp
Visit Booth
h #227 for Meeting
M
Disco
ounts
ȠǂȡȟȢ
www.thieme.com/tryjournal
Free Access to the Etiology of Epilepsy issue of Seminars in Neurology:
Simply visit www.thieme.com/tryjournal and enter
promo code SINAES15729712Nho1 for FREE access
Seminars in Neurology
SEMINARS IN
NEUROLOGY
ISSN 0271-8235
Issue 3
Volume 35
Editor-in-Chief: D.M. Greer
2016/Volume 36/6 issues p.a./ISSN 0271-8235
June 2015
USA and Canada
Individuals: $329 $263
20% OFF
for new
subscribers
Editor-in-Chief
David M. Greer, MD, MA, FCCM, FAHA, FNCS
Etiology of Epilepsy
Guest Editors
Institutions: $1,154
Mexico, Central and South America
Individuals: $356 $285
Institutions: $1,181
Contact customerservice@thieme.com
Etiology of Epilepsy
Philip Smith, MD, FRCP, FAcadMEd, and Rhys Thomas, BSc, MRCP, MSc, PhD
Introduction to the Guest Editors
Preface
Philip Smith, MD, FRCP, FAcadMEd, and
Rhys Thomas, BSc, MRCP, MSc, PhD
David M. Greer, MD, MA, FCCM, FAHA, FNCS, FAAN, FANA
Philip Smith, MD, FRCP, FAcadMEd, and Rhys Thomas, BSc, MRCP, MSc, PhD
2013
IMPACT FACTOR
Hippocampal Sclerosis: Causes and Prevention
Focal Cortical Dysplasia
Matthew Charles Walker, FRCP, PhD
Peter B. Crino, MD, PhD
www.thieme-connect.com/products
www.thieme.com/sin
ISSN 0271-8235
Tumors in Epilepsy
Mark Nowell, MBBS, MA, MRCS, Anna Miserocchi, MD, and Andrew W. McEvoy, FRCS
The Epidemiology of Posttraumatic Epilepsy
Intracranial Vascular Malformations and Epilepsy
Jakob Christensen, MD, PhD
Colin B. Josephson, MD, MSc, Felix Rosenow, MD, and Rustam Al-Shahi Salman, PhD
Infective Causes of Epilepsy
Autoimmune Causes of Epilepsy
M. Bonello, B.D. Michael, and T. Solomon
SUBSCRIBE
NOW AND
STAY UP-TO-DATE IN 2016
Visit www.thieme.com/journals in order to
subscribe or renew your subscription.
Take full advantage of your individual subscription by
registering online at
www.thieme-connect.com/products:
• Individual subscribers get free online access to
current and back issues of their journal(s)
• Advanced online access for select journals via the
eFirst service
• Compatibility with smartphones and mobile
devices
• Search across our entire library of journals via
optimized faceted search
Michel Toledano, MD, and Sean J. Pittock, MD
Rasmussen Syndrome and Other InÁammatory Epilepsies
Sophia Varadkar, MRCPI, PhD, and J. Helen Cross, FRCPCH, PhD
Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments
Megalencephaly and Macrocephaly
Anurag Saxena, and Julian R. Sampson
Kellen D. Winden, Christopher J. Yuskaitis, and Annapurna Poduri
ORDER TODAY
http://www.thieme.com
6SHFLDOLQWURGXFWRU\UDWHVDUHRQO\YDOLGIRUQHZVXEVFULEHUVDQGDUHOLPLWHGWRWKHÀUVW\HDURIVXEVFULSWLRQ
2QO\TXDOLÀHGSURIHVVLRQDOVDQGVWXGHQWVDUHHOLJLEOHIRULQGLYLGXDOVXEVFULSWLRQV
2UGHUVIURPLQGLYLGXDOVPXVWLQFOXGHWKHUHFLSLHQW
VQDPHDQGSULYDWHDGGUHVVDQGEHSDLGE\SULYDWHIXQGV
Become a fan at www.facebook.com/thiemepublishers.
Follow us @ThiemeNY
Challenge
eY
Your
our Thinkin
Thinking
ng on Topiramate
Topiramate
Exp
l
At
Booth 2
17
t
Qu
R
wi
h
Qudexy is a registered trademark of Upsher-Smith Laboratories, Inc.
© 2015 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369
110787.01
®
dexy
Di
Discover
why
h Qudexy
Q d ® XR is
i a topiramate
t i
t off today
t d att Bo
Booth
th 217.
hcp.QudexyXR.com
e
enc
er
e the diff
r
o
X
Eisai is proud to announcce
exciting news in the
treatm
ment of eepilepsy
Come see us at tthe
69th Annual AAmerican Epilepssy Society Meetting
Pennsylvania
ention Centeer, Philadelphia, PA
December 4-8, 22015
VISIT US AT
VIS
V
VISIT
AT
BOO
OO
OTH
501
LU
UNDBE CK AN NOUN CES
N W DATA
NEW
Vissit our scientifiic exhibit and learn
l
about thee latest
research updattes on difficult-to-tr
eat epilep
psies.
Come speak witth key opinion leaders and fin
nd out
what’s new at Lun
ndbeck.
Wheen: Sunday, Deecember 6, 2015, 8:00 AM to 11:00
1
AM
Wheere: Level 200 of
o the Pennsylvania
v
Conventio
on Center
Don’ t ffor
orrg
get to visit us at Booth 711 at the Front Hall
H entry!
y
©2015 Lundbeck. All
A rights reserved.
UBR-C-00106